"#",Jurisdiction,Kind,Display Key,Lens ID,Publication Date,Publication Year,Application Number,Application Date,Priority Numbers,Earliest Priority Date,Title,Abstract,Applicants,Inventors,Owners,URL,Document Type,Has Full Text,Cites Patent Count,Cited by Patent Count,Simple Family Size,Extended Family Size,Sequence Count,CPC Classifications,IPCR Classifications,US Classifications,NPL Citation Count,NPL Resolved Citation Count,NPL Resolved Lens ID(s),NPL Resolved External ID(s),NPL Citations,Legal Status
1,WO,A2,WO 2006/113152 A2,052-920-166-013-070,2006-10-26,2006,US 2006/0012883 W,2006-04-06,US 10695405 A,2005-04-15,BREAKAWAY PINATA,"A pinata-like device is formed from cardboard panels and sub-panels. The structure is formed and held together by masking tape which is partially cut, across the seams of the panels and sub-panels. The container has an access opening to facilitate placement of goodies into the cavity. Each panel and sub-panel is provided with a ribbon. By pulling on the ribbons, the panels are frangibly detachable from one another. The strength of the attachment of the ribbons to the panels and sub-panels exceeds the strength of the masking tape holding the panels and sub-panels into a container form. When the ribbons are pulled, preferably substantially simultaneously, the panels substantially detach from one another, and any contents disposed within the cavity are made available, usually in a somewhat explosive manner. An end of each ribbon is passed through one or more slits in each panel and securely attached to a surface of the panel.",AMSCAN INC,BELL JIM;;HARRIS RANDY,,https://lens.org/052-920-166-013-070,Patent Application,yes,0,0,3,3,0,A63H37/00;;A63H37/00,A63H33/00,,0,0,,,,PENDING
2,WO,A3,WO 2006/113152 A3,114-674-882-111-882,2007-07-05,2007,US 2006/0012883 W,2006-04-06,US 10695405 A,2005-04-15,BREAKAWAY PINATA,"A pinata-like device is formed from cardboard panels and sub-panels. The structure is formed and held together by masking tape which is partially cut, across the seams of the panels and sub-panels. The container has an access opening to facilitate placement of goodies into the cavity. Each panel and sub-panel is provided with a ribbon. By pulling on the ribbons, the panels are frangibly detachable from one another. The strength of the attachment of the ribbons to the panels and sub-panels exceeds the strength of the masking tape holding the panels and sub-panels into a container form. When the ribbons are pulled, preferably substantially simultaneously, the panels substantially detach from one another, and any contents disposed within the cavity are made available, usually in a somewhat explosive manner. An end of each ribbon is passed through one or more slits in each panel and securely attached to a surface of the panel.",AMSCAN INC,BELL JIM;;HARRIS RANDY,,https://lens.org/114-674-882-111-882,Search Report,yes,4,0,3,3,0,A63H37/00;;A63H37/00,A63H33/16;;A63H33/00,,0,0,,,,PENDING
3,US,A1,US 2006/0234595 A1,087-691-426-157-585,2006-10-19,2006,US 10695405 A,2005-04-15,US 10695405 A,2005-04-15,Breakaway pinata,"A piñata-like device is formed from cardboard panels and sub-panels. The structure is formed and held together by masking tape which is partially cut, across the seams of the panels and sub-panels. The container has an access opening to facilitate placement of goodies into the cavity. Each panel and sub-panel is provided with a ribbon. By pulling on the ribbons, the panels are frangibly detachable from one another. The strength of the attachment of the ribbons to the panels and sub-panels exceeds the strength of the masking tape holding the panels and sub-panels into a container form. When the ribbons are pulled, preferably substantially simultaneously, the panels substantially detach from one another, and any contents disposed within the cavity are made available, usually in a somewhat explosive manner. An end of each ribbon is passed through one or more slits in each panel and securely attached to a surface of the panel.",BELL JIM;;HARRIS RANDY,BELL JIM;;HARRIS RANDY,AMSCAN INC (2005-04-14),https://lens.org/087-691-426-157-585,Patent Application,yes,5,5,3,3,0,A63H37/00;;A63H37/00,A63H33/00,446/5,0,0,,,,DISCONTINUED
4,US,A1,US 2019/0372437 A1,134-584-684-248-147,2019-12-05,2019,US 201815994218 A,2018-05-31,US 201815994218 A,2018-05-31,METHOD FOR RESTORING SEPARATION BETWEEN LAMINATIONS OF GENERATOR STATOR CORE,A method for restoring a separation between laminations of a stator core of a generator is presented. The laminations are separated from each other by an insulation layer disposed between the laminations. Wicking resin is applied to an area where the laminations are in contact with each other. Etching using an etching solution is applied to the area where the laminations are in contact with each other until a separation between the laminations is restored. The wicking resin seals the insulation layer to prevent the etching solution from penetrating into the insulation layer and causing a detrimental effect on the insulation layer.,SIEMENS ENERGY INC,BELL SHANE;;WHITENER RANDY EDWARD,SIEMENS ENERGY INC (2018-05-25),https://lens.org/134-584-684-248-147,Patent Application,yes,0,0,2,2,0,H02K1/04;;H02K15/0006;;H02K1/16;;H02K11/20;;H02K15/0006;;H02K15/024;;H02K15/10;;H02K15/10;;H02K15/12,H02K15/00;;H02K1/16;;H02K11/20;;H02K15/02;;H02K15/10,,0,0,,,,DISCONTINUED
5,WO,A1,WO 2019/231695 A1,189-380-649-071-164,2019-12-05,2019,US 2019/0032565 W,2019-05-16,US 201815994218 A,2018-05-31,METHOD FOR RESTORING SEPARATION BETWEEN LAMINATIONS OF GENERATOR STATOR CORE,A method for restoring a separation between laminations of a stator core of a generator is presented. The laminations are separated from each other by an insulation layer disposed between the laminations. Wicking resin is applied to an area where the laminations are in contact with each other. Etching using an etching solution is applied to the area where the laminations are in contact with each other until a separation between the laminations is restored. The wicking resin seals the insulation layer to prevent the etching solution from penetrating into the insulation layer and causing a detrimental effect on the insulation layer.,SIEMENS ENERGY INC,BELL SHANE;;WHITENER RANDY EDWARD,,https://lens.org/189-380-649-071-164,Patent Application,yes,1,1,2,2,0,H02K1/04;;H02K15/0006;;H02K1/16;;H02K11/20;;H02K15/0006;;H02K15/024;;H02K15/10;;H02K15/10;;H02K15/12,H02K15/00;;H02K1/04;;H02K15/10;;H02K15/12,,2,1,012-352-204-089-321,10.1109/tmag.2017.2700471,"""IEEE Guide for Induction Machinery Maintenance Testing and Failure Analysis;IEEE Std 1415-2006 ED - Anonymous"", IEEE STANDARD; [IEEE STANDARD], IEEE, PISCATAWAY, NJ, USA, 30 April 2007 (2007-04-30), pages 1 - 58, XP068110471, ISBN: 978-0-7381-5564-7;;DENIS NICOLAS ET AL: ""Iron Loss Reduction in Permanent Magnet Synchronous Motor by Using Stator Core Made of Nanocrystalline Magnetic Material"", IEEE TRANSACTIONS ON MAGNETICS, IEEE SERVICE CENTER, NEW YORK, NY, US, vol. 53, no. 11, 1 November 2017 (2017-11-01), pages 1 - 6, XP011671505, ISSN: 0018-9464, [retrieved on 20171024], DOI: 10.1109/TMAG.2017.2700471",PENDING
6,EP,A3,EP 0243071 A3,068-181-310-885-629,1988-03-23,1988,EP 87303259 A,1987-04-14,US 85484686 A,1986-04-22,DI-T-BUTYLPHENOLS SUBSTITUTED BY A THENOYL GROUP,"Novel compounds which are 2, 6-di-t-butylphenols substituted on the 4 position by a thenoyl group, which thenoyl group is substituted by an acid group are useful as inhibitors of leukotriene synthesis and as antiallergic agents.","RIKER LABORATORIES, INC.","BELL, RANDY L.;;MOORE, GEORGE G.I.",,https://lens.org/068-181-310-885-629,Search Report,yes,4,0,7,7,0,A61P11/08;;A61P37/08;;A61P43/00;;C07D333/40;;C07D333/40;;C07D333/38;;C07D333/38,A61K31/38;;A61K31/381;;A61P11/08;;A61P37/08;;A61P43/00;;C07D333/38;;C07D333/40,,1,0,,,"CHEMICAL ABSTRACTS, vol. 101, no. 13, 24th September 1984, page 638, column 1, abstract no. 110722y, Columbus, Ohio, US; & JP-A-59 070 685 (SANKYO CO. LTD.) 21-04-1984",EXPIRED
7,EP,B1,EP 0243071 B1,115-344-618-991-299,1991-01-09,1991,EP 87303259 A,1987-04-14,US 85484686 A,1986-04-22,DI-T-BUTYLPHENOLS SUBSTITUTED BY A THENOYL GROUP,,"RIKER LABORATORIES, INC.","BELL, RANDY L.;;MOORE, GEORGE G.I.",,https://lens.org/115-344-618-991-299,Granted Patent,yes,4,0,7,7,0,A61P11/08;;A61P37/08;;A61P43/00;;C07D333/40;;C07D333/40;;C07D333/38;;C07D333/38,A61K31/38;;A61K31/381;;A61P11/08;;A61P37/08;;A61P43/00;;C07D333/38;;C07D333/40,,1,0,,,"CHEMICAL ABSTRACTS, vol. 101, no. 13, 24th September 1984, page 638, column 1, abstract no. 110722y, Columbus, Ohio, US; & JP - A - 59 70685 (SANKYO CO. LTD.) 21-04-1984",EXPIRED
8,US,A1,US 2004/0077567 A1,107-374-309-708-928,2004-04-22,2004,US 27272702 A,2002-10-16,US 27272702 A,2002-10-16,Antisense modulation of CD36 expression,"
   Antisense compounds, compositions and methods are provided for modulating the expression of CD36. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding CD36. Methods of using these compounds for modulation of CD36 expression and for treatment of diseases associated with expression of CD36 are provided. 
",ISIS PHARMACEUTICALS INC;;ABBOTT LAB,WATT ANDREW T;;BELL RANDY LANE,ISIS PHARMACEUTICALS INC (2002-10-11);;ABBOTT LABORATORIES (2002-09-27),https://lens.org/107-374-309-708-928,Patent Application,yes,12,3,1,1,102,A61K48/00;;C07H21/04;;Y02P20/582;;C07H21/04;;A61K48/00;;Y02P20/582,A61K48/00;;C07H21/04,514/44;;536/23.5,0,0,,,,DISCONTINUED
9,US,A1,US 2004/0077568 A1,091-451-873-424-990,2004-04-22,2004,US 27281002 A,2002-10-16,US 27281002 A,2002-10-16,Antisense modulation of Notch (Drosophila) homolog 4 expression,"
   Antisense compounds, compositions and methods are provided for modulating the expression of Notch (Drosophila) homolog 4. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Notch (Drosophila) homolog 4. Methods of using these compounds for modulation of Notch (Drosophila) homolog 4 expression and for treatment of diseases associated with expression of Notch (Drosophila) homolog 4 are provided. 
",ISIS PHARMACEUTICALS INC,WATT ANDREW T;;BELL RANDY LANE,ISIS PHARMACEUTICALS INC (2002-10-11);;ABBOTT LABORATORIES (2002-09-27),https://lens.org/091-451-873-424-990,Patent Application,yes,3,0,1,1,89,A61K48/00;;C07H21/04;;Y02P20/582;;C07H21/04;;A61K48/00;;Y02P20/582,A61K48/00;;C07H21/04,514/44;;536/23.5,0,0,,,,DISCONTINUED
10,WO,A1,WO 2019/231704 A1,061-003-632-641-305,2019-12-05,2019,US 2019/0032655 W,2019-05-16,US 201815994114 A,2018-05-31,FALSE TOOTH ASSEMBLY FOR GENERATOR STATOR CORE,A false tooth assembly for a generator stator core is presented. The false tooth assembly has a tapered shape including multiple tapered false tooth pieces. The multiple tapered false tooth pieces are installed into a damaged area in a tooth of a lamination of the stator core such that a wide end of the false tooth assembly is disposed into a wide opening of the damaged area and a narrow end of the false tooth assembly is flushed with a narrow opening of the damaged area at a tip of the tooth. The tapered shape of the false tooth assembly enables the false tooth assembly to fill the entire damaged area and to lock the false tooth assembly into the damaged area. The false tooth assembly can be used to repair stator core in any region of the stator core including step iron region without being dislodged during generator operation.,SIEMENS ENERGY INC,BELL SHANE;;WHITENER RANDY EDWARD;;YAFFEE DONALD,,https://lens.org/061-003-632-641-305,Patent Application,yes,4,0,11,11,0,H02K15/00;;H02K15/0006;;H02K1/165;;H02K3/28;;H02K7/116;;H01F41/305;;H02K1/16,H02K15/00,,0,0,,,,PENDING
11,EP,A1,EP 0211548 A1,035-206-157-215-303,1987-02-25,1987,EP 86305514 A,1986-07-17,US 75768685 A,1985-07-22,Antiallergic agents.,"Novel antiallergic agents are described which are carboxy-substituted 3,5-di(tertiary-butyl)-4-hydroxybenzophenones. Pharmaceutical compositions containing and pharmacological methods for using such compounds are also described, as are synthetic intermediates for preparing such compounds.",RIKER LABORATORIES INC,BELL RANDY L;;MOORE GEORGE G I,,https://lens.org/035-206-157-215-303,Patent Application,yes,7,3,10,11,0,A61P37/08;;A61P43/00;;C07C255/00;;C07C255/00;;C07C45/46;;C07C45/46;;C07C49/83;;C07C49/83;;C07C49/84;;C07C49/84;;C07C65/40;;C07C65/40,A61K31/12;;A61K31/19;;A61K31/215;;A61K31/235;;A61K31/275;;A61P37/08;;A61P43/00;;C07C45/00;;C07C45/46;;C07C49/83;;C07C49/84;;C07C51/00;;C07C65/32;;C07C65/40;;C07C67/00;;C07C69/76;;C07C219/14;;C07C253/00;;C07C255/51;;C07C255/56,,7,3,057-734-152-583-219;;061-748-941-841-26X;;055-078-725-662-171,5462381;;10.1016/0003-2697(70)90089-8;;pmc1457924;;511221;;10.1159/000233522;;6423553,"CHEMICAL ABSTRACTS, vol. 98, no. 11, 14th March 1983, page 523, left hand column, abstract no. 89010x, Columbus, Ohio, US; N. SERGOVSKAYA et al.: ""Study of compounds with juvernile detivity. XV Synthesis of 2,6-tert-butyl-4-acylphenols""; "" & ZH. ORG. KHIM. 1982, 18(10), 2167-2170 together with CHEMICAL ABSTRACTS, Formula Index, vol. 98, 1983, page 2042F, column 2, formula 6;;CHEMICAL ABSTRACTS, vol. 98, 1983, pages 523;;BEN AZIZ ET AL., ANAL. BIOCHEM., vol. 34, 1970, pages 88;;M. STEINHOFF ET AL., BIOCHIM. BIOPHYS. ACTA, vol. 68, 1980, pages 28;;AERINGHAUSE ET AL., FEBS LETTER, vol. 146, pages 111 - 114;;PIECHUTA ET AL., IMMUNOLOGY, vol. 38, 1979, pages 385;;HAMMERBECK; SWINGLE, INT. ARCHS. ALLERGY APPL. IMMUN., vol. 74, 1984, pages 84 - 90",EXPIRED
12,EP,B1,EP 0211548 B1,098-304-963-554-62X,1990-05-09,1990,EP 86305514 A,1986-07-17,US 75768685 A,1985-07-22,ANTIALLERGIC AGENTS,,"RIKER LABORATORIES, INCORPORATED","BELL, RANDY L.;;MOORE, GEORGE G. I.",,https://lens.org/098-304-963-554-62X,Granted Patent,yes,5,0,10,11,0,A61P37/08;;A61P43/00;;C07C255/00;;C07C255/00;;C07C45/46;;C07C45/46;;C07C49/83;;C07C49/83;;C07C49/84;;C07C49/84;;C07C65/40;;C07C65/40,A61K31/12;;A61K31/19;;A61K31/215;;A61K31/235;;A61K31/275;;A61P37/08;;A61P43/00;;C07C45/00;;C07C45/46;;C07C49/83;;C07C49/84;;C07C51/00;;C07C65/32;;C07C65/40;;C07C67/00;;C07C69/76;;C07C219/14;;C07C253/00;;C07C255/51;;C07C255/56,,1,0,,,"CHEMICAL ABSTRACTS, vol. 98, no. 11, 14th March 1983, page 523, left hand column, abstract no. 89010x, Columbus, Ohio, US; N. SERGOVSKAYA et al.: ""Study of compounds with juvernile detivity. XV Synthesis of 2,6-tert-butyl-4-acylphenols""; "" & ZH. ORG. KHIM. 1982, 18(10), 2167-2170 together with CHEMICAL ABSTRACTS, Formula Index, vol. 98, 1983, page 2042F, column 2, formula 6",EXPIRED
13,CA,A,CA 1264328 A,053-267-145-846-556,1990-01-09,1990,CA 514385 A,1986-07-22,US 75768685 A,1985-07-22,ANTIALLERGIC AGENTS,"- 22 - 40216 CAN 1A Novel antiallergic agents are described which are carboxy-substituted 3,5-di(tertiary-butyl)-4-hydroxybenzophenones. Pharmaceutical compositions containing and pharmacological methods for using such compounds are also described, as are synthetic intermediates for preparing such compounds.",RIKER LABORATORIES INC,BELL RANDY L;;MOORE GEORGE G I,,https://lens.org/053-267-145-846-556,Granted Patent,no,0,0,10,11,0,A61P37/08;;A61P43/00;;C07C255/00;;C07C255/00;;C07C45/46;;C07C45/46;;C07C49/83;;C07C49/83;;C07C49/84;;C07C49/84;;C07C65/40;;C07C65/40,A61K31/12;;A61K31/19;;A61K31/215;;A61K31/235;;A61K31/275;;A61P37/08;;A61P43/00;;C07C45/00;;C07C45/46;;C07C49/83;;C07C49/84;;C07C51/00;;C07C65/32;;C07C65/40;;C07C67/00;;C07C69/76;;C07C219/14;;C07C253/00;;C07C255/51;;C07C255/56,260-475.3,0,0,,,,EXPIRED
14,AU,A,AU 1986/060325 A,113-282-021-672-179,1987-01-29,1987,AU 1986/060325 A,1986-07-18,US 75768685 A,1985-07-22,DI-T-BUTYLPHENOLS CONTAINING A BENZOYL GROUP,,RIKER LABORATORIES INC,BELL RANDY L;;MOORE GEORGE G I,,https://lens.org/113-282-021-672-179,Patent Application,no,0,0,10,11,0,A61P37/08;;A61P43/00;;C07C255/00;;C07C255/00;;C07C45/46;;C07C45/46;;C07C49/83;;C07C49/83;;C07C49/84;;C07C49/84;;C07C65/40;;C07C65/40,A61K31/12;;A61K31/19;;A61K31/215;;A61K31/235;;A61K31/275;;A61P37/08;;A61P43/00;;C07C45/00;;C07C45/46;;C07C49/83;;C07C49/84;;C07C51/00;;C07C65/32;;C07C65/40;;C07C67/00;;C07C69/76;;C07C219/14;;C07C253/00;;C07C255/51;;C07C255/56,,0,0,,,,EXPIRED
15,US,B2,US 10910926 B2,047-484-705-966-438,2021-02-02,2021,US 201815994043 A,2018-05-31,US 201815994043 A,2018-05-31,Method for repairing generator stator core,A method for repairing a stator core of a generator is presented. The stator core includes laminations grouped into packs. A ventilation spacer is disposed between adjacent packs. Laminations are separated from each other by insulation layers. The ventilation spacer is removed between adjacent packs having a damaged insulation layer between the laminations to locally loosen the laminations in the adjacent packs which allows the damaged insulation layer between the laminations to be repaired. A new ventilation spacer is reinstalled between the adjacent packs where the ventilation spacer being removed to retighten the laminations in the adjacent packs after completion of the repair. The new ventilation spacer is adhesively secured between the adjacent packs.,SIEMENS ENERGY INC,BELL SHANE;;WHITENER RANDY EDWARD;;FELIX ALEJANDRO,SIEMENS ENERGY INC (2018-05-22),https://lens.org/047-484-705-966-438,Granted Patent,yes,5,0,3,3,0,H02K15/0006;;H02K15/0006;;H02K1/16;;H02K1/16;;H02K1/20;;H02K1/20;;H02K11/20;;H02K15/024;;H02K15/10;;H02K15/10;;Y10T29/49009,H02K15/00;;H02K1/16;;H02K1/20;;H02K11/20;;H02K15/02;;H02K15/10,,3,2,153-513-628-843-639;;016-421-283-220-595,10.1109/ieeestd.1977.120246;;10.1109/pcicon.2006.359698,"ANONYMOUS: ""IEEE Standard"", 15 March 1977, IEEE, Piscataway, NJ, USA, article ANONYMOUS: ""IEEE guide for insulation maintenance of large alternating-current rotating machinery (10,000 kVA and larger)"", XP017600799;;CHUCK YUNG: ""A New Method for Stator Core Repair Reduces Core Losses and Repair Time"", PETROLEUM AND CHEMICAL INDUSTRY CONFERENCE, 2006. INDUSTRY APPLICATION S SOCIETY 53RD ANNUAL, IEEE, PI, 1 September 2006 (2006-09-01), Pi, pages 1 - 10, XP031087710, ISBN: 978-1-4244-0558-9;;PCT International Search Report and Written Opinion dated Jul. 24, 2019 corresponding to PCT Application No. PCT/US2019/032571 filed May 16, 2019.",ACTIVE
16,NZ,A,NZ 231486 A,145-608-625-212-091,1991-03-26,1991,NZ 23148686 A,1986-07-15,NZ 21685386 A;;US 75768685 A,1985-07-22,CYANO-DI(TERTIARYBUTYL)-HYDROXYBENZOPHENONE AND PREPARATION THEREOF; USE OF SUCH COMPOUNDS FOR THE PREPARATION OF THE CORRESPONDING CARBOXYLIC ACIDS,,RIKER LABORATORIES INC,BELL RANDY L;;MOORE GEORGE G I,,https://lens.org/145-608-625-212-091,Patent Application,no,0,0,1,11,0,,,,0,0,,,,DISCONTINUED
17,CA,C,CA 3101979 C,174-457-491-340-421,2023-03-14,2023,CA 3101979 A,2019-05-16,US 201815994114 A;;US 2019/0032655 W,2018-05-31,FALSE TOOTH ASSEMBLY FOR GENERATOR STATOR CORE,A false tooth assembly for a generator stator core is presented. The false tooth assembly has a tapered shape including multiple tapered false tooth pieces. The multiple tapered false tooth pieces are installed into a damaged area in a tooth of a lamination of the stator core such that a wide end of the false tooth assembly is disposed into a wide opening of the damaged area and a narrow end of the false tooth assembly is flushed with a narrow opening of the damaged area at a tip of the tooth. The tapered shape of the false tooth assembly enables the false tooth assembly to fill the entire damaged area and to lock the false tooth assembly into the damaged area. The false tooth assembly can be used to repair stator core in any region of the stator core including step iron region without being dislodged during generator operation.,SIEMENS ENERGY INC,BELL SHANE;;WHITENER RANDY EDWARD;;YAFFEE DONALD,,https://lens.org/174-457-491-340-421,Granted Patent,no,0,0,11,11,0,H02K15/00;;H02K15/0006;;H02K1/165;;H02K3/28;;H02K7/116;;H01F41/305;;H02K1/16,H02K15/00,,0,0,,,,PENDING
18,EP,B1,EP 3785354 B1,033-792-344-054-72X,2023-07-26,2023,EP 19728262 A,2019-05-16,US 201815994114 A;;US 2019/0032655 W,2018-05-31,FALSE TOOTH ASSEMBLY FOR GENERATOR STATOR CORE,,SIEMENS ENERGY INC,BELL SHANE;;WHITENER RANDY EDWARD;;YAFFEE DONALD,,https://lens.org/033-792-344-054-72X,Granted Patent,yes,4,0,11,11,0,H02K15/00;;H02K15/0006;;H02K1/165;;H02K3/28;;H02K7/116;;H01F41/305;;H02K1/16,H02K15/00,,0,0,,,,ACTIVE
19,US,B2,US 10868456 B2,114-379-428-374-744,2020-12-15,2020,US 201815994114 A,2018-05-31,US 201815994114 A,2018-05-31,False tooth assembly for generator stator core,A false tooth assembly for a generator stator core is presented. The false tooth assembly has a tapered shape including multiple tapered false tooth pieces. The multiple tapered false tooth pieces are installed into a damaged area in a tooth of a lamination of the stator core such that a wide end of the false tooth assembly is disposed into a wide opening of the damaged area and a narrow end of the false tooth assembly is flushed with a narrow opening of the damaged area at a tip of the tooth. The tapered shape of the false tooth assembly enables the false tooth assembly to fill the entire damaged area and to lock the false tooth assembly into the damaged area. The false tooth assembly can be used to repair stator core in any region of the stator core including step iron region without being dislodged during generator operation.,SIEMENS ENERGY INC,BELL SHANE;;WHITENER RANDY EDWARD;;YAFFEE DONALD,SIEMENS ENERGY INC (2018-05-22),https://lens.org/114-379-428-374-744,Granted Patent,yes,13,0,11,11,0,H02K15/00;;H02K15/0006;;H02K1/165;;H02K3/28;;H02K7/116;;H01F41/305;;H02K1/16,H02K7/116;;H01F41/30;;H02K1/16;;H02K3/28,,1,0,,,"PCT International Search Report and Written Opinion dated Jul. 24, 2019 corresponding to PCT Application No. PCT/US2019/032655 filed May 16, 2019.",ACTIVE
20,US,A,US 4677113 A,001-033-541-776-176,1987-06-30,1987,US 85484686 A,1986-04-22,US 85484686 A,1986-04-22,Di-t-butylphenols substituted by a thenoyl group,"Novel compounds which are 2,6-di-t-butylphenols substituted on the 4 position by a thenoyl group, which thenoyl group is substituted by an acid group are useful as inhibitors of leukotriene synthesis and as antiallergic agents.",RIKER LABORATORIES INC,BELL RANDY L;;MOORE GEORGE G I,RIKER LABORATORIES INC. A CORP OF DE (1986-04-22),https://lens.org/001-033-541-776-176,Granted Patent,yes,5,15,7,7,0,A61P11/08;;A61P37/08;;A61P43/00;;C07D333/40;;C07D333/40;;C07D333/38;;C07D333/38,A61K31/38;;A61K31/381;;A61P11/08;;A61P37/08;;A61P43/00;;C07D333/38;;C07D333/40,514/448;;549/61;;549/70;;549/71;;549/72,0,0,,,,EXPIRED
21,US,A1,US 2019/0372429 A1,102-004-555-654-574,2019-12-05,2019,US 201815994114 A,2018-05-31,US 201815994114 A,2018-05-31,FALSE TOOTH ASSEMBLY FOR GENERATOR STATOR CORE,A false tooth assembly for a generator stator core is presented. The false tooth assembly has a tapered shape including multiple tapered false tooth pieces. The multiple tapered false tooth pieces are installed into a damaged area in a tooth of a lamination of the stator core such that a wide end of the false tooth assembly is disposed into a wide opening of the damaged area and a narrow end of the false tooth assembly is flushed with a narrow opening of the damaged area at a tip of the tooth. The tapered shape of the false tooth assembly enables the false tooth assembly to fill the entire damaged area and to lock the false tooth assembly into the damaged area. The false tooth assembly can be used to repair stator core in any region of the stator core including step iron region without being dislodged during generator operation.,SIEMENS ENERGY INC,BELL SHANE;;WHITENER RANDY EDWARD;;YAFFEE DONALD,SIEMENS ENERGY INC (2018-05-22),https://lens.org/102-004-555-654-574,Patent Application,yes,7,2,11,11,0,H02K15/00;;H02K15/0006;;H02K1/165;;H02K3/28;;H02K7/116;;H01F41/305;;H02K1/16,H02K7/116;;H02K1/16;;H02K3/28,,0,0,,,,ACTIVE
22,CA,A1,CA 3101979 A1,119-085-037-625-508,2019-12-05,2019,CA 3101979 A,2019-05-16,US 201815994114 A;;US 2019/0032655 W,2018-05-31,FALSE TOOTH ASSEMBLY FOR GENERATOR STATOR CORE,A false tooth assembly for a generator stator core is presented. The false tooth assembly has a tapered shape including multiple tapered false tooth pieces. The multiple tapered false tooth pieces are installed into a damaged area in a tooth of a lamination of the stator core such that a wide end of the false tooth assembly is disposed into a wide opening of the damaged area and a narrow end of the false tooth assembly is flushed with a narrow opening of the damaged area at a tip of the tooth. The tapered shape of the false tooth assembly enables the false tooth assembly to fill the entire damaged area and to lock the false tooth assembly into the damaged area. The false tooth assembly can be used to repair stator core in any region of the stator core including step iron region without being dislodged during generator operation.,SIEMENS ENERGY INC,BELL SHANE;;WHITENER RANDY EDWARD;;YAFFEE DONALD,,https://lens.org/119-085-037-625-508,Patent Application,no,0,0,11,11,0,H02K15/00;;H02K15/0006;;H02K1/165;;H02K3/28;;H02K7/116;;H01F41/305;;H02K1/16,H02K15/00,,0,0,,,,PENDING
23,NZ,A,NZ 216853 A,144-239-058-698-541,1991-03-26,1991,NZ 21685386 A,1986-07-15,US 75768685 A,1985-07-22,"3,5-DITERTIARYBUTYL-4-HYDROXYBENZOYLBENZOIC ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS",,RIKER LABORATORIES INC,BELL RANDY L;;MOORE GEORGE G I,,https://lens.org/144-239-058-698-541,Patent Application,no,0,0,10,11,0,A61P37/08;;A61P43/00;;C07C255/00;;C07C255/00;;C07C45/46;;C07C45/46;;C07C49/83;;C07C49/83;;C07C49/84;;C07C49/84;;C07C65/40;;C07C65/40,A61K31/12;;A61K31/19;;A61K31/215;;A61K31/235;;A61K31/275;;A61P37/08;;A61P43/00;;C07C45/00;;C07C45/46;;C07C49/83;;C07C49/84;;C07C51/00;;C07C65/32;;C07C65/40;;C07C67/00;;C07C69/76;;C07C219/14;;C07C253/00;;C07C255/51;;C07C255/56,,0,0,,,,DISCONTINUED
24,AU,B2,AU 591918 B2,168-430-280-834-301,1989-12-21,1989,AU 1986/060325 A,1986-07-18,US 75768685 A,1985-07-22,DI-T-BUTYLPHENOLS CONTAINING A BENZOYL GROUP,,RIKER LABORATORIES INC,BELL RANDY L;;MOORE GEORGE G I,,https://lens.org/168-430-280-834-301,Granted Patent,no,3,1,10,11,0,A61P37/08;;A61P43/00;;C07C255/00;;C07C255/00;;C07C45/46;;C07C45/46;;C07C49/83;;C07C49/83;;C07C49/84;;C07C49/84;;C07C65/40;;C07C65/40,A61K31/12;;A61K31/19;;A61K31/215;;A61K31/235;;A61K31/275;;A61P37/08;;A61P43/00;;C07C45/00;;C07C45/46;;C07C49/83;;C07C49/84;;C07C51/00;;C07C65/32;;C07C65/40;;C07C67/00;;C07C69/76;;C07C219/14;;C07C253/00;;C07C255/51;;C07C255/56,,0,0,,,,EXPIRED
25,EP,A2,EP 0243071 A2,094-307-088-021-38X,1987-10-28,1987,EP 87303259 A,1987-04-14,US 85484686 A,1986-04-22,Di-t-butylphenols substituted by a thenoyl group.,"Novel compounds which are 2, 6-di-t-butylphenols substituted on the 4 position by a thenoyl group, which thenoyl group is substituted by an acid group are useful as inhibitors of leukotriene synthesis and as antiallergic agents.",RIKER LABORATORIES INC,BELL RANDY L;;MOORE GEORGE G I,,https://lens.org/094-307-088-021-38X,Patent Application,yes,0,0,7,7,0,A61P11/08;;A61P37/08;;A61P43/00;;C07D333/40;;C07D333/40;;C07D333/38;;C07D333/38,A61K31/38;;A61K31/381;;A61P11/08;;A61P37/08;;A61P43/00;;C07D333/38;;C07D333/40,,0,0,,,,EXPIRED
26,DE,D1,DE 3767200 D1,153-082-970-354-134,1991-02-14,1991,DE 3767200 T,1987-04-14,US 85484686 A,1986-04-22,MIT EINER THENOYLGRUPPE SUBSTITUIERTE DI-T-BUTYLPHENOLE.,,RIKER LABORATORIES INC,BELL RANDY L;;MOORE GEORGE G I,,https://lens.org/153-082-970-354-134,Granted Patent,no,0,0,7,7,0,A61P11/08;;A61P37/08;;A61P43/00;;C07D333/40;;C07D333/40;;C07D333/38;;C07D333/38,A61K31/38;;A61K31/381;;A61P11/08;;A61P37/08;;A61P43/00;;C07D333/38;;C07D333/40,,0,0,,,,EXPIRED
27,CN,A,CN 112204862 A,020-012-264-836-21X,2021-01-08,2021,CN 201980036403 A,2019-05-16,US 201815994114 A;;US 2019/0032655 W,2018-05-31,FALSE TOOTH ASSEMBLY FOR GENERATOR STATOR CORE,A false tooth assembly for a generator stator core is presented. The false tooth assembly has a tapered shape including multiple tapered false tooth pieces. The multiple tapered false tooth pieces areinstalled into a damaged area in a tooth of a lamination of the stator core such that a wide end of the false tooth assembly is disposed into a wide opening of the damaged area and a narrow end of the false tooth assembly is flushed with a narrow opening of the damaged area at a tip of the tooth. The tapered shape of the false tooth assembly enables the false tooth assembly to fill the entire damaged area and to lock the false tooth assembly into the damaged area. The false tooth assembly can be used to repair stator core in any region of the stator core including step iron region without being dislodged during generator operation.,SIEMENS ENERGY INC,BELL SHANE;;WHITENER RANDY EDWARD;;YAFFEE DONALD,,https://lens.org/020-012-264-836-21X,Patent Application,no,7,0,11,11,0,H02K15/00;;H02K15/0006;;H02K1/165;;H02K3/28;;H02K7/116;;H01F41/305;;H02K1/16,H02K15/00,,0,0,,,,ACTIVE
28,WO,A1,WO 2019/231697 A1,157-915-834-243-893,2019-12-05,2019,US 2019/0032571 W,2019-05-16,US 201815994043 A,2018-05-31,METHOD FOR REPAIRING GENERATOR STATOR CORE,A method for repairing a stator core of a generator is presented. The stator core includes laminations grouped into packs. A ventilation spacer is disposed between adjacent packs. Laminations are separated from each other by insulation layers. The ventilation spacer is removed between adjacent packs having a damaged insulation layer between the laminations to locally loosen the laminations in the adjacent packs which allows the damaged insulation layer between the laminations to be repaired. A new ventilation spacer is reinstalled between the adjacent packs where the ventilation spacer being removed to retighten the laminations in the adjacent packs after completion of the repair. The new ventilation spacer is adhesively secured between the adjacent packs.,SIEMENS ENERGY INC,BELL SHANE;;WHITENER RANDY EDWARD;;FELIX ALEJANDRO,,https://lens.org/157-915-834-243-893,Patent Application,yes,3,0,3,3,0,H02K15/0006;;H02K15/0006;;H02K1/16;;H02K1/16;;H02K1/20;;H02K1/20;;H02K11/20;;H02K15/024;;H02K15/10;;H02K15/10;;Y10T29/49009,H02K15/00;;H02K1/16;;H02K1/20;;H02K15/10,,2,2,016-421-283-220-595;;153-513-628-843-639,10.1109/pcicon.2006.359698;;10.1109/ieeestd.1977.120246,"CHUCK YUNG ED - JOHN PROPST ET AL: ""A New Method for Stator Core Repair Reduces Core Losses and Repair Time"", PETROLEUM AND CHEMICAL INDUSTRY CONFERENCE, 2006. INDUSTRY APPLICATION S SOCIETY 53RD ANNUAL, IEEE, PI, 1 September 2006 (2006-09-01), pages 1 - 10, XP031087710, ISBN: 978-1-4244-0558-9;;ANONYMOUS ED - ANONYMOUS: ""IEEE guide for insulation maintenance of large alternating-current rotating machinery (10,000 kVA and larger)"", 15 March 1977, IEEE STANDARD; [IEEE STANDARD], IEEE, PISCATAWAY, NJ, USA, XP017600799",PENDING
29,JP,A,JP S638380 A,172-237-878-282-337,1988-01-14,1988,JP 9725987 A,1987-04-20,US 85484686 A,1986-04-22,THENOYL GROUP-SUBSTITUTED DI-T-BUTYLPHENOLS,,RIKER LABORATORIES INC,BELL RANDY L;;MOORE GEORGE G I,,https://lens.org/172-237-878-282-337,Patent Application,no,0,0,7,7,0,A61P11/08;;A61P37/08;;A61P43/00;;C07D333/40;;C07D333/40;;C07D333/38;;C07D333/38,A61K31/38;;A61K31/381;;A61P11/08;;A61P37/08;;A61P43/00;;C07D333/38;;C07D333/40,,0,0,,,,DISCONTINUED
30,US,A,US 4714776 A,160-091-773-619-189,1987-12-22,1987,US 75768685 A,1985-07-22,US 75768685 A,1985-07-22,Antiallergic agents,"Novel antiallergic agents are described which are carboxy-substituted 3,5-di(tertiary-butyl)-4-hydroxybenzophenones. Pharmaceutical compositions containing and pharmacological methods for using such compounds are also described, as are synthetic intermediates for preparing such compounds.",RIKER LABORATORIES INC,BELL RANDY L;;MOORE GEORGE G I,RIKER LABORATORIES INC. A CORP OF DE (1985-07-18),https://lens.org/160-091-773-619-189,Granted Patent,yes,3,17,10,11,0,A61P37/08;;A61P43/00;;C07C255/00;;C07C255/00;;C07C45/46;;C07C45/46;;C07C49/83;;C07C49/83;;C07C49/84;;C07C49/84;;C07C65/40;;C07C65/40,A61K31/12;;A61K31/19;;A61K31/215;;A61K31/235;;A61K31/275;;A61P37/08;;A61P43/00;;C07C45/00;;C07C45/46;;C07C49/83;;C07C49/84;;C07C51/00;;C07C65/32;;C07C65/40;;C07C67/00;;C07C69/76;;C07C219/14;;C07C253/00;;C07C255/51;;C07C255/56,562/460;;560/52;;558/415;;514/544;;514/568,2,0,,,"Sergouskayer, N. L. et al., Zh. Org. Khim 18(10) 2167 70, 1982.;;EPO application Publication No. 0 181 568, published 5/21/86.",EXPIRED
31,DE,D1,DE 3671010 D1,074-292-403-595-056,1990-06-13,1990,DE 3671010 T,1986-07-17,US 75768685 A,1985-07-22,ANTIALLERGISCHE MITTEL.,,RIKER LABORATORIES INC,BELL RANDY L;;MOORE GEORGE G I,,https://lens.org/074-292-403-595-056,Granted Patent,no,0,0,10,11,0,A61P37/08;;A61P43/00;;C07C255/00;;C07C255/00;;C07C45/46;;C07C45/46;;C07C49/83;;C07C49/83;;C07C49/84;;C07C49/84;;C07C65/40;;C07C65/40,A61K31/12;;A61K31/19;;A61K31/215;;A61K31/235;;A61K31/275;;A61P37/08;;A61P43/00;;C07C45/00;;C07C45/46;;C07C49/83;;C07C49/84;;C07C51/00;;C07C65/32;;C07C65/40;;C07C67/00;;C07C69/76;;C07C219/14;;C07C253/00;;C07C255/51;;C07C255/56,,0,0,,,,EXPIRED
32,US,A1,US 2019/0372436 A1,105-489-200-826-434,2019-12-05,2019,US 201815994043 A,2018-05-31,US 201815994043 A,2018-05-31,METHOD FOR REPAIRING GENERATOR STATOR CORE,A method for repairing a stator core of a generator is presented. The stator core includes laminations grouped into packs. A ventilation spacer is disposed between adjacent packs. Laminations are separated from each other by insulation layers. The ventilation spacer is removed between adjacent packs having a damaged insulation layer between the laminations to locally loosen the laminations in the adjacent packs which allows the damaged insulation layer between the laminations to be repaired. A new ventilation spacer is reinstalled between the adjacent packs where the ventilation spacer being removed to retighten the laminations in the adjacent packs after completion of the repair. The new ventilation spacer is adhesively secured between the adjacent packs.,SIEMENS ENERGY INC,BELL SHANE;;WHITENER RANDY EDWARD;;FELIX ALEJANDRO,SIEMENS ENERGY INC (2018-05-22),https://lens.org/105-489-200-826-434,Patent Application,yes,0,0,3,3,0,H02K15/0006;;H02K15/0006;;H02K1/16;;H02K1/16;;H02K1/20;;H02K1/20;;H02K11/20;;H02K15/024;;H02K15/10;;H02K15/10;;Y10T29/49009,H02K15/00;;H02K1/16;;H02K1/20;;H02K11/20;;H02K15/02;;H02K15/10,,0,0,,,,ACTIVE
33,EP,A1,EP 3785354 A1,057-877-701-215-231,2021-03-03,2021,EP 19728262 A,2019-05-16,US 201815994114 A;;US 2019/0032655 W,2018-05-31,FALSE TOOTH ASSEMBLY FOR GENERATOR STATOR CORE,,SIEMENS ENERGY INC,BELL SHANE;;WHITENER RANDY EDWARD;;YAFFEE DONALD,,https://lens.org/057-877-701-215-231,Patent Application,yes,0,0,11,11,0,H02K15/00;;H02K15/0006;;H02K1/165;;H02K3/28;;H02K7/116;;H01F41/305;;H02K1/16,H02K15/00,,0,0,,,,ACTIVE
34,US,A1,US 2021/0275952 A1,031-959-541-769-002,2021-09-09,2021,US 202117189680 A,2021-03-02,US 202117189680 A;;US 202062984472 P,2020-03-03,"FILTER KIT, ASSEMBLY, AND METHOD FOR INSTALLATION WITHIN A SUPPORT SURFACE ASSOCIATED WITH A HEAT EXCHANGER UNIT NOT LIMITED TO SUCH AS AN AIR COOLED LIQUID CHILLER","A filter and kit assembly for securing to one or more intake surfaces associated with a V-shaped heat exchanger unit. A screen includes a reinforced edge, within which is configured a plurality of spaced apart grommets aligning with and receiving therethrough engaging portions of the fasteners. In one variant, a frame is constructed for supporting the fasteners and attached filter and which is subsequently secured by clips against a flange surface surrounding the intake opening. In a further variant, the screen is configured in wrap-around fashion for supporting against first and second consecutively arranged intake openings along with an interconnecting intermediate flange surface.",THE NEWWAY COMPANY,SIMMONS RANDY;;GRENVILLE JOHN GORDON;;BELL STEVEN GEORGE,THE NEWWAY COMPANY (2021-03-01),https://lens.org/031-959-541-769-002,Patent Application,yes,13,4,6,6,0,B01D46/0005;;B01D46/10;;B01D46/005;;B01D35/02;;B01D46/001;;B01D46/10;;B01D46/001;;B01D46/0005;;B01D46/10,B01D46/00;;B01D46/10,,0,0,,,,ACTIVE
35,GB,A,GB 2610706 A,190-289-046-418-972,2023-03-15,2023,GB 202214379 A,2021-03-03,US 2021/0020584 W;;US 202062984472 P;;US 202117189680 A,2020-03-03,"Filter kit, assembly, and method for installation within a support surface associated with a heat exchanger unit not limited to such as an air cooled liquid c","A filter and kit assembly for securing to one or more intake surfaces associated with a V-shaped heat exchanger unit. A screen includes a reinforced edge, within which is configured a plurality of spaced apart grommets aligning with and receiving therethrough engaging portions of the fasteners. In one variant, a frame is constructed for supporting the fasteners and attached filter and which is subsequently secured by clips against a flange surface surrounding the intake opening. In a further variant, the screen is configured in wrap-around fashion for supporting against first and second consecutively arranged intake openings along with an interconnecting intermediate flange surface.",THE NEWWAY COMPANY,RANDY SIMMONS;;JOHN GORDON GRENVILLE;;STEVEN GEORGE BELL,,https://lens.org/190-289-046-418-972,Patent Application,no,5,0,6,6,0,B01D46/0005;;B01D46/10;;B01D46/005;;B01D35/02;;B01D46/001;;B01D46/10;;B01D46/001;;B01D46/0005;;B01D46/10,F28F19/01;;B01D35/02;;F28D1/053;;F28F9/007,,0,0,,,,PENDING
36,WO,A1,WO 2021/178476 A1,066-569-603-821-053,2021-09-10,2021,US 2021/0020584 W,2021-03-03,US 202062984472 P;;US 202117189680 A,2020-03-03,"FILTER KIT, ASSEMBLY, AND METHOD FOR INSTALLATION WITHIN A SUPPORT SURFACE ASSOCIATED WITH A HEAT EXCHANGER UNIT NOT LIMITED TO SUCH AS AN AIR COOLED LIQUID CHILLER","A filter and kit assembly for securing to one or more intake surfaces associated with a V-shaped heat exchanger unit. A screen includes a reinforced edge, within which is configured a plurality of spaced apart grommets aligning with and receiving therethrough engaging portions of the fasteners. In one variant, a frame is constructed for supporting the fasteners and attached filter and which is subsequently secured by clips against a flange surface surrounding the intake opening. In a further variant, the screen is configured in wrap-around fashion for supporting against first and second consecutively arranged intake openings along with an interconnecting intermediate flange surface.",THE NEWWAY COMPANY,SIMMONS RANDY;;GRENVILLE JOHN GORDON;;BELL STEVEN GEORGE,,https://lens.org/066-569-603-821-053,Patent Application,yes,5,0,6,6,0,B01D46/0005;;B01D46/10;;B01D46/005;;B01D35/02;;B01D46/001;;B01D46/10;;B01D46/001;;B01D46/0005;;B01D46/10,F28F19/01;;B01D35/02;;F28D1/053;;F28F9/007,,0,0,,,,PENDING
37,US,B2,US 11745130 B2,147-900-572-082-65X,2023-09-05,2023,US 202117189680 A,2021-03-02,US 202117189680 A;;US 202062984472 P,2020-03-03,"Filter kit, assembly, and method for installation within a support surface associated with a heat exchanger unit not limited to such as an air cooled liquid chiller","A filter and kit assembly for securing to one or more intake surfaces associated with a V-shaped heat exchanger unit. A screen includes a reinforced edge, within which is configured a plurality of spaced apart grommets aligning with and receiving therethrough engaging portions of the fasteners. In one variant, a frame is constructed for supporting the fasteners and attached filter and which is subsequently secured by clips against a flange surface surrounding the intake opening. In a further variant, the screen is configured in wrap-around fashion for supporting against first and second consecutively arranged intake openings along with an interconnecting intermediate flange surface.",THE NEWWAY COMPANY,SIMMONS RANDY;;GRENVILLE JOHN GORDON;;BELL STEVEN GEORGE,THE NEWWAY COMPANY (2021-03-01),https://lens.org/147-900-572-082-65X,Granted Patent,yes,32,0,6,6,0,B01D46/0005;;B01D46/10;;B01D46/005;;B01D35/02;;B01D46/001;;B01D46/10;;B01D46/001;;B01D46/0005;;B01D46/10,B01D46/00;;B01D46/10,,1,0,,,"International Search Report and Written Opinion issued by the Korean Intellectual Property Office acting as International Searching Authority for International Patent Application No. PCT/US2021/020584 dated Jun. 18, 2021 (9 pages in total).",ACTIVE
38,GB,A8,GB 2610706 A8,118-016-682-564-482,2023-03-29,2023,GB 202214379 A,2021-03-03,US 2021/0020584 W;;US 202062984472 P;;US 202117189680 A,2020-03-03,"Filter kit, assembly, and method for installation within a support surface associated with a heat exchanger unit not limited to such as an air cooled liquid chiller","A filter and kit assembly for securing to one or more intake surfaces associated with a V-shaped heat exchanger unit. A screen includes a reinforced edge, within which is configured a plurality of spaced apart grommets aligning with and receiving therethrough engaging portions of the fasteners. In one variant, a frame is constructed for supporting the fasteners and attached filter and which is subsequently secured by clips against a flange surface surrounding the intake opening. In a further variant, the screen is configured in wrap-around fashion for supporting against first and second consecutively arranged intake openings along with an interconnecting intermediate flange surface.",THE NEWWAY COMPANY,RANDY SIMMONS;;JOHN GORDON GRENVILLE;;STEVEN GEORGE BELL,,https://lens.org/118-016-682-564-482,Patent Application,no,0,0,6,6,0,B01D46/0005;;B01D46/10;;B01D46/005;;B01D35/02;;B01D46/001;;B01D46/10;;B01D46/001;;B01D46/0005;;B01D46/10,F28F19/01;;B01D35/02;;F28D1/053;;F28F9/007,,0,0,,,,PENDING
39,US,A1,US 2006/0277072 A1,067-710-526-287-710,2006-12-07,2006,US 14580505 A,2005-06-06,US 14580505 A,2005-06-06,System for creating a medical chart,A system of creating and maintaining medical records provides a central monitoring system for a patient-care facility. The system can include a real-time medical charting interface for consistent and objective patient data entry and logging the time identification of patient data entry. The interface can display real-time objective data and can include a first menu of first charting categories; a second menu populated with keywords based upon the charting category selected from the first menu; and a third menu populated with values for the keyword selected from the second menu. The menus can be concurrently presented for data entry allowing efficient charting of the patient's condition. Patient data can be digitized to be distributed on a network.,BELL CINDY;;SELL KIM;;PAUL RANDY;;MEDRANO OCTAVIO,BELL CINDY;;SELL KIM;;PAUL RANDY;;MEDRANO OCTAVIO,CLINICAL COMPUTER SYSTEMS INC (2005-05-20),https://lens.org/067-710-526-287-710,Patent Application,yes,6,12,1,1,0,G16H10/60;;G16H10/60;;G16H15/00;;G16H15/00;;G16H40/63;;G16H40/63,G06F19/00,705/3,0,0,,,,DISCONTINUED
40,US,A,US 4773488 A,183-191-106-541-472,1988-09-27,1988,US 63883084 A,1984-08-08,US 63883084 A,1984-08-08,Development well drilling,"A method for development drilling in a mineral producing field such as an oil and gas field wherein a plurality of wellbores are drilled in the earth through at least one mineral containing subsurface geologic formation, the plurality of wellbores being drilled from a central drill site radially outwardly therefrom wherein the wellbores are drilled at varying angles from vertical within the range of from about 30 to about 87.5 degrees from vertical, the wellbores passing through at least one formation at an angle from vertical.",ATLANTIC RICHFIELD CO,BELL LARRY N;;RUEDRICH RANDY A;;SCHUH FRANK J,ATLANTIC RICHFIELD COMPANY (1984-07-26);;PHILLIPS PETROLEUM COMPANY (2001-09-20),https://lens.org/183-191-106-541-472,Granted Patent,yes,4,23,2,2,0,E21B7/04;;E21B43/305;;E21B43/305;;E21B7/04,E21B7/04;;E21B43/30,175/61,2,0,,,"Russia Gang Drills , Oil and Gas Journal , Dec. 10, 1956, p. 105.;;Wells Drilled with Horizontal Drain Holes , The Petroleum Engineer , Feb. 1947, pp. 174 180.",EXPIRED
41,US,B2,US 10986160 B2,133-039-819-959-617,2021-04-20,2021,US 202016782494 A,2020-02-05,US 202016782494 A;;US 201514819043 A;;US 201462033497 P,2014-08-05,Systems and methods for client-side contextual engagement,"Disclosed is a new approach for client-side contextual engagement with a website visitor. A browser loads a page containing a reference to a script file implementing a visitor client. The visitor client may store visitor client data including site rules and a visitor profile locally on the client device. The visitor client may include a context monitor for calling the decision engine, a decision engine for evaluating the site rules relative to a context defined at least partially by events occurring on the page and the visitor profile, and a widget manager for managing visitor client data persisted on the client device. The content monitor may call the decision engine when the context changes. The decision engine may determine, in real time and relative to the context, that proactive or reactive engagement(s) may be appropriate and call the widget manager to launch and display corresponding engagement channel(s) on the page.",MOXIE SOFTWARE INC,GALLOWAY MICHAEL;;NASSON RANDY;;BELL JONATHAN LEE;;POLLOCK JONATHAN,MOXIE SOFTWARE INC (2015-07-03),https://lens.org/133-039-819-959-617,Granted Patent,yes,37,2,7,12,0,H04L67/02;;H04L67/60;;H04L67/60;;H04L67/02,G06F15/16;;H04L29/08,,13,0,,,"International Search Report and Written Opinion issued for PCT Patent Application No. PCT/US2015/043820, dated Oct. 28, 2015, 10 pages.;;International Search Report and Written Opinion issued for PCT Patent Application No. PCT/US2015/064745, dated Feb. 12, 2016, 8 pages.;;Office Action issued for U.S. Appl. No. 14/206,432, dated Mar. 10, 2016, 11 pages.;;International Preliminary Report on Patentability issued for PCT Application No. PCT/US2015/043820, dated Feb. 16, 2017, 9 pages.;;International Preliminary Report on Patentability issued for PCT Application No. PCT/US2015/064745, dated Jun. 22, 2017, 7 pages.;;Office Action issued for U.S. Appl. No. 14/819,043, dated Sep. 19, 2017, 21 pages.;;Office Action issued for U.S. Appl. No. 14/964,008, dated Oct. 17, 2017, 18 pages.;;Office Action issued for U.S. Appl. No. 14/819,043, dated Feb. 15, 2018, 30 pages.;;Office Action issued for U.S. Appl. No. 14/964,008, dated May 22, 2018, 22 pages.;;Office Action for U.S. Appl. No. 14/819,043, dated Feb. 25, 2019, 32 pgs.;;Office Action for U.S. Appl. No. 14/819,043, dated Jun. 18, 2019, 31 pgs.;;Notice of Allowance for U.S. Appl. No. 14/819,043, dated Oct. 29, 2019, 7 pgs.;;Office Action issued for U.S. Appl. No. 16/533,887, dated Jan. 21, 2021, 23 pages.",ACTIVE
42,CA,A,CA 1255288 A,007-167-014-238-773,1989-06-06,1989,CA 474832 A,1985-02-21,US 63883084 A,1984-08-08,DEVELOPMENT WELL DRILLING,"Abstract A method for development drilling in a mineral produc-ing field such as an oil and gas field wherein a plurality of wellbores are drilled in the earth through at least one mineral containing subsurface geologic formation, the plurality of wellbores being drilled from a central drill site radially outwardly therefrom wherein said wellbores are drilled at varying angles from vertical within the range of from about 30 to about 87.5 degrees from vertical, said wellbores passing through said at least one formation at said angle from vertical.",ATLANTIC RICHFIELD CO,BELL LARRY N;;RUEDRICH RANDY A;;SCHUH FRANK J,,https://lens.org/007-167-014-238-773,Granted Patent,no,0,0,2,2,0,E21B7/04;;E21B43/305;;E21B43/305;;E21B7/04,E21B7/04;;E21B43/30,255-6,0,0,,,,EXPIRED
43,US,A1,US 2016/0044083 A1,023-755-935-593-412,2016-02-11,2016,US 201514819043 A,2015-08-05,US 201514819043 A;;US 201462033497 P,2014-08-05,SYSTEMS AND METHODS FOR CLIENT-SIDE CONTEXTUAL ENGAGEMENT,"Disclosed is a new approach for client-side contextual engagement with a website visitor. A browser loads a page containing a reference to a script file implementing a visitor client. The visitor client may store visitor client data including site rules and a visitor profile locally on the client device. The visitor client may include a context monitor for calling the decision engine, a decision engine for evaluating the site rules relative to a context defined at least partially by events occurring on the page and the visitor profile, and a widget manager for managing visitor client data persisted on the client device. The content monitor may call the decision engine when the context changes. The decision engine may determine, in real time and relative to the context, that proactive or reactive engagement(s) may be appropriate and call the widget manager to launch and display corresponding engagement channel(s) on the page.",MOXIE SOFTWARE INC,GALLOWAY MICHAEL;;NASSON RANDY;;BELL JONATHAN LEE;;POLLOCK JONATHAN,MOXIE SOFTWARE INC. (2015-07-03),https://lens.org/023-755-935-593-412,Patent Application,yes,5,27,7,12,0,H04L67/02;;H04L67/60;;H04L67/60;;H04L67/02,H04L29/08,,0,0,,,,ACTIVE
44,US,A,US 5337979 A,055-107-733-237-343,1994-08-16,1994,US 82996192 A,1992-02-03,US 82996192 A;;US 80940591 A,1991-12-18,Track fitting for aircraft seats,"A seat leg and track fitting assembly for removably securing a seat to a generally channel-shaped track secured to the fuselage of an aircraft. The track fitting assembly includes a forged body member having a narrow finger portion; a plurality of spaced track lugs projecting laterally from the narrow finger portion, and an enlarged boss portion having a recess formed therein. The recess extends through the narrow finger portion to form a pair of shoulders adjacent opposite sides of the recess and a plunger has surfaces positioned between the shoulders such that the shoulders limit movement of the plunger. An actuating arm is secured to the plungers in each of a plurality of track fitting assemblies to move the plungers in the recesses between first positions wherein the lower ends of the plungers are positioned adjacent the lower edge of the narrow finger portion of each body and an elevated position wherein the plungers are retracted from the track.",WEBER AIRCRAFT INC,BALES RANDY J;;GILBERT KLAY E;;BELL STEVEN R,WEBER AIRCRAFT INC (1992-01-24),https://lens.org/055-107-733-237-343,Granted Patent,yes,23,65,1,3,0,B64D11/0696;;B64D11/0696,B64D11/06,244/118.1;;248/503.1;;410/105;;410/115;;244/118.6;;X244122R,0,0,,,,EXPIRED
45,US,B2,US 10587672 B2,134-683-929-780-793,2020-03-10,2020,US 201514819043 A,2015-08-05,US 201514819043 A;;US 201462033497 P,2014-08-05,Systems and methods for client-side contextual engagement,"Disclosed is a new approach for client-side contextual engagement with a website visitor. A browser loads a page containing a reference to a script file implementing a visitor client. The visitor client may store visitor client data including site rules and a visitor profile locally on the client device. The visitor client may include a context monitor for calling the decision engine, a decision engine for evaluating the site rules relative to a context defined at least partially by events occurring on the page and the visitor profile, and a widget manager for managing visitor client data persisted on the client device. The content monitor may call the decision engine when the context changes. The decision engine may determine, in real time and relative to the context, that proactive or reactive engagement(s) may be appropriate and call the widget manager to launch and display corresponding engagement channel(s) on the page.",MOXIE SOFTWARE INC,GALLOWAY MICHAEL;;NASSON RANDY;;BELL JONATHAN LEE;;POLLOCK JONATHAN,MOXIE SOFTWARE INC. (2015-07-03),https://lens.org/134-683-929-780-793,Granted Patent,yes,35,3,7,12,0,H04L67/02;;H04L67/60;;H04L67/60;;H04L67/02,G06F15/16;;H04L29/08,,8,0,,,"International Preliminary Report on Patentability issued for PCT Application No. PCT/US2015/043820, dated Feb. 16, 2017, 9 pages.;;International Search Report and Written Opinion issued for PCT Patent Application No. PCT/US2015/043820, dated Oct. 28, 2015, 10 pages.;;Office Action issued for U.S. Appl. No. 14/206,432, dated Mar. 10, 2016, 11 pages.;;International Search Report and Written Opinion issued for PCT Patent Application No. PCT/US2015/064745, dated Feb. 12, 2016, 8 pages.;;International Preliminary Report on Patentability issued for PCT Application No. PCT/US2015/064745, dated Jun. 22, 2017, 7 pages.;;Office Action issued for U.S. Appl. No. 14/964,008, dated Oct. 17, 2017, 18 pages.;;Office Action issued for U.S. Appl. No. 14/964,008, dated May 22, 2018, 22 pages.;;Notice of Allowance for U.S. Appl. No. 14/964,008, dated May 15, 2019, 7 pgs.",ACTIVE
46,US,A1,US 2020/0177666 A1,087-420-340-434-241,2020-06-04,2020,US 202016782494 A,2020-02-05,US 202016782494 A;;US 201514819043 A;;US 201462033497 P,2014-08-05,SYSTEMS AND METHODS FOR CLIENT-SIDE CONTEXTUAL ENGAGEMENT,"Disclosed is a new approach for client-side contextual engagement with a website visitor. A browser loads a page containing a reference to a script file implementing a visitor client. The visitor client may store visitor client data including site rules and a visitor profile locally on the client device. The visitor client may include a context monitor for calling the decision engine, a decision engine for evaluating the site rules relative to a context defined at least partially by events occurring on the page and the visitor profile, and a widget manager for managing visitor client data persisted on the client device. The content monitor may call the decision engine when the context changes. The decision engine may determine, in real time and relative to the context, that proactive or reactive engagement(s) may be appropriate and call the widget manager to launch and display corresponding engagement channel(s) on the page.",MOXIE SOFTWARE INC,GALLOWAY MICHAEL;;NASSON RANDY;;BELL JONATHAN LEE;;POLLOCK JONATHAN,,https://lens.org/087-420-340-434-241,Patent Application,yes,0,2,7,12,0,H04L67/02;;H04L67/60;;H04L67/60;;H04L67/02,H04L29/08,,0,0,,,,ACTIVE
47,WO,A1,WO 2016/022693 A1,025-627-938-855-621,2016-02-11,2016,US 2015/0043820 W,2015-08-05,US 201462033497 P,2014-08-05,SYSTEMS AND METHODS FOR CLIENT-SIDE CONTEXTUAL ENGAGEMENT,"Disclosed is a new approach for client-side contextual engagement with a website visitor. A browser loads a page containing a reference to a script file implementing a visitor client. The visitor client may store visitor client data including site rules and a visitor profile locally on the client device. The visitor client may include a context monitor for calling the decision engine, a decision engine for evaluating the site rules relative to a context defined at least partially by events occurring on the page and the visitor profile, and a widget manager for managing visitor client data persisted on the client device. The content monitor may call the decision engine when the context changes. The decision engine may determine, in real time and relative to the context, that proactive or reactive engagement(s) may be appropriate and call the widget manager to launch and display corresponding engagement channel(s) on the page.",MOXIE SOFTWARE INC,GALLOWAY MICHAEL;;NASSON RANDY;;BELL JONATHAN LEE;;POLLOCK JONATHAN,,https://lens.org/025-627-938-855-621,Patent Application,yes,4,0,7,12,0,H04L67/02;;H04L67/60;;H04L67/60;;H04L67/02,G06F15/16,,0,0,,,,PENDING
48,US,S,US D0333420 S,045-052-901-165-994,1993-02-23,1993,US 80940591 F,1991-12-18,US 80940591 F,1991-12-18,Track fitting for vehicle seats,,WEBER AIRCRAFT INC,BALES RANDY J;;GILBERT KLAY E;;BELL STEVEN R,WEBER AIRCRAFT INC. A CORP. OF DELAWARE (1991-12-10),https://lens.org/045-052-901-165-994,Design Right,yes,20,8,1,1,0,,,D 8349,0,0,,,,EXPIRED
49,US,A1,US 2021/0234916 A1,153-348-834-842-200,2021-07-29,2021,US 202117230903 A,2021-04-14,US 201462033497 P;;US 202117230903 A;;US 202016782494 A;;US 201514819043 A,2014-08-05,SYSTEMS AND METHODS FOR CLIENT-SIDE CONTEXTUAL ENGAGEMENT,"Disclosed is a new approach for client-side contextual engagement with a website visitor. A browser loads a page containing a reference to a script file implementing a visitor client. The visitor client may store visitor client data including site rules and a visitor profile locally on the client device. The visitor client may include a context monitor for calling the decision engine, a decision engine for evaluating the site rules relative to a context defined at least partially by events occurring on the page and the visitor profile, and a widget manager for managing visitor client data persisted on the client device. The content monitor may call the decision engine when the context changes. The decision engine may determine, in real time and relative to the context, that proactive or reactive engagement(s) may be appropriate and call the widget manager to launch and display corresponding engagement channel(s) on the page.",MOXIE SOFTWARE INC,GALLOWAY MICHAEL;;NASSON RANDY;;BELL JONATHAN LEE;;POLLOCK JONATHAN,MOXIE SOFTWARE INC (2015-07-03),https://lens.org/153-348-834-842-200,Patent Application,yes,2,1,7,12,0,H04L67/02;;H04L67/60;;H04L67/60;;H04L67/02,H04L29/08,,0,0,,,,ACTIVE
50,US,B2,US 11689603 B2,173-514-243-255-203,2023-06-27,2023,US 202117230903 A,2021-04-14,US 201462033497 P;;US 202117230903 A;;US 202016782494 A;;US 201514819043 A,2014-08-05,Systems and methods for client-side contextual engagement,"Disclosed is a new approach for client-side contextual engagement with a website visitor. A browser loads a page containing a reference to a script file implementing a visitor client. The visitor client may store visitor client data including site rules and a visitor profile locally on the client device. The visitor client may include a context monitor for calling the decision engine, a decision engine for evaluating the site rules relative to a context defined at least partially by events occurring on the page and the visitor profile, and a widget manager for managing visitor client data persisted on the client device. The content monitor may call the decision engine when the context changes. The decision engine may determine, in real time and relative to the context, that proactive or reactive engagement(s) may be appropriate and call the widget manager to launch and display corresponding engagement channel(s) on the page.",MOXIE SOFTWARE INC,GALLOWAY MICHAEL;;NASSON RANDY;;BELL JONATHAN LEE;;POLLOCK JONATHAN,MOXIE SOFTWARE INC (2015-07-03),https://lens.org/173-514-243-255-203,Granted Patent,yes,44,0,7,12,0,H04L67/02;;H04L67/60;;H04L67/60;;H04L67/02,H04L67/02;;H04L67/60,,15,0,,,"International Search Report and Written Opinion issued for PCT Patent Application No. PCT/US2015/043820, dated Oct. 28, 2015, 10 pages.;;International Search Report and Written Opinion issued for PCT Patent Application No. PCT/US2015/064745, dated Feb. 12, 2016, 8 pages.;;Office Action issued for U.S. Appl. No. 14/206,432, dated Mar. 10, 2016, 11 pages.;;International Preliminary Report on Patentability issued for PCT Application No. PCT/US2015/043820, dated Feb. 16, 2017, 9 pages.;;International Preliminary Report on Patentability issued for PCT Application No. PCT/US2015/064745, dated Jun. 22, 2017, 7 pages.;;Office Action issued for U.S. Appl. No. 14/819,043, dated Sep. 19, 2017, 21 pages.;;Office Action issued for U.S. Appl. No. 14/964,008, dated Oct. 17, 2017, 18 pages.;;Office Action issued for U.S. Appl. No. 14/819,043, dated Feb. 15, 2018, 30 pages.;;Office Action issued for U.S. Appl. No. 14/964,008, dated May 22, 2018, 22 pages.;;Office Action for U.S. Appl. No. 14/819,043, dated Feb. 25, 2019, 32 pages.;;Notice of Allowance for U.S. Appl. No. 14/964,008, dated May 15, 2019, 7 pages.;;Office Action for U.S. Appl. No. 14/819,043, dated Jun. 18, 2019, 31 pages.;;Notice of Allowance for U.S. Appl. No. 14/819,043, dated Oct. 29, 2019, 7 pages.;;Notice of Allowance issued for U.S. Appl. No. 16/782,494, dated Dec. 4, 2020, 21 pages.;;Office Action issued for U.S. Appl. No. 16/533,887, dated Jan. 21, 2021, 23 pages.",ACTIVE
51,US,A1,US 2006/0019583 A1,065-788-895-529-76X,2006-01-26,2006,US 89967804 A,2004-07-26,US 89967804 A,2004-07-26,Method and apparatus for conditioning a polishing pad,"A method and apparatus for polishing a thin film on a semiconductor substrate is described. A polishing pad is rotated and a wafer to be polished is placed on the rotating polishing pad. The polishing pad has grooves that channels slurry between the wafer and polishing pad and rids excess material from the wafer, allowing an efficient polishing of the surface of the wafer. The polishing pad smoothes out due to the polishing of the wafer and must be conditioned to restore effectiveness. A conditioning assembly with a plurality of diamonds is provided. The diamonds have predetermined angles that provide strength to the diamond. This allows for an optimal rotation speed and downward force in effective conditioning of the polishing pad, while reducing diamond fracture rate.",SKOCYPEC RANDY S;;LA BELL ADAM P;;WHISLER WADE R,SKOCYPEC RANDY S;;LA BELL ADAM P;;WHISLER WADE R,INTEL CORPORATION (2004-09-30),https://lens.org/065-788-895-529-76X,Patent Application,yes,16,0,12,12,0,B24B53/017;;B24B53/017;;B24B53/12;;B24B53/12,B24B1/00;;B24B53/007;;B24B53/12,451/56,0,0,,,,INACTIVE
52,US,A1,US 2006/0019584 A1,153-524-138-726-273,2006-01-26,2006,US 11032705 A,2005-04-19,US 11032705 A;;US 89967804 A,2004-07-26,Method and apparatus for conditioning a polishing pad,"A method and apparatus for polishing a thin film on a semiconductor substrate is described. A polishing pad is rotated and a wafer to be polished is placed on the rotating polishing pad. The polishing pad has grooves that channels slurry between the wafer and polishing pad and rids excess material from the wafer, allowing an efficient polishing of the surface of the wafer. The polishing pad smoothes out due to the polishing of the wafer and must be conditioned to restore effectiveness. A conditioning assembly with a plurality of diamonds is provided. The diamonds have predetermined angles that provide strength to the diamond. This allows for an optimal rotation speed and downward force in effective conditioning of the polishing pad, while reducing diamond fracture rate.",SKOCYPEC RANDY S;;LA BELL ADAM P;;WHISLER WADE R,SKOCYPEC RANDY S;;LA BELL ADAM P;;WHISLER WADE R,,https://lens.org/153-524-138-726-273,Patent Application,yes,16,2,12,12,0,B24B53/017;;B24B53/017;;B24B53/12;;B24B53/12,B24B1/00;;B24B53/007;;B24B53/12,451/56,0,0,,,,INACTIVE
53,TW,B,TW I298667 B,175-373-308-399-870,2008-07-11,2008,TW 94123925 A,2005-07-14,US 89967804 A,2004-07-26,A method and apparatus for conditioning a polishing pad,,INTEL CORP,SKOCYPEC RANDY S;;LA BELL ADAM P;;WHISLER WADE R,,https://lens.org/175-373-308-399-870,Granted Patent,no,0,7,12,12,0,B24B53/017;;B24B53/017;;B24B53/12;;B24B53/12,B24B53/007,,0,0,,,,INACTIVE
54,US,B2,US 7097542 B2,069-564-328-515-540,2006-08-29,2006,US 89967804 A,2004-07-26,US 89967804 A,2004-07-26,Method and apparatus for conditioning a polishing pad,"A method and apparatus for polishing a thin film on a semiconductor substrate is described. A polishing pad is rotated and a wafer to be polished is placed on the rotating polishing pad. The polishing pad has grooves that channels slurry between the wafer and polishing pad and rids excess material from the wafer, allowing an efficient polishing of the surface of the wafer. The polishing pad smoothes out due to the polishing of the wafer and must be conditioned to restore effectiveness. A conditioning assembly with a plurality of diamonds is provided. The diamonds have predetermined angles that provide strength to the diamond. This allows for an optimal rotation speed and downward force in effective conditioning of the polishing pad, while reducing diamond fracture rate.",INTEL CORP,SKOCYPEC RANDY S;;LA BELL ADAM P;;WHISLER WADE R,INTEL CORPORATION (2004-09-30),https://lens.org/069-564-328-515-540,Granted Patent,yes,17,3,12,12,0,B24B53/017;;B24B53/017;;B24B53/12;;B24B53/12,B24B1/00;;B24B21/18;;B24B33/00;;B24B53/007;;B24B53/12,451/56;;451/443;;451/444,2,0,,,"Rohm Haas, DiaGrid Pad Conditioners, Mar. 2005.;;PCT Int'l. Search Report, Int'l. Application No. PCT/US2005/024890, Int'l. filing date Jul. 15, 2005, mailing date Oct. 13, 2005, 12 pages.",INACTIVE
55,US,B2,US 7175510 B2,070-830-914-290-30X,2007-02-13,2007,US 11032705 A,2005-04-19,US 11032705 A;;US 89967804 A,2004-07-26,Method and apparatus for conditioning a polishing pad,"A method and apparatus for polishing a thin film on a semiconductor substrate is described. A polishing pad is rotated and a wafer to be polished is placed on the rotating polishing pad. The polishing pad has grooves that channels slurry between the wafer and polishing pad and rids excess material from the wafer, allowing an efficient polishing of the surface of the wafer. The polishing pad smoothes out due to the polishing of the wafer and must be conditioned to restore effectiveness. A conditioning assembly with a plurality of diamonds is provided. The diamonds have predetermined angles that provide strength to the diamond. This allows for an optimal rotation speed and downward force in effective conditioning of the polishing pad, while reducing diamond fracture rate.",INTEL CORP,SKOCYPEC RANDY S;;LA BELL ADAM P;;WHISLER WADE R,,https://lens.org/070-830-914-290-30X,Granted Patent,yes,17,6,12,12,0,B24B53/017;;B24B53/017;;B24B53/12;;B24B53/12,B24B1/00;;B24B5/00;;B24B21/18;;B24B29/00;;B24B33/00;;B24B47/26;;B24B53/007;;B24B53/12;;B24B55/00,451/56;;451/443;;451/285;;451/286;;451/287;;451/288,2,0,,,"Rohm Haas, DiaGrid Pad Conditioners, Mar. 2005.;;PCT Int'l. Search Report, Int'l. Application No. PCT/US2005/024890, Int'l. filing date Jul. 15, 2005, mailing date Oct. 13, 2005, 12 pages.",INACTIVE
56,TW,A,TW 200603945 A,090-014-300-574-017,2006-02-01,2006,TW 94123925 A,2005-07-14,US 89967804 A,2004-07-26,A method and apparatus for conditioning a polishing pad,"A method and apparatus for polishing a thin film on a semiconductor substrate is described. A polishing pad is rotated and a wafer to be polished is placed on the rotating polishing pad. The polishing pad has grooves that channels slurry between the wafer and polishing pad and rids excess material from the wafer, allowing an efficient polishing of the surface of the wafer. The polishing pad smoothes out due to the polishing of the wafer and must be conditioned to restore effectiveness. A conditioning assembly with a plurality of diamonds is provided. The diamonds have predetermined angles that provide strength to the diamond. This allows for an optimal rotation speed and downward force in effective conditioning of the polishing pad, while reducing diamond fracture rate.",INTEL CORP,SKOCYPEC RANDY S;;LA BELL ADAM P;;WHISLER WADE R,,https://lens.org/090-014-300-574-017,Patent of Addition,no,0,0,12,12,0,B24B53/017;;B24B53/017;;B24B53/12;;B24B53/12,B24B53/12;;B24B37/04;;B24B53/007;;H01L21/304,,0,0,,,,INACTIVE
57,WO,A1,WO 1996/032377 A1,126-542-944-909-082,1996-10-17,1996,US 9603907 W,1996-03-22,US 42112595 A,1995-04-12,LIPOXYGENASE AND CYCLOOXYGENASE INHIBITING COMPOUNDS,"Compounds having the structure of general formula (I) or a pharmaceutically acceptable salt thereof have activity as inhibitors of cyclooxygenase and 5-lipoxygenase, reduce the biosynthesis of leukotrienes B4, C4, D4, and E4 and cyclooxygenase products such as prostaglandins and thromboxane and are useful in the treatment of inflammatory and allergic disease states. The compounds have the structure indicated above wherein A is selected from (a) optionally susbtituted carbocyclic aryl, (b) optionally substituted furyl, (c) optionally substituted benzo[b]furyl, (d) optionally substituted thienyl, (e) optionally substituted pyridyloxy, (f) optionally substituted pyridylalkyl, (g) optionally substituted benzo[b]thienyl, (h) optionally substituted pyridyl, (i) optionally substituted quinolyl, and (j) optionally substituted indolyl; X is selected from (a) optionally susbtituted alkyl, (b) optionally substituted alkenyl, and (c) optionally substituted alkynyl; R?1 and R2¿ are independently selected from hydrogen, hydroxy, and alkyl; and Z is a residue of a non-steroidal anti-inflammatory drug of the general formula Z-COOH.",ABBOTT LAB,BROOKS CLINT D W;;STEWART ANDREW O;;BASHA ANWER;;BELL RANDY L,,https://lens.org/126-542-944-909-082,Patent Application,yes,5,2,2,2,0,C07C275/64;;C07D307/52;;C07D333/20;;C07D333/58;;C07D409/12;;C07D409/12;;C07C275/64;;C07D333/20;;C07D307/52;;C07D333/58,C07C275/64;;C07D307/52;;C07D333/20;;C07D333/58;;C07D409/12,,0,0,,,,PENDING
58,US,A,US 5516789 A,104-638-628-848-546,1996-05-14,1996,US 42112595 A,1995-04-12,US 42112595 A,1995-04-12,Lipoxygenase and cyclooxygenase inhibiting compounds,"Compounds having the structure ##STR1## or a pharmaceutically acceptable salt thereof have activity as inhibitors of cylooxygenase and 5-lipoxygenase, reduce the biosynthesis of leukotrienes B.sub.4, C.sub.4, D.sub.4, and E.sub.4 and cylooxygenase products such as prostaglandins and thromboxane and are useful in the treatment of inflammatory and allergic disease states. The compounds have the structure indicated above wherein A is selected from (a) optinally substituted carbocyclic aryl, (b) optinally substituted furyl, (c) optinally substituted benzo[b]furyl, (d) optinally substituted thienyl, (e) optinally substituted pyridyloxy, (f) optinally substituted pyridylalkyl, (g) optinally substituted benzo[b]thienyl, (h) optinally substituted pyridyl, (i) optinally substituted quinolyl, and (j) optinally substituted indolyl; X is selected from (a) optionally substituted alkyl, (b) optinally substituted alkenyl, and (c) optinally substituted alkynyl; R.sup.1 and R.sup.2 are independently selected from hydrogen, hydroxy, and alkyl; and Z is a residue of a non-steroidal anti-inflammatory drug of the general formula Z--COOH.",ABBOTT LAB,BROOKS CLINT D W;;STEWART ANDREW O;;BASHA ANWER;;BELL RANDY L,ABBOTT LABORATORIES (1995-04-12),https://lens.org/104-638-628-848-546,Granted Patent,yes,8,15,2,2,0,C07C275/64;;C07D307/52;;C07D333/20;;C07D333/58;;C07D409/12;;C07D409/12;;C07C275/64;;C07D333/20;;C07D307/52;;C07D333/58,C07C275/64;;C07D307/52;;C07D333/20;;C07D333/58;;C07D409/12,514/414;;514/224.8;;514/375;;514/406;;514/411;;514/416;;514/419;;514/427;;514/443;;514/445;;514/471;;514/595;;544/58.1;;548/224;;548/364.1;;548/375.1;;548/443;;548/445;;548/471;;548/472;;548/507;;548/526;;548/527;;548/561;;548/454;;564/56,0,0,,,,EXPIRED
59,US,A,US 4559535 A,153-630-770-086-037,1985-12-17,1985,US 39712782 A,1982-07-12,US 39712782 A,1982-07-12,System for displaying information with multiple shades of a color on a thin-film EL matrix display panel,"A plurality of memory sections is provided each storing binary data to be employed for refreshing picture elements of a thin-film EL matrix display panel on successive frame time periods constituting an integration time period. The number of frame time periods in an integration time period corresponds to the number of different shades to be displayed on the panel. The binary data stored in each of the memory sections differs. Thus, when the binary data in the memory sections are read out on successive frame time periods, some of the picture elements on the panel are refreshed more than others during the integration time period. Accordingly, the eye of the viewer receives more light from some picture elements than others during each integration time period which results in the relative brightness levels and, therefore, the shades of the picture elements to vary. In a modified embodiment of the present invention each of the memory sections is binarily weighted and, during an integration time period, each memory section is read out a number of frame time periods corresponding to its binary weight in order to obtain the different brightness levels or shades on the panel.",SIGMATRON NOVA INC,WATKINS RANDY W;;BELL ROBERT J;;MARTORANO JOSEPH A;;ESSINGER WALTER F,SIGMATRON NOVA INC (1985-09-17);;SIGMATRON ASSOCIATES A CALIF. LIMITED PARTNERSHIP (1982-07-07),https://lens.org/153-630-770-086-037,Granted Patent,yes,4,115,1,1,0,G09G3/30;;G09G3/30;;G09G3/2018;;G09G3/2018;;H04N3/12;;H04N3/12,G09G3/20;;G09G3/30;;H04N3/12,340/793;;340/781;;340/825.81;;358/241,0,0,,,,EXPIRED
60,DE,T5,DE 112009001835 T5,101-724-158-907-661,2011-07-21,2011,DE 112009001835 T,2009-06-26,US 18289808 A;;US 2009/0048742 W,2008-07-30,System und Verfahren zum Betreiben eines Gasturbinenantriebs mit einem alternativen Arbeitsfluid,"Verfahren zum Betreiben eines Turbinenantriebssystem, wobei das Verfahren aufweist: Zuführen einer Sauerstoffströmung zu einer Brennkammer, die in dem Turbinenantriebssystem definiert ist; Zuführen einer Strömung eines kohlenwasserstoffhaltigen Brennstoffs zu der Brennkammer; und Zuführen eines Arbeitsfluids zu einem Einlass des Turbinenantriebssystems, wobei das Arbeitsfluid im Wesentlichen stickstofffrei ist und wobei das Turbinenantriebssystem mit dem resultierenden Brennstoff-Sauerstoff-Arbeitsfluid-Gemisch betrieben werden kann.",GEN ELECTRIC;;UNIV WYOMING,FRANER MATTHEW;;LEWIS RANDY;;BELL DAVID;;ARGYLE MORRIS;;TOWLER BRIAN;;ACKERMANN JOHN FREDERICK,,https://lens.org/101-724-158-907-661,Patent Application,no,0,0,8,8,0,B01D2256/22;;B01D2257/80;;F02C3/20;;F02C3/34;;F05D2210/12;;F02C3/20;;F02C3/34;;F02C3/34;;B01D2256/22;;B01D2257/80;;F02C3/20;;F05D2210/12,F02C3/20;;F02C3/34,,0,0,,,,DISCONTINUED
61,US,B2,US 11175800 B2,050-636-229-001-86X,2021-11-16,2021,US 201916533887 A,2019-08-07,US 201916533887 A;;US 201514964008 A;;US 201462089680 P,2014-12-09,Element mapping and rule building systems and methods for contextual site visitor engagement,"A new element mapper is provided for mapping elements of a page using user-provided or automatically generated terms or names. Specifically, a user may direct an application displaying a page to enter into an in-context element mapping mode, in which page elements eligible for mapping may be identified and highlighted whenever one is moused or hovered over. Responsive to the user selecting a page element of interest, the element mapper may provide a dialog with an input field. The dialog may be displayed near the page element of interest or as part of the page. Based on a user-provided or automatically generated name, the element mapper may generate a mapping output and store it in association with a selector for the page element of interest. The mapping output can be used to build a site rule in context of the page element of interest.",MOXIE SOFTWARE INC,NASSON RANDY;;GALLOWAY MICHAEL;;WRIGHT PRESCOTT;;POLLOCK JONATHAN;;SHERMAN SHANE E;;BELL JONATHAN LEE,MOXIE SOFTWARE INC (2015-11-30),https://lens.org/050-636-229-001-86X,Granted Patent,yes,41,0,3,12,0,G06F3/0482;;G06F3/0483;;G06F3/0486;;G06F16/958;;H04L67/025,G06F3/0483;;G06F3/0486;;H04L29/08,,14,0,,,"International Search Report and Written Opinion for PCT Patent Application No. PCT/US2015/043820, dated Oct. 28, 2015, 10 pgs.;;International Search Report and Written Opinion for PCT Patent Application No. PCT/US2015/064745, dated Feb. 12, 2016, 8 pgs.;;Office Action for U.S. Appl. No. 14/206,432, dated Mar. 10, 2016, 11 pgs.;;International Preliminary Report on Patentability for PCT Application No. PCT/US2015/043820, dated Feb. 16, 2017, 9 pgs.;;International Preliminary Report on Patentability for PCT Application No. PCT/US2015/064745, dated Jun. 22, 2017, 7 pgs.;;Office Action for U.S. Appl. No. 14/819,043, dated Sep. 19, 2017, 21 pgs.;;Office Action for U.S. Appl. No. 14/964,008, dated Oct. 17, 2017, 18 pgs.;;Office Action for U.S. Appl. No. 14/819,043, dated Feb. 15, 2018, 30 pgs.;;Office Action for U.S. Appl. No. 14/964,008, dated May 22, 2018, 22 pgs.;;Office Action for U.S. Appl. No. 14/819,043, dated Feb. 25, 2019, 32 pgs.;;Notice of Allowance for U.S. Appl. No. 14/964,008, dated May 15, 2019, 7 pgs.;;Office Action for U.S. Appl. No. 14/819,043, dated Jun. 18, 2018, 31 pgs.;;Notice of Allowance for U.S. Appl. No. 14/819,043, dated Oct. 29, 2019, 7 pages.;;Notice of Allowance issued for U.S. Appl. No. 16/782,494, dated Dec. 4, 2020, 21 pages.",ACTIVE
62,WO,A1,WO 2016/094534 A1,018-614-346-539-469,2016-06-16,2016,US 2015/0064745 W,2015-12-09,US 201462089680 P,2014-12-09,ELEMENT MAPPING AND RULE BUILDING SYSTEMS AND METHODS FOR CONTEXTUAL SITE VISITOR ENGAGEMENT,"A new element mapper is provided for mapping elements of a page using user- provided or automatically generated terms or names. Specifically, a user may direct an application displaying a page to enter into an in-context element mapping mode, in which page elements eligible for mapping may be identified and highlighted whenever one is moused or hovered over. Responsive to the user selecting a page element of interest, the element mapper may provide a dialog with an input field. The dialog may be displayed near the page element of interest or as part of the page. Based on a user-provided or automatically generated name, the element mapper may generate a mapping output and store it in association with a selector for the page element of interest. The mapping output can be used to build a site rule in context of the page element of interest.",MOXIE SOFTWARE INC,NASSON RANDY;;GALLOWAY MICHAEL;;WRIGHT PRESCOTT;;POLLOCK JONATHAN;;SHERMAN SHANE E;;BELL JONATHAN LEE,,https://lens.org/018-614-346-539-469,Patent Application,yes,4,0,3,12,0,G06F3/0482;;G06F3/0483;;G06F3/0486;;G06F16/958;;H04L67/025,G06F3/0482;;G06F17/00;;G06F17/30,,0,0,,,,PENDING
63,US,A1,US 2020/0081593 A1,084-577-842-983-327,2020-03-12,2020,US 201916533887 A,2019-08-07,US 201916533887 A;;US 201514964008 A;;US 201462089680 P,2014-12-09,ELEMENT MAPPING AND RULE BUILDING SYSTEMS AND METHODS FOR CONTEXTUAL SITE VISITOR ENGAGEMENT,"A new element mapper is provided for mapping elements of a page using user-provided or automatically generated terms or names. Specifically, a user may direct an application displaying a page to enter into an in-context element mapping mode, in which page elements eligible for mapping may be identified and highlighted whenever one is moused or hovered over. Responsive to the user selecting a page element of interest, the element mapper may provide a dialog with an input field. The dialog may be displayed near the page element of interest or as part of the page. Based on a user-provided or automatically generated name, the element mapper may generate a mapping output and store it in association with a selector for the page element of interest. The mapping output can be used to build a site rule in context of the page element of interest.",MOXIESOFTWARE INC,NASSON RANDY;;GALLOWAY MICHAEL;;WRIGHT PRESCOTT;;POLLOCK JONATHAN;;SHERMAN SHANE E;;BELL JONATHAN LEE,MOXIE SOFTWARE INC (2015-11-30),https://lens.org/084-577-842-983-327,Patent Application,yes,0,4,3,12,0,G06F3/0482;;G06F3/0483;;G06F3/0486;;G06F16/958;;H04L67/025,G06F3/0483;;G06F3/0486;;H04L29/08,,0,0,,,,ACTIVE
64,US,A1,US 2016/0162140 A1,047-940-299-590-426,2016-06-09,2016,US 201514964008 A,2015-12-09,US 201514964008 A;;US 201462089680 P;;US 201514819043 A;;US 201462033497 P,2014-08-05,ELEMENT MAPPING AND RULE BUILDING SYSTEMS AND METHODS FOR CONTEXTUAL SITE VISITOR ENGAGEMENT,"A new element mapper is provided for mapping elements of a page using user-provided or automatically generated terms or names. Specifically, a user may direct an application displaying a page to enter into an in-context element mapping mode, in which page elements eligible for mapping may be identified and highlighted whenever one is moused or hovered over. Responsive to the user selecting a page element of interest, the element mapper may provide a dialog with an input field. The dialog may be displayed near the page element of interest or as part of the page. Based on a user-provided or automatically generated name, the element mapper may generate a mapping output and store it in association with a selector for the page element of interest. The mapping output can be used to build a site rule in context of the page element of interest.",MOXIE SOFTWARE INC,NASSON RANDY;;GALLOWAY MICHAEL;;WRIGHT PRESCOTT;;POLLOCK JONATHAN;;SHERMAN SHANE E;;BELL JONATHAN LEE,MOXIE SOFTWARE INC (2015-11-30),https://lens.org/047-940-299-590-426,Patent Application,yes,2,12,2,12,0,G06F9/451;;G06F9/451;;G06F9/45529;;G06F9/45529;;G06F16/958;;G06F16/958;;H04L67/34;;H04L67/34;;H04L67/02;;H04L67/02,G06F3/0483;;G06F3/0484;;H04L29/08,,0,0,,,,ACTIVE
65,US,B2,US 10425501 B2,089-345-136-825-910,2019-09-24,2019,US 201514964008 A,2015-12-09,US 201514964008 A;;US 201462089680 P;;US 201514819043 A;;US 201462033497 P,2014-08-05,Element mapping and rule building systems and methods for contextual site visitor engagement,"A new element mapper is provided for mapping elements of a page using user-provided or automatically generated terms or names. Specifically, a user may direct an application displaying a page to enter into an in-context element mapping mode, in which page elements eligible for mapping may be identified and highlighted whenever one is moused or hovered over. Responsive to the user selecting a page element of interest, the element mapper may provide a dialog with an input field. The dialog may be displayed near the page element of interest or as part of the page. Based on a user-provided or automatically generated name, the element mapper may generate a mapping output and store it in association with a selector for the page element of interest. The mapping output can be used to build a site rule in context of the page element of interest.",MOXIE SOFTWARE INC,NASSON RANDY;;GALLOWAY MICHAEL;;WRIGHT PRESCOTT;;POLLOCK JONATHAN;;SHERMAN SHANE E;;BELL JONATHAN LEE,MOXIE SOFTWARE INC (2015-11-30),https://lens.org/089-345-136-825-910,Granted Patent,yes,31,27,2,12,0,G06F9/451;;G06F9/451;;G06F9/45529;;G06F9/45529;;G06F16/958;;G06F16/958;;H04L67/34;;H04L67/34;;H04L67/02;;H04L67/02,G06F3/0483;;G06F3/0484;;G06F9/451;;G06F9/455;;G06F16/958;;H04L29/08,,7,0,,,"International Search Report and Written Opinion issued for PCT Patent Application No. PCT/US2015/064745, dated Feb. 12, 2016, 8 pages.;;International Preliminary Report on Patentability issued for PCT Application No. PCT/US2015/043820, dated Feb. 16, 2017, 9 pages.;;International Preliminary Report on Patentability issued for PCT Application No. PCT/US2015/064745, dated Jun. 22, 2017, 7 pages.;;Office Action issued for U.S. Appl. No. 14/819,043, dated Sep. 19, 2017, 21 pages.;;International Search Report and Written Opinion issued for PCT Patent Application No. PCT/US2015/043820, dated Oct. 28, 2015, 10 pages.;;Office Action issued for U.S. Appl. No. 14/206,432, dated Mar. 10, 2016, 11 pages.;;Office Action issued for U.S. Appl. No. 14/819,043, dated Feb. 15, 2018, 30 pages.",ACTIVE
66,US,S,US D0449553 S,044-796-712-285-888,2001-10-23,2001,US 13558001 F,2001-01-13,US 13558001 F,2001-01-13,Fashion scale,,SUNBEAM PRODUCTS INC,MONTAGNINO JAMES G;;WONG ANSON;;MURGUIA RICARDO;;CHATTERJEE MONIQUE;;HSU ELLIOTT;;HOLDERFIELD GREG;;BELL RANDY;;PETERSON DAN,SUNBEAM PRODUCTS INC (2001-03-03),https://lens.org/044-796-712-285-888,Design Right,yes,3,0,2,2,0,,,D10/92;;1004,0,0,,,,EXPIRED
67,US,S,US D0448691 S,006-456-679-221-313,2001-10-02,2001,US 13558101 F,2001-01-13,US 13558101 F,2001-01-13,Fashion scale,,SUNBEAM PRODUCTS INC,MONTAGNINO JAMES G;;WONG ANSON;;MURGUIA RICARDO;;CHATTERJEE MONIQUE;;HSU ELLIOTT;;HOLDERFIELD GREG;;BELL RANDY;;PETERSON DAN,SUNBEAM PRODUCTS INC (2001-03-03),https://lens.org/006-456-679-221-313,Design Right,yes,2,9,1,1,0,,,D10/92;;1004,0,0,,,,EXPIRED
68,CO,A2,CO 6331296 A2,142-072-620-972-444,2011-10-20,2011,CO 10134183 A,2010-10-28,US 12583408 P;;US 13428308 P;;US 19719108 P;;US 19900908 P,2008-04-29,INMUNOGLOBULINAS DE DOMINIO VARIABLE DUAL Y USOS DE LAS MISMAS,"La presente invención se relaciona con proteínas de unión multivalentes y multiespecíficas diseñadas, con los métodos de preparación y específicamente con sus usos en la prevención, diagnóstico y/o tratamiento de enfermedad.",ABBOTT LAB,GHAYUR TARIQ;;MORGAN-LAPPE SUSAN;;YING HUA;;BELL RANDY;;WANG JIEYI;;PHILLIPS ANDREW;;KINGSBURY GILIAN;;REILLY EDWARD,,https://lens.org/142-072-620-972-444,Patent Application,no,0,0,31,32,0,A61K2039/505;;C07K16/22;;C07K16/28;;C07K16/2863;;C07K16/32;;C07K2317/31;;C07K2317/64;;C07K2317/71;;C07K2317/73;;C07K2317/732;;C07K2317/734;;C07K2317/92;;C07K2319/00;;C07K16/468;;C07K2317/76;;Y10S435/81;;A61P1/04;;A61P1/14;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/06;;A61P11/16;;A61P13/02;;A61P13/08;;A61P13/12;;A61P15/02;;A61P15/08;;A61P17/02;;A61P17/04;;A61P17/06;;A61P17/14;;A61P19/02;;A61P19/04;;A61P19/06;;A61P19/08;;A61P19/10;;A61P21/00;;A61P21/02;;A61P21/04;;A61P25/00;;A61P25/04;;A61P25/08;;A61P25/10;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/24;;A61P25/28;;A61P25/30;;A61P25/32;;A61P27/02;;A61P27/16;;A61P29/00;;A61P3/14;;A61P31/00;;A61P31/04;;A61P31/08;;A61P31/14;;A61P31/16;;A61P31/18;;A61P31/22;;A61P33/00;;A61P33/02;;A61P33/06;;A61P35/00;;A61P35/02;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/00;;A61P43/00;;A61P5/00;;A61P5/14;;A61P5/18;;A61P5/50;;A61P7/02;;A61P7/04;;A61P7/06;;A61P9/04;;A61P9/06;;A61P9/08;;A61P9/10;;A61P9/12;;A61P9/14;;A61P3/10;;Y02A50/30;;A61K2039/505;;C07K16/22;;C07K16/28;;C07K16/2863;;C07K16/32;;C07K2317/31;;C07K2317/64;;C07K2317/71;;C07K2317/73;;C07K2317/732;;C07K2317/734;;C07K2317/92;;C07K2319/00;;Y02A50/30;;C07K16/468;;A61K39/39533;;A61K45/06;;C07K2317/565;;C07K2317/76;;G01N33/6872;;G01N33/74;;G01N2333/515;;G01N2333/705;;Y10S435/81,A61K39/00,,0,0,,,,DISCONTINUED
69,US,S,US D0449554 S,190-136-547-334-26X,2001-10-23,2001,US 13558201 F,2001-01-13,US 13558201 F,2001-01-13,Fashion scale,,SUNBEAM PRODUCTS INC,MONTAGNINO JAMES G;;WONG ANSON;;MURGUIA RICARDO;;CHATTERJEE MONIQUE;;HSU ELLIOTT;;HOLDERFIELD GREG;;BELL RANDY;;PETERSON DAN,SUNBEAM PRODUCTS INC (2001-03-03),https://lens.org/190-136-547-334-26X,Design Right,yes,1,0,2,2,0,,,D10/92;;1004,0,0,,,,EXPIRED
70,US,S,US D0449242 S,102-437-023-603-622,2001-10-16,2001,US 13557401 F,2001-01-13,US 13557401 F,2001-01-13,Fashion scale,,SUNBEAM PRODUCTS INC,MONTAGNINO JAMES G;;WONG ANSON;;MURGUIA RICARDO;;CHATTERJEE MONIQUE;;HSU ELLIOTT;;HOLDERFIELD GREG;;BELL RANDY;;PETERSON DAN,SUNBEAM PRODUCTS INC (2001-03-03),https://lens.org/102-437-023-603-622,Design Right,yes,2,0,2,2,0,,,D10/92;;1004,0,0,,,,EXPIRED
71,US,S,US D0448692 S,158-569-021-605-049,2001-10-02,2001,US 13558601 F,2001-01-13,US 13558601 F,2001-01-13,Fashion scale,,SUNBEAM PRODUCTS INC,MONTAGNINO JAMES G;;WONG ANSON;;MURGUIA RICARDO;;CHATTERJEE MONIQUE;;HSU ELLIOTT;;HOLDERFIELD GREG;;BELL RANDY;;PETERSON DAN,SUNBEAM PRODUCTS INC (2001-03-03),https://lens.org/158-569-021-605-049,Design Right,yes,2,0,2,2,0,,,D10/92;;1004,0,0,,,,EXPIRED
72,US,S,US D0449551 S,045-248-259-040-602,2001-10-23,2001,US 13553401 F,2001-01-13,US 13553401 F,2001-01-13,Fashion scale,,SUNBEAM PRODUCTS INC,MONTAGNINO JAMES G;;WONG ANSON;;MURGUIA RICARDO;;CHATTERJEE MONIQUE;;HSU ELLIOTT;;HOLDERFIELD GREG;;BELL RANDY;;PETERSON DAN,SUNBEAM PRODUCTS INC (2001-03-20),https://lens.org/045-248-259-040-602,Design Right,yes,1,0,2,2,0,,,D10/92;;1004,0,0,,,,EXPIRED
73,DE,T5,DE 112009001807 T5,125-191-278-724-634,2011-06-09,2011,DE 112009001807 T,2009-06-24,US 18284208 A;;US 2009/0048473 W,2008-07-30,System und Verfahren zum Betreiben eines Gasturbinenantriebs mit einem alternativen Arbeitsfluid,,GEN ELECTRIC;;UNIV WYOMING,ACKERMANN JOHN FREDERICK;;LEWIS RANDY LEE;;BELL DAVID ALLEN;;ARGYLE MORRIS DEE;;TOWLER BRAIN FRANCIS;;FRANER MATTHEW TIMOTHY,,https://lens.org/125-191-278-724-634,Patent Application,no,0,0,8,8,0,F02C3/22;;F02C3/34;;F05D2260/61;;F02C3/22;;F02C3/34;;F02C3/22;;F05D2260/61;;F02C3/34,F02C3/00;;F02C7/12,,0,0,,,,DISCONTINUED
74,DE,T5,DE 112009001834 T5,147-006-379-081-94X,2011-09-29,2011,DE 112009001834 T,2009-07-08,US 18283708 A;;US 2009/0049856 W,2008-07-30,System und Verfahren zum Betreiben eines Energieerzeugungssystems mit einem alternativen Arbeitsfluid,"Es werden ein Verfahren zum Betreiben eines Turbinenmaschinensystems und ein Turbinenmaschinensystem bereitgestellt. Das Verfahren weist Schritte der Zuführung eines Sauerstoffstroms zu einer Brennkammer, die in mehreren seriell miteinander in dem Turbinenmaschinensystem gekoppelten Turbinen definiert ist, der Zuführung eines Stroms von Kohlenwasserstoffbrennstoff zu den Brennkammern von jeder der mehreren Turbinen in dem Turbinenmaschinensystem und der Zuführung eines Arbeitsfluids zu einem Einlass einer ersten mit dem Turbinenmaschinensystem gekoppelten Turbinenmaschine auf, wobei das Arbeitsfluid im Wesentlichen stickstofffrei ist, und wobei jede von den in dem Turbinenmaschinensystem gekoppelten Turbinen mit dem sich ergebenden Brennstoff-Sauerstoff-Arbeitsfluid-Gemisch betrieben werden kann.",GEN ELECTRIC COMPANY N D GES D STAATES NEW YORK;;UNIV WYOMING,ACKERMANN JOHN FREDERICK;;FRANER MATTHEW TIMOTHY;;TOWLER BRIAN FRANCIS;;ARGYLE MORRIS DEE;;BELL DAVID ALLEN;;LEWIS RANDY LEE,,https://lens.org/147-006-379-081-94X,Patent Application,no,0,0,11,11,0,F02C3/34;;F01K21/04;;F02C3/34;;F02C3/34,F02C3/34;;F01K21/04,,0,0,,,,DISCONTINUED
75,CA,A1,CA 2732176 A1,030-367-816-587-211,2010-04-01,2010,CA 2732176 A,2009-06-24,US 18284208 A;;US 2009/0048473 W,2008-07-30,SYSTEM AND METHOD OF OPERATING A GAS TURBINE ENGINE WITH AN ALTERNATIVE WORKING FLUID,"A gas turbine engine system (100) is provided. The gas turbine engine includes a gas turbine engine (10) comprising at least one compressor (14,18,118), at least one combustion chamber (120) downstream from the at least one compressor, and at least one turbine (26,30) downstream from the at least one combustion chamber, the at least one combustion chamber coupled in flow communication to a source of hydrocarbonaceous fuel (130) and to a source of oxygen (132), the gas turbine engine operable with a working fluid (150) that is substantially nitrogen-free, an exhaust gas (108) conditioning system coupled between a discharge outlet of the gas turbine engine and an inlet of the gas turbine engine, the exhaust gas conditioning system receives all of the exhaust discharged from the gas turbine engine, and a sequestration chamber (142) for storing carbon dioxide, the sequestration chamber coupled to the gas turbine engine for receiving working fluid bled from the turbine upstream from the at least one combustion chamber.",GEN ELECTRIC;;UNIV WYOMING,ACKERMAN JOHN FREDERICK;;LEWIS RANDY LEE;;BELL DAVID ALLEN;;ARGYLE MORRIS DEE;;TOWLER BRIAN FRANCIS;;FRANER MATTHEW TIMOTHY,,https://lens.org/030-367-816-587-211,Patent Application,no,0,0,8,8,0,F02C3/22;;F02C3/34;;F05D2260/61;;F02C3/22;;F02C3/34;;F02C3/22;;F05D2260/61;;F02C3/34,F02C3/22;;F02C3/34;;F02C7/12,,0,0,,,,DISCONTINUED
76,WO,A1,WO 2010/039318 A1,069-982-409-102-862,2010-04-08,2010,US 2009/0049856 W,2009-07-08,US 18283708 A,2008-07-30,SYSTEM AND METHOD OF OPERATING A POWER GENERATION SYSTEM WITH AN ALTERNATIVE WORKING FLUID,"A method of operating a turbine engine system and a turbine engine system are provided. The method comprises supplying a flow of oxygen to a combustion chamber defined within a plurality of turbines coupled serially together within the turbine engine system, supplying a flow of hydrocarbonaceous fuel to the combustion chambers of each of the plurality of turbines in the turbine engine system, and supplying a working fluid to an inlet of a first turbine engine coupled within the turbine engine system, wherein the working fluid is substantially nitrogen-free and wherein each of the turbines coupled within the turbine engine system is operable with the resulting fuel-oxygen- working fluid mixture.",GEN ELECTRIC;;ACKERMAN JOHN FREDERICK;;FRANER MATTHEW TIMOTHY;;TOWLER BRIAN FRANCIS;;ARGYLE MORRIS DEE;;BELL DAVID ALLEN;;LEWIS RANDY LEE;;UNIV WYOMING WYOMING RES PRODU,ACKERMAN JOHN FREDERICK;;FRANER MATTHEW TIMOTHY;;TOWLER BRIAN FRANCIS;;ARGYLE MORRIS DEE;;BELL DAVID ALLEN;;LEWIS RANDY LEE,,https://lens.org/069-982-409-102-862,Patent Application,yes,4,0,11,11,0,F02C3/34;;F01K21/04;;F02C3/34;;F02C3/34,F01K21/04;;F02C3/34,,0,0,,,,PENDING
77,CA,A1,CA 2732273 A1,011-501-645-322-512,2010-04-08,2010,CA 2732273 A,2009-07-08,US 18283708 A;;US 2009/0049856 W,2008-07-30,SYSTEM AND METHOD OF OPERATING A POWER GENERATION SYSTEM WITH AN ALTERNATIVE WORKING FLUID,"A method of operating a turbine engine system and a turbine engine system are provided. The method comprises supplying a flow of oxygen to a combustion chamber defined within a plurality of turbines coupled serially together within the turbine engine system, supplying a flow of hydrocarbonaceous fuel to the combustion chambers of each of the plurality of turbines in the turbine engine system, and supplying a working fluid to an inlet of a first turbine engine coupled within the turbine engine system, wherein the working fluid is substantially nitrogen-free and wherein each of the turbines coupled within the turbine engine system is operable with the resulting fuel-oxygen- working fluid mixture.",GEN ELECTRIC;;UNIV WYOMING,ACKERMAN JOHN FREDERICK;;FRANER MATTHEW TIMOTHY;;TOWLER BRIAN FRANCIS;;ARGYLE MORRIS DEE;;BELL DAVID ALLEN;;LEWIS RANDY LEE,,https://lens.org/011-501-645-322-512,Patent Application,no,0,0,11,11,0,F02C3/34;;F01K21/04;;F02C3/34;;F02C3/34,F02C3/34;;F01K21/04,,0,0,,,,INACTIVE
78,US,A1,US 2010/0024381 A1,031-857-203-929-475,2010-02-04,2010,US 18283708 A,2008-07-30,US 18283708 A,2008-07-30,SYSTEM AND METHOD OF OPERATING A POWER GENERATION SYSTEM WITH AN ALTERNATIVE WORKING FLUID,"A method of operating a turbine engine system and a turbine engine system are provided. The method comprises supplying a flow of oxygen to a combustion chamber defined within a plurality of turbines coupled serially together within the turbine engine system, supplying a flow of hydrocarbonaccous fuel to the combustion chambers of each of the plurality of turbines in the turbine engine system, and supplying a working fluid to an inlet of a first turbine engine coupled within the turbine engine system, wherein the working fluid is substantially nitrogen-free and wherein each of the turbines coupled within the turbine engine system is operable with the resulting fuel-oxygen-working fluid mixture.",ACKERMANN JOHN FREDERICK;;FRANER MATTHEW TIMOTHY;;LEWIS RANDY LEE;;BELL DAVID ALLEN;;ARGYLE MORRIS DEE;;TOWLER BRIAN FRANCIS,ACKERMANN JOHN FREDERICK;;FRANER MATTHEW TIMOTHY;;LEWIS RANDY LEE;;BELL DAVID ALLEN;;ARGYLE MORRIS DEE;;TOWLER BRIAN FRANCIS,THE UNIVERSITY OF WYOMING (2009-02-06);;GENERAL ELECTRIC COMPANY (2009-07-01),https://lens.org/031-857-203-929-475,Patent Application,yes,29,35,11,11,0,F02C3/34;;F01K21/04;;F02C3/34;;F02C3/34,F02C6/02,60/39.17;;60/774;;60/39.5,0,0,,,,ACTIVE
79,GB,B,GB 2474389 B,077-560-887-923-358,2013-04-24,2013,GB 201100837 A,2009-07-08,US 2009/0049856 W;;US 18283708 A,2008-07-30,System and method of operating a power generation system with an alternative working fluid,,GEN ELECTRIC,ACKERMAN JOHN FREDERICK;;FRANER MATTHEW TIMOTHY;;TOWLER BRIAN FRANCIS;;ARGYLE MORRIS DEE;;BELL DAVID ALLEN;;LEWIS RANDY LEE,,https://lens.org/077-560-887-923-358,Granted Patent,no,5,0,11,11,0,F02C3/34;;F01K21/04;;F02C3/34;;F02C3/34,F02C3/34;;F01K21/04,,0,0,,,,INACTIVE
80,GB,A,GB 2474398 A,168-036-065-399-970,2011-04-13,2011,GB 201101287 A,2009-06-26,US 2009/0048742 W;;US 18289808 A,2008-07-30,System and method of operating a gas turbine engine with an alternate working fluid,A gas turbine engine system is provided. The gas turbine engine system includes a gas turbine engine and an exhaust gas conditioning system. The gas turbine engine includes at least one combustion chamber and at least one turbine down-stream from the combustion chamber. The combustion chamber is coupled in flow communication to a source of hydrocarbonaceous fuel and to a source of oxygen. The gas turbine engine is operable with a working fluid that is substantially nitrogen- free. The exhaust gas conditioning system is coupled between a discharge outlet of the gas turbine engine and an inlet of the gas turbine engine.,GEN ELECTRIC,FRANER MATTHEW TIMOTHY;;LEWIS RANDY LEE;;BELL DAVID ALLEN;;ARGYLE MORRIS DEE;;TOWLER BRIAN FRANCIS;;ACKERMAN JOHN FREDERICK,,https://lens.org/168-036-065-399-970,Patent Application,no,5,0,8,8,0,B01D2256/22;;B01D2257/80;;F02C3/20;;F02C3/34;;F05D2210/12;;F02C3/20;;F02C3/34;;F02C3/34;;B01D2256/22;;B01D2257/80;;F02C3/20;;F05D2210/12,F02C3/20;;F02C3/34,,0,0,,,,DISCONTINUED
81,WO,A3,WO 2010/036432 A3,170-573-790-017-854,2011-01-20,2011,US 2009/0048473 W,2009-06-24,US 18284208 A,2008-07-30,SYSTEM AND METHOD OF OPERATING GAS TURBINE ENGINE WITH AN ALTERNATIVE WORKING FLUID,"A gas turbine engine system (100) is provided. The gas turbine engine includes a gas turbine engine (10) comprising at least one compressor (14,18,118), at least one combustion chamber (22,120) downstream from the at least one compressor, and at least one turbine (26,30,122) downstream from the at least one combustion chamber, the at least one combustion chamber coupled in flow communication to a source of hydrocarbonaceous fuel (130) and to a source of oxygen (132), the gas turbine engine operable with a working fluid (150) that is substantially nitrogen-free, an exhaust gas (108) conditioning system (112) coupled between a discharge outlet of the gas turbine engine and an inlet of the gas turbine engine, the exhaust gas conditioning system receives all of the exhaust discharged from the gas turbine engine, and a sequestration chamber (142) for storing carbon dioxide, the sequestration chamber coupled to the gas turbine engine for receiving working fluid bled from the turbine upstream from the at least one combustion chamber.",GEN ELECTRIC;;UNIV WYOMING;;ACKERMANN JOHN FREDERICK;;LEWIS RANDY LEE;;BELL DAVID ALLEN;;ARGYLE MORRIS DEE;;TOWLER BRAIN FRANCIS;;FRANER MATTHEW TIMOTHY,ACKERMANN JOHN FREDERICK;;LEWIS RANDY LEE;;BELL DAVID ALLEN;;ARGYLE MORRIS DEE;;TOWLER BRAIN FRANCIS;;FRANER MATTHEW TIMOTHY,,https://lens.org/170-573-790-017-854,Search Report,yes,4,0,8,8,0,F02C3/22;;F02C3/34;;F05D2260/61;;F02C3/22;;F02C3/34;;F02C3/22;;F05D2260/61;;F02C3/34,F02C3/34;;F02C3/22,,0,0,,,,PENDING
82,WO,A2,WO 2010/036432 A2,020-808-791-273-344,2010-04-01,2010,US 2009/0048473 W,2009-06-24,US 18284208 A,2008-07-30,SYSTEM AND METHOD OF OPERATING GAS TURBINE ENGINE WITH AN ALTERNATIVE WORKING FLUID,"A gas turbine engine system (100) is provided. The gas turbine engine includes a gas turbine engine (10) comprising at least one compressor (14,18,118), at least one combustion chamber (120) downstream from the at least one compressor, and at least one turbine (26,30) downstream from the at least one combustion chamber, the at least one combustion chamber coupled in flow communication to a source of hydrocarbonaceous fuel (130) and to a source of oxygen (132), the gas turbine engine operable with a working fluid (150) that is substantially nitrogen-free, an exhaust gas (108) conditioning system coupled between a discharge outlet of the gas turbine engine and an inlet of the gas turbine engine, the exhaust gas conditioning system receives all of the exhaust discharged from the gas turbine engine, and a sequestration chamber (142) for storing carbon dioxide, the sequestration chamber coupled to the gas turbine engine for receiving working fluid bled from the turbine upstream from the at least one combustion chamber.",GEN ELECTRIC;;UNIV WYOMING;;ACKERMANN JOHN FREDERICK;;LEWIS RANDY LEE;;BELL DAVID ALLEN;;ARGYLE MORRIS DEE;;TOWLER BRAIN FRANCIS;;FRANER MATTHEW TIMOTHY,ACKERMANN JOHN FREDERICK;;LEWIS RANDY LEE;;BELL DAVID ALLEN;;ARGYLE MORRIS DEE;;TOWLER BRAIN FRANCIS;;FRANER MATTHEW TIMOTHY,,https://lens.org/020-808-791-273-344,Patent Application,yes,0,0,8,8,0,F02C3/22;;F02C3/34;;F05D2260/61;;F02C3/22;;F02C3/34;;F02C3/22;;F05D2260/61;;F02C3/34,F02C7/12;;F02C3/00,,0,0,,,,PENDING
83,GB,A,GB 2474389 A,036-578-692-928-229,2011-04-13,2011,GB 201100837 A,2009-07-08,US 2009/0049856 W;;US 18283708 A,2008-07-30,System and method of operating a power generation system with an alternative working fluid,"A method of operating a turbine engine system and a turbine engine system are provided. The method comprises supplying a flow of oxygen to a combustion chamber defined within a plurality of turbines coupled serially together within the turbine engine system, supplying a flow of hydrocarbonaceous fuel to the combustion chambers of each of the plurality of turbines in the turbine engine system, and supplying a working fluid to an inlet of a first turbine engine coupled within the turbine engine system, wherein the working fluid is substantially nitrogen-free and wherein each of the turbines coupled within the turbine engine system is operable with the resulting fuel-oxygen- working fluid mixture.",GEN ELECTRIC,ACKERMAN JOHN FREDERICK;;FRANER MATTHEW TIMOTHY;;TOWLER BRIAN FRANCIS;;ARGYLE MORRIS DEE;;BELL DAVID ALLEN;;LEWIS RANDY LEE,,https://lens.org/036-578-692-928-229,Patent Application,no,4,0,11,11,0,F02C3/34;;F01K21/04;;F02C3/34;;F02C3/34,F02C3/34;;F01K21/04,,0,0,,,,INACTIVE
84,US,B2,US 8806849 B2,048-304-374-161-998,2014-08-19,2014,US 18283708 A,2008-07-30,US 18283708 A,2008-07-30,System and method of operating a power generation system with an alternative working fluid,"A method of operating a turbine engine system and a turbine engine system are provided. The method comprises supplying a flow of oxygen to a combustion chamber defined within a plurality of turbines coupled serially together within the turbine engine system, supplying a flow of hydrocarbonaccous fuel to the combustion chambers of each of the plurality of turbines in the turbine engine system, and supplying a working fluid to an inlet of a first turbine engine coupled within the turbine engine system, wherein the working fluid is substantially nitrogen-free and wherein each of the turbines coupled within the turbine engine system is operable with the resulting fuel-oxygen-working fluid mixture.",ACKERMAN JOHN FREDERICK;;FRANER MATTHEW TIMOTHY;;LEWIS RANDY LEE;;BELL DAVID ALLEN;;ARGYLE MORRIS DEE;;TOWLER BRIAN FRANCIS;;UNIV WYOMING;;GEN ELECTRIC,ACKERMAN JOHN FREDERICK;;FRANER MATTHEW TIMOTHY;;LEWIS RANDY LEE;;BELL DAVID ALLEN;;ARGYLE MORRIS DEE;;TOWLER BRIAN FRANCIS,THE UNIVERSITY OF WYOMING (2009-02-06);;GENERAL ELECTRIC COMPANY (2009-07-01),https://lens.org/048-304-374-161-998,Granted Patent,yes,35,0,11,11,0,F02C3/34;;F01K21/04;;F02C3/34;;F02C3/34,F02C3/34;;F02C6/00;;F02C6/18,60/39.5;;60/39.52;;60/39.15,2,0,,,"International Search Report issued in connection with corresponding PCT Application No. PCT/ US2009/049856 on Feb. 23, 2010.;;Office Action from JP Application No. 20-521161 dated Jul. 23, 2013 along with unofficial English translation.",ACTIVE
85,GB,A,GB 2474399 A,025-564-578-702-625,2011-04-13,2011,GB 201101304 A,2009-06-24,US 2009/0048473 W;;US 18284208 A,2008-07-30,System and method of operating gas turbine engine with an alternative working fluid,"A gas turbine engine system (100) is provided. The gas turbine engine includes a gas turbine engine (10) comprising at least one compressor (14,18,118), at least one combustion chamber (120) downstream from the at least one compressor, and at least one turbine (26,30) downstream from the at least one combustion chamber, the at least one combustion chamber coupled in flow communication to a source of hydrocarbonaceous fuel (130) and to a source of oxygen (132), the gas turbine engine operable with a working fluid (150) that is substantially nitrogen-free, an exhaust gas (108) conditioning system coupled between a discharge outlet of the gas turbine engine and an inlet of the gas turbine engine, the exhaust gas conditioning system receives all of the exhaust discharged from the gas turbine engine, and a sequestration chamber (142) for storing carbon dioxide, the sequetration chamber coupled to the gas turbine engine for receiving working fluid bled from the turbine upstream from the at least one combustion chamber.",GEN ELECTRIC,ACKERMANN JOHN FREDERICK;;LEWIS RANDY LEE;;BELL DAVID ALLEN;;TOWLER BRIAN FRANCIS;;FRANER MATTHEW TIMOTHY;;ARGYLE MORRIS DEE,,https://lens.org/025-564-578-702-625,Patent Application,no,4,0,8,8,0,F02C3/22;;F02C3/34;;F05D2260/61;;F02C3/22;;F02C3/34;;F02C3/22;;F05D2260/61;;F02C3/34,F02C3/22;;F02C3/34,,0,0,,,,DISCONTINUED
86,CA,A1,CA 2732125 A1,095-625-456-917-658,2010-02-04,2010,CA 2732125 A,2009-06-26,US 18289808 A;;US 2009/0048742 W,2008-07-30,SYSTEM AND METHOD OF OPERATING A GAS TURBINE ENGINE WITH AN ALTERNATIVE WORKING FLUID,A gas turbine engine system is provided. The gas turbine engine system includes a gas turbine engine and an exhaust gas conditioning system. The gas turbine engine includes at least one combustion chamber and at least one turbine downstream from the combustion chamber. The combustion chamber is coupled in flow communication to a source of hydrocarbonaceous fuel and to a source of oxygen. The gas turbine engine is operable with a working fluid that is substantially nitrogen- free. The exhaust gas conditioning system is coupled between a discharge outlet of the gas turbine engine and an inlet of the gas turbine engine.,GEN ELECTRIC;;UNIV WYOMING,FRANER MATTHEW TIMOTHY;;LEWIS RANDY LEE;;BELL DAVID ALLEN;;ARGYLE MORRIS DEE;;TOWLER BRIAN FRANCIS;;ACKERMAN JOHN FREDERICK,,https://lens.org/095-625-456-917-658,Patent Application,no,0,0,8,8,0,B01D2256/22;;B01D2257/80;;F02C3/20;;F02C3/34;;F05D2210/12;;F02C3/20;;F02C3/34;;F02C3/34;;B01D2256/22;;B01D2257/80;;F02C3/20;;F05D2210/12,F02C3/20;;F02C3/34,,0,0,,,,DISCONTINUED
87,WO,A2,WO 2010/014324 A2,027-760-604-838-747,2010-02-04,2010,US 2009/0048742 W,2009-06-26,US 18289808 A,2008-07-30,SYSTEM AND METHOD OF OPERATING A GAS TURBINE ENGINE WITH AN ALTERNATE WORKING FLUID,A gas turbine engine system is provided. The gas turbine engine system includes a gas turbine engine and an exhaust gas conditioning system. The gas turbine engine includes at least one combustion chamber and at least one turbine downstream from the combustion chamber. The combustion chamber is coupled in flow communication to a source of hydrocarbonaceous fuel and to a source of oxygen. The gas turbine engine is operable with a working fluid that is substantially nitrogen- free. The exhaust gas conditioning system is coupled between a discharge outlet of the gas turbine engine and an inlet of the gas turbine engine.,GEN ELECTRIC;;UNIV WYOMING;;FRANER MATTHEW TIMOTHY;;LEWIS RANDY LEE;;BELL DAVID ALLEN;;ARGYLE MORRIS DEE;;TOWLER BRIAN FRANCIS;;ACKERMAN JOHN FREDERICK,FRANER MATTHEW TIMOTHY;;LEWIS RANDY LEE;;BELL DAVID ALLEN;;ARGYLE MORRIS DEE;;TOWLER BRIAN FRANCIS;;ACKERMAN JOHN FREDERICK,,https://lens.org/027-760-604-838-747,Patent Application,yes,0,0,8,8,0,B01D2256/22;;B01D2257/80;;F02C3/20;;F02C3/34;;F05D2210/12;;F02C3/20;;F02C3/34;;F02C3/34;;B01D2256/22;;B01D2257/80;;F02C3/20;;F05D2210/12,,,0,0,,,,PENDING
88,WO,A3,WO 2010/014324 A3,060-303-820-205-875,2011-01-06,2011,US 2009/0048742 W,2009-06-26,US 18289808 A,2008-07-30,SYSTEM AND METHOD OF OPERATING A GAS TURBINE ENGINE WITH AN ALTERNATE WORKING FLUID,A gas turbine engine system is provided. The gas turbine engine system includes a gas turbine engine and an exhaust gas conditioning system. The gas turbine engine includes at least one combustion chamber and at least one turbine downstream from the combustion chamber. The combustion chamber is coupled in flow communication to a source of hydrocarbonaceous fuel and to a source of oxygen. The gas turbine engine is operable with a working fluid that is substantially nitrogen- free. The exhaust gas conditioning system is coupled between a discharge outlet of the gas turbine engine and an inlet of the gas turbine engine.,GEN ELECTRIC;;UNIV WYOMING;;FRANER MATTHEW TIMOTHY;;LEWIS RANDY LEE;;BELL DAVID ALLEN;;ARGYLE MORRIS DEE;;TOWLER BRIAN FRANCIS;;ACKERMAN JOHN FREDERICK,FRANER MATTHEW TIMOTHY;;LEWIS RANDY LEE;;BELL DAVID ALLEN;;ARGYLE MORRIS DEE;;TOWLER BRIAN FRANCIS;;ACKERMAN JOHN FREDERICK,,https://lens.org/060-303-820-205-875,Search Report,yes,5,0,8,8,0,B01D2256/22;;B01D2257/80;;F02C3/20;;F02C3/34;;F05D2210/12;;F02C3/20;;F02C3/34;;F02C3/34;;B01D2256/22;;B01D2257/80;;F02C3/20;;F05D2210/12,F02C3/20;;F02C3/34,,0,0,,,,PENDING
89,US,A1,US 2010/0024378 A1,031-410-137-085-92X,2010-02-04,2010,US 18289808 A,2008-07-30,US 18289808 A,2008-07-30,SYSTEM AND METHOD OF OPERATING A GAS TURBINE ENGINE WITH AN ALTERNATIVE WORKING FLUID,A gas turbine engine system is provided. The gas turbine engine system includes a gas turbine engine and an exhaust gas conditioning system. The gas turbine engine includes at least one combustion chamber and at least one turbine downstream from the combustion chamber. The combustion chamber is coupled in flow communication to a source of hydrocarbonaceous fuel and to a source of oxygen. The gas turbine engine is operable with a working fluid that is substantially nitrogen-free. The exhaust gas conditioning system is coupled between a discharge outlet of the gas turbine engine and an inlet of the gas turbine engine.,ACKERMANN JOHN FREDERICK;;FRANER MATTHEW TIMOTHY;;LEWIS RANDY LEE;;BELL DAVID ALLEN;;ARGYLE MORRIS DEE;;TOWLER BRIAN FRANCIS,ACKERMANN JOHN FREDERICK;;FRANER MATTHEW TIMOTHY;;LEWIS RANDY LEE;;BELL DAVID ALLEN;;ARGYLE MORRIS DEE;;TOWLER BRIAN FRANCIS,THE UNIVERSITY OF WYOMING (2009-06-24);;GENERAL ELECTRIC COMPANY (2009-07-01),https://lens.org/031-410-137-085-92X,Patent Application,yes,33,31,8,8,0,B01D2256/22;;B01D2257/80;;F02C3/20;;F02C3/34;;F05D2210/12;;F02C3/20;;F02C3/34;;F02C3/34;;B01D2256/22;;B01D2257/80;;F02C3/20;;F05D2210/12,F02C7/141,60/39.5;;60/772,0,0,,,,DISCONTINUED
90,US,A1,US 2020/0096349 A1,110-708-672-310-151,2020-03-26,2020,US 201916582580 A,2019-09-25,US 201916582580 A;;US 201862735894 P,2018-09-25,DETERMINING ITEM LOCATIONS USING CROWDSOURCED DATA,"In some implementations, a method performed by data processing apparatuses includes receiving, from a requestor device, an item location request for an item. Map information is received for a mapped space in which the item is located. Item location coordinates are received corresponding to locations within the mapped space at which the item has been previously selected or scanned. The item location coordinates are mapped with respect to the mapped space, and a plurality of clusters are determined for the item location coordinates. For each cluster, a representative location of the cluster is determined. One of the clusters is selected, based at least in part on its representative location, and an estimated location of the item is provided to the requestor device, based at least in part on the representative location of the selected cluster.",TARGET BRANDS INC,BLACK CLAYTON;;DECKER AARON;;RUNQUIST ERIC;;PODOLL BEN;;CARLSON RANDY;;STERNBERG JOAKIM;;OKEY CHELSEA;;BELL DEBBIE;;LISSICK MICHAEL,TARGET BRANDS INC (2019-09-23),https://lens.org/110-708-672-310-151,Patent Application,yes,5,4,2,2,0,G06Q30/0643;;G01C21/206;;G01C21/3896;;G01C21/383;;G01C21/3841;;G01C21/3644;;G01C21/367;;G01C21/3679;;G06Q30/0643;;G01C21/3896;;G01C21/3841;;G01C21/383,G01C21/32;;G01C21/36;;G06Q30/06,,1,0,,,Translation of FR-3054060-A1 (Year: 2018),ACTIVE
91,US,A1,US 2010/0024433 A1,069-566-535-495-30X,2010-02-04,2010,US 18284208 A,2008-07-30,US 18284208 A,2008-07-30,SYSTEM AND METHOD OF OPERATING A GAS TURBINE ENGINE WITH AN ALTERNATIVE WORKING FLUID,"A gas turbine engine system is provided. The gas turbine engine system includes a gas turbine engine, an exhaust gas conditioning system, and a sequestration chamber. The gas turbine engine includes at least one compressor, at least one combustion chamber downstream from the compressor, and at least one turbine downstream from the combustion chamber. The combustion chamber is coupled in flow communication to a source of hydrocarbonaceous fuel and to a source of oxygen. The gas turbine engine is operable with a working fluid that is substantially nitrogen-free. The exhaust gas conditioning system is coupled between a discharge outlet and an inlet of the gas turbine engine. The exhaust gas conditioning system receives all of the exhaust discharged from the gas turbine engine. The sequestration chamber stores carbon dioxide and is coupled to the gas turbine engine for receiving working fluid bled from the turbine upstream from combustion chamber.",ACKERMANN JOHN FREDERICK;;FRANER MATTHEW TIMOTHY;;LEWIS RANDY LEE;;BELL DAVID ALLEN;;ARGYLE MORRIS DEE;;TOWLER BRIAN FRANCIS,ACKERMANN JOHN FREDERICK;;FRANER MATTHEW TIMOTHY;;LEWIS RANDY LEE;;BELL DAVID ALLEN;;ARGYLE MORRIS DEE;;TOWLER BRIAN FRANCIS,THE UNIVERSITY OF WYOMING (2009-06-24);;GENERAL ELECTRIC COMPANY (2009-07-01),https://lens.org/069-566-535-495-30X,Patent Application,yes,8,34,8,8,0,F02C3/22;;F02C3/34;;F05D2260/61;;F02C3/22;;F02C3/34;;F02C3/22;;F05D2260/61;;F02C3/34,F02C3/00;;F02C7/12,60/783;;60/39.5;;415/169.1,0,0,,,,DISCONTINUED
92,CA,C,CA 2732273 C,132-775-663-799-934,2017-06-13,2017,CA 2732273 A,2009-07-08,US 18283708 A;;US 2009/0049856 W,2008-07-30,SYSTEM AND METHOD OF OPERATING A POWER GENERATION SYSTEM WITH AN ALTERNATIVE WORKING FLUID,"A method of operating a turbine engine system and a turbine engine system are provided. The method comprises supplying a flow of oxygen to a combustion chamber defined within a plurality of turbines coupled serially together within the turbine engine system, supplying a flow of hydrocarbonaceous fuel to the combustion chambers of each of the plurality of turbines in the turbine engine system, and supplying a working fluid to an inlet of a first turbine engine coupled within the turbine engine system, wherein the working fluid is substantially nitrogen-free and wherein each of the turbines coupled within the turbine en-gine system is operable with the resulting fuel-oxygen- working fluid mixture.",GEN ELECTRIC;;THE UNIV OF WYOMING,ACKERMAN JOHN FREDERICK;;FRANER MATTHEW TIMOTHY;;TOWLER BRIAN FRANCIS;;ARGYLE MORRIS DEE;;BELL DAVID ALLEN;;LEWIS RANDY LEE,,https://lens.org/132-775-663-799-934,Granted Patent,no,0,0,11,11,0,F02C3/34;;F01K21/04;;F02C3/34;;F02C3/34,F02C3/34;;F01K21/04,,0,0,,,,INACTIVE
93,US,B2,US 11808603 B2,176-425-054-566-47X,2023-11-07,2023,US 201916582580 A,2019-09-25,US 201916582580 A;;US 201862735894 P,2018-09-25,Determining item locations using crowdsourced data,"In some implementations, a method performed by data processing apparatuses includes receiving, from a requestor device, an item location request for an item. Map information is received for a mapped space in which the item is located. Item location coordinates are received corresponding to locations within the mapped space at which the item has been previously selected or scanned. The item location coordinates are mapped with respect to the mapped space, and a plurality of clusters are determined for the item location coordinates. For each cluster, a representative location of the cluster is determined. One of the clusters is selected, based at least in part on its representative location, and an estimated location of the item is provided to the requestor device, based at least in part on the representative location of the selected cluster.",TARGET BRANDS INC,BLACK CLAYTON;;DECKER AARON;;RUNQUIST ERIC;;PODOLL BEN;;CARLSON RANDY;;STERNBERG JOAKIM;;KANE CHELSEA;;BELL DEBBIE;;LISSICK MICHAEL,TARGET BRANDS INC (2019-09-23),https://lens.org/176-425-054-566-47X,Granted Patent,yes,15,0,2,2,0,G06Q30/0643;;G01C21/206;;G01C21/3896;;G01C21/383;;G01C21/3841;;G01C21/3644;;G01C21/367;;G01C21/3679;;G06Q30/0643;;G01C21/3896;;G01C21/3841;;G01C21/383,G01C21/00;;G01C21/36;;G06Q30/0601,,8,1,007-696-447-227-176,10.1016/j.proeng.2015.10.106,"Millon, Louis, “Translation of FR 3054060 A1”, Jan. 18, 2018 (Year: 2018).;;Translation of FR-3054060-A1 (Year: 2018).;;Aisle411.com [online], “Aisle411: the power of indoor navigation & augmented reality,” [retrieved Feb. 2, 2018], retrieved from: URL <http://aisle411.com/>.;;Gizmodo.com [online] “This Segway-Based Robot Inventories an Entire Store in Less Than an Hour,” Apr. 18, 2016, [retrieved Sep. 25, 2019], retrieved from: URL <https://gizmodo.com/this-segway-based-robot-inventories-an-entire-store-in-1771723686>.;;Hardis-Group.com [online], “Eyesee: the drone allowing to automate inventory in warehouses,”[retrieved Feb. 2, 2018], retrieved from: URL <https://www.hardis-group.com/en/our-activities/logistics-solutions/eyesee-drone-allowing-automate-inventory-warehouses>.;;PointInside, “Indoor Mapping and the Retail Store,” 3 pages.;;PointInside.com [online], “Boost Operational Efficiency,” [retrieved Feb. 2, 2018], retrieved from: URL <https://www.pointinside.com/boost-operational-efficiency/>.;;Song et al., “A cost effective material tracking and locating solution for material laydown yard,” Procedia Engineering 123, Jan. 2015, 538-545.",ACTIVE
94,WO,A1,WO 2010/138578 A1,088-505-919-272-543,2010-12-02,2010,US 2010/0036187 W,2010-05-26,US 18154509 P,2009-05-27,PYRIMIDINE INHIBITORS OF KINASE ACTIVITY,"Described herein are compounds of formula (I) or pharmaceutical acceptable salts or solvates thereof, wherein L 1 , R 1 , R 2 , R 3 , R 4 , R 5 , and m are defined in the description. Methods of making said compounds, and compositions containing said compounds which are useful for inhibiting kinases such as IGF-IR are also disclosed.",ABBOTT LAB;;WANG GARY T;;MANTEI ROBERT A;;ERICKSON SCOTT A;;FIDANZE STEVE D;;SHEPPARD GEORGE S;;WANG JIEYI;;BELL RANDY L,WANG GARY T;;MANTEI ROBERT A;;ERICKSON SCOTT A;;FIDANZE STEVE D;;SHEPPARD GEORGE S;;WANG JIEYI;;BELL RANDY L,,https://lens.org/088-505-919-272-543,Patent Application,yes,4,8,10,10,0,C07D401/14;;C07D403/12;;C07D403/14;;C07D413/12;;C07D413/14;;C07D417/12;;C07D417/14;;A61P35/00;;A61P43/00;;C07D403/12;;C07D417/14;;C07D401/14;;C07D413/12;;C07D403/14;;C07D417/12;;C07D413/14,C07D401/14;;A61K31/506;;A61K35/00;;C07D403/12;;C07D403/14;;C07D413/12;;C07D413/14;;C07D417/12;;C07D417/14,,62,54,021-004-384-485-879;;046-717-070-604-887;;052-505-137-934-008;;044-748-831-090-972;;024-924-012-347-732;;097-392-576-160-344;;044-748-831-090-972;;072-621-254-838-609;;008-089-455-773-996;;080-996-521-481-773;;026-670-023-742-960;;071-057-152-903-173;;064-534-981-503-13X;;074-824-348-386-95X;;080-346-733-584-964;;029-747-914-293-195;;044-597-437-785-535;;042-630-235-998-291;;028-531-800-105-513;;012-282-318-544-467;;032-557-229-419-547;;089-802-856-721-299;;008-885-430-835-895;;070-311-797-413-117;;031-616-493-083-780;;075-361-202-778-14X;;038-171-112-628-544;;031-278-140-393-389;;038-171-112-628-544;;034-722-452-108-337;;044-840-255-404-305;;096-575-429-954-828;;004-488-094-610-499;;018-219-156-278-616;;006-946-979-586-164;;045-239-664-066-895;;036-055-037-431-299;;059-716-462-209-269;;158-567-940-979-261;;011-001-797-370-811;;040-239-601-782-040;;020-325-142-341-03X;;011-291-416-015-882;;111-677-879-548-551;;066-219-111-588-400;;129-970-610-939-855;;018-470-195-336-786;;133-233-905-398-202;;095-485-454-240-24X;;070-792-654-417-452;;084-104-328-681-684;;016-327-462-571-496;;029-924-070-880-959;;099-503-061-558-195,10.1517/13543776.17.1.25;;10.1038/nrc1387;;15229476;;10961344;;10.1007/pl00000744;;8697095;;10.1016/1357-2725(95)00168-9;;10.1038/sj.onc.1206058;;12447687;;10.1210/endo.139.8.6165;;10.1210/en.139.8.3578;;9681510;;8697095;;10.1016/1357-2725(95)00168-9;;10.1074/jbc.m605269200;;16793764;;pmc1132689;;1599389;;10.1042/bj2840001;;10.1016/s1097-2765(00)80155-0;;9844629;;16997283;;10.1016/j.bcp.2006.08.011;;10.1159/000095161;;16917171;;16844299;;10.1016/j.bbcan.2006.05.003;;10.1007/s00018-006-6036-4;;16786222;;10.1016/s0304-3835(03)00159-9;;12767520;;16931767;;10.1210/er.2006-0001;;pmc360815;;10.1128/mcb.10.2.464-473.1990;;10.1128/mcb.10.2.464;;2153917;;7790393;;10.1002/jcp.1041640126;;pmc358831;;8007963;;10.1128/mcb.14.7.4588-4595.1994;;10.1128/mcb.14.7.4588;;7636972;;pmc189367;;10.1128/jvi.69.9.5300-5303.1995;;10.1128/mcb.14.6.3604;;pmc358728;;8196606;;10.1128/mcb.14.6.3604-3612.1994;;8248231;;10.1073/pnas.90.23.11217;;pmc47953;;10.1002/j.1460-2075.1994.tb06630.x;;8045259;;pmc395225;;2553250;;8216340;;10.1006/bbrc.1993.2220;;9751624;;10.1038/sj.onc.1202984;;10557096;;10791772;;10.1023/a:1009523501499;;10.1038/sj.onc.1202984;;10557096;;11550779;;10.1007/s003450100220;;10.1016/0016-5085(92)70001-r;;1312970;;10.1016/0016-5085(92)90744-j;;10.1007/s00384-004-0675-4;;15650828;;10.1002/ijc.2910620502;;7665217;;7743492;;12002750;;10.1080/10428190290011958;;16328478;;10.1007/s00277-005-0031-y;;10226794;;10.1055/s-2007-978711;;pmc1187072;;11477136;;10.1136/mp.54.4.227;;12060623;;10.1073/pnas.89.11.4874;;1594587;;pmc49190;;10.1073/pnas.93.14.7263;;8692980;;pmc38971;;10.1158/1078-0432.ccr-03-0762;;15217929;;10.1210/jcem.87.1.8142;;10.1210/jc.87.1.245;;11788654;;11376121;;pmc1187048;;10.1136/mp.54.3.121;;10.1016/j.bcp.2004.05.029;;15313394;;10.1593/neo.04643;;15967097;;pmc1501162;;10.1097/01.ju.0000036380.10325.2a;;10.1016/s0022-5347(05)63999-7;;10.1097/00005392-200302000-00071;;12544349;;15517912;;10.1007/s10585-005-1198-2;;16035620;;10.1016/j.ijom.2006.09.009;;17113753;;16986125;;10.1002/cncr.22214;;10.1038/sj.onc.1209674;;16715137;;14551500;;10.1097/00001813-200310000-00001;;10.1177/108705719900400605;;10838427,"SARMA ET AL.: ""Progress in the development of small molecule inhibitors of insulin-like growth factor-1 receptor kinase"", EXPERT OPINION ON THERAPEUTIC PATENTS, INFORMA HEALTHCARE, GB LNKD- DOI:10.1517/13543776.17.1.25, vol. 17, no. 1, 1 January 2007 (2007-01-01), pages 25 - 35, XP002502298, ISSN: 1354-3776;;POLLAK, M N ET AL., NATURE REVIEWS CANCER, vol. 4, no. 7, 2004, pages 505 - 518;;ADAMS ET AL., CELL. MOL. LIFE SCI., vol. 57, 2000, pages 1050 - 1093;;BENITO, M ET AL., INT J BIOCHEM CELL BIOL, vol. 28, no. 5, 1996, pages 499 - 510;;SCIACCA L., ONCOGENE, vol. 21, no. 54, 2002, pages 8240 - 8250;;DANDEKAR, A A ET AL., ENDOCRINOLOGY, vol. 139, no. 8, 1998, pages 3578 - 3584;;BENITO, INT J BIOCHEM CELL BIOL, 1996;;LI, W ET AL., J. BIOL. CHEM., vol. 281, no. 33, 2006, pages 23785 - 23791;;BROWN, G C ET AL., BIOCHEM. J, vol. 284, 1992, pages 1 - 13;;BRUNING, J C ET AL., MOL. CELL, vol. 2, no. 5, 1998, pages 559 - 569;;NIMWEGEN, M J ET AL., BIOCHEM. PHARMACOL., vol. 73, no. 5, 2007, pages 597 - 609;;WALENKAMP, M J ET AL., HORM. RES., vol. 66, no. 5, 2006, pages 221 - 230;;KURMASHEVA, R. T ET AL., BIOCHIM. BIOPHYS. ACTA-REV ON CANCER, vol. 1766, no. 1, 2006, pages 1 - 22;;BATEMAN, J M ET AL., CELL. MOL. LIFE SCI., vol. 63, no. 15, 2006, pages 1701 - 1705;;LEROITH, D ET AL., CAN. LETT., vol. 195, 2003, pages 127 - 137;;SAMANI A ET AL., ENDOCRINE REVIEWS, vol. 28, no. 1, pages 20 - 47;;KURMASHEVA, BIOCHIM. BIOPHYS. ACTA, 2006;;KALEKO M ET AL., MOL CELL BIOL., vol. 10, no. 2, 1990, pages 464 - 473;;DEANGELIS T ET AL., CELL. PHYSIOL., vol. 1640, 1995, pages 214 - 221;;COPPOLA D ET AL., MOL. CELL. BIOL., vol. 14, no. 7, 1994, pages 4588 - 4595;;MORRIONE A J, VIROL., 1995, pages 695300 - 5303;;SELL C ET AL., MOL. CELL. BIOL., vol. 14, no. 6, 1994, pages 3604 - 3612;;SELL C ET AL., PROC. NATL. ACAD. SCI. USA, vol. 90, no. 23, 1993, pages 11217 - 11221;;HARRINGTON ET AL., EMBO J., vol. 13, 1994, pages 3286 - 3295;;ARTEAGA C ET AL., CANCER RES., vol. 49, no. 22, 1989, pages 6237 - 6241;;LI ET AL., BIOCHEM. BIOPHYS. RES. COM., vol. 196, no. 1, 1993, pages 92 - 98;;SCOTLANDI K ET AL., CANCER RES., vol. 58, no. 18, 1998, pages 4127 - 4131;;JIANG ET AL., ONCOGENE, vol. 18, no. 44, 1999, pages 6071 - 6077;;SURMACZ, J, MAMMARY GLAND BIO. NEOPLASIA, vol. 5, no. 1, 2000, pages 95 - 105;;LEROITH, CAN. LETT., 2003;;ARTEGA, CANCER RES., 1989;;SCOTLANDI, CANCER RES., 1998;;JIANG, Y ET AL., ONCOGENE, vol. 18, 1999, pages 6071 - 6077;;DJAVAN ET AL., WORLD J UROL., vol. 19, no. 4, 2001, pages 225 - 233;;O'BRIEN ET AL., UROLOGY, vol. 58, no. 1, 2001, pages 1 - 7;;GUO ET AL., GASTROENTEROLOGY, vol. 102, 1992, pages 1101 - 1108;;DURAI, R ET AL., INT. J COLORECTAL DIS., vol. 20, no. 3, 2005, pages 203 - 220;;KELLERER M. ET AL., INT. J. CANCER, vol. 62, no. 5, 1995, pages 501 - 507;;BERGMANN, U ET AL., CANCER RES., vol. 55, no. 10, 1995, pages 2007 - 2011;;ZUMKELLER W ET AL., LEUK. LYMPH, vol. 43, no. 3, 2002, pages 487 - 491;;QI, ANN HEMATOL., vol. 85, 2006, pages 95 - 101;;ZUMKELLER, W ET AL., HORM. METAB. RES., vol. 31, 1999, pages 138 - 141;;ZUMKELLER, W ET AL., MOL. PATHOL., vol. 54, no. 4, 2001, pages 227 - 229;;DEL VALLE L ET AL., CLIN. CANCER RES., vol. 8, 2002, pages 1822 - 1830;;TROJAN ET AL., PROC. NATL. ACAD. SCI. USA, vol. 89, 1992, pages 4874 - 4878;;BURFEIND P ET AL., PNAS, vol. 93, 1996, pages 7263 - 7268;;WU X. ET AL., CLIN. CANCER RES., vol. 10, 2004, pages 3988 - 95;;VELLA V ET AL., J. CLIN. ENDOCRINOL. METAB., vol. 87, 2002, pages 245 - 254;;VELLA V ET AL., MOL. PATHOL., vol. 54, no. 3, 2001, pages 121 - 124;;ALEXIA, C ET AL., BIOCHEM. PHARMACOL., vol. 68, 2004, pages 1003 - 1015;;NEUVIANS T P ET AL., NEOPLASIA, vol. 7, 2005, pages 446 - 56;;ZHAO H. ET AL., J. UROLOGY, vol. 169, 2003, pages 714 - 717;;SOHDA M ET AL., ANTICANCER RESEARCH., vol. 24, 2004, pages 3029 - 3034;;JIANG, Y ET AL., CLINICAL & EXPERIMENTAL METASTASIS, vol. 21, 2004, pages 755 - 64;;BRADY G ET AL., INT. J. OF ORAL & MAXILLOFACIAL SURG., vol. 36, 2007, pages 259 - 62;;TRENT J C ET AL., CANCER, vol. 107, 2006, pages 1898 - 908;;YEH A H ET AL., ONCOGENE, vol. 25, 2006, pages 6574 - 81;;BOHULA E A ET AL., ANTICANCER DRUGS, vol. 14, no. 9, 2003, pages 669 - 682;;FUNDAMENTAL STEREOCHEMISTRY, PURE APPL. CHEM., vol. 45, 1976, pages 13 - 30;;MATHIS, G., HTRF(R) TECHNOLOGY. J BIOMOL SCREEN, vol. 4, no. 6, 1999, pages 309 - 314;;NATURE REVIEWS CANCER, vol. 8, 2008, pages 915;;S. M. BERGE ET AL.: ""pharmaceutically acceptable salts in detail"", J. PHARMACEUTICAL SCIENCES, vol. 66, 1977, pages 1",PENDING
95,CL,A1,CL 2009001033 A1,160-666-982-575-674,2010-11-12,2010,CL 2009001033 A,2009-04-29,US 12583408 P;;US 13428308 P;;US 19719108 P;;US 19900908 P,2008-04-29,"Inmunoglobulinas de dominio variable dual; acido nucleico, vector, celulas huesped, composicion y metodo para generar un dominio variable dual de inmunoglobulina capaz de unir dos antigenos.",Proteína de unión multivalente y multiespecífica; y método para generar un dominio variable dual de inmunoglobulina capaz de unir dos antígenos.,ABBOTT LAB,ANDREW PHILLIPS;;TARIQ GHAYUR;;EDWARD B REILLY;;RANDY L BELL;;YINGCHUN LI;;HUA YING;;SUSAN E MORGAN-LAPPE;;GILLIAN A,,https://lens.org/160-666-982-575-674,Patent Application,no,0,0,31,32,0,A61K2039/505;;C07K16/22;;C07K16/28;;C07K16/2863;;C07K16/32;;C07K2317/31;;C07K2317/64;;C07K2317/71;;C07K2317/73;;C07K2317/732;;C07K2317/734;;C07K2317/92;;C07K2319/00;;C07K16/468;;C07K2317/76;;Y10S435/81;;A61P1/04;;A61P1/14;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/06;;A61P11/16;;A61P13/02;;A61P13/08;;A61P13/12;;A61P15/02;;A61P15/08;;A61P17/02;;A61P17/04;;A61P17/06;;A61P17/14;;A61P19/02;;A61P19/04;;A61P19/06;;A61P19/08;;A61P19/10;;A61P21/00;;A61P21/02;;A61P21/04;;A61P25/00;;A61P25/04;;A61P25/08;;A61P25/10;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/24;;A61P25/28;;A61P25/30;;A61P25/32;;A61P27/02;;A61P27/16;;A61P29/00;;A61P3/14;;A61P31/00;;A61P31/04;;A61P31/08;;A61P31/14;;A61P31/16;;A61P31/18;;A61P31/22;;A61P33/00;;A61P33/02;;A61P33/06;;A61P35/00;;A61P35/02;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/00;;A61P43/00;;A61P5/00;;A61P5/14;;A61P5/18;;A61P5/50;;A61P7/02;;A61P7/04;;A61P7/06;;A61P9/04;;A61P9/06;;A61P9/08;;A61P9/10;;A61P9/12;;A61P9/14;;A61P3/10;;Y02A50/30;;A61K2039/505;;C07K16/22;;C07K16/28;;C07K16/2863;;C07K16/32;;C07K2317/31;;C07K2317/64;;C07K2317/71;;C07K2317/73;;C07K2317/732;;C07K2317/734;;C07K2317/92;;C07K2319/00;;Y02A50/30;;C07K16/468;;A61K39/39533;;A61K45/06;;C07K2317/565;;C07K2317/76;;G01N33/6872;;G01N33/74;;G01N2333/515;;G01N2333/705;;Y10S435/81,C07K16/18;;G01N33/53,,0,0,,,,PENDING
96,EP,B1,EP 2435422 B1,187-894-247-889-129,2014-12-17,2014,EP 10726735 A,2010-05-26,US 2010/0036187 W;;US 18154509 P,2009-05-27,PYRIMIDINE INHIBITORS OF KINASE ACTIVITY,,ABBVIE INC,WANG GARY T;;MANTEI ROBERT A;;ERICKSON SCOTT A;;FIDANZE STEVE D;;SHEPPARD GEORGE S;;WANG JIEYI;;BELL RANDY L,ABBVIE INC. (2013-06-12),https://lens.org/187-894-247-889-129,Granted Patent,yes,4,0,10,10,0,C07D401/14;;C07D403/12;;C07D403/14;;C07D413/12;;C07D413/14;;C07D417/12;;C07D417/14;;A61P35/00;;A61P43/00;;C07D403/12;;C07D417/14;;C07D401/14;;C07D413/12;;C07D403/14;;C07D417/12;;C07D413/14,C07D401/14;;A61K31/506;;A61K35/00;;C07D403/12;;C07D403/14;;C07D413/12;;C07D413/14;;C07D417/12;;C07D417/14,,1,0,,,"SARMA ET AL.: ""Progress in the development of small molecule inhibitors of insulin-like growth factor-1 receptor kinase"" EXPERT OPINION ON THERAPEUTIC PATENTS, INFORMA HEALTHCARE, GB LNKD- DOI:10.1517/13543776.17.1.25, vol. 17, no. 1, 1 January 2007 (2007-01-01), pages 25-35, XP002502298 ISSN: 1354-3776",ACTIVE
97,EP,A1,EP 2435422 A1,027-945-843-700-682,2012-04-04,2012,EP 10726735 A,2010-05-26,US 2010/0036187 W;;US 18154509 P,2009-05-27,PYRIMIDINE INHIBITORS OF KINASE ACTIVITY,,ABBOTT LAB,WANG GARY T;;MANTEI ROBERT A;;ERICKSON SCOTT A;;FIDANZE STEVE D;;SHEPPARD GEORGE S;;WANG JIEYI;;BELL RANDY L,ABBVIE INC. (2013-06-12),https://lens.org/027-945-843-700-682,Patent Application,yes,0,0,10,10,0,C07D401/14;;C07D403/12;;C07D403/14;;C07D413/12;;C07D413/14;;C07D417/12;;C07D417/14;;A61P35/00;;A61P43/00;;C07D403/12;;C07D417/14;;C07D401/14;;C07D413/12;;C07D403/14;;C07D417/12;;C07D413/14,C07D401/14;;A61K31/506;;A61K35/00;;C07D403/12;;C07D403/14;;C07D413/12;;C07D413/14;;C07D417/12;;C07D417/14,,0,0,,,,ACTIVE
98,CN,A,CN 102459236 A,141-746-610-274-361,2012-05-16,2012,CN 201080033863 A,2010-05-26,US 2010/0036187 W;;US 18154509 P,2009-05-27,Pyrimidine inhibitors of kinase activity,"Described herein are compounds of formula (I) or pharmaceutical acceptable salts or solvates thereof, wherein L1, R1, R2, R3, R4, R5, and m are defined in the description. Methods of making said compounds, and compositions containing said compounds which are useful for inhibiting kinases such as IGF-IR are also disclosed.",ABBOTT LAB,WANG GARY T;;MANTEI ROBERT A;;ERICKSON SCOTT A;;FIDANZE STEVE D;;SHEPPARD GEORGE S;;JIEYI WANG;;BELL RANDY L,ABBVIE COMPANY (2013-06-20),https://lens.org/141-746-610-274-361,Patent Application,no,4,3,10,10,0,C07D401/14;;C07D403/12;;C07D403/14;;C07D413/12;;C07D413/14;;C07D417/12;;C07D417/14;;A61P35/00;;A61P43/00;;C07D403/12;;C07D417/14;;C07D401/14;;C07D413/12;;C07D403/14;;C07D417/12;;C07D413/14,C07D401/14;;A61K31/506;;A61K35/00;;C07D403/12;;C07D403/14;;C07D413/12;;C07D413/14;;C07D417/12;;C07D417/14,,1,0,,,"SARMA, ET AL.,: ""Progress in the development of small molecule inhibitors of insulin-like growth factor-1 receptor kinase"", 《EXPERT OPINION ON THERAPEUTIC PATENTS》",INACTIVE
99,CA,A1,CA 2763633 A1,176-470-840-318-142,2010-12-02,2010,CA 2763633 A,2010-05-26,US 18154509 P;;US 2010/0036187 W,2009-05-27,PYRIMIDINE INHIBITORS OF KINASE ACTIVITY,"Described herein are compounds of formula (I) or pharmaceutical acceptable salts or solvates thereof, wherein L1, R1, R2, R3, R4, R5, and m are defined in the description. Methods of making said compounds, and compositions containing said compounds which are useful for inhibiting kinases such as IGF-IR are also disclosed.",ABBOTT LAB,WANG GARY T;;MANTEI ROBERT A;;ERICKSON SCOTT A;;FIDANZE STEVE D;;SHEPPARD GEORGE S;;WANG JIEYI;;BELL RANDY L,,https://lens.org/176-470-840-318-142,Patent Application,no,0,0,10,10,0,C07D401/14;;C07D403/12;;C07D403/14;;C07D413/12;;C07D413/14;;C07D417/12;;C07D417/14;;A61P35/00;;A61P43/00;;C07D403/12;;C07D417/14;;C07D401/14;;C07D413/12;;C07D403/14;;C07D417/12;;C07D413/14,C07D401/14;;A61K31/506;;A61K35/00;;C07D403/12;;C07D403/14;;C07D413/12;;C07D413/14;;C07D417/12;;C07D417/14,,0,0,,,,DISCONTINUED
100,US,B2,US 8486933 B2,064-251-716-426-786,2013-07-16,2013,US 78773510 A,2010-05-26,US 78773510 A;;US 18154509 P,2009-05-27,Pyrimidine inhibitors of kinase activity,"Described herein are compounds of formula (I) or pharmaceutical acceptable salts or solvates thereof, wherein L 1 , R 1 , R 2 , R 3 , R 4 , R 5 , and m are defined in the description. Methods of making said compounds, and compositions containing said compounds which are useful for inhibiting kinases such as IGF-1R are also disclosed.",WANG GARY T;;MANTEI ROBERT A;;ERICKSON SCOTT A;;FIDANZE STEVE D;;SHEPPARD GEORGE S;;WANG JIEYI;;BELL RANDY L;;ABBVIE INC,WANG GARY T;;MANTEI ROBERT A;;ERICKSON SCOTT A;;FIDANZE STEVE D;;SHEPPARD GEORGE S;;WANG JIEYI;;BELL RANDY L,ABBVIE INC (2012-08-01);;ABBOTT LABORATORIES (2010-08-11),https://lens.org/064-251-716-426-786,Granted Patent,yes,4,3,10,10,0,C07D401/14;;C07D403/12;;C07D403/14;;C07D413/12;;C07D413/14;;C07D417/12;;C07D417/14;;A61P35/00;;A61P43/00;;C07D403/12;;C07D417/14;;C07D401/14;;C07D413/12;;C07D403/14;;C07D417/12;;C07D413/14,A61K31/541;;A61K31/496;;A61K31/506;;A61K31/5377;;C07D403/14;;C07D413/14;;C07D417/14,514/228.2;;514/252.19;;514/252.18;;514/256;;514/234.5;;544/295;;544/333;;544/122;;544/62,58,57,052-505-137-934-008;;066-219-111-588-400;;070-311-797-413-117;;074-824-348-386-95X;;044-748-831-090-972;;007-364-858-655-289;;018-219-156-278-616;;029-924-070-880-959;;070-792-654-417-452;;008-089-455-773-996;;080-996-521-481-773;;040-239-601-782-040;;028-531-800-105-513;;180-631-728-571-083;;097-392-576-160-344;;042-630-235-998-291;;158-567-940-979-261;;034-722-452-108-337;;096-575-429-954-828;;044-840-255-404-305;;008-885-430-835-895;;095-485-454-240-24X;;038-171-112-628-544;;044-597-437-785-535;;004-488-094-610-499;;064-534-981-503-13X;;080-346-733-584-964;;031-616-493-083-780;;072-621-254-838-609;;099-503-061-558-195;;012-282-318-544-467;;129-970-610-939-855;;065-696-055-011-37X;;003-003-981-633-908;;046-717-070-604-887;;027-931-512-533-165;;045-239-664-066-895;;029-747-914-293-195;;021-004-384-485-879;;024-924-012-347-732;;075-361-202-778-14X;;032-557-229-419-547;;089-802-856-721-299;;133-233-905-398-202;;031-278-140-393-389;;084-104-328-681-684;;011-001-797-370-811;;026-670-023-742-960;;011-291-416-015-882;;111-677-879-548-551;;071-057-152-903-173;;020-325-142-341-03X;;016-327-462-571-496;;018-470-195-336-786;;036-055-037-431-299;;059-716-462-209-269;;006-946-979-586-164,10961344;;10.1007/pl00000744;;10.1016/j.bcp.2004.05.029;;15313394;;2553250;;10.1007/s00018-006-6036-4;;16786222;;8697095;;10.1016/1357-2725(95)00168-9;;10.1002/jps.2600660104;;833720;;7743492;;14551500;;10.1097/00001813-200310000-00001;;10.1016/j.ijom.2006.09.009;;17113753;;pmc1132689;;1599389;;10.1042/bj2840001;;10.1016/s1097-2765(00)80155-0;;9844629;;10.1073/pnas.93.14.7263;;8692980;;pmc38971;;pmc358831;;8007963;;10.1128/mcb.14.7.4588-4595.1994;;10.1128/mcb.14.7.4588;;10.1351/pac197645010011;;10.1210/endo.139.8.6165;;10.1210/en.139.8.3578;;9681510;;7790393;;10.1002/jcp.1041640126;;12060623;;11550779;;10.1007/s003450100220;;10.1007/s00384-004-0675-4;;15650828;;10.1016/0016-5085(92)70001-r;;1312970;;10.1016/0016-5085(92)90744-j;;10.1002/j.1460-2075.1994.tb06630.x;;8045259;;pmc395225;;10.1007/s10585-005-1198-2;;16035620;;10.1038/sj.onc.1202984;;10557096;;pmc360815;;10.1128/mcb.10.2.464-473.1990;;10.1128/mcb.10.2.464;;2153917;;10.1002/ijc.2910620502;;7665217;;16844299;;10.1016/j.bbcan.2006.05.003;;10.1016/s0304-3835(03)00159-9;;12767520;;8216340;;10.1006/bbrc.1993.2220;;10.1074/jbc.m605269200;;16793764;;10.1177/108705719900400605;;10838427;;7636972;;pmc189367;;10.1128/jvi.69.9.5300-5303.1995;;10.1593/neo.04643;;15967097;;pmc1501162;;10.1016/s0090-4295(01)01004-4;;11445469;;19029956;;10.1038/nrc2536;;10.1038/nrc1387;;15229476;;10.1016/s0091-679x(08)60468-9;;794631;;16328478;;10.1007/s00277-005-0031-y;;16931767;;10.1210/er.2006-0001;;10.1517/13543776.17.1.25;;10.1038/sj.onc.1206058;;12447687;;9751624;;10.1128/mcb.14.6.3604;;pmc358728;;8196606;;10.1128/mcb.14.6.3604-3612.1994;;8248231;;10.1073/pnas.90.23.11217;;pmc47953;;15517912;;10791772;;10.1023/a:1009523501499;;16986125;;10.1002/cncr.22214;;10.1073/pnas.89.11.4874;;1594587;;pmc49190;;16997283;;10.1016/j.bcp.2006.08.011;;10.1210/jcem.87.1.8142;;10.1210/jc.87.1.245;;11788654;;11376121;;pmc1187048;;10.1136/mp.54.3.121;;10.1159/000095161;;16917171;;10.1158/1078-0432.ccr-03-0762;;15217929;;10.1038/sj.onc.1209674;;16715137;;10.1097/01.ju.0000036380.10325.2a;;10.1016/s0022-5347(05)63999-7;;10.1097/00005392-200302000-00071;;12544349;;10226794;;10.1055/s-2007-978711;;pmc1187072;;11477136;;10.1136/mp.54.4.227;;12002750;;10.1080/10428190290011958,"Adams T. E., et al., ""Structure and function of the type 1 insulin-like growth factor receptor"", Cellular and Molecular Life Sciences, 2000, vol. 57 (7), pp. 1050-1093.;;Alexia C., et al., ""An evaluation of the role of insulin-like growth factors (IGF) and of type-I IGF receptor signalling in hepatocarcinogenesis and in the resistance of hepatocarcinoma cells against drug-induced apoptosis"", Biochem Pharmacol, 2004, vol. 68 (6), pp. 1003-1015.;;Arteaga C.L., et al., ""Growth Inhibition of Human Breast Cancer Cells in Vitro with an Antibody Against the Type I Somatomedin Receptor,"" Cancer Research, 1989, vol. 49 (22), pp. 6237-6241.;;Bateman J. M., et al., ""Insulin/IGF Signalling in Neurogenesis,"" Cellular and Molecular Life Sciences, 2006, vol. 63 (15), pp. 1701-1705.;;Benito M., et al., ""IGF-I: A Mitogen also Involved in Differentiation Processes in Mammalian Cells,"" The International Journal of Biochemistry & Cell Biology, 1996, vol. 28 (5), pp. 499-510.;;Berge S. M., et al., ""Pharmaceutical Salts"", J Pharmaceutical Sciences, 1977, vol. 66 (1), pp. 1-19.;;Bergmann U., et al., ""Insulin-like growth factor I overexpression in human pancreatic cancer: evidence for autocrine and paracrine roles"", Cancer Research , 1995, vol. 55 (10), pp. 2007-2011.;;Bohula E. A., et al., ""Targeting the type 1 insulin-like growth factor receptor as anti-cancer treatment"", Anti-cancer Drugs., 2003, vol. 14 (9), pp. 669-682.;;Brady G., et al., ""Serum levels of insulin-like growth factors (IGFs) and their binding proteins (IGFBPs), -1, -2, -3, in oral cancer"", International Journal of Oral and Maxillofacal Surgery, 2007, vol. 36 (3), pp. 259-262.;;Brown Guy C., ""Control of respiration and ATP synthesis in mammalian mitochondria and cells"", Biochemical, 1992, vol. 284, pp. 1-13.;;Bruning Jens C., et al., ""A Muscle-Specific Insulin Receptor Knockout Exhibits Features of the Metabolic Syndrome of NIDDM without Altering Glucose Tolerance"", Molecular Cell, 1998, vol. 2 (5), pp. 559-569.;;Burfeind P., et al., ""Antisense RNA to the type I insulin-like growth factor receptor suppresses tumor growth and prevents invasion by rat prostate cancer cells in vivo"", The Proceedings of the National Academy of Sciences of the United States of America, 1996, vol. 93 (14), pp. 7263-7268.;;Coppola D., et al., ""A Functional Insulin-Like Growth Factor I Receptor is Required for the Mitogenic and Transforming Activities of the Epidermal Growth Factor Receptor,"" Molecular and Cellular Biology, 1994, vol. 14 (7), pp. 4588-4595.;;Cross L.C., et al., ""IUPAC Commission on Nomenclature of Organic Chemistry: Rules for the Nomenclature of Organic Chemistry, Section E: Stereochemistry,"" Pure and Applied Chemistry, 1976, vol. 45, pp. 11-30.;;Dandekar Ajai A., et al., ""Comparison of the Signaling Abilities of the Cytoplasmic Domains of the Insulin Receptor and the Insulin Receptor-Related Receptor in 3T3-L1 Adipocytes"", Endocrinology, 1998, vol. 139 (8), pp. 3578-3584.;;Deangelis T., et al., ""Insulin-Like Growth Factor I Receptor is Required for the Mitogenic and Transforming Activities of the Platelet-Derived Growth Factor Receptor,"" Journal of Cellular Physiology, 1995, vol. 164 (1), pp. 214-221.;;Del Valle L., et al., ""Insulin-like growth factor I receptor activity in human medulloblastomas"", Clinical Cancer Research, 2002, vol. 8 (6), pp. 1822-1830.;;Djavan B., et al., ""Insulin-like growth factors and prostate cancer"", World Journal of Urology , 2001, vol. 19 (4), pp. 225-233.;;Durai R., et al., ""The role of the insulin-like growth factor system in colorectal cancer: review of current knowledge"", International Journal Colorectal Diseases., 2005, vol. 20 (3), pp. 203-220.;;Greene T., et al., ""Protective Groups in Organic Synthesis,"" 1999, Third Edition, Table of Contents.;;Guo Y S., et al., ""Characterization of insulinlike growth factor I receptors in human colon cancer"", Gastroenterology, 1992, vol. 102 (4), pp. 1101-1108.;;Harrington E. A., et al., ""C-Myc-Induced Apoptosis in Fibroblasts is Inhibited by Specific Cytokines,"" The EMBO Journal, 1994, vol. 13 (14), pp. 3286-3295.;;Jiang Y., et al., ""A high expression level of insulin-like growth factor I receptor is associated with increased expression of transcription factor Sp1 and regional lymph node metastasis of human gastric cancer"", 2004, vol. 21 (8), pp. 755-764.;;Jiang Y., et al., ""Induction of Tumor Suppression and Glandular Differentiation of A549 Lung Carcinoma Cells by Dominant-Negative IGF-I Receptor,"" Oncogene, 1999, vol. 18, pp. 6071-6077.;;Kaleko M., et al., ""Overexpression of the Human Insulinlike Growth Factor I Receptor Promotes Ligand-Dependent Neoplastic Transformation,"" Molecular and Cellular Biology, 1990, vol. 10 (2), pp. 464-473.;;Kellerer M., et al., ""Insulin- and insulin-like growth-factor-I receptor tyrosine-kinase activities in human renal carcinoma"", 1995, vol. 62 (5), pp. 501-507.;;Kurmasheva R.T., et al., ""IGF-I Mediated Survival Pathways in Normal and Malignant Cells,"" Biochimica et Biophysica Acta, 2006, vol. 1766, pp. 1-22.;;Leroith D., et al., ""The Insulin-Like Growth Factor System and Cancer,"" Cancer Letters, 2003, vol. 195, pp. 127-137.;;Li, et al. , ""Two New Monoclonal Antibodies against the ? Subunit of the Human Insulin-Like Growth Factor-I Receptor,"" Biochemical and Biophysical Research Communications, 1993, vol. 196 (1), pp. 92-98.;;Li Wanqing, et al., ""Role of the Activation Loop Tyrosines in Regulation of the Insulin-like Growth Factor I Receptor-tyrosine Kinase"", The Journal of Biological Chemistry, 2006, vol. 281 (33), pp. 23785-23791.;;Mathis G.,, ""HTRF(R) Technology"", J Biomol Screen, 1999, 4 (6), 309-314.;;Morrione A., et al., ""Failure of the Bovine Papillomavirus to Transform Mouse Embryo Fibroblasts with a Targeted Disruption of the Insulin-Like Growth Factor I Receptor Genes,"" Journal of Virology, 1995, vol. 69 (9), pp. 5300-5303.;;Neuvians T P., et al., ""Differential expression of IGF components and insulin receptor isoforms in human seminoma versus normal testicular tissue"", 2005, vol. 7 (5), pp. 446-456.;;O'Brien M F., et al., ""Insulin-like growth factor I and prostate cancel"", Urology, 2001, vol. 58 (1), pp. 1-7.;;Pollak M N., et al., ""Insulin and insulin-like growth factor signalling in neoplasia"", 2008, vol. 8 (12), pp. 915-928.;;Pollak Michael N., et al., ""Insulin-Like Growth Factors and Neoplasia"", Nature Reviews Cancer, 2004, vol. 4, pp. 505-518.;;Poste, et al., ""Chapter 4: Lipid Vesicles as Carriers for Introducing Biologically Active Materials into Cells"" in: Methods in Cell Biology, Prescott D.M., ed., Academic Press, 1976, vol. 14, pp. 33-71.;;Qi H., et al., ""Expression of type 1 insulin-like growth factor receptor in marrow nucleated cells in malignant hematological disorders: correlation with apoptosis,"" 2006, vol. 85 (2), pp. 95-101.;;Samani A.A., et al., ""The Role of the IGF System in Cancer Growth and Metastasis: Overview and Recent Insights,"" Endocrine Reviews, 2007, vol. 28 (1), pp. 20-47.;;Sarma P.K.S., et al., ""Progress in the Development of Small Molecule Inhibitors of Insulin-Like Growth Factor-1 Receptor Kinase,"" Expert Opinion on Therapeutic Patents, 2007, vol. 17 (1), pp. 25-35.;;Sciacca Laura, et al., ""In IGF-I receptor-deficient leiomyosarcoma cells autocrine IGF-II induces cell invasion and protection from apoptosis via the insulin receptor isoform A"", Oncogene, 2002, vol. 21, pp. 8240-8250.;;Scotlandi K., et al., ""Blockage of Insulin-like Growth Factor-I Receptor Inhibits the Growth of Ewing's Sarcoma in Athymic Mice,"" Cancer Research, 1998, vol. 58, pp. 4127-4131.;;Sell C., et al., ""Effect of a Null Mutation of the Insulin-Like Growth Factor I Receptor Gene on Growth and Transformation of Mouse Embryo Fibroblasts,"" Molecular and Cellular Biology, 1994, vol. 14 (6), pp. 3604-3612.;;Sell C., et al., ""Simian Virus 40 Large Tumor Antigen is Unable to Transform Mouse Embryonic Fibroblasts Lacking Type 1 Insulin-Like Growth Factor Receptor,"" Proceedings of the National Academy of Sciences, 1993, vol. 90, pp. 11217-11221.;;Sohda M., et al., ""The role of insulin-like growth factor 1 and insulin-like growth factor binding protein 3 in human esophageal cancer"", Anticancer Res. , 2004, vol. 24 (5A), pp. 3029-3034.;;Surmacz E., et al., ""Function of the IGF-I Receptor in Breast Cancer,"" Journal of Mammary Gland Biology and Neoplasia, 2000, vol. 5 (1), pp. 95-105.;;Trent J C., et al., ""Early effects of imatinib mesylate on the expression of insulin-like growth factor binding protein-3 and positron emission tomography in patients with gastrointestinal stromal tumor"", Cancer, 2006, vol. 107 (8), pp. 1898-1908.;;Trojan J., et al., ""Loss of tumorigenicity of rat glioblastoma directed by episome-based antisense cDNA transcription of insulin-like growth factor I"", Proc Natl Acad Sci, 1992, vol. 89 (11), pp. 4874-4878.;;Van Nimwegen M. J. et al., ""Focal Adhesion Kinase: A Potential Target in Cancer Therapy,"" Biochemical Pharmacology, 2007, vol. 73, pp. 597-609.;;Vella V., et al., ""A novel autocrine loop involving IGF-II and the insulin receptor isoform-A stimulates growth of thyroid cancer"", J Clin Endocrinol Metab., 2002, vol. 87 (1), pp. 245-254.;;Vella V., et al., ""The IGF system in thyroid cancer: new concepts"", Mol Pathol., 2001, vol. 54 (3), pp. 121-124.;;Walenkamp M.J.E., et al., ""Genetic Disorders in the Growth Hormone-Insulin-Like Growth Factor-I Axis,"" Hormone Research, 2006, vol. 66, pp. 221-230.;;Wu X., et al., ""Serum levels of insulin growth factor (IGF-I) and IGF-binding protein predict risk of second primary tumors in patients with head and neck cancer"", Clinical Cancer Research, 2004, vol. 10 (12), pp. 3988-3995.;;Yeh A H., et al., ""Human melanoma cells expressing V600E B-RAF are susceptible to IGF1R targeting by small interfering RNAs"", Oncogene, 2006, vol. 25 (50), pp. 6574-6581.;;Zhao H., et al., ""Plasma levels of insulin-like growth factor-1 and binding protein-3, and their association with bladder cancer risk"", The Journal of urology, 2003, vol. 169 (2), pp. 714-717.;;Zumkeller W., et al., ""Insulin-like growth factor system in neuroblastoma tumorigenesis and apoptosis: potential diagnostic and therapeutic perspectives"", Horm Metab Res. , 1999, vol. 31 (2-3), pp. 138-141.;;Zumkeller W., et al., ""The IGF/IGFBP system in CNS malignancy"", Mol Pathol. , 2001, vol. 54 (4), pp. 227-229.;;Zumkeller W., et al., ""The insulin-like growth factor system in hematopoietic cells"", Leuk Lymphoma. , 2002, vol. 43 (3), pp. 487-491.",INACTIVE
101,MX,A,MX 2011012632 A,178-861-839-622-228,2012-03-06,2012,MX 2011012632 A,2010-05-26,US 18154509 P;;US 2010/0036187 W,2009-05-27,PYRIMIDINE INHIBITORS OF KINASE ACTIVITY.,"Described herein are compounds of formula (I) or pharmaceutical acceptable salts or solvates thereof, wherein L<sup>1</sup>, R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, and m are defined in the description. Methods of making said compounds, and compositions containing said compounds which are useful for inhibiting kinases such as IGF-IR are also disclosed.",ABBOTT LAB,ERICKSON SCOTT A;;SHEPPARD GEORGE S;;WANG JIEYI;;FIDANZE STEVE D;;WANG GARY T;;BELL RANDY L;;MANTEI ROBERT A,ABBVIE INC. (2013-08-09),https://lens.org/178-861-839-622-228,Patent Application,no,0,0,10,10,0,C07D401/14;;C07D403/12;;C07D403/14;;C07D413/12;;C07D413/14;;C07D417/12;;C07D417/14;;A61P35/00;;A61P43/00;;C07D403/12;;C07D417/14;;C07D401/14;;C07D413/12;;C07D403/14;;C07D417/12;;C07D413/14,A61K31/506;;C07D401/14;;A61K35/00;;C07D403/12;;C07D403/14;;C07D413/12;;C07D413/14;;C07D417/12;;C07D417/14,,0,0,,,,ACTIVE
102,US,A1,US 2010/0305112 A1,051-442-998-109-075,2010-12-02,2010,US 78773510 A,2010-05-26,US 78773510 A;;US 18154509 P,2009-05-27,PYRIMIDINE INHIBITORS OF KINASE ACTIVITY,"Described herein are compounds of formula (I) or pharmaceutical acceptable salts or solvates thereof, wherein L 1 , R 1 , R 2 , R 3 , R 4 , R 5 , and m are defined in the description. Methods of making said compounds, and compositions containing said compounds which are useful for inhibiting kinases such as IGF-1R are also disclosed.",ABBOTT LAB,WANG GARY T;;MANTEI ROBERT A;;ERICKSON SCOTT A;;FIDANZE STEVE D;;SHEPPARD GEORGE S;;WANG JIEYI;;BELL RANDY L,ABBVIE INC (2012-08-01);;ABBOTT LABORATORIES (2010-08-11),https://lens.org/051-442-998-109-075,Patent Application,yes,0,1,10,10,0,C07D401/14;;C07D403/12;;C07D403/14;;C07D413/12;;C07D413/14;;C07D417/12;;C07D417/14;;A61P35/00;;A61P43/00;;C07D403/12;;C07D417/14;;C07D401/14;;C07D413/12;;C07D403/14;;C07D417/12;;C07D413/14,A61K31/541;;A61K31/496;;A61K31/506;;A61K31/5377;;A61P35/00;;C07D403/14;;C07D413/14;;C07D417/14,514/228.2;;544/295;;514/252.19;;514/252.18;;544/333;;514/256;;514/234.5;;544/122;;544/62,0,0,,,,INACTIVE
103,WO,A3,WO 2007/079164 A3,027-905-826-625-266,2007-09-27,2007,US 2006/0049461 W,2006-12-28,US 75468505 P,2005-12-29,PROTEIN KINASE INHIBITORS,"Compounds of formula (I) that inhibit protein kinases, compositions containing the compounds and methods of treating diseases using the compounds are disclosed.",ABBOTT LAB;;SHEPPARD GEORGE;;WANG GARY;;PALAZZO FABIO;;BELL RANDY;;MANTEI ROBERT;;WANG JIEYI;;HUBBARD ROBERT;;KAWAI MEGUMI;;ERICKSON SCOTT;;BAMAUNG NWE;;FIDANZE STEVE,SHEPPARD GEORGE;;WANG GARY;;PALAZZO FABIO;;BELL RANDY;;MANTEI ROBERT;;WANG JIEYI;;HUBBARD ROBERT;;KAWAI MEGUMI;;ERICKSON SCOTT;;BAMAUNG NWE;;FIDANZE STEVE,,https://lens.org/027-905-826-625-266,Search Report,yes,8,0,15,15,0,C07D487/04;;A61P35/00;;A61P35/02;;A61P43/00;;C07D487/04,C07D487/04;;A61K31/4985;;A61K31/519;;A61P35/00,,0,0,,,,PENDING
104,TW,A,TW 200801008 A,081-108-413-992-267,2008-01-01,2008,TW 95149591 A,2006-12-28,US 75468505 P,2005-12-29,Protein kinase inhibitors,"Compounds that inhibit protein kinases, compositions containing the compounds and methods of treating diseases using the compounds are disclosed.",ABBOTT LAB,SHEPPARD GEORGE;;WANG GARY;;PALAZZO FABIO;;BELL RANDY;;MANTEI ROBERT;;WANG JIEYI;;HUBBARD ROBERT;;KAWAI MEGUMI;;ERICKSON SCOTT;;BAMAUNG NWE;;FIDANZE STEVE,,https://lens.org/081-108-413-992-267,Patent of Addition,no,0,0,15,15,0,C07D487/04;;A61P35/00;;A61P35/02;;A61P43/00;;C07D487/04,C07D487/04;;A61K31/519;;A61P35/00,,0,0,,,,PENDING
105,JP,A,JP 2014088397 A,084-237-048-991-978,2014-05-15,2014,JP 2013254737 A,2013-12-10,US 75468505 P,2005-12-29,PROTEIN KINASE INHIBITOR,"PROBLEM TO BE SOLVED: To provide a chemical compound that inhibits protein kinase, a composition containing the chemical compound, and a method of treating diseases using the compound.SOLUTION: There are provided a chemical compound that is the compound represented by the formula (I) and selected from trans-1-(4-(2-methoxyethoxy)cyclohexyl)-3-(2-phenyl-1H-benzimidazole-5-yl)-1H-pyrazolo[3,4-d]pyrimidine-4-amine, cis-1-(4-(4-methylpiperazin-1-yl)cyclohexyl)-3-(2-phenyl-1H-benzimidazole-5-yl)-1H-pyrazolo[3,4-d]pyrimidine-4-amine, or trans-1-(4-morpholine-4-ylcyclohexyl)-3-(2-phenyl-1H-benzimidazole-5-yl)-1H-pyrazolo[3,4-d]pyrimidine-4-amine or the like for example, or salts of the chemical compound.",ABBVIE INC,GEORGE SHEPPARD;;GARY WANG;;FABIO PALAZZO;;RANDY BELL;;ROBERT MANTEI;;JIEYI WANG;;ROBERT HUBBARD;;MEGUMI KAWAI;;SCOTT ERICKSON;;NWE BAMAUNG;;STEVE FIDANZE,,https://lens.org/084-237-048-991-978,Patent Application,no,10,0,15,15,0,C07D487/04;;A61P35/00;;A61P35/02;;A61P43/00;;C07D487/04,C07D487/04;;A61K31/519;;A61K31/5377;;A61K31/54;;A61P35/00;;A61P35/02;;A61P43/00;;C07D519/00,,0,0,,,,PENDING
106,CN,A,CN 101389630 A,010-588-135-445-166,2009-03-18,2009,CN 200680053518 A,2006-12-28,US 75468505 P,2005-12-29,Protein kinase inhibitors,"The invention discloses compounds that inhibit protein kinases, compositions containing the compounds and methods of treating diseases using the compounds are disclosed.",ABBOTT LAB,GARY WANG;;FABIO PALAZZO;;ROBERT MANTEI;;JIEYI WANG;;STEVE FIDANZE;;NWE BAMAUNG;;SCOTT ERICKSON;;ROBERT HUBBARD;;MEGUMI KAWAI;;RANDY BELL;;GEORGE SHEPPARD,,https://lens.org/010-588-135-445-166,Patent Application,no,0,4,15,15,0,C07D487/04;;A61P35/00;;A61P35/02;;A61P43/00;;C07D487/04,C07D487/04;;A61K31/4985;;A61K31/519;;A61P35/00,,0,0,,,,DISCONTINUED
107,ES,T3,ES 2545907 T3,154-978-040-649-487,2015-09-16,2015,ES 06846085 T,2006-12-28,US 75468505 P;;US 2006/0049461 W,2005-12-29,Inhibidores de proteína quinasa,"Un compuesto que tiene Fórmula (25) **Fórmula** o una sal de la misma, donde Rx es un sustituyente opcional seleccionado entre el grupo que consiste en R6, OR6, SR6, S(O)R6, SO2R6, NH2, NHR6, N(R6)2, C(O)R6, C(O)OR6, C(O)NH2, C(O)NHR6, C(O)N(R6)2, NHC(O)R6, NR6C(O)R6, NHSO2R6, NR6SO2R6, NHC(O)OR6, NR6C(O)OR6, SO2NH2, SO2NHR6, SO2 N(R6)2, NHC(O)NH2, NHC(O)NHR6, NHC(O)N(R6)2, NR6C(O)N(R6)2, C(N)NH2, C(N)NHR6, C(N)N(R6)2, NHC(N)NH2, NHC(N)NHR6, NHC(N)N(R6)2, OH, (O), C(O)H, C(O)OH, NO2, CN, CF3, OCF3, CF2CF3, F, Cl, Br o I; B1 es R3, R4, R5 o W1; R3 es fenilo que está sin condensar o condensado con benceno, heteroareno o R3A; R3A es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno; R4 es heteroarilo que está sin condensar o condensado con benceno, heteroareno o R4A; R4A es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno; R5 es cicloalquilo, cicloalquenilo, heterocicloalquilo o heterocicloalquenilo, cada uno de los cuales está sin condensar o condensados con benceno, heteroareno o R5A; R5A es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno; W1 es alquilo, alquenilo o alquinilo, cada uno de los cuales está sin sustituir o sustituido con uno o dos de W2, W3, W4, OH, OW5, SW5, S(O)W5, SO2W5, NH2, NHW5, N(W5)2, C(O)NH2, C(O)NHW5, C(O)N(W5)2, NHC(O)W5 o NW5SC(O)W5 seleccionados independientemente; W2 es fenilo que está sin condensar o condensado con benceno, heteroareno o W2A; W2A es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno; W3 es heteroarilo que está sin condensar o condensado con benceno, heteroareno o W3A; W3A es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno; W4 es cicloalquilo, cicloalquenilo, heterocicloalquilo o heterocicloalquenilo, cada uno de los cuales está sin condensar o condensado con benceno, heteroareno o W5A; W5A es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno; W5 es alquilo, alquenilo o alquinilo; donde los restos representados por B1, W2, W3 y W4 están independientemente sin sustituir o sustituidos con uno o dos o tres o cuatro de R6, OR6, SR6, S(O)R6, SO2R6, NH2, NHR6, N(R6)2, C(O)R6, C(O)OR6, C(O)NH2, C(O)NHR6, C(O)N(R6)2, NHC(O)R6, NR6C(O)R6, NHSO2R6, NR6SO2R6, NHC(O)OR6, NR6C(O)OR6, SO2NH2, SO2NHR6, SO2 N(R6)2, NHC(O)NH2, NHC(O)NHR6, NHC(O)N(R6)2, NR6C(O)N(R6)2, C(N)NH2, C(N)NHR6, C(N)N(R6)2, NHC(N)NH2, NHC(N)NHR6, NHC(N)N(R6)2, OH, (O), C(O)H, C(O)OH, NO2, CN, CF3, OCF3, CF2CF3, F, Cl, Br o I seleccionados independientemente; R6 es R7, R8, R9 o R10; R7 es fenilo que está sin condensar o condensado con benceno, heteroareno o R7A; R7A es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno; R8 es heteroarilo que está sin condensar o condensado con benceno, heteroareno o R8A; R8A es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno; R9 es cicloalquilo, cicloalquenilo, heterocicloalquilo o heterocicloalquenilo, cada uno de los cuales está sin condensar o condensado con benceno, heteroareno o R9A; R9A es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno; R10 es alquilo, alquenilo o alquinilo, cada uno de los cuales está sin sustituir o sustituido con uno o dos de R11, OR11, SR11, S(O)R11, SO2R11, NH2, NHR11, N(R11)2, C(O)R11, C(O)NH2, C(O)NHR11, C(O)N(R11)2, NHC(O)R11, NR11C(O)R11, NHSO2R11, NR11SO2R11, NHC(O)OR11, NR11C(O)OR11, SO2NH2, SO2NHR11, SO2 N(R11)2, NHC(O)NH2, NHC(O)NHR11, NHC(O)N(R11)2, NR11C(O)N(R11)2 OH, (O), C(O)OH, CN, CF3, OCF3,CF2CF3, F, Cl, Br o I seleccionados independientemente; R11 es alquilo, alquenilo, alquinilo, R12, R13, R14 o T1; R12 es fenilo que está sin condensar o condensado con benceno, heteroareno o R12A; R12A es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno; R13 es heteroarilo que está sin condensar o condensado con benceno, heteroareno o R13A; R13A es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno; y R14 es cicloalquilo, cicloalquenilo, heterocicloalquilo o heterocicloalquenilo, cada uno de los cuales está sin condensar o condensado con benceno, heteroareno o R14A; R14A es cicloalcano, cicloalqueno, heterocicloalcano o heterocicloalqueno; T1 es alquilo, alquenilo o alquinilo, cada uno de los cuales está sustituido con uno o dos de OH, OT2, ST2, S(O)T2, NH2, NHT2 o N(T2)2 seleccionados independientemente; T2 es alquilo, alquenilo o alquinilo; donde los restos representados por R7, R8, R9 y R11 están independientemente sin sustituir o sustituidos con uno o dos o tres o cuatro de R15, OR15, SR15, S(O)R15, SO2R15, C(O)R15, C(O)(O)R15, C(O)NH2, C(O)NHR15, C(O)N(R15)2, OH, (O), C(O)OH, CN, CF3, OCF3, CF2CF3, F , Cl, Br o I seleccionados independientemente; donde R15 es alquilo, alquenilo, alquinilo, cada uno de los cuales está sin sustituir o sustituido con fenilo, heteroarilo, cicloalquilo, heterocicloalquilo, OH, OR16, C(O)NH2, C(O)NHR16, C(O)N(R16)2, donde R16 es alquilo, alquenilo o alquinilo; y donde el fenilo, heteroarilo, cicloalquilo y heterocicloalquilo de R15 están sin sustituir o sustituidos con O(alquilo).",ABBVIE INC,SHEPPARD GEORGE;;WANG GARY;;PALAZZO FABIO;;BELL RANDY;;MANTEI ROBERT;;WANG JIEYI;;HUBBARD ROBERT;;KAWAI MEGUMI;;ERICKSON SCOTT;;BAMAUNG NWE;;FIDANZE STEVE,,https://lens.org/154-978-040-649-487,Granted Patent,no,0,0,15,15,0,C07D487/04;;A61P35/00;;A61P35/02;;A61P43/00;;C07D487/04,C07D487/04,,0,0,,,,ACTIVE
108,CA,C,CA 2635231 C,014-680-329-928-315,2014-07-15,2014,CA 2635231 A,2006-12-28,US 75468505 P;;US 2006/0049461 W,2005-12-29,PROTEIN KINASE INHIBITORS,"Compounds of formula (I) that inhibit protein kinases, compositions containing the compounds and methods of treating diseases using the compounds are disclosed.",ABBOTT LAB,SHEPPARD GEORGE;;WANG GARY;;PALAZZO FABIO;;BELL RANDY;;MANTEI ROBERT;;WANG JIEYI;;HUBBARD ROBERT;;KAWAI MEGUMI;;ERICKSON SCOTT;;BAMAUNG NWE;;FIDANZE STEVE,,https://lens.org/014-680-329-928-315,Granted Patent,no,0,0,15,15,0,C07D487/04;;A61P35/00;;A61P35/02;;A61P43/00;;C07D487/04,C07D487/04;;A61K31/4985;;A61K31/519;;A61P35/00,,0,0,,,,INACTIVE
109,TW,A,TW 201307354 A,189-055-771-874-543,2013-02-16,2013,TW 101142523 A,2006-12-28,US 75468505 P,2005-12-29,Protein kinase inhibitors,"Compounds that inhibit protein kinases, compositions containing the compounds and methods of treating diseases using the compounds are disclosed.",ABBOTT LAB,GEORGE SHEPPARD;;WANG GARY;;PALAZZO FABIO;;BELL RANDY;;MANTEI ROBERT;;WANG JIEYI;;HUBBARD ROBERT;;KAWAI MEGUMI;;ERICKSON SCOTT;;BAMAUNG NWE;;FIDANZE STEVE,,https://lens.org/189-055-771-874-543,Patent of Addition,no,0,0,15,15,0,C07D487/04;;A61P35/00;;A61P35/02;;A61P43/00;;C07D487/04,C07D487/04;;A61K31/519;;A61P35/00,,0,0,,,,PENDING
110,CA,A1,CA 2635231 A1,050-552-017-420-642,2007-07-12,2007,CA 2635231 A,2006-12-28,US 75468505 P;;US 2006/0049461 W,2005-12-29,PROTEIN KINASE INHIBITORS,,ABBOTT LAB,WANG GARY;;PALAZZO FABIO;;MANTEI ROBERT;;WANG JIEYI;;FIDANZE STEVE;;BAMAUNG NWE;;ERICKSON SCOTT;;HUBBARD ROBERT;;KAWAI MEGUMI;;BELL RANDY;;SHEPPARD GEORGE,,https://lens.org/050-552-017-420-642,Patent Application,no,0,0,15,15,0,C07D487/04;;A61P35/00;;A61P35/02;;A61P43/00;;C07D487/04,C07D487/04;;A61K31/4985;;A61K31/519;;A61P35/00,,0,0,,,,INACTIVE
111,EP,A2,EP 1973917 A2,196-398-987-356-276,2008-10-01,2008,EP 06846085 A,2006-12-28,US 2006/0049461 W;;US 75468505 P,2005-12-29,PROTEIN KINASE INHIBITORS,,ABBOTT LAB,SHEPPARD GEORGE;;WANG GARY;;PALAZZO FABIO;;BELL RANDY;;MANTEI ROBERT;;WANG JIEYI;;HUBBARD ROBERT;;KAWAI MEGUMI;;ERICKSON SCOTT;;BAMAUNG NWE;;FIDANZE STEVE,ABBVIE INC. (2013-06-12),https://lens.org/196-398-987-356-276,Patent Application,yes,0,0,15,15,0,C07D487/04;;A61P35/00;;A61P35/02;;A61P43/00;;C07D487/04,C07D487/04,,0,0,,,,ACTIVE
112,WO,A2,WO 2007/079164 A2,005-846-202-710-053,2007-07-12,2007,US 2006/0049461 W,2006-12-28,US 75468505 P,2005-12-29,PROTEIN KINASE INHIBITORS,"Compounds that inhibit protein kinases, compositions containing the compounds and methods of treating diseases using the compounds are disclosed.",ABBOTT LAB;;SHEPPARD GEORGE;;WANG GARY;;PALAZZO FABIO;;BELL RANDY;;MANTEI ROBERT;;WANG JIEYI;;HUBBARD ROBERT;;KAWAI MEGUMI;;ERICKSON SCOTT;;BAMAUNG NWE;;FIDANZE STEVE,SHEPPARD GEORGE;;WANG GARY;;PALAZZO FABIO;;BELL RANDY;;MANTEI ROBERT;;WANG JIEYI;;HUBBARD ROBERT;;KAWAI MEGUMI;;ERICKSON SCOTT;;BAMAUNG NWE;;FIDANZE STEVE,,https://lens.org/005-846-202-710-053,Patent Application,yes,0,126,15,15,0,C07D487/04;;A61P35/00;;A61P35/02;;A61P43/00;;C07D487/04,,,15,5,099-503-061-558-195;;082-027-526-395-831;;000-032-742-203-955;;100-242-062-723-667;;033-240-400-895-908,10.1177/108705719900400605;;10838427;;10.1016/0304-419x(94)90012-4;;7819273;;11248153;;10.1056/nejm200103153441101;;10.1006/bbrc.1997.8043;;9480838;;10.1002/0470021209,"PURE APPL. CHEM., vol. 45, 1976, pages 13 - 10;;MATHIS, G.: ""HTRF(R) Technology"", J BIOMOL. SCREEN, vol. 4, no. 6, 1999, pages 309 - 314;;ENDOCRINE REV., vol. 21, 2000, pages 215;;BR. J. CANCER, vol. 92, 2005, pages 1467;;CYTOKINE GROWTH FACTOR REV., vol. 7, 1996, pages 133;;BIOCHEM. PHARM., vol. 51, 1996, pages 1101;;BIOCHEM. BIOPHYS. ACTA, vol. 1198, 1994, pages 165;;NEW ENG. J. MED., vol. 344, 2001, pages 783;;CANCER METASTASIS REV, vol. 22, 2003, pages 337;;J. CLIN. INVEST., vol. 91, 1993, pages 53;;BBRC, vol. 243, 1998, pages 503;;SCIENCE, vol. 279, 1998, pages 577;;NELM, vol. 344, 2001, pages 1038;;J. TSUJI: ""Palladium Reagents And Catalysts: New Perspeotives For The 21st Century"", 2004, JOHN WILEY & SONS, LTD., pages: 1 - 670;;J. TSUJI: ""Palladium Reagents And Catalysts: New Perspectives For The 21st Century"", 2004, JOHN WILEY & SONS, LTD., pages: 1 - 670",PENDING
113,EP,B1,EP 1973917 B1,182-008-394-236-514,2015-06-10,2015,EP 06846085 A,2006-12-28,US 2006/0049461 W;;US 75468505 P,2005-12-29,PROTEIN KINASE INHIBITORS,,ABBVIE INC,SHEPPARD GEORGE;;WANG GARY;;PALAZZO FABIO;;BELL RANDY;;MANTEI ROBERT;;WANG JIEYI;;HUBBARD ROBERT;;KAWAI MEGUMI;;ERICKSON SCOTT;;BAMAUNG NWE;;FIDANZE STEVE,ABBVIE INC. (2013-06-12),https://lens.org/182-008-394-236-514,Granted Patent,yes,8,0,15,15,0,C07D487/04;;A61P35/00;;A61P35/02;;A61P43/00;;C07D487/04,C07D487/04,,0,0,,,,ACTIVE
114,US,A1,US 2005/0014116 A1,114-744-149-148-579,2005-01-20,2005,US 30581102 A,2002-11-27,US 30581102 A,2002-11-27,Testing information comprehension of contact center users,New functions for a contact center system include: testing user's comprehension of informational messages with a quiz; capturing insight of superior users having a KPI score above a threshold by having those users submit information on why they perform so well; dynamically ordering solutions to issues by re-ranking the solutions periodically based on recency and frequency; integrating information for use by a contact center representative while online with a customer and information for use when not online; storing content items in a telecommunications industry taxonomy; directing user feedback on a content item to the proper owner/manager of that content; communicating solution information using a solutions taxonomy; displaying a dual information system having a CRM application as well as reference material that is context-appropriate; enforcing completion of a group of templates when creating a content item to be published; ensuring a group of templates for a content item are complete before publishing them; and searching within a contact center system portal using a continuum of search functions.,REID GREGORY S.;;RINGO TIMOTHY;;LANE DAVID P.;;LIAN ELIZABETH H.;;FARRELL DANIEL C.;;FENTON CRAIG;;SHEARING ELISE;;BELL RANDY;;WONG SEVASTI;;LINGHAM ANTHONY;;FORRESTER AUDREY,REID GREGORY S;;RINGO TIMOTHY;;LANE DAVID P;;LIAN ELIZABETH H;;FARRELL DANIEL C;;FENTON CRAIG;;SHEARING ELISE;;BELL RANDY;;WONG SEVASTI;;LINGHAM ANTHONY;;FORRESTER AUDREY,ACCENTURE GLOBAL SERVICES GMBH (2003-03-12),https://lens.org/114-744-149-148-579,Patent Application,yes,98,7,2,16,0,G09B7/00;;G09B7/00,G09B7/00,434/322;;434/323,0,0,,,,DISCONTINUED
115,AU,B2,AU 2008/207336 B2,178-321-977-753-835,2011-05-12,2011,AU 2008/207336 A,2008-08-15,AU 2003/304335 A;;AU 2008/207336 A;;IB 0306512 W;;US 30581102 A;;US 30657702 A,2002-11-27,Information system for contact center users,,ACCENTURE GLOBAL SERVICES LTD,BELL RANDY;;FENTON CRAIG;;REID GREGORY S;;LINGHAM ANTHONY;;LANE DAVID P;;SHEARING ELISE;;FARRELL DANIEL C;;RINGO TIMOTHY;;WONG SEVASTI;;FORRESTER AUDREY;;LIAN ELIZABETH H,ACCENTURE GLOBAL SERVICES LIMITED (2010-12-09),https://lens.org/178-321-977-753-835,Granted Patent,no,4,0,12,16,0,G09B7/00,G09B5/00;;G09B7/00,,0,0,,,,EXPIRED
116,US,B2,US 7502997 B2,166-048-445-689-246,2009-03-10,2009,US 30656302 A,2002-11-27,US 30656302 A;;US 30602602 A,2002-11-27,Ensuring completeness when publishing to a content management system,New functions for a contact center system include: testing user's comprehension of informational messages with a quiz; capturing insight of superior users having a KPI score above a threshold by having those users submit information on why they perform so well; dynamically ordering solutions to issues by re-ranking the solutions periodically based on recency and frequency; integrating information for use by a contact center representative while online with a customer and information for use when not online; storing content items in a telecommunications industry taxonomy; directing user feedback on a content item to the proper owner/manager of that content; communicating solution information using a solutions taxonomy; displaying a dual information system having a CRM application as well as reference material that is context-appropriate; enforcing completion of a group of templates when creating a content item to be published; ensuring a group of templates for a content item are complete before publishing them; and searching within a contact center system portal using a continuum of search functions.,ACCENTURE GLOBAL SERVICES GMBH,REID GREGORY S;;RINGO TIMOTHY;;LANE DAVID P;;LIAN ELIZABETH H;;FARRELL DANIEL C;;FENTON CRAIG;;SHEARING ELISE;;BELL RANDY;;WONG SEVASTI;;LINGHAM ANTHONY;;FORRESTER AUDREY,ACCENTURE GLOBAL SERVICES LIMITED (2010-09-01);;ACCENTURE GLOBAL SERVICES GMBH (2003-11-02),https://lens.org/166-048-445-689-246,Granted Patent,yes,105,7,12,12,0,G06F16/957;;G06F16/957,G06F17/00;;G06F7/00,715/243;;715/234;;715/255;;715/751;;705/1;;719/316,37,0,,,"M.J. Allend and J.P. Furming, ""Methods for Using Global Position System to Find Close Services"", IBM Technical Disclosure Bulletin, Jan. 1998, pp. 693, vol. 41 No. 1.;;Dayco Statement Regarding Related Applications.;;Cunliffe, Alison, Super systems capture expertise of the specialist Toronto Star, Nov. 2, 1986.;;Emvolve Performance Manager Release 1.5 Customer Inter@action Solutions, vol. 20, No. 5, Nov. 20, 2001, pp. 53-56.;;ServiceSoft Delivers ""Smart Answers"" at Xerox Business Wire, Aug. 4, 1998.;;Tiwana, Amrit, The Knowledge Management Toolkit Prentice Hall, Dec. 1999, ISN: 0-13-012853-8.;;Office Action issued Sep. 20, 2007 by EPO on Chinese Application No. 200380106314.X.;;Office Action issued Oct. 19, 2007 by US PTO on U.S. Appl. No. 10/305,858.;;Office Action issued by US PTO on U.S. Appl. No. 10/306,705, dated Oct. 9, 2007.;;Office Action issued by EPO on Application No. 03808324.2-2221 dated Jul. 30, 2007 regarding summons to attend oral proceedings on Dec. 13, 2007.;;Alban, Oscar, Customer interaction monitoring: your key to measuring service performance, Australian Banking & Finance, vol. 10, No. 6, Apr. 18, 2001.;;Click2Coach Web Pages, Retrieved from www.envisiontelephony.com, 2001.;;eOn Communications and Eyretel Partner to Deliver Performance Improvement For Contact Centers, PR Newswire, Apr. 4, 2002.;;Feasel, Marnie et al., Training Can Produce Better Reps, Call Center Solutions, vol. 17, No. 4, Oct. 1998, pp. 138-143.;;Kelly Services Expands KellyConnect Call Center Solution, PR Newswire, Jan. 14, 2002.;;Kelly Services Offers Improved Call Center Solution, PR Newswire, Apr. 24, 2000.;;Knowlagent and Eyretel Partner to Deliver Integrated E-Learning Platform to Global Clients, PR Newswire, May 10, 2001.;;Primus Taps OutSights to Deliver Expertise to Customers Shifting to Knowledge-Based Support, Business Wire, Jun. 29, 1999.;;Rosati, Marlene et al., Measuring the Reality of the Customer Experience, Customer Interaction Solutions, May 2002, pp. 38-43.;;Televista Integrates eLearning and Quality Monitoring The Ascent Group, Inc. Call Center E-Journal, Aug. 2001.;;What makes your contact agents truly effective?, Envision Telephony, Click2Coach, 2000.;;Examiner's Report No. 2 issued by IP australia May 29, 2008 on Application #2003302349.;;Office Action issued Jun. 9, 2008 by US PTO on U.S. Appl. No. 10/306,564.;;Office Action issued Dec. 8, 2007 by EPO on Japanese Application No. 2004-554864.;;Office Action issued Dec. 8, 2007 by EPO on Japanese Application No. 2004-554863.;;Office Action issued Dec. 8, 2007 by EPO on Japanese Application No. 2004-554862.;;Office Action issued Dec. 8, 2007 by EPO on Japanese Application No. 2004-554870.;;Office Action issued Feb. 22, 2008 by EPO regarding decision on oral proceedings on Application No. 03808324.2-221.;;Office Action issued Mar. 19, 2008 by US PTO on U.S. Appl. No. 10/307,705.;;Notice of Allowance issued Apr. 9, 2008 by the US PTO on U.S. Appl. No. 10/306,025.;;Office Action issued Dec. 11, 20007 by US PTO on U.S. Appl. No. 10/306,025.;;Office Action issued Dec. 11, 2007 by US PTO on U.S. Appl. No. 10/306,386.;;Office Action issued Jan. 7, 2008 by US PTO on U.S. Appl. No. 10/306,248.;;Office Action issued Jan. 7, 2008 by US PTO on U.S. Appl. No. 10/306,564.;;Office Action issued Jan. 18, 2008 by US PTO on U.S. Appl. No. 10/305,811.;;Office Action issued Jan. 28, 2008 by US PTO on U.S. Appl. No. 10/306,026.;;Office Action issued Jan. 29, 2008 by US PTO on U.S. Appl. No. 10/306,386.",EXPIRED
117,AU,A1,AU 2003/304335 A1,195-012-463-028-06X,2005-01-28,2005,AU 2003/304335 A,2003-11-26,IB 0306512 W;;US 30581102 A;;US 30657702 A,2002-11-27,INFORMATION SYSTEM FOR CONTACT CENTER USERS,,ACCENTURE GLOBAL SERVICES GMBH,REID GREGORY S;;RINGO TIMOTHY;;LANE DAVID P;;LIAN ELIZABETH H;;FARRELL DANIEL C;;FENTON CRAIG;;SHEARING ELISE;;BELL RANDY;;WONG SEVASTI;;LINGHAM ANTHONY;;FORRESTER AUDREY,ACCENTURE GLOBAL SERVICES LIMITED (2010-12-09),https://lens.org/195-012-463-028-06X,Patent Application,no,0,1,12,16,0,G09B7/00,G09B5/00;;G09B7/00,,0,0,,,,EXPIRED
118,AU,B2,AU 2003/302251 B2,099-598-930-530-384,2008-05-22,2008,AU 2003/302251 A,2003-11-26,IB 0306438 W;;US 30602602 A;;US 30656302 A,2002-11-27,Template completion for a content management system,,ACCENTURE GLOBAL SERVICES LTD,REID GREGORY S;;BELL RANDY;;LANE DAVID P;;FARRELL DANIEL C;;FORRESTER AUDREY;;RINGO TIMOTHY;;WONG SEVASTI;;FENTON CRAIG;;SHEARING ELISE;;LIAN ELIZABETH H;;LINGHAM ANTHONY,ACCENTURE GLOBAL SERVICES LIMITED (2010-12-09),https://lens.org/099-598-930-530-384,Granted Patent,no,1,0,12,12,0,G06F16/957;;G06F16/957,G06Q90/00;;G06F7/00;;G06F17/00,,0,0,,,,EXPIRED
119,AU,B9,AU 2003/304335 B9,181-805-297-302-036,2008-07-24,2008,AU 2003/304335 A,2003-11-26,IB 0306512 W;;US 30581102 A;;US 30657702 A,2002-11-27,Information system for contact center users,,ACCENTURE GLOBAL SERVICES LTD,REID GREGORY S;;LANE DAVID P;;FORRESTER AUDREY;;FENTON CRAIG;;BELL RANDY;;WONG SEVASTI;;LIAN ELIZABETH H;;RINGO TIMOTHY;;FARRELL DANIEL C;;LINGHAM ANTHONY;;SHEARING ELISE,ACCENTURE GLOBAL SERVICES LIMITED (2010-12-09),https://lens.org/181-805-297-302-036,Amended Patent,no,2,0,12,16,0,G09B7/00,G09B5/00;;G09B7/00,,0,0,,,,EXPIRED
120,US,A1,US 2004/0100493 A1,070-712-055-192-316,2004-05-27,2004,US 30670502 A,2002-11-27,US 30670502 A,2002-11-27,Dynamically ordering solutions,"
   New functions for a contact center system include: testing user's comprehension of informational messages with a quiz; capturing insight of superior users having a KPI score above a threshold by having those users submit information on why they perform so well; dynamically ordering solutions to issues by re-ranking the solutions periodically based on recency and frequency; integrating information for use by a contact center representative while online with a customer and information for use when not online; storing content items in a telecommunications industry taxonomy; directing user feedback on a content item to the proper owner/manager of that content; communicating solution information using a solutions taxonomy; displaying a dual information system having a CRM application as well as reference material that is context-appropriate; enforcing completion of a group of templates when creating a content item to be published; ensuring a group of templates for a content item are complete before publishing them; and searching within a contact center system portal using a continuum of search functions. 
",REID GREGORY S.;;RINGO TIMOTHY;;LANE DAVID P.;;LIAN ELIZABETH H.;;FARRELL DANIEL C.;;FENTON CRAIG;;SHEARING ELISE;;BELL RANDY;;WONG SEVASTI;;LINGHAM ANTHONY;;FORRESTER AUDREY,REID GREGORY S;;RINGO TIMOTHY;;LANE DAVID P;;LIAN ELIZABETH H;;FARRELL DANIEL C;;FENTON CRAIG;;SHEARING ELISE;;BELL RANDY;;WONG SEVASTI;;LINGHAM ANTHONY;;FORRESTER AUDREY,ACCENTURE GLOBAL SERVICES GMBH (2003-03-11),https://lens.org/070-712-055-192-316,Patent Application,yes,81,12,1,13,0,G06Q10/10;;G06Q30/02;;G06Q10/10;;G06Q30/02,G06Q10/10;;G06Q30/02,345/745,0,0,,,,DISCONTINUED
121,WO,A8,WO 2004/049220 A8,120-135-404-849-991,2004-09-10,2004,IB 0306438 W,2003-11-26,US 30602602 A;;US 30656302 A,2002-11-27,TEMPLATE COMPLETION FOR A CONTENT MANAGEMENT SYSTEM,,ACCENTURE GLOBAL SERVICES GMBH,REID GREGORY S;;RINGO TIMOTHY;;LANE DAVID P;;LIAN ELIZABETH H;;FARRELL DANIEL C;;FENTON CRAIG;;SHEARING ELISE;;BELL RANDY;;WONG SEVASTI;;LINGHAM ANTHONY;;FORRESTER AUDREY,,https://lens.org/120-135-404-849-991,Patent Application,no,0,0,12,12,0,G06F16/957;;G06F16/957,G06F7/00;;G06F17/00,,0,0,,,,PENDING
122,AU,B2,AU 2003/304335 B2,160-703-269-861-333,2008-05-29,2008,AU 2003/304335 A,2003-11-26,IB 0306512 W;;US 30581102 A;;US 30657702 A,2002-11-27,Information system for contact center users,,ACCENTURE GLOBAL SERVICES GMBH,REID GREGORY S;;LANE DAVID P;;FORRESTER AUDREY;;FENTON CRAIG;;BELL RANDY;;WONG SEVASTI;;LIAN ELIZABETH H;;RINGO TIMOTHY;;FARRELL DANIEL C;;LINGHAM ANTHONY;;SHEARING ELISE,ACCENTURE GLOBAL SERVICES LIMITED (2010-12-09),https://lens.org/160-703-269-861-333,Granted Patent,no,2,0,12,16,0,G09B7/00,G09B5/00;;G09B7/00,,0,0,,,,EXPIRED
123,CA,A1,CA 2507608 A1,161-977-417-369-573,2004-06-10,2004,CA 2507608 A,2003-11-26,IB 0306438 W;;US 30602602 A;;US 30656302 A,2002-11-27,TEMPLATE COMPLETION FOR A CONTENT MANAGEMENT SYSTEM,Published without an,ACCENTURE GLOBAL SERVICES GMBH,FORRESTER AUDREY;;BELL RANDY;;FARRELL DANIEL C;;LANE DAVID P;;RINGO TIMOTHY;;WONG SEVASTI;;REID GREGORY S;;LIAN ELIZABETH H;;LINGHAM ANTHONY;;SHEARING ELISE;;FENTON CRAIG,,https://lens.org/161-977-417-369-573,Patent Application,no,0,0,12,12,0,G06F16/957;;G06F16/957,G06F7/00;;G06F17/00,,0,0,,,,PENDING
124,WO,A9,WO 2005/006565 A9,089-013-659-693-477,2005-05-26,2005,IB 0306512 W,2003-11-26,US 30581102 A;;US 30657702 A,2002-11-27,INFORMATION SYSTEM FOR CONTACT CENTER USERS,,ACCENTURE GLOBAL SERVICES GMBH,REID GREGORY S;;RINGO TIMOTHY;;LANE DAVID P;;LIAN ELIZABETH H;;FARRELL DANIEL C;;FENTON CRAIG;;SHEARING ELISE;;BELL RANDY;;WONG SEVASTI;;LINGHAM ANTHONY;;FORRESTER AUDREY,,https://lens.org/089-013-659-693-477,Patent Application,no,0,0,12,16,0,G09B7/00,G09B5/00;;G09B7/00,,0,0,,,,PENDING
125,US,A1,US 2004/0162801 A1,196-979-667-734-253,2004-08-19,2004,US 30657702 A,2002-11-27,US 30657702 A,2002-11-27,Dual information system for contact center users,"
   New functions for a contact center system include: testing user's comprehension of informational messages with a quiz; capturing insight of superior users having a KPI score above a threshold by having those users submit information on why they perform so well; dynamically ordering solutions to issues by re-ranking the solutions periodically based on recency and frequency; integrating information for use by a contact center representative while online with a customer and information for use when not online; storing content items in a telecommunications industry taxonomy; directing user feedback on a content item to the proper owner/manager of that content; communicating solution information using a solutions taxonomy; displaying a dual information system having a CRM application as well as reference material that is context-appropriate; enforcing completion of a group of templates when creating a content item to be published; ensuring a group of templates for a content item are complete before publishing them; and searching within a contact center system portal using a continuum of search functions. 
",REID GREGORY S.;;RINGO TIMOTHY;;LANE DAVID P.;;LIAN ELIZABETH H.;;FARRELL DANIEL C.;;FENTON CRAIG;;SHEARING ELISE;;BELL RANDY;;WONG SEVASTI;;LINGHAM ANTHONY;;FORRESTER AUDREY,REID GREGORY S;;RINGO TIMOTHY;;LANE DAVID P;;LIAN ELIZABETH H;;FARRELL DANIEL C;;FENTON CRAIG;;SHEARING ELISE;;BELL RANDY;;WONG SEVASTI;;LINGHAM ANTHONY;;FORRESTER AUDREY,ACCENTURE GLOBAL SERVICES LIMITED (2010-09-01);;ACCENTURE GLOBAL SERVICES GMBH (2003-11-02),https://lens.org/196-979-667-734-253,Patent Application,yes,61,2,2,16,0,G09B7/00;;G09B7/00;;Y10S707/99945;;Y10S707/99948,G09B7/00,707/1,0,0,,,,EXPIRED
126,AU,B8,AU 2003/304335 B8,003-016-425-368-86X,2008-07-10,2008,AU 2003/304335 A,2003-11-26,IB 0306512 W;;US 30581102 A;;US 30657702 A,2002-11-27,Information system for contact center users,,ACCENTURE GLOBAL SERVICES GMBH,REID GREGORY S;;LANE DAVID P;;FORRESTER AUDREY;;FENTON CRAIG;;BELL RANDY;;WONG SEVASTI;;LIAN ELIZABETH H;;RINGO TIMOTHY;;FARRELL DANIEL C;;LINGHAM ANTHONY;;SHEARING ELISE,ACCENTURE GLOBAL SERVICES LIMITED (2010-12-09),https://lens.org/003-016-425-368-86X,Amended Patent,no,2,0,12,16,0,G09B7/00,G09B5/00;;G09B7/00,,0,0,,,,EXPIRED
127,EP,A2,EP 1565859 A2,068-088-834-236-324,2005-08-24,2005,EP 03808324 A,2003-11-26,IB 0306438 W;;US 30602602 A;;US 30656302 A,2002-11-27,TEMPLATE COMPLETION FOR A CONTENT MANAGEMENT SYSTEM,,ACCENTURE GLOBAL SERVICES GMBH,REID GREGORY S;;RINGO TIMOTHY;;LANE DAVID P;;LIAN ELIZABETH H;;FARRELL DANIEL C;;FENTON CRAIG;;SHEARING ELISE;;BELL RANDY;;WONG SEVASTI;;LINGHAM ANTHONY;;FORRESTER AUDREY,ACCENTURE GLOBAL SERVICES GMBH (2005-08-31),https://lens.org/068-088-834-236-324,Patent Application,yes,0,0,12,12,0,G06F16/957;;G06F16/957,G06F7/00;;G06F17/00,,0,0,,,,DISCONTINUED
128,WO,A8,WO 2005/006565 A8,189-026-025-604-792,2005-07-14,2005,IB 0306512 W,2003-11-26,US 30581102 A;;US 30657702 A,2002-11-27,INFORMATION SYSTEM FOR CONTACT CENTER USERS,,ACCENTURE GLOBAL SERVICES GMBH,REID GREGORY S;;RINGO TIMOTHY;;LANE DAVID P;;LIAN ELIZABETH H;;FARRELL DANIEL C;;FENTON CRAIG;;SHEARING ELISE;;BELL RANDY;;WONG SEVASTI;;LINGHAM ANTHONY;;FORRESTER AUDREY,,https://lens.org/189-026-025-604-792,Patent Application,no,0,0,12,16,0,G09B7/00,G09B5/00;;G09B7/00,,0,0,,,,PENDING
129,EP,A2,EP 1565864 A2,179-040-471-395-618,2005-08-24,2005,EP 03817417 A,2003-11-26,IB 0306512 W;;US 30581102 A;;US 30657702 A,2002-11-27,INFORMATION SYSTEM FOR CONTACT CENTER USERS,,ACCENTURE GLOBAL SERVICES GMBH,REID GREGORY S;;RINGO TIMOTHY;;LANE DAVID P;;LIAN ELIZABETH H;;FARRELL DANIEL C;;FENTON CRAIG;;SHEARING ELISE;;BELL RANDY;;WONG SEVASTI;;LINGHAM ANTHONY;;FORRESTER AUDREY,ACCENTURE GLOBAL SERVICES GMBH (2005-08-31),https://lens.org/179-040-471-395-618,Patent Application,yes,0,0,12,16,0,G09B7/00,G09B5/00;;G09B7/00,,0,0,,,,DISCONTINUED
130,US,A1,US 2004/0103089 A1,004-163-175-443-607,2004-05-27,2004,US 30602602 A,2002-11-27,US 30602602 A;;US 30656302 A,2002-11-27,Enforcing template completion when publishing to a content management system,"
   New functions for a contact center system include: testing user's comprehension of informational messages with a quiz; capturing insight of superior users having a KPI score above a threshold by having those users submit information on why they perform so well; dynamically ordering solutions to issues by re-ranking the solutions periodically based on recency and frequency; integrating information for use by a contact center representative while online with a customer and information for use when not online; storing content items in a telecommunications industry taxonomy; directing user feedback on a content item to the proper owner/manager of that content; communicating solution information using a solutions taxonomy; displaying a dual information system having a CRM application as well as reference material that is context-appropriate; enforcing completion of a group of templates when creating a content item to be published; ensuring a group of templates for a content item are complete before publishing them; and searching within a contact center system portal using a continuum of search functions. 
",LANE DAVID P.;;REID GREGORY S.;;RINGO TIMOTHY;;LIAN ELIZABETH H.;;FARRELL DANIEL C.;;FENTON CRAIG;;SHEARING ELISE;;BELL RANDY;;WONG SEVASTI;;LINGHAM ANTHONY;;FORRESTER AUDREY,LANE DAVID P;;REID GREGORY S;;RINGO TIMOTHY;;LIAN ELIZABETH H;;FARRELL DANIEL C;;FENTON CRAIG;;SHEARING ELISE;;BELL RANDY;;WONG SEVASTI;;LINGHAM ANTHONY;;FORRESTER AUDREY,ACCENTURE GLOBAL SERVICES LIMITED (2010-09-01);;ACCENTURE GLOBAL SERVICES GMBH (2003-11-02),https://lens.org/004-163-175-443-607,Patent Application,yes,66,15,12,12,0,G06F16/957;;G06F16/957,G06F7/00;;G06F17/00,707/3,0,0,,,,EXPIRED
131,US,A1,US 2004/0128611 A1,148-430-372-989-68X,2004-07-01,2004,US 30656302 A,2002-11-27,US 30656302 A;;US 30602602 A,2002-11-27,Ensuring completeness when publishing to a content management system,"
   New functions for a contact center system include: testing user's comprehension of informational messages with a quiz; capturing insight of superior users having a KPI score above a threshold by having those users submit information on why they perform so well; dynamically ordering solutions to issues by re-ranking the solutions periodically based on recency and frequency; integrating information for use by a contact center representative while online with a customer and information for use when not online; storing content items in a telecommunications industry taxonomy; directing user feedback on a content item to the proper owner/manager of that content; communicating solution information using a solutions taxonomy; displaying a dual information system having a CRM application as well as reference material that is context-appropriate; enforcing completion of a group of templates when creating a content item to be published; ensuring a group of templates for a content item are complete before publishing them; and searching within a contact center system portal using a continuum of search functions. 
",REID GREGORY S.;;RINGO TIMOTHY;;LANE DAVID P.;;LIAN ELIZABETH H.;;FARRELL DANIEL C.;;FENTON CRAIG;;SHEARING ELISE;;BELL RANDY;;WONG SEVASTI;;LINGHAM ANTHONY;;FORRESTER AUDREY,REID GREGORY S;;RINGO TIMOTHY;;LANE DAVID P;;LIAN ELIZABETH H;;FARRELL DANIEL C;;FENTON CRAIG;;SHEARING ELISE;;BELL RANDY;;WONG SEVASTI;;LINGHAM ANTHONY;;FORRESTER AUDREY,ACCENTURE GLOBAL SERVICES LIMITED (2010-09-01);;ACCENTURE GLOBAL SERVICES GMBH (2003-11-02),https://lens.org/148-430-372-989-68X,Patent Application,yes,49,11,12,12,0,G06F16/957;;G06F16/957,G06F7/00;;G06F17/00,7155,0,0,,,,EXPIRED
132,WO,A2,WO 2004/049220 A2,140-152-412-642-173,2004-06-10,2004,IB 0306438 W,2003-11-26,US 30602602 A;;US 30656302 A,2002-11-27,TEMPLATE COMPLETION FOR A CONTENT MANAGEMENT SYSTEM,"A method for enforcing template usage or completion when entering a content item into a content management system may include providing a set of content authoring templates. Then the content item may be categorized as a content type. A set of templates (from the plurality of content authoring templates) may be chosen for the user based on the content type. The set of templates may be presented to the user to describe the content item. In one embodiment, the categorizing may be based on a position of the content item within a content taxonomy. In one embodiment, a pre-defined content authoring workflow for enforcing full completion of the chosen set of templates may be used. Such a workflow may include a series of steps for content authoring that are scheduled and executed using user tasks. A personal work stack may be provided to the user, which supplies the user with the user tasks to complete and information on the state of completion for the chosen set of templates. In one embodiment, template usage may be enforced when entering a content item into a content management system. To ensure completeness when publishing information on products and services after the group of templates is provided to the user(s), pieces of content for the templates may be received. In one embodiment, it may be determined if the received pieces of content satisfy a predetermined criteria establishing publication readiness. Publication may be prohibited in one embodiment until the predetermined criteria is satisfied. Once the criteria is met, a publisher may request publication (such as perhaps with a single click of a computer mouse). Once this occurs, the information from the group of components and corresponding templates may be automatically published to a user interface without further interaction from the publisher.",ACCENTURE GLOBAL SERVICES GMBH,REID GREGORY S;;RINGO TIMOTHY;;LANE DAVID P;;LIAN ELIZABETH H;;FARRELL DANIEL C;;FENTON CRAIG;;SHEARING ELISE;;BELL RANDY;;WONG SEVASTI;;LINGHAM ANTHONY;;FORRESTER AUDREY,,https://lens.org/140-152-412-642-173,Patent Application,yes,0,10,12,12,0,G06F16/957;;G06F16/957,G06F7/00;;G06F17/00,,0,0,,,,PENDING
133,WO,A2,WO 2005/006565 A2,026-457-659-265-212,2005-01-20,2005,IB 0306512 W,2003-11-26,US 30581102 A;;US 30657702 A,2002-11-27,INFORMATION SYSTEM FOR CONTACT CENTER USERS,,ACCENTURE GLOBAL SERVICES GMBH,REID GREGORY S;;RINGO TIMOTHY;;LANE DAVID P;;LIAN ELIZABETH H;;FARRELL DANIEL C;;FENTON CRAIG;;SHEARING ELISE;;BELL RANDY;;WONG SEVASTI;;LINGHAM ANTHONY;;FORRESTER AUDREY,,https://lens.org/026-457-659-265-212,Patent Application,yes,0,0,12,16,0,G09B7/00,G09B5/00;;G09B7/00,,0,0,,,,PENDING
134,AU,A1,AU 2003/302251 A1,124-862-105-628-618,2004-06-18,2004,AU 2003/302251 A,2003-11-26,IB 0306438 W;;US 30602602 A;;US 30656302 A,2002-11-27,TEMPLATE COMPLETION FOR A CONTENT MANAGEMENT SYSTEM,,ACCENTURE GLOBAL SERVICES GMBH,LIAN ELIZABETH H;;FARRELL DANIEL C;;FENTON CRAIG;;SHEARING ELISE;;BELL RANDY;;WONG SEVASTI;;LINGHAM ANTHONY;;FORRESTER AUDREY;;REID GREGORY S;;RINGO TIMOTHY;;LANE DAVID P,ACCENTURE GLOBAL SERVICES LIMITED (2010-12-09),https://lens.org/124-862-105-628-618,Patent Application,no,0,1,12,12,0,G06F16/957;;G06F16/957,G06F7/00;;G06F17/00,,0,0,,,,EXPIRED
135,US,B2,US 7200614 B2,181-246-558-327-031,2007-04-03,2007,US 30657702 A,2002-11-27,US 30657702 A,2002-11-27,Dual information system for contact center users,A dual information system for a representative of a contact center includes a first set of information directed for reference by the representative while the representative is online with a customer and a second set of information directed for reference or capability enhancement by the representative while the representative is offline from customers wherein the second set of information includes information automatically directed to the representative based on the representative's online contact with the customer. One of these sets of information may enhance role-based capabilities of the representative.,ACCENTURE GLOBAL SERVICES GMBH,REID GREGORY S;;RINGO TIMOTHY;;LANE DAVID P;;LIAN ELIZABETH H;;FARRELL DANIEL C;;FENTON CRAIG;;SHEARING ELISE;;BELL RANDY;;WONG SEVASTI;;LINGHAM ANTHONY;;FORRESTER AUDREY,ACCENTURE GLOBAL SERVICES LIMITED (2010-09-01);;ACCENTURE GLOBAL SERVICES GMBH (2003-11-02),https://lens.org/181-246-558-327-031,Granted Patent,yes,91,79,2,16,0,G09B7/00;;G09B7/00;;Y10S707/99945;;Y10S707/99948,G06F17/30;;G09B7/00,707/104.1;;379/265.06;;379/265.09,1,0,,,Dayco Statement Regarding Related Applications.,EXPIRED
136,AU,A1,AU 2008/207336 A1,046-681-177-883-474,2008-10-16,2008,AU 2008/207336 A,2008-08-15,AU 2003/304335 A;;AU 2008/207336 A;;IB 0306512 W;;US 30581102 A;;US 30657702 A,2002-11-27,Information system for contact center users,,ACCENTURE GLOBAL SERVICES GMBH,BELL RANDY;;FENTON CRAIG;;REID GREGORY S;;LINGHAM ANTHONY;;LANE DAVID P;;SHEARING ELISE;;FARRELL DANIEL C;;RINGO TIMOTHY;;WONG SEVASTI;;FORRESTER AUDREY;;LIAN ELIZABETH H,ACCENTURE GLOBAL SERVICES LIMITED (2010-12-09),https://lens.org/046-681-177-883-474,Patent Application,no,0,0,12,16,0,G09B7/00,G09B5/00;;G09B7/00,,0,0,,,,EXPIRED
137,CA,A1,CA 2507638 A1,105-197-166-338-108,2005-01-20,2005,CA 2507638 A,2003-11-26,IB 0306512 W;;US 30581102 A;;US 30657702 A,2002-11-27,INFORMATION SYSTEM FOR CONTACT CENTER USERS,Published without an,ACCENTURE GLOBAL SERVICES GMBH,RINGO TIMOTHY;;FORRESTER AUDREY;;LANE DAVID P;;FENTON CRAIG;;BELL RANDY;;REID GREGORY S;;LINGHAM ANTHONY;;FARRELL DANIEL C;;LIAN ELIZABETH H;;WONG SEVASTI;;SHEARING ELISE,,https://lens.org/105-197-166-338-108,Patent Application,no,0,0,12,16,0,G09B7/00,G09B5/00;;G09B7/00,,0,0,,,,DISCONTINUED
138,US,B2,US 7395499 B2,104-690-788-804-25X,2008-07-01,2008,US 30602602 A,2002-11-27,US 30602602 A;;US 30656302 A,2002-11-27,Enforcing template completion when publishing to a content management system,New functions for a contact center system include: testing user's comprehension of informational messages with a quiz; capturing insight of superior users having a KPI score above a threshold by having those users submit information on why they perform so well; dynamically ordering solutions to issues by re-ranking the solutions periodically based on recency and frequency; integrating information for use by a contact center representative while online with a customer and information for use when not online; storing content items in a telecommunications industry taxonomy; directing user feedback on a content item to the proper owner/manager of that content; communicating solution information using a solutions taxonomy; displaying a dual information system having a CRM application as well as reference material that is context-appropriate; enforcing completion of a group of templates when creating a content item to be published; ensuring a group of templates for a content item are complete before publishing them; and searching within a contact center system portal using a continuum of search functions.,ACCENTURE GLOBAL SERVICES GMBH,LANE DAVID P;;REID GREGORY S;;RINGO TIMOTHY A;;LIAN ELIZABETH H;;FARRELL DANIEL C;;FENTON CRAIG;;CLARKE ELISE;;BELL RANDY;;WONG SEVASTI;;LINGHAM ANTHONY;;FORRESTER AUDREY,ACCENTURE GLOBAL SERVICES LIMITED (2010-09-01);;ACCENTURE GLOBAL SERVICES GMBH (2003-11-02),https://lens.org/104-690-788-804-25X,Granted Patent,yes,114,17,12,12,0,G06F16/957;;G06F16/957,G06F17/00;;G06F7/00,715/243;;715/234;;715/255;;705/1,31,0,,,"Dayco Statement Regarding Related Applications.;;U.S. Appl. No. 10/305,858, filed Nov. 27, 2002, Capturing Insight of Superior Users of a Contact Center.;;U.S. Appl. No. 10/306,705, filed Nov. 27, 2002, Dynamically Ordering Solutions.;;U.S. Appl. No. 10/306,577, filed Nov. 27, 2002, Dual Information System for Contact Center Users.;;U.S. Appl. No. 10/305,835, filed Nov. 27, 2002, Content Management System for the Telecommunications Industry.;;U.S. Appl. No. 10/305,811, filed Nov. 27, 2002, Testing Information Comprehension of Contact Center Users.;;U.S. Appl. No. 10/306,025, filed Nov. 27, 2002, Content Feedback in a Multiple-Owner Content Management System.;;U.S. Appl. No. 10/306,248, filed Nov. 27, 2002, Communicating Solution Information in a Knowledge Management System.;;U.S. Appl. No. 10/306,386, filed Nov. 27, 2002, Presenting Linked Information in a CRM System.;;U.S. Appl. No. 10/306,563, filed Nov. 27, 2002, Ensuring Completeness When Publishing to a Content Management System.;;U.S. Appl. No. 10/306,564, filed Nov. 27, 2002, Searching Within a Contact Center Portal.;;M.J. Allend and J.P. Furming, ""Methods for Using Global Position System to Find Close Services"", IBM Technical Disclosure Bulletin, Jan. 1998, pp. 693, vol. 41 No. 1.;;Alban, Oscar, Customer interaction monitoring: your key to measuring service performance, Australian Banking & Finance, vol. 10, No. 6, Apr. 18, 2001.;;Click2Coach Web Pages, Retrieved from www.envisiontelephony.com, 2001.;;eOn Communications and Eyretel Partner to Deliver Performance Improvement For Contact Centers, PR Newswire, Apr. 4, 2002.;;Feasel, Marnie et al., Training Can Produce Better Reps, Call Center Solutions, vol. 17, No. 4, Oct. 1998, pp. 138-143.;;Kelly Services Expands KellyConnect Call Center Solution, PR Newswire, Jan. 14, 2002.;;Kelly Services Offer Improved Call Center Solution, PR Newswire, Apr. 24, 2000.;;Knowlagent and Eyretel Partner to Deliver Integrated E-Learning Platform to Global Clients, PR Newswire, May 10, 2001.;;Primus Taps OutSights to Deliver Expertise to Customers Shifting to Knowledge-Based Support, Business Wire, Jun. 29, 1999.;;Rosati, Marlene et al., Measuring the Reality of the Customer Experience, Customer Interaction Solutions, May 2002, pp. 38-43.;;Televista Integrates eLearning and Quality Monitoring The Ascent Group, Inc. Call Cener E-Journal, Aug. 2001.;;What makes your contact center agents truly effective?, Envision Telephony, Click2Coach, 2000.;;Office Action issued by US PTO on U.S. Appl. No. 10/306,705, dated Oct. 9, 2007.;;Office Action issued by EPO on U.S. Appl. No. 03808324.2 - 2221 dated Jul. 30, 2007 regarding summons to attend oral proceedings on Dec. 13, 2007.;;Cunliffe, Alison, Super systems capture expertise of the specialist Toronto Star, Nov. 2, 1986.;;Emvolve Performance Manager Release 1.5 Customer Inter@action Solutions, vol. 20. No. 5, Nov. 20, 2001; pp. 53-56.;;ServiceSoft Delivers ""Smart Answers"" at Xerox Business Wire, Aug. 4, 1998.;;Tiwana, Amrit, The Knowledge Management Toolkit Prentice Hall, Dec. 1999, ISN: 0-13-012853-8.;;Office Action issued Sep. 20, 2007 by EPO on Chinese Application No. 200380106314.X.;;Office Action issued Oct. 19, 2007 by US PTO on U.S. Appl. No. 10/305,858.",EXPIRED
139,JP,A,JP 2014193170 A,041-100-254-370-198,2014-10-09,2014,JP 2014099291 A,2014-05-13,US 12583408 P;;US 13428308 P;;US 19719108 P;;US 19900908 P,2008-04-29,DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND USES THEREOF,"PROBLEM TO BE SOLVED: To provide: engineered multivalent and multispecific binding proteins; methods of making them; and their method for the diagnosis, prevention and/or treatment of acute and chronic inflammatory diseases, cancer, and other diseases.SOLUTION: A binding protein comprises first and second polypeptide chains. The polypeptide chains each independently comprises VD1-(X1)n-VD2-C-(X2)n (VD1 is a first variable domain; VD2 is a second variable domain; C is a constant domain; X1 is a linker; X2 is an Fc region; and n is 0 or 1). In the binding protein, VD1 domains of first and second polypeptide chains form a first functional target-binding region, and VD2 domains of first and second polypeptide chains form a second functional target-binding region.",ABBVIE INC,GHAYUR TARIQ;;SUSAN E MORGAN-LAPPE;;REILLY EDWARD B;;GILLIAN A KINGSBURY;;ANDREW PHILLIPS;;JIEYI WANG;;RANDY L BELL;;SUZANNE M NORVELL;;LI YINGCHUN;;LIU JUNJIAN;;YING HUA,,https://lens.org/041-100-254-370-198,Patent Application,no,1,0,31,32,873,A61K2039/505;;C07K16/22;;C07K16/28;;C07K16/2863;;C07K16/32;;C07K2317/31;;C07K2317/64;;C07K2317/71;;C07K2317/73;;C07K2317/732;;C07K2317/734;;C07K2317/92;;C07K2319/00;;C07K16/468;;C07K2317/76;;Y10S435/81;;A61P1/04;;A61P1/14;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/06;;A61P11/16;;A61P13/02;;A61P13/08;;A61P13/12;;A61P15/02;;A61P15/08;;A61P17/02;;A61P17/04;;A61P17/06;;A61P17/14;;A61P19/02;;A61P19/04;;A61P19/06;;A61P19/08;;A61P19/10;;A61P21/00;;A61P21/02;;A61P21/04;;A61P25/00;;A61P25/04;;A61P25/08;;A61P25/10;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/24;;A61P25/28;;A61P25/30;;A61P25/32;;A61P27/02;;A61P27/16;;A61P29/00;;A61P3/14;;A61P31/00;;A61P31/04;;A61P31/08;;A61P31/14;;A61P31/16;;A61P31/18;;A61P31/22;;A61P33/00;;A61P33/02;;A61P33/06;;A61P35/00;;A61P35/02;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/00;;A61P43/00;;A61P5/00;;A61P5/14;;A61P5/18;;A61P5/50;;A61P7/02;;A61P7/04;;A61P7/06;;A61P9/04;;A61P9/06;;A61P9/08;;A61P9/10;;A61P9/12;;A61P9/14;;A61P3/10;;Y02A50/30;;A61K2039/505;;C07K16/22;;C07K16/28;;C07K16/2863;;C07K16/32;;C07K2317/31;;C07K2317/64;;C07K2317/71;;C07K2317/73;;C07K2317/732;;C07K2317/734;;C07K2317/92;;C07K2319/00;;Y02A50/30;;C07K16/468;;A61K39/39533;;A61K45/06;;C07K2317/565;;C07K2317/76;;G01N33/6872;;G01N33/74;;G01N2333/515;;G01N2333/705;;Y10S435/81,C12N15/09;;A61K38/00;;A61K39/395;;A61K45/00;;A61P1/04;;A61P1/14;;A61P1/16;;A61P3/10;;A61P3/14;;A61P5/00;;A61P5/14;;A61P5/18;;A61P5/50;;A61P7/02;;A61P7/04;;A61P7/06;;A61P9/04;;A61P9/06;;A61P9/08;;A61P9/10;;A61P9/12;;A61P9/14;;A61P11/00;;A61P11/02;;A61P11/06;;A61P11/16;;A61P13/02;;A61P13/08;;A61P13/12;;A61P15/02;;A61P15/08;;A61P17/02;;A61P17/04;;A61P17/06;;A61P17/14;;A61P19/02;;A61P19/04;;A61P19/06;;A61P19/08;;A61P19/10;;A61P21/00;;A61P21/02;;A61P21/04;;A61P25/00;;A61P25/04;;A61P25/08;;A61P25/10;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/24;;A61P25/28;;A61P25/30;;A61P25/32;;A61P27/02;;A61P27/16;;A61P29/00;;A61P31/00;;A61P31/04;;A61P31/08;;A61P31/14;;A61P31/16;;A61P31/18;;A61P31/22;;A61P33/00;;A61P33/02;;A61P33/06;;A61P35/00;;A61P35/02;;A61P37/06;;A61P37/08;;A61P39/00;;A61P43/00;;C07K16/28;;C07K16/46;;C12N1/15;;C12N1/19;;C12N1/21;;C12N5/10;;C12P21/08;;G01N33/53;;G01N33/531;;G01N33/536,,0,0,,,,PENDING
140,AU,A1,AU 2009/241589 A1,110-698-571-394-740,2009-11-05,2009,AU 2009/241589 A,2009-04-28,US 12583408 P;;US 13428308 P;;US 19719108 P;;US 19900908 P;;US 2009/0041945 W,2008-04-29,Dual variable domain immunoglobulins and uses thereof,,ABBOTT LAB,REILLY EDWARD B;;YING HUA;;NORVELL SUZANNE M;;GHAYUR TARIQ;;MORGAN-LAPPE SUSAN E;;LI YINGCHUN;;PHILLIPS ANDREW;;LIU JUNJIAN;;BELL RANDY L;;KINGSBURY GILLIAN A;;WANG JIEYI,ABBVIE INC. (2013-05-16),https://lens.org/110-698-571-394-740,Patent Application,no,0,0,31,32,0,A61K2039/505;;C07K16/22;;C07K16/28;;C07K16/2863;;C07K16/32;;C07K2317/31;;C07K2317/64;;C07K2317/71;;C07K2317/73;;C07K2317/732;;C07K2317/734;;C07K2317/92;;C07K2319/00;;C07K16/468;;C07K2317/76;;Y10S435/81;;A61P1/04;;A61P1/14;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/06;;A61P11/16;;A61P13/02;;A61P13/08;;A61P13/12;;A61P15/02;;A61P15/08;;A61P17/02;;A61P17/04;;A61P17/06;;A61P17/14;;A61P19/02;;A61P19/04;;A61P19/06;;A61P19/08;;A61P19/10;;A61P21/00;;A61P21/02;;A61P21/04;;A61P25/00;;A61P25/04;;A61P25/08;;A61P25/10;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/24;;A61P25/28;;A61P25/30;;A61P25/32;;A61P27/02;;A61P27/16;;A61P29/00;;A61P3/14;;A61P31/00;;A61P31/04;;A61P31/08;;A61P31/14;;A61P31/16;;A61P31/18;;A61P31/22;;A61P33/00;;A61P33/02;;A61P33/06;;A61P35/00;;A61P35/02;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/00;;A61P43/00;;A61P5/00;;A61P5/14;;A61P5/18;;A61P5/50;;A61P7/02;;A61P7/04;;A61P7/06;;A61P9/04;;A61P9/06;;A61P9/08;;A61P9/10;;A61P9/12;;A61P9/14;;A61P3/10;;Y02A50/30;;A61K2039/505;;C07K16/22;;C07K16/28;;C07K16/2863;;C07K16/32;;C07K2317/31;;C07K2317/64;;C07K2317/71;;C07K2317/73;;C07K2317/732;;C07K2317/734;;C07K2317/92;;C07K2319/00;;Y02A50/30;;C07K16/468;;A61K39/39533;;A61K45/06;;C07K2317/565;;C07K2317/76;;G01N33/6872;;G01N33/74;;G01N2333/515;;G01N2333/705;;Y10S435/81,A61K39/00;;G01N33/53,,0,0,,,,INACTIVE
141,WO,A2,WO 2009/134776 A2,190-969-160-193-913,2009-11-05,2009,US 2009/0041945 W,2009-04-28,US 12583408 P;;US 13428308 P;;US 19719108 P;;US 19900908 P,2008-04-29,DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND USES THEREOF,"The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.",ABBOTT LAB;;GHAYUR TARIQ;;MORGAN-LAPPE SUSAN E;;REILLY EDWARD B;;KINGSBURY GILLIAN A;;PHILLIPS ANDREW;;WANG JIEYI;;BELL RANDY L;;NORVELL SUZANNE M;;LI YINGCHUN;;LIU JUNJIAN;;YING HUA,GHAYUR TARIQ;;MORGAN-LAPPE SUSAN E;;REILLY EDWARD B;;KINGSBURY GILLIAN A;;PHILLIPS ANDREW;;WANG JIEYI;;BELL RANDY L;;NORVELL SUZANNE M;;LI YINGCHUN;;LIU JUNJIAN;;YING HUA,,https://lens.org/190-969-160-193-913,Patent Application,yes,0,147,31,32,0,A61K2039/505;;C07K16/22;;C07K16/28;;C07K16/2863;;C07K16/32;;C07K2317/31;;C07K2317/64;;C07K2317/71;;C07K2317/73;;C07K2317/732;;C07K2317/734;;C07K2317/92;;C07K2319/00;;C07K16/468;;C07K2317/76;;Y10S435/81;;A61P1/04;;A61P1/14;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/06;;A61P11/16;;A61P13/02;;A61P13/08;;A61P13/12;;A61P15/02;;A61P15/08;;A61P17/02;;A61P17/04;;A61P17/06;;A61P17/14;;A61P19/02;;A61P19/04;;A61P19/06;;A61P19/08;;A61P19/10;;A61P21/00;;A61P21/02;;A61P21/04;;A61P25/00;;A61P25/04;;A61P25/08;;A61P25/10;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/24;;A61P25/28;;A61P25/30;;A61P25/32;;A61P27/02;;A61P27/16;;A61P29/00;;A61P3/14;;A61P31/00;;A61P31/04;;A61P31/08;;A61P31/14;;A61P31/16;;A61P31/18;;A61P31/22;;A61P33/00;;A61P33/02;;A61P33/06;;A61P35/00;;A61P35/02;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/00;;A61P43/00;;A61P5/00;;A61P5/14;;A61P5/18;;A61P5/50;;A61P7/02;;A61P7/04;;A61P7/06;;A61P9/04;;A61P9/06;;A61P9/08;;A61P9/10;;A61P9/12;;A61P9/14;;A61P3/10;;Y02A50/30;;A61K2039/505;;C07K16/22;;C07K16/28;;C07K16/2863;;C07K16/32;;C07K2317/31;;C07K2317/64;;C07K2317/71;;C07K2317/73;;C07K2317/732;;C07K2317/734;;C07K2317/92;;C07K2319/00;;Y02A50/30;;C07K16/468;;A61K39/39533;;A61K45/06;;C07K2317/565;;C07K2317/76;;G01N33/6872;;G01N33/74;;G01N2333/515;;G01N2333/705;;Y10S435/81,G01N33/53,,0,0,,,,PENDING
142,SG,A1,SG 190572 A1,085-084-355-715-844,2013-06-28,2013,SG 2013030655 A,2009-04-28,US 12583408 P;;US 13428308 P;;US 19719108 P;;US 19900908 P,2008-04-29,DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND USES THEREOF,,ABBOTT LAB,GHAYUR TARIQ;;MORGAN-LAPPE SUSAN E;;REILLY EDWARD B;;KINGSBURY GILLIAN A;;PHILLIPS ANDREW;;WANG JIEYI;;BELL RANDY L;;NORVELL SUZANNE M;;LI YINGCHUN;;LIU JUNJIAN;;YING HUA,,https://lens.org/085-084-355-715-844,Patent Application,no,0,0,31,32,0,A61K2039/505;;C07K16/22;;C07K16/28;;C07K16/2863;;C07K16/32;;C07K2317/31;;C07K2317/64;;C07K2317/71;;C07K2317/73;;C07K2317/732;;C07K2317/734;;C07K2317/92;;C07K2319/00;;C07K16/468;;C07K2317/76;;Y10S435/81;;A61P1/04;;A61P1/14;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/06;;A61P11/16;;A61P13/02;;A61P13/08;;A61P13/12;;A61P15/02;;A61P15/08;;A61P17/02;;A61P17/04;;A61P17/06;;A61P17/14;;A61P19/02;;A61P19/04;;A61P19/06;;A61P19/08;;A61P19/10;;A61P21/00;;A61P21/02;;A61P21/04;;A61P25/00;;A61P25/04;;A61P25/08;;A61P25/10;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/24;;A61P25/28;;A61P25/30;;A61P25/32;;A61P27/02;;A61P27/16;;A61P29/00;;A61P3/14;;A61P31/00;;A61P31/04;;A61P31/08;;A61P31/14;;A61P31/16;;A61P31/18;;A61P31/22;;A61P33/00;;A61P33/02;;A61P33/06;;A61P35/00;;A61P35/02;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/00;;A61P43/00;;A61P5/00;;A61P5/14;;A61P5/18;;A61P5/50;;A61P7/02;;A61P7/04;;A61P7/06;;A61P9/04;;A61P9/06;;A61P9/08;;A61P9/10;;A61P9/12;;A61P9/14;;A61P3/10;;Y02A50/30;;A61K2039/505;;C07K16/22;;C07K16/28;;C07K16/2863;;C07K16/32;;C07K2317/31;;C07K2317/64;;C07K2317/71;;C07K2317/73;;C07K2317/732;;C07K2317/734;;C07K2317/92;;C07K2319/00;;Y02A50/30;;C07K16/468;;A61K39/39533;;A61K45/06;;C07K2317/565;;C07K2317/76;;G01N33/6872;;G01N33/74;;G01N2333/515;;G01N2333/705;;Y10S435/81,,,0,0,,,,PENDING
143,UY,A,UY 31792 A,092-370-563-045-751,2009-12-14,2009,UY 31792 A,2009-04-29,US 12583408 P;;US 13428308 P;;US 19719108 P;;US 19900908 P,2008-04-29,INMUNOGLOBULINAS CON DOMINIO VARIABLE DUAL Y USOS DE LAS MISMAS,"Proteínas de unión multivalentes y multiespecíficas diseñadas, métodos para elaborarlas y, específicamente, sus usos en la prevención, el diagnóstico y/o el tratamiento de enfermedades.",ABBOTT LAB,TARIQ GHAYUR;;JIEYI WANG;;REILLY EDWARD B;;MORGAN-LAPPE SUSAN E;;KINSGSBURY GILLIAN A;;ANDREW PHILLIPS;;BELL RANDY L;;NORVELL SUZANNE M;;YINGCHUN LI;;JUNJIAN LIU;;HUA YING,,https://lens.org/092-370-563-045-751,Patent Application,no,0,0,31,32,0,A61K2039/505;;C07K16/22;;C07K16/28;;C07K16/2863;;C07K16/32;;C07K2317/31;;C07K2317/64;;C07K2317/71;;C07K2317/73;;C07K2317/732;;C07K2317/734;;C07K2317/92;;C07K2319/00;;C07K16/468;;C07K2317/76;;Y10S435/81;;A61P1/04;;A61P1/14;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/06;;A61P11/16;;A61P13/02;;A61P13/08;;A61P13/12;;A61P15/02;;A61P15/08;;A61P17/02;;A61P17/04;;A61P17/06;;A61P17/14;;A61P19/02;;A61P19/04;;A61P19/06;;A61P19/08;;A61P19/10;;A61P21/00;;A61P21/02;;A61P21/04;;A61P25/00;;A61P25/04;;A61P25/08;;A61P25/10;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/24;;A61P25/28;;A61P25/30;;A61P25/32;;A61P27/02;;A61P27/16;;A61P29/00;;A61P3/14;;A61P31/00;;A61P31/04;;A61P31/08;;A61P31/14;;A61P31/16;;A61P31/18;;A61P31/22;;A61P33/00;;A61P33/02;;A61P33/06;;A61P35/00;;A61P35/02;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/00;;A61P43/00;;A61P5/00;;A61P5/14;;A61P5/18;;A61P5/50;;A61P7/02;;A61P7/04;;A61P7/06;;A61P9/04;;A61P9/06;;A61P9/08;;A61P9/10;;A61P9/12;;A61P9/14;;A61P3/10;;Y02A50/30;;A61K2039/505;;C07K16/22;;C07K16/28;;C07K16/2863;;C07K16/32;;C07K2317/31;;C07K2317/64;;C07K2317/71;;C07K2317/73;;C07K2317/732;;C07K2317/734;;C07K2317/92;;C07K2319/00;;Y02A50/30;;C07K16/468;;A61K39/39533;;A61K45/06;;C07K2317/565;;C07K2317/76;;G01N33/6872;;G01N33/74;;G01N2333/515;;G01N2333/705;;Y10S435/81,A61K39/395;;A61P25/28;;A61P35/00;;C07K16/18;;C07K16/22;;C07K16/30;;C07K16/32;;C12N15/09;;C12N15/85,,0,0,,,,DISCONTINUED
144,AU,A1,AU 2013/219136 A1,004-559-068-763-083,2013-09-05,2013,AU 2013/219136 A,2013-08-19,AU 2009/241589 A;;AU 2013/219136 A,2009-04-28,Dual variable domain immunoglobulins and uses thereof,"Abstract Dual Variable Domain Immunoglobulins and Uses Thereof The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.",ABBVIE INC,PHILLIPS ANDREW;;REILLY EDWARD B;;KINGSBURY GILLIAN A;;YING HUA;;WANG JIEYI;;LI YINGCHUN;;BELL RANDY L;;MORGAN-LAPPE SUSAN E;;NORVELL SUZANNE M;;GHAYUR TARIQ;;LIU JUNJIAN,,https://lens.org/004-559-068-763-083,Patent Application,no,0,1,1,1,0,Y02A50/30,A61K39/00;;G01N33/53,,0,0,,,,DISCONTINUED
145,EC,A,EC SP10010580 A,062-972-061-303-503,2010-11-30,2010,EC SP10010580 A,2010-10-28,US 12583408 P;;US 13428308 P;;US 19719108 P;;US 19900908 P,2008-04-29,INMUNOGLOBULINAS DUALES DE DOMINIO VARIABLE Y SUS APLICACIONES,"La presente invencion se refiere a las proteinas ligadoras la ingenieria de proteinas ligadoras multivalentes y multiespecificas, metodos de fabricacion, y especificamente para su uso en la prevencion, diagnostico y/o tratamiento de enfermedad.",ABBOTT LAB,WANG JIEYI;;GHAYUR TARIQ;;YING HUA;;MORGAN-LAPPE SUSAN E;;REILLY EDWARD B;;KINSGBURY GILLIAN A;;PHILLIPS ANDREW;;BELL RANDY L;;NORVELL SUZANNE M;;LI YINGCHUN;;LIU JUNJIAN,,https://lens.org/062-972-061-303-503,Patent Application,no,0,0,31,32,0,A61K2039/505;;C07K16/22;;C07K16/28;;C07K16/2863;;C07K16/32;;C07K2317/31;;C07K2317/64;;C07K2317/71;;C07K2317/73;;C07K2317/732;;C07K2317/734;;C07K2317/92;;C07K2319/00;;C07K16/468;;C07K2317/76;;Y10S435/81;;A61P1/04;;A61P1/14;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/06;;A61P11/16;;A61P13/02;;A61P13/08;;A61P13/12;;A61P15/02;;A61P15/08;;A61P17/02;;A61P17/04;;A61P17/06;;A61P17/14;;A61P19/02;;A61P19/04;;A61P19/06;;A61P19/08;;A61P19/10;;A61P21/00;;A61P21/02;;A61P21/04;;A61P25/00;;A61P25/04;;A61P25/08;;A61P25/10;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/24;;A61P25/28;;A61P25/30;;A61P25/32;;A61P27/02;;A61P27/16;;A61P29/00;;A61P3/14;;A61P31/00;;A61P31/04;;A61P31/08;;A61P31/14;;A61P31/16;;A61P31/18;;A61P31/22;;A61P33/00;;A61P33/02;;A61P33/06;;A61P35/00;;A61P35/02;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/00;;A61P43/00;;A61P5/00;;A61P5/14;;A61P5/18;;A61P5/50;;A61P7/02;;A61P7/04;;A61P7/06;;A61P9/04;;A61P9/06;;A61P9/08;;A61P9/10;;A61P9/12;;A61P9/14;;A61P3/10;;Y02A50/30;;A61K2039/505;;C07K16/22;;C07K16/28;;C07K16/2863;;C07K16/32;;C07K2317/31;;C07K2317/64;;C07K2317/71;;C07K2317/73;;C07K2317/732;;C07K2317/734;;C07K2317/92;;C07K2319/00;;Y02A50/30;;C07K16/468;;A61K39/39533;;A61K45/06;;C07K2317/565;;C07K2317/76;;G01N33/6872;;G01N33/74;;G01N2333/515;;G01N2333/705;;Y10S435/81,G01N33/53,,0,0,,,,PENDING
146,US,B2,US 9029508 B2,095-655-232-939-468,2015-05-12,2015,US 43146009 A,2009-04-28,US 43146009 A;;US 12583408 P;;US 13428308 P;;US 19719108 P;;US 19900908 P,2008-04-29,Dual variable domain immunoglobulins and uses thereof,"The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.",GHAYUR TARIQ;;MORGAN-LAPPE SUSAN E;;REILLY EDWARD B;;KINGSBURY GILLIAN A;;PHILLIPS ANDREW;;WANG JIEYI;;BELL RANDY L;;NORVELL SUZANNE M;;LI YINGCHUN;;LIU JUNJIAN;;YING HUA;;ABBVIE INC,GHAYUR TARIQ;;MORGAN-LAPPE SUSAN E;;REILLY EDWARD B;;KINGSBURY GILLIAN A;;PHILLIPS ANDREW;;WANG JIEYI;;BELL RANDY L;;NORVELL SUZANNE M;;LI YINGCHUN;;LIU JUNJIAN;;YING HUA,ABBVIE INC (2012-08-01);;ABBOTT LABORATORIES (2009-06-25),https://lens.org/095-655-232-939-468,Granted Patent,yes,103,52,31,32,873,A61K2039/505;;C07K16/22;;C07K16/28;;C07K16/2863;;C07K16/32;;C07K2317/31;;C07K2317/64;;C07K2317/71;;C07K2317/73;;C07K2317/732;;C07K2317/734;;C07K2317/92;;C07K2319/00;;C07K16/468;;C07K2317/76;;Y10S435/81;;A61P1/04;;A61P1/14;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/06;;A61P11/16;;A61P13/02;;A61P13/08;;A61P13/12;;A61P15/02;;A61P15/08;;A61P17/02;;A61P17/04;;A61P17/06;;A61P17/14;;A61P19/02;;A61P19/04;;A61P19/06;;A61P19/08;;A61P19/10;;A61P21/00;;A61P21/02;;A61P21/04;;A61P25/00;;A61P25/04;;A61P25/08;;A61P25/10;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/24;;A61P25/28;;A61P25/30;;A61P25/32;;A61P27/02;;A61P27/16;;A61P29/00;;A61P3/14;;A61P31/00;;A61P31/04;;A61P31/08;;A61P31/14;;A61P31/16;;A61P31/18;;A61P31/22;;A61P33/00;;A61P33/02;;A61P33/06;;A61P35/00;;A61P35/02;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/00;;A61P43/00;;A61P5/00;;A61P5/14;;A61P5/18;;A61P5/50;;A61P7/02;;A61P7/04;;A61P7/06;;A61P9/04;;A61P9/06;;A61P9/08;;A61P9/10;;A61P9/12;;A61P9/14;;A61P3/10;;Y02A50/30;;A61K2039/505;;C07K16/22;;C07K16/28;;C07K16/2863;;C07K16/32;;C07K2317/31;;C07K2317/64;;C07K2317/71;;C07K2317/73;;C07K2317/732;;C07K2317/734;;C07K2317/92;;C07K2319/00;;Y02A50/30;;C07K16/468;;A61K39/39533;;A61K45/06;;C07K2317/565;;C07K2317/76;;G01N33/6872;;G01N33/74;;G01N2333/515;;G01N2333/705;;Y10S435/81,C07K16/00;;A61K39/00;;A61K39/395;;A61K39/40;;C07H21/04;;C07K1/00;;C07K16/22;;C07K16/28;;C07K16/32;;C07K16/46;;C12N1/20;;C12N5/02;;C12N15/00;;C12N15/09;;C12P21/04;;C12P21/08;;G01N33/53,530/387.1;;530/387.3;;530/388.1;;530/388.16;;530/388.23;;530/388.24;;530/391.1;;530/391.3;;530/391.7;;536/23.5;;435/7.1;;435/69.1;;435/69.6;;435/325;;435/326;;435/252.3;;435/320.1;;435/810;;424/130.1;;424/133.1;;424/134.1;;424/136.1;;424/141.1;;424/142.1;;424/145.1,101,85,020-789-896-622-570;;108-567-706-608-928;;020-015-323-887-871;;181-448-152-035-827;;026-561-800-449-708;;128-342-109-634-579;;106-734-684-181-494;;005-522-074-909-162;;087-448-981-335-707;;077-648-240-151-912;;065-145-385-150-339;;016-251-721-517-200;;112-274-634-016-522;;018-961-022-027-383;;024-741-755-965-636;;066-841-655-291-162;;020-564-178-660-209;;022-991-704-737-86X;;007-533-420-325-730;;033-822-326-656-852;;005-112-559-456-657;;041-863-374-864-841;;022-947-416-700-263;;018-846-180-145-197;;042-087-767-680-696;;025-757-247-754-114;;035-081-115-342-527;;134-765-566-083-663;;009-735-032-185-236;;009-483-512-107-343;;019-274-769-847-453;;049-134-753-209-354;;024-995-475-936-443;;034-331-211-704-877;;075-547-110-214-465;;127-795-964-859-002;;031-719-370-148-435;;027-377-613-079-875;;028-513-653-434-288;;041-909-244-299-232;;078-432-639-041-575;;068-192-134-475-965;;062-963-364-091-355;;044-317-656-227-593;;018-658-965-693-603;;041-751-525-317-92X;;010-514-045-696-373;;120-634-752-697-142;;012-452-642-146-566;;026-531-521-458-647;;009-759-809-259-879;;017-980-777-820-301;;063-873-022-003-842;;079-067-762-059-918;;035-872-873-163-027;;174-783-722-981-415;;018-634-106-105-088;;014-976-519-660-455;;010-468-964-951-588;;072-509-376-457-062;;052-219-543-437-800;;028-900-321-386-005;;039-571-432-444-268;;025-395-146-381-464;;085-277-440-303-853;;033-688-911-017-272;;018-690-938-104-543;;072-378-691-723-546;;032-516-001-353-042;;054-966-694-554-694;;035-617-860-785-670;;005-119-615-003-591;;100-049-580-404-573;;035-232-237-838-497;;010-488-381-022-259;;066-749-017-721-197;;034-731-754-790-903;;011-962-497-035-168;;029-694-380-116-357;;075-499-401-604-101;;028-948-486-931-641;;043-425-934-172-29X;;008-195-244-544-850;;033-797-614-829-293;;002-264-966-090-625,10413102;;10.1016/s0014-5793(99)00782-6;;12728922;;10.4049/jimmunol.170.9.4854;;10.1093/intimm/6.11.1799;;7532432;;7658022;;10.1016/0022-1759(95)00086-p;;15893169;;10.1016/j.jacc.2005.01.048;;15457210;;pmc524347;;10.1038/sj.emboj.7600415;;10.1385/1-59259-334-8:305;;12412482;;10.1016/s0009-9120(02)00343-0;;12413604;;8755564;;pmc38836;;10.1073/pnas.93.15.7843;;9382891;;pmc2199154;;10.1084/jem.186.11.1933;;pmc52428;;10.1073/pnas.88.18.7978;;1896445;;10.1073/pnas.91.9.3809;;pmc43671;;8170992;;16142748;;10.1002/art.21249;;10.1126/science.3285471;;3285471;;pmc1536886;;6839548;;10.1126/science.1494-b;;10.1126/science.242.4885.1494-b;;10.1016/s0002-9440(10)63945-4;;pmc1850262;;11141480;;10.1084/jem.20050584;;pmc2212041;;15967817;;15884771;;10.1016/j.jaci.2007.02.009;;17379289;;10.1126/science.3925553;;3925553;;10.1016/0022-1759(95)00016-4;;7769243;;10.1021/jm061152t;;17256834;;7423373;;10.1038/nrd1854;;16224456;;10.1016/j.addr.2006.01.021;;16581153;;10.1016/s0065-2776(08)60674-4;;7872158;;10.1038/72262;;10655104;;10.1517/14712598.4.11.1821;;15500410;;10.1073/pnas.89.10.4285;;1350088;;pmc49066;;11169443;;10.1002/1521-4141(200101)31:1<94::aid-immu94>3.0.co;2-j;;10.1002/1521-4141(200101)31:1&#60;94::aid-immu94&#62;3.0.co;2-j;;10.1002/1521-4141(200101)31:1<94::aid-immu94>3.3.co;2-a;;10.1016/0022-2836(87)90412-8;;3681981;;10.1038/342877a0;;2687698;;10.1038/352624a0;;1907718;;8232322;;10.1016/0161-5890(93)90097-u;;15967818;;pmc2212032;;10.1084/jem.20050901;;10.1038/nbt0297-159;;9035142;;10.1016/j.ymeth.2005.11.006;;16473524;;10.1021/bi980270i;;9649307;;12391234;;10.4049/jimmunol.169.9.5171;;10.1074/jbc.m604292200;;16793771;;10.1084/jem.176.5.1387;;1357073;;pmc2119437;;12808450;;10.1038/nm890;;8619098;;10.1016/s0889-857x(21)00466-x;;1426677;;10.1002/prot.20302;;15526297;;12471249;;10.1126/science.1072165;;18432810;;10.1016/j.jns.2005.03.023;;15949495;;10.1002/ana.410250406;;2634975;;10.1093/nar/30.2.e9;;pmc99848;;11788735;;10.1038/nm811;;12483208;;10.1097/00001756-199604260-00023;;8817534;;10.1093/intimm/dxh281;;16000330;;1367769;;10.1038/nbt1291-1369;;10.1038/nbt1291-1373;;1369462;;10907088;;10.2144/00291ov01;;9106075;;10.1007/s001090050103;;16162882;;10.1056/nejmoa050524;;10.1038/nbt0797-637;;9219265;;2958547;;10.4049/jimmunol.139.7.2367;;8354036;;pmc409841;;10562301;;10.1172/jci7317;;1565653;;pmc48911;;10.1073/pnas.89.8.3576;;10.1038/ng0594-13;;8075633;;pmc2212477;;10.1084/jem.188.3.483;;9687526;;10779742;;10.4049/jimmunol.164.9.4433;;10.1002/j.1460-2075.1993.tb05706.x;;pmc413258;;7679990;;10.1074/jbc.270.13.7543;;7706301;;10577975;;pmc1766581;;10.1136/ard.58.2008.i61;;10.1067/mai.2001.116576;;11496242;;10.1016/0022-2836(92)90639-2;;1507232;;1385989;;10.3233/hab-1992-3204;;10.1016/j.surfcoat.2005.11.086;;14699147;;10.1074/jbc.c300470200;;8341653;;10.1073/pnas.90.14.6444;;pmc46948;;10.1007/s002620050414;;9435855;;10.1093/nar/19.15.4133;;pmc328552;;1908075;;10.1016/s0167-5699(00)01667-4;;10916139;;10.1016/s0167-7799(97)84205-9;;9081300;;9035132;;10.1038/nbt0297-125;;10.3171/jns.1989.71.1.0105;;2567778;;10.1038/264415a0;;1004567;;2531466;;10.1126/science.2531466;;10.1073/pnas.85.16.5879;;3045807;;pmc281868,"Alt, Muller, and Kontermann. Novel tetravalent and bispecific IgG-like antibody molecules combining single-chain diabodies with the immunoglobulin gamma1 Fc or CH3 region. FEBS Letters, 1999. vol. 454, pp. 90-94.;;Miller, Meng, Liu, Hurst, Hsei, Wong, Ekert, Lawrence, Sherwood, De Forge, Gaudreault, Keller, Sliwkowski, Ashkenazi, and Presta. Design, construction and in vitro analysis of multivalent antibodies. Journal of Immunology, 2003. vol. 170, pp. 4854-4861.;;Alderson et al., ""Regulation of apoptosis and T cell activation by Fas-specific mAb,"" Int. Immunol., 6(11): 1799-1806 (1994).;;Ames et al., ""Conversion of murine Fabs isolated from a combinatorial phage display library to full length immunoglobulins,"" J. Immunol. Methods, 184: 177-186 (1995).;;Aoki et al., ""Endothelial Progenitor Cell Capture by Stents Coated with Antibody Against CD34,"" J. Am. Coll. Cardiol., 45(10): 1574-1579 (2005).;;Arancio et al., ""RAGE potentiates Abeta-induced perturbation of neuronal function in transgenic mice,"" EMBO J., 23: 4096-4105 (2004).;;Arndt et al., ""Bispecific Diabodies for Cancer Therapy,"" Methods Mol. Biol., 207: 305-321 (2003).;;Azzazy et al., ""Phage display technology: clinical applications and recent innovations,"" Clin. Biochem., 35: 425-445 (2002).;;Babcook et al., ""A novel strategy for generating monoclonal antibodies from single, isolated lymphocytes producing antibodies of defined specificities,"" Proc. Natl. Acad. Sci. USA, 93: 7843-7848 (1996).;;Bäckström et al., ""Signaling Efficiency of the T Cell Receptor Controlled by a Single Amino Acid in the beta Chain Constant Region,"" J. Exp. Med., 186(11): 1933-1938 (1997).;;Barbas et al., ""Assembly of combinatorial antibody libraries on phage surfaces: The gene III site,"" Proc. Natl. Acad. Sci. USA, 88: 7978-7982 (1991).;;Barbas et al., ""In vitro evolution of a neutralizing human antibody to human immunodeficiency virus type 1 to enhance affinity and broaden strain cross-reactivity,"" Proc. Natl. Acad. Sci. USA, 91: 3809-3813 (1994).;;Baslund et al., ""Targeting interleukin-15 in patients with rheumatoid arthritis,"" Arthritis Rheum., 52(9): 2686-2692 (2005).;;Baumgartner et al., ""Double blind, placebo controlled trial of tumor necrosis factor receptor fusion protein (TNFR:Fc) in active rheumatoid arthritis,"" Biomedicine '96. Medical Research from Bench to Bedside. Washington, DC, May 3-6, 1996. J. Invest. Med., 44(3):235A (Mar. 1996) (Abstract).;;Bessis et al., ""Use of hollow fibers filled with cells engineered to secrete IL-4 or IL-13 for treatment of experimental arthritis,"" (Abstract No. 1681), Arthritis Rheum., 39(9Suppl.): S308 (1996).;;Better et al., ""Escherichia coli Secretion of an Active Chimeric Antibody Fragment,"" Science, 240: 1041-1043 (1988).;;Biewenga et al., ""IgA1 half molecules in human multiple myeloma and the in vitro production of similar fragments from intact IgA1 molecules,"" Clin. Exp. Immunol., 51: 395-400 (1983).;;Bird et al., ""Single-Chain Antigen-Binding Proteins,"" Science, 242: 423-426 (1988).;;Bornemann et al., ""Abeta-Induced Inflammatory Processes in Microglia Cells of APP23 Transgenic Mice,"" Am. J. Pathol., 158(1): 63-73 (2001).;;Boyce et al., ""No audible wheezing: nuggets and conundrums from mouse asthma models,"" J. Exp. Med., 201(12): 1869-1873 (2005).;;Brand, D.D., ""Rodent Models of Rheumatoid Arthritis,"" Comparative Medicine, 55(2): 114-122 (2005).;;Bree et al., ""IL-13 blockade reduces lung inflammation after Ascaris suum challenge in cynomolgus monkeys,"" J. Allergy Clin. Immunol., 119(5): 1251-1257 (2007).;;Brennan et al., ""Preparation of Bispecific Antibodies by Chemical Recombination of Monoclonal Immunoglobulin G1 Fragments,"" Science, 229: 81-83 (1985).;;Brinkmann et al., ""Phage display of disulfide-stabilized Fv fragments,"" J. Immunol. Methods, 182: 41-50 (1995).;;Brüsselbach et al., ""Enzyme recruitment and tumor cell killing in vitro by a secreted bispecific single-chain diabody,"" Tumor Targeting, 4: 115-123 (1999).;;Bruncko et al., ""Studies leading to potent, dual inhibitors of Bcl-2 and Bcl-xL,"" J. Med. Chem., 50(4): 641-662 (2007).;;Buchwald et al., ""Long-term, continuous intravenous heparin administration by an implantable infusion pump in ambulatory patients with recurrent venous thrombosis,"" Surgery, 88: 507-516 (1980).;;Buras et al., ""Animal Models of Sepsis: Setting the Stage,"" Nat. Rev. Drug. Discovery, 4: 854-865 (2005).;;Burke et al., ""Zotarolimus (ABT-578) eluting stents,"" Adv. Drug Del. Rev., 58: 437-446 (2006).;;Burton et al., ""Human Antibodies from Combinatorial Libraries,"" Adv. Immunol., 57: 191-280 (1994).;;Calandra et al., ""Protection from septic shock by neutralization of macrophage migration inhibitory factor,"" Nature Med., 6(2): 164-170 (2000).;;Carroll et al., ""The selection of high-producing cell lines using flow cytometry and cell sorting,"" Expert Opin. Biol. Ther., 4: 1821-1829 (2004).;;Carter et al., ""Humanization of an anti-p185HER2 antibody for human cancer therapy,"" Proc. Natl. Acad. Sci. USA, 89: 4285-4289 (1992).;;Chikanza et al., ""Treatment of patients with rheumatoid arthritis with RP73401 phosphodiesterase Type IV inhibitor,""Abstract No. 1527), Arthritis Rheum., 39(9 Suppl.): S282 (1996).;;Choi et al., ""Recombinant chimeric OKT3 scFv IgM antibodies mediate immune suppression while reducing T cell activation in vitro,"" Eur. J. Immunol., 31(1): 94-106 (2001).;;Chothia et al., ""Canonical Structures for the Hypervariable Regions of Immunoglobulins,"" J. Mol. Biol., 196: 901-917 (1987).;;Chothia et al., ""Conformations of immunoglobulin hypervariable regions,"" Nature, 342: 877-883 (1989).;;Clackson et al., ""Making antibody fragments using phage display libraries,"" Nature, 352: 624-628 (1991).;;Cleek et al., ""Biodegradable Polymeric Carriers for a bFGF Antibody for Cardiovascular Application,"" Proceed. Intl. Symp. Control. Rel. Bioact. Mater., 24: 853-854 (1997).;;Co et al., ""Genetically Engineered Deglycosylation of the Variable Domain Increases the Affinity of an Anti-CD33 Monoclonal Antibody,"" Mol. Immunol., 30(15): 1361-1367 (1993).;;Coffman et al., ""Nonhuman primate models of asthma,"" J. Exp. Med., 201(12): 1875-1879 (2005).;;Coloma et al., ""Design and production of novel tetravalent bispecific antibodies,"" Nature Biotechnol., 15: 159-163 (1997).;;Cox et al., ""Measurement of cytokine release at the single cell level using the ELISPOT assay,"" Methods, 38(4): 274-282 (2006).;;Dall'Acqua et al., ""Contribution of Domain Interface Residues to the Stability of Antibody CH3 Domain Homodimers,"" Biochemistry, 37: 9266-9273 (1998).;;Dall'Acqua et al., ""Increasing the affinity of a human IgG1 for the neonatal Fc receptor: biological consequences,"" J. Immunol., 169(9): 5171-5180 (2002).;;Dall'Acqua et al., ""Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn),"" J. Biol. Chem., 281: 23514-23524 (2006).;;D'Andrea et al., ""Production of Natural Killer Cell Stimulatory Factor (Interleukin 12) by Peripheral Blood Mononuclear Cells,"" J. Exp. Med., 176: 1387-1398 (1992).;;Deane et al., ""RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain,"" Nature Med., 9(7): 907-913 (2003).;;Deluca et al., ""Marine and botanical lipids as immunomodulatory and therapeutic agents in the treatment of rheumatoid arthritis,"" Rheum. Dis. Clin. North Am., 21: 759-777 (1995).;;Descotes, J., ""Immunotoxicology of Immunomodulators,"" Develop. Biol. Standard, 77: 99-102 (1992).;;Desmet et al., ""Anchor profiles of HLA-specific peptides: analysis by a novel affinity scoring method and experimental validation,"" Proteins, 58: 53-69 (2005).;;Dickson, B.J., ""Molecular Mechanisms of Axon Guidance,"" Science, 298: 1959-1964 (2002).;;Dinarello et al., ""Measurement of soluble and membrane-bound interleukin 1 using a fibroblast bioassay,"" Unit 6.2, In Current Protocols in Immunology, pp. 6.21-6.27 (2000).;;Domeniconi et al., ""Overcoming inhibitors in myelin to promote axonal regeneration,"" J. Neurological Sciences, 233: 43-47 (2005).;;During et al., ""Controlled Release of Dopamine from a Polymeric Brain Implant: In Vivo Characterization,"" Ann. Neurol., 25(4): 351-356 (1989).;;Durocher et al., ""High-level and high-throughput recombinant protein production by transient transfection of suspension-growing human 293-EBNA1 cells,"" Nucl. Acids Res., 30(2): e9, (9 pages) (2002).;;Economides et al., ""Cytokine traps: multi-component, high-affinity blockers of cytokine action,"" Nature Med., 9(1): 47-52 (2003).;;Enrich et al., ""Demonstration of selective COX-2 inhibition by MK-966 in humans,"" (Abstract No. 328), Arthritis Rheum., 39(9 Suppl.): S81 (1996).;;Enrich et al., ""Efficacy of MK-966, a highly selective inhibitor of COX-2, in the treatment of postoperative dental pain,"" (Abstract No. 329), Arthritis Rheum., 39(9Suppl.): S81 (1996).;;Evans et al., ""Efficacy of tumor necrosis factor binding protein (TNF-bp) in the streptococcal cell wall-induced reactivation model of arthritis,"" (Abstract No. 1540), Arthritis Rheum., 39(9 Suppl.): S284 (1996).;;Farr et al., ""Sulphasalazine (SASP) in rheumatoid arthritis (RA): A 5 year prospective study,"" (Abstract No. 1519), Arthritis Rheum., 39(9 Suppl.): S281 (1996).;;Fiebich et al., ""Effects of NSAIDs on IL-1-beta-induced IL-6 mRNA and protein synthesis in human astrocytoma cells,"" NeuroReport,7: 1209-1213 (1996).;;Finnegan et al., ""Leflunomide inhibits immunoglobulin production by two separate mechanisms,"" (Abstract No. 627), Arthritis Rheum., 39(9 (Suppl.): S131 (1996).;;Finotto, et al., ""Asthmatic changes in mice lacking T-bet are mediated by IL-13,"" Int. Immunol., 17(8): 993-1007 (2005).;;Fuchs et al., ""Targeting Recombinant Antibodies to the Surface of Escherichia coli: Fusion to a Peptidoglycan Associated Lipoprotein,"" Bio/Technology, 9: 1369-1372 (1991).;;Garrard et al., ""FAB Assembly and Enrichment in a Monovalent Phage Display System,"" Bio/Technology, 9: 1373-1377 (1991).;;Gavilondo et al., ""Antibody Engineering at the Millennium,"" Biotechniques, 29: 128-145 (2000).;;Genain et al., ""Creation of a model for multiple sclerosis in Callithrix jacchus marmosets,"" J. Mol. Med., 75(3): 187-197 (1997).;;Genovese et al., ""Abatacept for Rheumatoid Arthritis Refractory to Tumor Necrosis Factor alpha Inhibition,"" N. Engl. J. Med., 353: 1114-1123 (2005).;;Ghetie et al., ""Increasing the serum persistence of an IgG fragment by random mutagenesis,"" Nature Biotechnol., 15(7): 637-640 (1997).;;Giegé et al., Chapter 1, In Crystallization of Nucleic Acids and Proteins, a Practical Approach, 2nd ed., (Ducruix and Giegé, eds.) (Oxford University Press, New York, 1999) pp. 1-16.;;Glennie et al., ""Preparation and Performance of Bispecific F(ab'gamma)2 Antibody Containing Thioether-Linked Fab'gamma Fragments,"" J. Immunol., 139(7): 2367-2375 (1987).;;Goldspiel et al., ""Human Gene Therapy,"" Clin. Pharm., 12: 488-505 (1993).;;Goodson, J.M., ""Dental Applications,"" Chapter 6, In Medical Applications of Controlled Release, vol. II, Applications and Evaluation, (Langer and Wise, eds.) (CRC Press, Inc., Boca Raton, 1984), pp. 115-138.;;Gracie et al., ""A proinflammatory role for IL-18 in rheumatoid arthritis,"" J. Clin. Invest., 104(10): 1393-1401 (1999).;;Gram et al., ""In vitro selection and affinity maturation of antibodies from a naive combinatorial immunoglobulin library,"" Proc. Natl. Acad. Sci. USA, 89: 3576-3580 (1992).;;Green et al., ""Antigen-specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs,"" Nature Genetics, 7: 13-21 (1994).;;Green et al., ""Regulation of B Cell Development by Variable Gene Complexity in Mice Reconstituted with Human Immunoglobulin Yeast Artificial Chromosomes,"" J. Exp. Med., 188(3): 483-495 (1998).;;Griffin et al., ""Blockade of T Cell Activation Using a Surface-Linked Single Chain Antibody to CTLA-4 (CD152),"" J. Immunol., 164: 4433-4442 (2000).;;Griffiths et al., ""Human anti-self antibodies with high specificity from phage display libraries,"" EMBO J., 12(2): 725-734 (1993).;;Guttadauria, M., ""Tenidap in Rheumatoid Arthritis Collaborative International Study (TRACIS): a 6-month interim analysis,"" (Abstract No. 1516), Arthritis Rheum., 39(9 Suppl.): S280 (1996).;;Hammerling et al., eds., ""Appendix: Production of Antibody-Producing Hybridomas in the Rodent Systems,"" In Monoclonal Antibodies and T-Cell Hybridomas,Research Monographs In Immunology, vol. 3 (J.L. Turk, General Editor) (Elsevier, New York, 1981), pp. 563-587.;;Hanasaki et al., ""Binding of Human Plasma Sialoglycoproteins by the B Cell-specific Lectin CD22,"" J. Biol. Chem., 270(13): 7543-7550 (1995).;;Hara et al., ""Therapeutic effect of T-614, a new anti-arthritic agent, on rheumatoid arthritis,"" (Abstract No. 1526), Arthritis Rheum., 39(9 Suppl.): S282 (1996).;;Harriman et al., ""Summary of clinical trials in rheumatoid arthritis using infliximab, an anti-TNFalpha treatment,"" Ann. Rheum. Dis., 58(Suppl. I): I61-I64 (1999).;;Hart et al., ""Preclinical efficacy and safety of mepolizumab (SB-240563), a humanized monoclonal antibody to IL-5, in cynomolgus monkeys,"" J. Allergy Clin. Immunol., 108(2): 250-257 (2001).;;Hawkins et al., ""Selection of Phage Antibodies by Binding Affinity Mimicking Affinity Maturation,"" J. Mol. Biol., 226: 889-896 (1992).;;Hay et al., ""Bacteriophage cloning and Escherichia coli expression of a human IgM Fab,"" Hum. Antibod. Hybridomas, 3: 81-85 (1992).;;Hickey et al., ""The Rheumatoid Arthritis Azathioprine Registry (RAAR)-interim analysis of malignancy and mortality,"" (Abstract No. 1521), Arthritis Rheum., 39(9 Suppl.): S281 (1996).;;Hildebrand et al., ""Surface coatings for biological activation and functionalization of medical devices,"" Surface & Coatings Technology, 200: 6318-6324 (2006).;;Hinton et al., ""Engineered human IgG antibodies with longer serum half-lives in primates,"" J. Biol. Chem. 279(8): 6213-6216 (2004).;;Holliger et al., ""'Diabodies': Small bivalent and bispecific antibody fragments,"" Proc. Natl. Acad. Sci. USA, 90: 6444-6448 (1993).;;Holliger et al., ""Diabodies: small bispecific antibody fragments,"" Cancer Immunol. Immunother., 45: 128-130 (1997).;;Hoogenboom et al., ""Multi-subunit proteins on the surface of filamentous phage: methodologies for displaying antibody (Fab) heavy and light chains,"" Nucl. Acids Res., 19(15): 4133-4137 (1991).;;Hoogenboom et al., ""Natural and designer binding sites made by phage display technology,"" Immunol. Today, 21(8): 371-378 (2000).;;Hoogenboom, H.R., ""Designing and optimizing library selection strategies for generating high-affinity antibodies,"" Trends Biotechnol., 15: 62-70 (1997).;;Hoogenboom, H.R., ""Mix and match: Building manifold binding sites,"" Nature Biotechnol., 15: 125-126 (1997).;;Howard et al., ""Intracerebral drug delivery in rats with lesion-induced memory deficits,"" J. Neurosurg., 71: 105-112 (1989).;;Huber et al., ""Crystallographic structure studies of an IgG molecule and an Fc fragment,"" Nature, 264: 415-420 (1976).;;Huse et al., ""Generation of a Large Combinatorial Library of the Immunoglobulin Repertoire in Phage Lambda,"" Science, 246: 1275-1281 (1989).;;Huston et al., ""Protein engineering of antibody binding sites: Recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli,"" Proc. Natl. Acad. Sci. USA, 85: 5879-5883 (1988).",ACTIVE
147,CA,A1,CA 2722466 A1,167-235-128-932-054,2009-11-05,2009,CA 2722466 A,2009-04-28,US 12583408 P;;US 13428308 P;;US 19719108 P;;US 19900908 P;;US 2009/0041945 W,2008-04-29,DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND USES THEREOF,"The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.",ABBOTT LAB,GHAYUR TARIQ;;MORGAN-LAPPE SUSAN E;;REILLY EDWARD B;;KINGSBURY GILLIAN A;;PHILLIPS ANDREW;;WANG JIEYI;;BELL RANDY L;;NORVELL SUZANNE M;;LI YINGCHUN;;LIU JUNJIAN;;YING HUA,,https://lens.org/167-235-128-932-054,Patent Application,no,0,0,31,32,873,A61K2039/505;;C07K16/22;;C07K16/28;;C07K16/2863;;C07K16/32;;C07K2317/31;;C07K2317/64;;C07K2317/71;;C07K2317/73;;C07K2317/732;;C07K2317/734;;C07K2317/92;;C07K2319/00;;C07K16/468;;C07K2317/76;;Y10S435/81;;A61P1/04;;A61P1/14;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/06;;A61P11/16;;A61P13/02;;A61P13/08;;A61P13/12;;A61P15/02;;A61P15/08;;A61P17/02;;A61P17/04;;A61P17/06;;A61P17/14;;A61P19/02;;A61P19/04;;A61P19/06;;A61P19/08;;A61P19/10;;A61P21/00;;A61P21/02;;A61P21/04;;A61P25/00;;A61P25/04;;A61P25/08;;A61P25/10;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/24;;A61P25/28;;A61P25/30;;A61P25/32;;A61P27/02;;A61P27/16;;A61P29/00;;A61P3/14;;A61P31/00;;A61P31/04;;A61P31/08;;A61P31/14;;A61P31/16;;A61P31/18;;A61P31/22;;A61P33/00;;A61P33/02;;A61P33/06;;A61P35/00;;A61P35/02;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/00;;A61P43/00;;A61P5/00;;A61P5/14;;A61P5/18;;A61P5/50;;A61P7/02;;A61P7/04;;A61P7/06;;A61P9/04;;A61P9/06;;A61P9/08;;A61P9/10;;A61P9/12;;A61P9/14;;A61P3/10;;Y02A50/30;;A61K2039/505;;C07K16/22;;C07K16/28;;C07K16/2863;;C07K16/32;;C07K2317/31;;C07K2317/64;;C07K2317/71;;C07K2317/73;;C07K2317/732;;C07K2317/734;;C07K2317/92;;C07K2319/00;;Y02A50/30;;C07K16/468;;A61K39/39533;;A61K45/06;;C07K2317/565;;C07K2317/76;;G01N33/6872;;G01N33/74;;G01N2333/515;;G01N2333/705;;Y10S435/81,G01N33/53,,0,0,,,,PENDING
148,EP,A2,EP 2282769 A2,005-243-995-313-513,2011-02-16,2011,EP 09739578 A,2009-04-28,US 2009/0041945 W;;US 12583408 P;;US 13428308 P;;US 19719108 P;;US 19900908 P,2008-04-29,DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND USES THEREOF,,ABBOTT LAB,GHAYUR TARIQ;;MORGAN-LAPPE SUSAN E;;REILLY EDWARD B;;KINGSBURY GILLIAN A;;PHILLIPS ANDREW;;WANG JIEYI;;BELL RANDY L;;NORVELL SUZANNE M;;LI YINGCHUN;;LIU JUNJIAN;;YING HUA,ABBVIE INC. (2013-06-12),https://lens.org/005-243-995-313-513,Patent Application,yes,0,0,31,32,873,A61K2039/505;;C07K16/22;;C07K16/28;;C07K16/2863;;C07K16/32;;C07K2317/31;;C07K2317/64;;C07K2317/71;;C07K2317/73;;C07K2317/732;;C07K2317/734;;C07K2317/92;;C07K2319/00;;C07K16/468;;C07K2317/76;;Y10S435/81;;A61P1/04;;A61P1/14;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/06;;A61P11/16;;A61P13/02;;A61P13/08;;A61P13/12;;A61P15/02;;A61P15/08;;A61P17/02;;A61P17/04;;A61P17/06;;A61P17/14;;A61P19/02;;A61P19/04;;A61P19/06;;A61P19/08;;A61P19/10;;A61P21/00;;A61P21/02;;A61P21/04;;A61P25/00;;A61P25/04;;A61P25/08;;A61P25/10;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/24;;A61P25/28;;A61P25/30;;A61P25/32;;A61P27/02;;A61P27/16;;A61P29/00;;A61P3/14;;A61P31/00;;A61P31/04;;A61P31/08;;A61P31/14;;A61P31/16;;A61P31/18;;A61P31/22;;A61P33/00;;A61P33/02;;A61P33/06;;A61P35/00;;A61P35/02;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/00;;A61P43/00;;A61P5/00;;A61P5/14;;A61P5/18;;A61P5/50;;A61P7/02;;A61P7/04;;A61P7/06;;A61P9/04;;A61P9/06;;A61P9/08;;A61P9/10;;A61P9/12;;A61P9/14;;A61P3/10;;Y02A50/30;;A61K2039/505;;C07K16/22;;C07K16/28;;C07K16/2863;;C07K16/32;;C07K2317/31;;C07K2317/64;;C07K2317/71;;C07K2317/73;;C07K2317/732;;C07K2317/734;;C07K2317/92;;C07K2319/00;;Y02A50/30;;C07K16/468;;A61K39/39533;;A61K45/06;;C07K2317/565;;C07K2317/76;;G01N33/6872;;G01N33/74;;G01N2333/515;;G01N2333/705;;Y10S435/81,C07K16/28;;C07K16/46,,0,0,,,,DISCONTINUED
149,US,A1,US 2015/0104452 A1,161-369-172-351-172,2015-04-16,2015,US 201414301305 A,2014-06-10,US 201414301305 A;;US 43146009 A;;US 12583408 P;;US 13428308 P;;US 19719108 P;;US 19900908 P,2008-04-29,DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND USES THEREOF,"The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.",ABBVIE INC,GHAYUR TARIQ;;REILLY EDWARD B;;PHILLIPS ANDREW;;BELL RANDY L;;LI YINGCHUN;;YING HUA;;MORGAN-LAPPE SUSAN E;;KINGSBURY GILLIAN A;;WANG JIEYI;;NORVELL SUZANNE M;;LIU JUNJIAN,,https://lens.org/161-369-172-351-172,Patent Application,yes,1,19,31,32,873,A61K2039/505;;C07K16/22;;C07K16/28;;C07K16/2863;;C07K16/32;;C07K2317/31;;C07K2317/64;;C07K2317/71;;C07K2317/73;;C07K2317/732;;C07K2317/734;;C07K2317/92;;C07K2319/00;;C07K16/468;;C07K2317/76;;Y10S435/81;;A61P1/04;;A61P1/14;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/06;;A61P11/16;;A61P13/02;;A61P13/08;;A61P13/12;;A61P15/02;;A61P15/08;;A61P17/02;;A61P17/04;;A61P17/06;;A61P17/14;;A61P19/02;;A61P19/04;;A61P19/06;;A61P19/08;;A61P19/10;;A61P21/00;;A61P21/02;;A61P21/04;;A61P25/00;;A61P25/04;;A61P25/08;;A61P25/10;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/24;;A61P25/28;;A61P25/30;;A61P25/32;;A61P27/02;;A61P27/16;;A61P29/00;;A61P3/14;;A61P31/00;;A61P31/04;;A61P31/08;;A61P31/14;;A61P31/16;;A61P31/18;;A61P31/22;;A61P33/00;;A61P33/02;;A61P33/06;;A61P35/00;;A61P35/02;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/00;;A61P43/00;;A61P5/00;;A61P5/14;;A61P5/18;;A61P5/50;;A61P7/02;;A61P7/04;;A61P7/06;;A61P9/04;;A61P9/06;;A61P9/08;;A61P9/10;;A61P9/12;;A61P9/14;;A61P3/10;;Y02A50/30;;A61K2039/505;;C07K16/22;;C07K16/28;;C07K16/2863;;C07K16/32;;C07K2317/31;;C07K2317/64;;C07K2317/71;;C07K2317/73;;C07K2317/732;;C07K2317/734;;C07K2317/92;;C07K2319/00;;Y02A50/30;;C07K16/468;;A61K39/39533;;A61K45/06;;C07K2317/565;;C07K2317/76;;G01N33/6872;;G01N33/74;;G01N2333/515;;G01N2333/705;;Y10S435/81,A61K39/395;;C07K16/46;;A61K45/06;;C07K16/22;;C07K16/28;;G01N33/68;;G01N33/74,424/136.1;;530/387.3;;530/391.3;;530/391.7;;536/23.53;;435/188;;435/320.1;;435/252.33;;435/328;;435/419;;435/254.11;;435/254.2;;435/254.21;;435/69.6;;436/501;;435/7.92,0,0,,,,DISCONTINUED
150,NZ,A,NZ 588554 A,188-856-303-603-367,2013-03-28,2013,NZ 58855409 A,2009-04-28,US 19900908 P;;US 19719108 P;;US 13428308 P;;US 12583408 P;;US 2009/0041945 W,2008-04-29,DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND USES THEREOF,"Disclosed is a binding protein comprising first and second polypeptide chains, each independently comprising VD1-(X1)n-VD2-C-(X2)n, wherein VD1 is a first variable domain; VD2 is a second variable domain; C is a constant domain; X1 is a linker with the proviso that it is not CH1; X2 is an Fc region; n is 0 or 1. Furthermore, the VD1 domains on the first and second polypeptide chains form a first functional target binding site and the VD2 domains on the first and second polypeptide chains form a second functional target binding site and are as defined in the specification. The disclosed binding protein is capable of binding to VEGF with an EC50 of at most about 28.25 nM, as measured by direct bind ELISA, and/or the binding protein is capable of binding to DLL4 with an EC50 of at most about 2.12nM, as measured by direct bind ELISA.",ABBOTT LAB,GHAYUR TARIQ;;MORGAN-LAPPE SUSAN E;;REILLY EDWARD B;;KINGSBURY GILLIAN A;;PHILLIPS ANDREW;;WANG JIEYI;;BELL RANDY L;;NORVELL SUZANNE M;;LI YINGCHUN;;LIU JUNJIAN;;YING HUA,"ABBOTT LABORATORIES, US (2011-08-26);;ABBVIE INC., US (2013-08-01)",https://lens.org/188-856-303-603-367,Patent Application,no,0,0,31,32,0,A61K2039/505;;C07K16/22;;C07K16/28;;C07K16/2863;;C07K16/32;;C07K2317/31;;C07K2317/64;;C07K2317/71;;C07K2317/73;;C07K2317/732;;C07K2317/734;;C07K2317/92;;C07K2319/00;;C07K16/468;;C07K2317/76;;Y10S435/81;;A61P1/04;;A61P1/14;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/06;;A61P11/16;;A61P13/02;;A61P13/08;;A61P13/12;;A61P15/02;;A61P15/08;;A61P17/02;;A61P17/04;;A61P17/06;;A61P17/14;;A61P19/02;;A61P19/04;;A61P19/06;;A61P19/08;;A61P19/10;;A61P21/00;;A61P21/02;;A61P21/04;;A61P25/00;;A61P25/04;;A61P25/08;;A61P25/10;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/24;;A61P25/28;;A61P25/30;;A61P25/32;;A61P27/02;;A61P27/16;;A61P29/00;;A61P3/14;;A61P31/00;;A61P31/04;;A61P31/08;;A61P31/14;;A61P31/16;;A61P31/18;;A61P31/22;;A61P33/00;;A61P33/02;;A61P33/06;;A61P35/00;;A61P35/02;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/00;;A61P43/00;;A61P5/00;;A61P5/14;;A61P5/18;;A61P5/50;;A61P7/02;;A61P7/04;;A61P7/06;;A61P9/04;;A61P9/06;;A61P9/08;;A61P9/10;;A61P9/12;;A61P9/14;;A61P3/10;;Y02A50/30;;A61K2039/505;;C07K16/22;;C07K16/28;;C07K16/2863;;C07K16/32;;C07K2317/31;;C07K2317/64;;C07K2317/71;;C07K2317/73;;C07K2317/732;;C07K2317/734;;C07K2317/92;;C07K2319/00;;Y02A50/30;;C07K16/468;;A61K39/39533;;A61K45/06;;C07K2317/565;;C07K2317/76;;G01N33/6872;;G01N33/74;;G01N2333/515;;G01N2333/705;;Y10S435/81,A61K39/00,,0,0,,,,DISCONTINUED
151,EP,A4,EP 2282769 A4,022-937-813-830-767,2012-04-25,2012,EP 09739578 A,2009-04-28,US 2009/0041945 W;;US 12583408 P;;US 13428308 P;;US 19719108 P;;US 19900908 P,2008-04-29,DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND USES THEREOF,,ABBOTT LAB,GHAYUR TARIQ;;MORGAN-LAPPE SUSAN E;;REILLY EDWARD B;;KINGSBURY GILLIAN A;;PHILLIPS ANDREW;;WANG JIEYI;;BELL RANDY L;;NORVELL SUZANNE M;;LI YINGCHUN;;LIU JUNJIAN;;YING HUA,ABBVIE INC. (2013-06-12),https://lens.org/022-937-813-830-767,Search Report,no,3,0,31,32,873,A61K2039/505;;C07K16/22;;C07K16/28;;C07K16/2863;;C07K16/32;;C07K2317/31;;C07K2317/64;;C07K2317/71;;C07K2317/73;;C07K2317/732;;C07K2317/734;;C07K2317/92;;C07K2319/00;;C07K16/468;;C07K2317/76;;Y10S435/81;;A61P1/04;;A61P1/14;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/06;;A61P11/16;;A61P13/02;;A61P13/08;;A61P13/12;;A61P15/02;;A61P15/08;;A61P17/02;;A61P17/04;;A61P17/06;;A61P17/14;;A61P19/02;;A61P19/04;;A61P19/06;;A61P19/08;;A61P19/10;;A61P21/00;;A61P21/02;;A61P21/04;;A61P25/00;;A61P25/04;;A61P25/08;;A61P25/10;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/24;;A61P25/28;;A61P25/30;;A61P25/32;;A61P27/02;;A61P27/16;;A61P29/00;;A61P3/14;;A61P31/00;;A61P31/04;;A61P31/08;;A61P31/14;;A61P31/16;;A61P31/18;;A61P31/22;;A61P33/00;;A61P33/02;;A61P33/06;;A61P35/00;;A61P35/02;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/00;;A61P43/00;;A61P5/00;;A61P5/14;;A61P5/18;;A61P5/50;;A61P7/02;;A61P7/04;;A61P7/06;;A61P9/04;;A61P9/06;;A61P9/08;;A61P9/10;;A61P9/12;;A61P9/14;;A61P3/10;;Y02A50/30;;A61K2039/505;;C07K16/22;;C07K16/28;;C07K16/2863;;C07K16/32;;C07K2317/31;;C07K2317/64;;C07K2317/71;;C07K2317/73;;C07K2317/732;;C07K2317/734;;C07K2317/92;;C07K2319/00;;Y02A50/30;;C07K16/468;;A61K39/39533;;A61K45/06;;C07K2317/565;;C07K2317/76;;G01N33/6872;;G01N33/74;;G01N2333/515;;G01N2333/705;;Y10S435/81,C07K16/28;;C07K16/46,,5,5,008-411-420-307-533;;017-924-597-005-768;;049-121-326-213-831;;012-713-614-244-110;;040-803-846-951-724,17934452;;10.1038/nbt1345;;10.1182/blood-2007-08-110072;;pmc2234056;;18025153;;10.1074/jbc.m307002200;;12947084;;12969563;;10.1016/s0022-1759(03)00251-5;;10.1038/nbt1107-1233;;17989683,"CHENGBIN W U ET AL: ""Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin"", NATURE BIOTECHNOLOGY, NATURE PUBLISHING GROUP, NEW YORK, NY, US, vol. 25, no. 11, 1 November 2007 (2007-11-01), pages 1290 - 1297, XP002542446, ISSN: 1087-0156, DOI: 10.1038/NBT1345;;ZHENGXING QU ET AL: ""Bispecific anti-CD20/22 antibodies inhibit B-cell lymphoma proliferation by a unique mechanism of action"", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 111, no. 4, 19 November 2007 (2007-11-19), pages 2211 - 2219, XP008143615, ISSN: 0006-4971, [retrieved on 20071119], DOI: 10.1182/BLOOD-2007-08-110072;;JENDREYKO NINA ET AL: ""Intradiabodies, bispecific, tetravalent antibodies for the simultaneous functional knockout of two cell surface receptors"", JOURNAL OF BIOLOGICAL CHEMISTRY, THE AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, INC, US, vol. 278, no. 48, 28 November 2003 (2003-11-28), pages 47812 - 47819, XP002430788, ISSN: 0021-9258, DOI: 10.1074/JBC.M307002200;;LU DAN ET AL: ""Di-diabody: A novel tetravalent bispecific antibody molecule by design"", JOURNAL OF IMMUNOLOGICAL METHODS, ELSEVIER SCIENCE PUBLISHERS B.V.,AMSTERDAM, NL, vol. 279, no. 1-2, 1 August 2003 (2003-08-01), pages 219 - 232, XP002542445, ISSN: 0022-1759, DOI: 10.1016/S0022-1759(03)00251-5;;MORRISON S L: ""Two heads are better than one"", NATURE BIOTECHNOLOGY, NATURE PUBLISHING GROUP, NEW YORK, NY, US, vol. 25, no. 11, 1 November 2007 (2007-11-01), pages 1233 - 1234, XP002470803, ISSN: 1087-0156, DOI: 10.1038/NBT1107-1233",DISCONTINUED
152,DO,A,DO P2010000325 A,045-905-903-493-440,2010-11-15,2010,DO 2010000325 A,2010-10-27,US 12583408 P;;US 13428308 P;;US 19719108 P;;US 19900908 P,2008-04-29,INMUNOGLOBULINAS CON DOMINIO VARIABLE DUAL Y USOS DE LAS MISMAS,"Proteínas de unión multivalentes y multiespecíficas diseñadas, métodos para elaborarlas y, específicamente, sus usos en la prevención, el diagnóstico y/o el tratamiento de enfermedades.",ABBOTT LAB,GHAYUR TARQ;;MORGAN-LAPPE SUSAN E;;REILLY EDWARD B;;KINGSBURY GILLIAN A;;PHILLIPS ANDREW;;WANG JIEYI;;BELL RANDY L;;NORVELL SUZANNE M;;LI YINGCHUN;;LIU JUNJIAN;;YING HUA,,https://lens.org/045-905-903-493-440,Patent Application,no,0,0,31,32,0,A61K2039/505;;C07K16/22;;C07K16/28;;C07K16/2863;;C07K16/32;;C07K2317/31;;C07K2317/64;;C07K2317/71;;C07K2317/73;;C07K2317/732;;C07K2317/734;;C07K2317/92;;C07K2319/00;;C07K16/468;;C07K2317/76;;Y10S435/81;;A61P1/04;;A61P1/14;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/06;;A61P11/16;;A61P13/02;;A61P13/08;;A61P13/12;;A61P15/02;;A61P15/08;;A61P17/02;;A61P17/04;;A61P17/06;;A61P17/14;;A61P19/02;;A61P19/04;;A61P19/06;;A61P19/08;;A61P19/10;;A61P21/00;;A61P21/02;;A61P21/04;;A61P25/00;;A61P25/04;;A61P25/08;;A61P25/10;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/24;;A61P25/28;;A61P25/30;;A61P25/32;;A61P27/02;;A61P27/16;;A61P29/00;;A61P3/14;;A61P31/00;;A61P31/04;;A61P31/08;;A61P31/14;;A61P31/16;;A61P31/18;;A61P31/22;;A61P33/00;;A61P33/02;;A61P33/06;;A61P35/00;;A61P35/02;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/00;;A61P43/00;;A61P5/00;;A61P5/14;;A61P5/18;;A61P5/50;;A61P7/02;;A61P7/04;;A61P7/06;;A61P9/04;;A61P9/06;;A61P9/08;;A61P9/10;;A61P9/12;;A61P9/14;;A61P3/10;;Y02A50/30;;A61K2039/505;;C07K16/22;;C07K16/28;;C07K16/2863;;C07K16/32;;C07K2317/31;;C07K2317/64;;C07K2317/71;;C07K2317/73;;C07K2317/732;;C07K2317/734;;C07K2317/92;;C07K2319/00;;Y02A50/30;;C07K16/468;;A61K39/39533;;A61K45/06;;C07K2317/565;;C07K2317/76;;G01N33/6872;;G01N33/74;;G01N2333/515;;G01N2333/705;;Y10S435/81,,,0,0,,,,PENDING
153,CR,A,CR 11795 A,069-828-003-256-188,2011-01-12,2011,CR 11795 A,2010-11-17,US 13428308 P;;US 12583408 P;;US 19719108 P;;US 19900908 P,2008-04-29,INMUNOGLOBULINAS CON DOMINIO VARIABLE DUAL Y USOS DE LAS MISMAS,"Proteínas de unión multivalentes y multiespecíficas diseñadas, métodos para elaborarlas y, específicamente, sus uos en la prevención, el diagnóstico y/o tratamiento de enfermedades.",ABBOTT LAB,GHAYUR TARIQ;;MORGAN-LAPPE SUSAN E;;REILLY EDWARD B;;KINGSBURY GILLIAN A;;PHILLIPS ANDREW;;WANG JIEYI;;BELL RANDY L;;NORVELL SUZZANNE M;;LIU JUNJIAN;;LI YINGEHUN;;YING HUA,,https://lens.org/069-828-003-256-188,Patent Application,no,0,0,31,32,0,A61K2039/505;;C07K16/22;;C07K16/28;;C07K16/2863;;C07K16/32;;C07K2317/31;;C07K2317/64;;C07K2317/71;;C07K2317/73;;C07K2317/732;;C07K2317/734;;C07K2317/92;;C07K2319/00;;C07K16/468;;C07K2317/76;;Y10S435/81;;A61P1/04;;A61P1/14;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/06;;A61P11/16;;A61P13/02;;A61P13/08;;A61P13/12;;A61P15/02;;A61P15/08;;A61P17/02;;A61P17/04;;A61P17/06;;A61P17/14;;A61P19/02;;A61P19/04;;A61P19/06;;A61P19/08;;A61P19/10;;A61P21/00;;A61P21/02;;A61P21/04;;A61P25/00;;A61P25/04;;A61P25/08;;A61P25/10;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/24;;A61P25/28;;A61P25/30;;A61P25/32;;A61P27/02;;A61P27/16;;A61P29/00;;A61P3/14;;A61P31/00;;A61P31/04;;A61P31/08;;A61P31/14;;A61P31/16;;A61P31/18;;A61P31/22;;A61P33/00;;A61P33/02;;A61P33/06;;A61P35/00;;A61P35/02;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/00;;A61P43/00;;A61P5/00;;A61P5/14;;A61P5/18;;A61P5/50;;A61P7/02;;A61P7/04;;A61P7/06;;A61P9/04;;A61P9/06;;A61P9/08;;A61P9/10;;A61P9/12;;A61P9/14;;A61P3/10;;Y02A50/30;;A61K2039/505;;C07K16/22;;C07K16/28;;C07K16/2863;;C07K16/32;;C07K2317/31;;C07K2317/64;;C07K2317/71;;C07K2317/73;;C07K2317/732;;C07K2317/734;;C07K2317/92;;C07K2319/00;;Y02A50/30;;C07K16/468;;A61K39/39533;;A61K45/06;;C07K2317/565;;C07K2317/76;;G01N33/6872;;G01N33/74;;G01N2333/515;;G01N2333/705;;Y10S435/81,G01N33/53,,0,0,,,,DISCONTINUED
154,AU,A1,AU 2007/249152 A1,048-438-767-160-519,2008-01-24,2008,AU 2007/249152 A,2007-12-20,AU 2003/300686 A;;AU 2007/249152 A,2003-11-26,Solution information for knowledge management system,,ACCENTURE GLOBAL SERVICES LTD,RINGO TIMOTHY;;LIAN ELIZABETH H;;BELL RANDY;;LINGHAM ANTHONY;;IVES WILLIAM;;FENTON CRAIG;;LANE DAVID P;;REID GREGORY S;;SHEARING ELISE;;FORRESTER AUDREY;;WONG SEVASTI;;FARRELL DANIEL C,ACCENTURE GLOBAL SERVICES LIMITED (2010-12-09),https://lens.org/048-438-767-160-519,Patent Application,no,0,0,1,1,0,,G06F17/30;;G06Q30/00,,0,0,,,,DISCONTINUED
155,CN,B,CN 102076355 B,198-015-863-285-770,2014-05-07,2014,CN 200980125167 A,2009-04-28,US 2009/0041945 W;;US 12583408 P;;US 13428308 P;;US 19719108 P;;US 19900908 P,2008-04-29,Dual varistructure domain immunoglobulins and uses thereof,,ABBOTT LAB,GHAYUR TARIQ;;MORGAN-LAPPE SUSAN E;;REILLY EDWARD B;;KINGSBURY GILLIAN A;;PHILLIPS ANDREW;;WANG JIEYI;;BELL RANDY L;;NORVELL SUZANNE M;;LI YINGCHUN;;LIU JUNJIAN;;YING HUA,ABBVIE COMPANY (2013-06-21),https://lens.org/198-015-863-285-770,Granted Patent,no,0,0,31,32,0,A61K2039/505;;C07K16/22;;C07K16/28;;C07K16/2863;;C07K16/32;;C07K2317/31;;C07K2317/64;;C07K2317/71;;C07K2317/73;;C07K2317/732;;C07K2317/734;;C07K2317/92;;C07K2319/00;;C07K16/468;;C07K2317/76;;Y10S435/81;;A61P1/04;;A61P1/14;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/06;;A61P11/16;;A61P13/02;;A61P13/08;;A61P13/12;;A61P15/02;;A61P15/08;;A61P17/02;;A61P17/04;;A61P17/06;;A61P17/14;;A61P19/02;;A61P19/04;;A61P19/06;;A61P19/08;;A61P19/10;;A61P21/00;;A61P21/02;;A61P21/04;;A61P25/00;;A61P25/04;;A61P25/08;;A61P25/10;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/24;;A61P25/28;;A61P25/30;;A61P25/32;;A61P27/02;;A61P27/16;;A61P29/00;;A61P3/14;;A61P31/00;;A61P31/04;;A61P31/08;;A61P31/14;;A61P31/16;;A61P31/18;;A61P31/22;;A61P33/00;;A61P33/02;;A61P33/06;;A61P35/00;;A61P35/02;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/00;;A61P43/00;;A61P5/00;;A61P5/14;;A61P5/18;;A61P5/50;;A61P7/02;;A61P7/04;;A61P7/06;;A61P9/04;;A61P9/06;;A61P9/08;;A61P9/10;;A61P9/12;;A61P9/14;;A61P3/10;;Y02A50/30;;A61K2039/505;;C07K16/22;;C07K16/28;;C07K16/2863;;C07K16/32;;C07K2317/31;;C07K2317/64;;C07K2317/71;;C07K2317/73;;C07K2317/732;;C07K2317/734;;C07K2317/92;;C07K2319/00;;Y02A50/30;;C07K16/468;;A61K39/39533;;A61K45/06;;C07K2317/565;;C07K2317/76;;G01N33/6872;;G01N33/74;;G01N2333/515;;G01N2333/705;;Y10S435/81,A61K39/00,,0,0,,,,INACTIVE
156,KR,A,KR 20110014607 A,085-696-566-704-552,2011-02-11,2011,KR 20107026459 A,2009-04-28,US 12583408 P;;US 13428308 P;;US 19719108 P;;US 19900908 P,2008-04-29,DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND USES THEREOF,,ABBOTT LAB,GHAYUR TARIQ;;MORGAN LAPPE SUSAN E;;REILLY EDWARD B;;KINGSBURY GILLIAN A;;PHILLIPS ANDREW;;WANG JIEYI;;BELL RANDY L;;NORVELL SUZANNE M;;LI YINGCHUN;;LIU JUNJIAN;;YING HUA,,https://lens.org/085-696-566-704-552,Patent Application,no,0,2,31,32,12,A61K2039/505;;C07K16/22;;C07K16/28;;C07K16/2863;;C07K16/32;;C07K2317/31;;C07K2317/64;;C07K2317/71;;C07K2317/73;;C07K2317/732;;C07K2317/734;;C07K2317/92;;C07K2319/00;;C07K16/468;;C07K2317/76;;Y10S435/81;;A61P1/04;;A61P1/14;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/06;;A61P11/16;;A61P13/02;;A61P13/08;;A61P13/12;;A61P15/02;;A61P15/08;;A61P17/02;;A61P17/04;;A61P17/06;;A61P17/14;;A61P19/02;;A61P19/04;;A61P19/06;;A61P19/08;;A61P19/10;;A61P21/00;;A61P21/02;;A61P21/04;;A61P25/00;;A61P25/04;;A61P25/08;;A61P25/10;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/24;;A61P25/28;;A61P25/30;;A61P25/32;;A61P27/02;;A61P27/16;;A61P29/00;;A61P3/14;;A61P31/00;;A61P31/04;;A61P31/08;;A61P31/14;;A61P31/16;;A61P31/18;;A61P31/22;;A61P33/00;;A61P33/02;;A61P33/06;;A61P35/00;;A61P35/02;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/00;;A61P43/00;;A61P5/00;;A61P5/14;;A61P5/18;;A61P5/50;;A61P7/02;;A61P7/04;;A61P7/06;;A61P9/04;;A61P9/06;;A61P9/08;;A61P9/10;;A61P9/12;;A61P9/14;;A61P3/10;;Y02A50/30;;A61K2039/505;;C07K16/22;;C07K16/28;;C07K16/2863;;C07K16/32;;C07K2317/31;;C07K2317/64;;C07K2317/71;;C07K2317/73;;C07K2317/732;;C07K2317/734;;C07K2317/92;;C07K2319/00;;Y02A50/30;;C07K16/468;;A61K39/39533;;A61K45/06;;C07K2317/565;;C07K2317/76;;G01N33/6872;;G01N33/74;;G01N2333/515;;G01N2333/705;;Y10S435/81,A61K39/395;;C07K16/28,,0,0,,,,DISCONTINUED
157,AU,B2,AU 2009/241589 B2,090-247-907-288-049,2013-10-10,2013,AU 2009/241589 A,2009-04-28,US 12583408 P;;US 13428308 P;;US 19719108 P;;US 19900908 P;;US 2009/0041945 W,2008-04-29,Dual variable domain immunoglobulins and uses thereof,"The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.",ABBVIE INC,LIU JUNJIAN;;YING HUA;;NORVELL SUZANNE M;;KINGSBURY GILLIAN A;;MORGAN-LAPPE SUSAN E;;WANG JIEYI;;LI YINGCHUN;;BELL RANDY L;;GHAYUR TARIQ;;REILLY EDWARD B;;PHILLIPS ANDREW,ABBVIE INC. (2013-05-16),https://lens.org/090-247-907-288-049,Granted Patent,no,1,0,31,32,0,A61K2039/505;;C07K16/22;;C07K16/28;;C07K16/2863;;C07K16/32;;C07K2317/31;;C07K2317/64;;C07K2317/71;;C07K2317/73;;C07K2317/732;;C07K2317/734;;C07K2317/92;;C07K2319/00;;C07K16/468;;C07K2317/76;;Y10S435/81;;A61P1/04;;A61P1/14;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/06;;A61P11/16;;A61P13/02;;A61P13/08;;A61P13/12;;A61P15/02;;A61P15/08;;A61P17/02;;A61P17/04;;A61P17/06;;A61P17/14;;A61P19/02;;A61P19/04;;A61P19/06;;A61P19/08;;A61P19/10;;A61P21/00;;A61P21/02;;A61P21/04;;A61P25/00;;A61P25/04;;A61P25/08;;A61P25/10;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/24;;A61P25/28;;A61P25/30;;A61P25/32;;A61P27/02;;A61P27/16;;A61P29/00;;A61P3/14;;A61P31/00;;A61P31/04;;A61P31/08;;A61P31/14;;A61P31/16;;A61P31/18;;A61P31/22;;A61P33/00;;A61P33/02;;A61P33/06;;A61P35/00;;A61P35/02;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/00;;A61P43/00;;A61P5/00;;A61P5/14;;A61P5/18;;A61P5/50;;A61P7/02;;A61P7/04;;A61P7/06;;A61P9/04;;A61P9/06;;A61P9/08;;A61P9/10;;A61P9/12;;A61P9/14;;A61P3/10;;Y02A50/30;;A61K2039/505;;C07K16/22;;C07K16/28;;C07K16/2863;;C07K16/32;;C07K2317/31;;C07K2317/64;;C07K2317/71;;C07K2317/73;;C07K2317/732;;C07K2317/734;;C07K2317/92;;C07K2319/00;;Y02A50/30;;C07K16/468;;A61K39/39533;;A61K45/06;;C07K2317/565;;C07K2317/76;;G01N33/6872;;G01N33/74;;G01N2333/515;;G01N2333/705;;Y10S435/81,A61K39/00;;G01N33/53,,0,0,,,,INACTIVE
158,BR,A2,BR PI0910482 A2,027-201-022-010-420,2019-09-24,2019,BR PI0910482 A,2009-04-28,US 2009/0041945 W;;US 12583408 P;;US 13428308 P;;US 19719108 P;;US 19900908 P,2008-04-29,imunoglobinas de domínio variável duplo e usos das mesmas,,ABBOTT LAB,ANDREW PHILLIPS;;EDWARD B REILLY;;GILLIAN A KINGSBURY;;HUA YING;;JIEYI WANG;;JUNJIAN LIU;;RANDY L BELL;;SUSAN E MORGAN-LAPPEN;;SUZANNE M NORVELL;;TARIQ GHAYUR;;YINGCHUN LI,ABBOTT LABORATORIES (US) (2020-03-31),https://lens.org/027-201-022-010-420,Patent Application,no,0,0,31,32,0,A61K2039/505;;C07K16/22;;C07K16/28;;C07K16/2863;;C07K16/32;;C07K2317/31;;C07K2317/64;;C07K2317/71;;C07K2317/73;;C07K2317/732;;C07K2317/734;;C07K2317/92;;C07K2319/00;;C07K16/468;;C07K2317/76;;Y10S435/81;;A61P1/04;;A61P1/14;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/06;;A61P11/16;;A61P13/02;;A61P13/08;;A61P13/12;;A61P15/02;;A61P15/08;;A61P17/02;;A61P17/04;;A61P17/06;;A61P17/14;;A61P19/02;;A61P19/04;;A61P19/06;;A61P19/08;;A61P19/10;;A61P21/00;;A61P21/02;;A61P21/04;;A61P25/00;;A61P25/04;;A61P25/08;;A61P25/10;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/24;;A61P25/28;;A61P25/30;;A61P25/32;;A61P27/02;;A61P27/16;;A61P29/00;;A61P3/14;;A61P31/00;;A61P31/04;;A61P31/08;;A61P31/14;;A61P31/16;;A61P31/18;;A61P31/22;;A61P33/00;;A61P33/02;;A61P33/06;;A61P35/00;;A61P35/02;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/00;;A61P43/00;;A61P5/00;;A61P5/14;;A61P5/18;;A61P5/50;;A61P7/02;;A61P7/04;;A61P7/06;;A61P9/04;;A61P9/06;;A61P9/08;;A61P9/10;;A61P9/12;;A61P9/14;;A61P3/10;;Y02A50/30;;A61K2039/505;;C07K16/22;;C07K16/28;;C07K16/2863;;C07K16/32;;C07K2317/31;;C07K2317/64;;C07K2317/71;;C07K2317/73;;C07K2317/732;;C07K2317/734;;C07K2317/92;;C07K2319/00;;Y02A50/30;;C07K16/468;;A61K39/39533;;A61K45/06;;C07K2317/565;;C07K2317/76;;G01N33/6872;;G01N33/74;;G01N2333/515;;G01N2333/705;;Y10S435/81,A61K39/00,,0,0,,,,DISCONTINUED
159,US,A1,US 2010/0076178 A1,056-072-670-227-461,2010-03-25,2010,US 43146009 A,2009-04-28,US 43146009 A;;US 12583408 P;;US 13428308 P;;US 19719108 P;;US 19900908 P,2008-04-29,Dual Variable Domain Immumoglobulins and Uses Thereof,"The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.",ABBOTT LAB,GHAYUR TARIQ;;MORGAN-LAPPE SUSAN E;;REILLY EDWARD B;;KINGSBURY GILLIAN A;;PHILLIPS ANDREW;;WANG JIEYI;;BELL RANDY L;;NORVELL SUZANNE M;;LI YINGCHUN;;LIU JUNJIAN;;YING HUA,ABBVIE INC (2012-08-01);;ABBOTT LABORATORIES (2009-06-25),https://lens.org/056-072-670-227-461,Patent Application,yes,99,76,31,32,873,A61K2039/505;;C07K16/22;;C07K16/28;;C07K16/2863;;C07K16/32;;C07K2317/31;;C07K2317/64;;C07K2317/71;;C07K2317/73;;C07K2317/732;;C07K2317/734;;C07K2317/92;;C07K2319/00;;C07K16/468;;C07K2317/76;;Y10S435/81;;A61P1/04;;A61P1/14;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/06;;A61P11/16;;A61P13/02;;A61P13/08;;A61P13/12;;A61P15/02;;A61P15/08;;A61P17/02;;A61P17/04;;A61P17/06;;A61P17/14;;A61P19/02;;A61P19/04;;A61P19/06;;A61P19/08;;A61P19/10;;A61P21/00;;A61P21/02;;A61P21/04;;A61P25/00;;A61P25/04;;A61P25/08;;A61P25/10;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/24;;A61P25/28;;A61P25/30;;A61P25/32;;A61P27/02;;A61P27/16;;A61P29/00;;A61P3/14;;A61P31/00;;A61P31/04;;A61P31/08;;A61P31/14;;A61P31/16;;A61P31/18;;A61P31/22;;A61P33/00;;A61P33/02;;A61P33/06;;A61P35/00;;A61P35/02;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/00;;A61P43/00;;A61P5/00;;A61P5/14;;A61P5/18;;A61P5/50;;A61P7/02;;A61P7/04;;A61P7/06;;A61P9/04;;A61P9/06;;A61P9/08;;A61P9/10;;A61P9/12;;A61P9/14;;A61P3/10;;Y02A50/30;;A61K2039/505;;C07K16/22;;C07K16/28;;C07K16/2863;;C07K16/32;;C07K2317/31;;C07K2317/64;;C07K2317/71;;C07K2317/73;;C07K2317/732;;C07K2317/734;;C07K2317/92;;C07K2319/00;;Y02A50/30;;C07K16/468;;A61K39/39533;;A61K45/06;;C07K2317/565;;C07K2317/76;;G01N33/6872;;G01N33/74;;G01N2333/515;;G01N2333/705;;Y10S435/81,C07K16/00,530/387.3,0,0,,,,ACTIVE
160,EP,A1,EP 2899209 A1,054-910-917-997-116,2015-07-29,2015,EP 15153941 A,2009-04-28,US 12583408 P;;US 13428308 P;;US 19719108 P;;US 19900908 P;;EP 09739578 A,2008-04-29,Dual Variable Domain Immunoglobulins and uses thereof,"The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.
",ABBVIE INC,GHAYUR TARIQ;;MORGAN-LAPPE SUSAN E;;REILLY EDWARD B;;KINGSBURY GILLIAN A;;PHILLIPS ANDREW;;WANG JIEYI;;BELL RANDY L;;NORVELL SUZANNE M;;LI YINGCHUN;;LIU JUNJIAN;;YING HUA,,https://lens.org/054-910-917-997-116,Patent Application,yes,227,0,31,32,873,A61K2039/505;;C07K16/22;;C07K16/28;;C07K16/2863;;C07K16/32;;C07K2317/31;;C07K2317/64;;C07K2317/71;;C07K2317/73;;C07K2317/732;;C07K2317/734;;C07K2317/92;;C07K2319/00;;C07K16/468;;C07K2317/76;;Y10S435/81;;A61P1/04;;A61P1/14;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/06;;A61P11/16;;A61P13/02;;A61P13/08;;A61P13/12;;A61P15/02;;A61P15/08;;A61P17/02;;A61P17/04;;A61P17/06;;A61P17/14;;A61P19/02;;A61P19/04;;A61P19/06;;A61P19/08;;A61P19/10;;A61P21/00;;A61P21/02;;A61P21/04;;A61P25/00;;A61P25/04;;A61P25/08;;A61P25/10;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/24;;A61P25/28;;A61P25/30;;A61P25/32;;A61P27/02;;A61P27/16;;A61P29/00;;A61P3/14;;A61P31/00;;A61P31/04;;A61P31/08;;A61P31/14;;A61P31/16;;A61P31/18;;A61P31/22;;A61P33/00;;A61P33/02;;A61P33/06;;A61P35/00;;A61P35/02;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/00;;A61P43/00;;A61P5/00;;A61P5/14;;A61P5/18;;A61P5/50;;A61P7/02;;A61P7/04;;A61P7/06;;A61P9/04;;A61P9/06;;A61P9/08;;A61P9/10;;A61P9/12;;A61P9/14;;A61P3/10;;Y02A50/30;;A61K2039/505;;C07K16/22;;C07K16/28;;C07K16/2863;;C07K16/32;;C07K2317/31;;C07K2317/64;;C07K2317/71;;C07K2317/73;;C07K2317/732;;C07K2317/734;;C07K2317/92;;C07K2319/00;;Y02A50/30;;C07K16/468;;A61K39/39533;;A61K45/06;;C07K2317/565;;C07K2317/76;;G01N33/6872;;G01N33/74;;G01N2333/515;;G01N2333/705;;Y10S435/81,C07K16/22;;A61K39/39;;G01N33/68,,294,222,020-564-002-939-564;;066-624-861-380-886;;125-269-916-334-305;;008-411-420-307-533;;117-775-899-628-564;;022-063-113-247-939;;005-112-559-456-657;;052-219-543-437-800;;052-714-495-277-870;;017-980-777-820-301;;124-979-763-332-236;;039-571-432-444-268;;020-970-300-419-261;;105-557-470-423-186;;106-734-684-181-494;;015-993-052-983-170;;043-968-156-521-588;;066-749-017-721-197;;034-731-754-790-903;;006-296-336-890-224;;092-325-088-257-225;;064-912-888-572-443;;108-567-706-608-928;;083-682-746-271-264;;008-195-244-544-850;;017-195-617-198-871;;028-513-653-434-288;;024-741-755-965-636;;004-693-912-584-687;;086-764-123-669-338;;024-566-886-688-557;;074-817-300-512-106;;017-150-654-990-340;;002-264-966-090-625;;066-749-017-721-197;;001-467-559-709-949;;021-485-212-364-595;;075-499-401-604-101;;005-522-074-909-162;;018-634-106-105-088;;029-694-380-116-357;;071-707-020-428-907;;038-836-532-167-549;;012-369-544-741-057;;010-916-105-450-247;;016-251-721-517-200;;026-048-786-530-595;;085-727-974-637-837;;005-119-615-003-591;;094-863-547-996-627;;049-134-753-209-354;;024-995-475-936-443;;048-623-783-675-63X;;095-334-545-560-259;;022-474-955-131-082;;024-362-609-661-351;;044-369-216-298-341;;003-762-234-479-609;;087-448-981-335-707;;085-277-440-303-853;;016-219-576-017-946;;033-688-911-017-272;;100-049-580-404-573;;033-797-614-829-293;;030-630-100-818-462;;072-378-691-723-546;;034-331-211-704-877;;025-395-146-381-464;;011-962-497-035-168;;065-145-385-150-339;;181-448-152-035-827;;055-542-669-483-094;;064-741-687-897-846;;035-081-115-342-527;;019-080-688-368-615;;018-961-022-027-383;;009-217-085-655-748;;063-263-492-125-344;;070-972-809-242-473;;014-729-984-201-416;;022-023-983-891-895;;010-157-107-750-37X;;039-004-732-914-566;;042-204-626-457-327;;006-574-964-805-278;;045-094-249-115-990;;093-067-181-692-392;;049-134-753-209-354;;009-483-512-107-343;;069-144-826-896-138;;057-372-565-834-164;;016-022-310-471-691;;063-313-137-541-979;;038-070-808-976-085;;009-735-032-185-236;;036-865-524-655-059;;000-191-540-583-29X;;042-204-626-457-327;;034-982-192-386-234;;064-667-501-146-970;;041-751-525-317-92X;;102-346-112-440-85X;;045-156-939-863-428;;027-266-865-902-838;;078-432-639-041-575;;020-126-213-879-311;;040-681-566-996-415;;072-509-376-457-062;;041-909-244-299-232;;010-488-381-022-259;;100-005-254-245-234;;070-585-583-638-335;;027-377-613-079-875;;019-274-769-847-453;;012-380-017-030-592;;037-980-852-232-119;;023-918-308-836-52X;;129-327-796-343-271;;123-926-156-295-511;;165-130-157-892-588;;048-912-774-157-612;;028-060-073-250-504;;010-908-213-247-81X;;053-206-529-796-448;;051-940-176-386-905;;029-667-686-534-996;;003-097-377-914-607;;075-547-110-214-465;;094-685-907-794-422;;034-352-146-381-268;;019-186-073-533-210;;003-752-183-823-430;;093-403-816-040-92X;;003-925-559-236-588;;018-690-938-104-543;;025-757-247-754-114;;035-232-237-838-497;;005-587-177-844-522;;026-561-800-449-708;;079-067-762-059-918;;068-593-765-232-158;;127-795-964-859-002;;045-505-116-312-134;;022-991-704-737-86X;;061-672-528-494-614;;108-223-684-987-613;;018-658-965-693-603;;035-617-860-785-670;;054-966-694-554-694;;103-691-656-745-495;;010-468-964-951-588;;112-274-634-016-522;;007-533-420-325-730;;071-649-353-796-262;;034-060-539-054-589;;110-191-046-016-095;;085-666-458-436-776;;014-976-519-660-455;;035-933-379-226-797;;072-998-459-840-358;;004-110-248-126-540;;041-596-267-059-683;;042-087-767-680-696;;134-765-566-083-663;;061-092-617-576-207;;002-240-737-175-661;;088-194-780-630-143;;018-329-990-293-487;;020-564-178-660-209;;062-963-364-091-355;;001-615-435-171-763;;099-234-864-970-105;;012-452-642-146-566;;072-273-992-212-079;;010-514-045-696-373;;031-137-091-874-354;;002-421-415-916-968;;072-399-135-190-753;;003-021-651-454-287;;004-701-796-869-470;;008-987-034-464-639;;018-846-180-145-197;;047-388-844-780-414;;058-206-259-826-732;;026-531-521-458-647;;043-425-934-172-29X;;045-149-256-448-908;;129-722-134-945-53X;;095-386-846-016-358;;137-933-044-086-604;;028-900-321-386-005;;051-931-763-767-505;;049-193-575-982-626;;004-912-179-216-140;;147-162-083-899-675;;147-556-573-144-832;;033-459-816-867-43X;;098-513-251-868-998;;063-873-022-003-842;;044-317-656-227-593;;022-947-416-700-263;;050-129-558-345-819;;106-002-465-051-338;;031-693-481-397-220;;052-396-504-150-679;;009-834-359-838-087;;018-739-484-132-607;;129-277-633-038-069;;011-557-225-473-026;;003-940-631-287-482;;019-056-777-302-554;;133-481-101-889-252;;071-155-323-758-994;;008-243-180-100-102;;119-726-733-538-800;;062-808-477-748-149;;015-110-020-909-687;;083-682-746-271-264;;165-656-069-035-195;;083-682-746-271-264;;009-759-809-259-879;;004-883-288-083-797,10.1038/nature05313;;17183323;;17596567;;10.1093/jnci/djm056;;17457300;;10.1038/nrc2130;;17934452;;10.1038/nbt1345;;10.1038/305537a0;;6137772;;2859527;;10.1038/314628a0;;10.1126/science.3925553;;3925553;;2958547;;10.4049/jimmunol.139.7.2367;;10.1016/s1389-0344(01)00083-1;;11535414;;10.1038/nm811;;12483208;;10.1146/annurev.immunol.19.1.423;;11244043;;pmc409841;;10562301;;10.1172/jci7317;;10843707;;10.4049/jimmunol.164.12.6495;;12707362;;10.4049/jimmunol.170.9.4802;;10.1385/1-59259-334-8:305;;12412482;;10.1042/bst0300507;;12196124;;pmc41463;;7624362;;10.1073/pnas.92.15.7021;;8341653;;10.1073/pnas.90.14.6444;;pmc46948;;10.1007/s002620050414;;9435855;;9237094;;10.1016/s1380-2933(97)00067-5;;8844834;;10.1093/protein/9.7.617;;14576153;;10.1074/jbc.m310132200;;12728922;;10.4049/jimmunol.170.9.4854;;1698283;;10.1093/nar/18.17.5322;;pmc332193;;10.1038/264415a0;;1004567;;10512716;;10.1006/jmbi.1999.3128;;10.1021/bi980270i;;9649307;;pmc1536886;;6839548;;10933786;;010933786;;10.1021/bi000749m;;10.1002/eji.1830240308;;8125126;;pmc2409116;;18420934;;10.1126/science.1154315;;10.1038/341544a0;;2677748;;3140379;;10.1126/science.3140379;;10.1073/pnas.85.16.5879;;3045807;;pmc281868;;8341653;;10.1073/pnas.90.14.6444;;pmc46948;;10.1016/s0969-2126(94)00113-8;;7704521;;10.1093/protein/8.10.1057;;8771187;;10.1016/s0167-7799(97)84205-9;;9081300;;10.1016/s0009-9120(02)00343-0;;12413604;;10907088;;10.2144/00291ov01;;10.1016/s0167-5699(00)01667-4;;10916139;;1475190;;10.1093/nar/20.23.6287;;pmc334518;;10.1016/s0958-1669(02)00354-3;;12482519;;10.1016/s0167-5699(00)01668-6;;10916138;;10.1038/nbt0792-779;;1368267;;10.1073/pnas.91.9.3809;;pmc43671;;8170992;;10.1016/0378-1119(95)00821-7;;8647439;;7897213;;10.4049/jimmunol.154.7.3310;;10.1016/0022-2836(92)90639-2;;1507232;;10.1111/j.1749-6632.1971.tb13550.x;;5290024;;10.1016/0022-2836(87)90412-8;;3681981;;10.1038/342877a0;;2687698;;10.1096/fasebj.9.1.7821752;;7821752;;10.1006/jmbi.1996.0548;;8876650;;10.1615/critrevimmunol.v22.i3.20;;12498382;;10.1007/978-1-4615-1291-2_2;;11418978;;7541226;;10.1002/jmr.300080122;;7108955;;10.1016/0022-2836(82)90515-0;;8755564;;pmc38836;;10.1073/pnas.93.15.7843;;10.1038/ng0594-13;;8075633;;10.1038/ng0297-146;;9020839;;pmc2212477;;10.1084/jem.188.3.483;;9687526;;1385989;;10.3233/hab-1992-3204;;2531466;;10.1126/science.2531466;;10.1038/348552a0;;2247164;;10.1002/j.1460-2075.1993.tb05706.x;;pmc413258;;7679990;;10.1038/352624a0;;1907718;;1565653;;pmc48911;;10.1073/pnas.89.8.3576;;10.1093/nar/19.15.4133;;pmc328552;;1908075;;pmc52428;;10.1073/pnas.88.18.7978;;1896445;;7658022;;10.1016/0022-1759(95)00086-p;;10.1002/eji.1830240426;;8149964;;10.1016/s0378-1119(96)00627-0;;10.1016/s0065-2776(08)60674-4;;7872158;;1642894;;10.1126/science.3285471;;3285471;;10.1016/0076-6879(91)03005-2;;10.1016/0076-6879(91)96002-9;;1762568;;pmc47274;;8367454;;10.1073/pnas.90.17.7995;;3285470;;10.1126/science.3285470;;9356443;;10.1073/pnas.94.23.12297;;pmc24913;;10.1016/0161-5890(91)90163-e;;1905784;;10.1093/protein/7.6.805;;7937712;;8302875;;pmc521435;;10.1073/pnas.91.3.969;;3127726;;10.1038/332323a0;;10.1038/321522a0;;3713831;;10.1126/science.2451287;;2451287;;7688398;;10.4049/jimmunol.151.4.2296;;10.1016/0022-2836(87)90412-8;;3681981;;10.1073/pnas.89.10.4285;;1350088;;pmc49066;;8360482;;10.4049/jimmunol.151.5.2623;;10850810;;10.1110/ps.9.5.1002;;pmc2144631;;10.4049/jimmunol.170.11.5571;;12759435;;10.1021/bk-1994-0567.ch002;;10596374;;10.1385/mb:12:2:173;;10.1517/14712598.4.11.1821;;15500410;;15529164;;10.1038/nbt1026;;10.1021/bp0501524;;16454525;;3127726;;10.1038/332323a0;;10.1093/protein/9.10.895;;8931129;;15848072;;10.1016/j.ymeth.2005.01.003;;10.1002/prot.20302;;15526297;;10.1097/00002371-200011000-00006;;11186153;;16904789;;10.1016/j.addr.2006.01.026;;10.1517/14712598.6.11.1161;;17049014;;10.1074/jbc.m604292200;;16793771;;17077181;;10.1093/intimm/dxl110;;17116867;;pmc1693727;;10.1073/pnas.0606304103;;10.1038/nbt0797-637;;9219265;;12391234;;10.4049/jimmunol.169.9.5171;;14699147;;10.1074/jbc.c300470200;;9358610;;10.1158/1078-0432.ccr-04-0730;;15475440;;10.1016/j.ymeth.2005.11.006;;16473524;;11169443;;10.1002/1521-4141(200101)31:1<94::aid-immu94>3.0.co;2-j;;10.1002/1521-4141(200101)31:1&#60;94::aid-immu94&#62;3.0.co;2-j;;10.1002/1521-4141(200101)31:1<94::aid-immu94>3.3.co;2-a;;10.1016/j.jaci.2005.08.003;;16210043;;2434025;;10.1016/0003-9861(87)90062-2;;2831241;;10.1002/jcb.240350406;;1798701;;10.1093/protein/4.7.773;;7534211;;10.1007/bf03033871;;8094290;;10.1038/bjc.1993.48;;pmc1968163;;10.1038/bjc.1996.40;;pmc2074316;;8546911;;12673691;;10.1002/ijc.11055;;10.1016/s1380-2933(97)00065-1;;9154469;;12515857;;10.1073/pnas.232686499;;pmc141049;;10.1073/pnas.77.7.4216;;pmc349802;;6933469;;6292436;;10.1016/0022-2836(82)90103-6;;15903235;;10.1021/bp040016j;;8232322;;10.1016/0161-5890(93)90097-u;;2459288;;pmc2189025;;10.1084/jem.168.3.1099;;1717254;;pmc452979;;10.1002/j.1460-2075.1991.tb07819.x;;10.1016/j.jbiotec.2007.04.025;;17559959;;11986321;;10.1074/jbc.m202069200;;16020511;;10.1182/blood-2005-03-1338;;10.1038/35069118;;11279502;;10779742;;10.4049/jimmunol.164.9.4433;;10.1016/j.addr.2006.01.021;;16581153;;10.1016/j.surfcoat.2005.11.086;;16337266;;10.1016/j.biomaterials.2005.11.031;;15893169;;10.1016/j.jacc.2005.01.048;;10.1093/intimm/dxh281;;16000330;;15944318;;10.4049/jimmunol.174.12.8097;;15967818;;pmc2212032;;10.1084/jem.20050901;;11293118;;10.1016/s0065-2776(01)77019-8;;10.1084/jem.20050584;;pmc2212041;;15967817;;10.1111/j.1365-2222.2005.02137.x;;15725184;;10.1016/0300-483x(94)90180-5;;7940563;;1426677;;10.1067/mai.2001.116576;;11496242;;10577975;;pmc1766581;;10.1136/ard.58.2008.i61;;10.1002/art.20303;;15188351;;16162882;;10.1056/nejmoa050524;;16142748;;10.1002/art.21249;;15884771;;16093832;;10.1097/01.bor.0000172798.26249.fc;;15286389;;10.1385/1-59259-805-6:227;;16153891;;10.1016/j.it.2005.08.014;;3931271;;10.1007/bf00197296;;pmc7087536;;9106075;;10.1007/s001090050103;;pmc2193005;;10.1084/jem.189.7.1033;;10190894;;10.1016/s0733-8619(18)30061-6;;7739505;;16177124;;10.4049/jimmunol.175.7.4761;;16100700;;10.1038/nrd1854;;16224456;;10.1038/72262;;10655104;;16250840;;10.2174/138161205774370843;;10.1016/s0197-0186(02)00050-5;;12176077;;10.1186/1742-2094-2-23;;16232318;;pmc1276812;;10.1038/nm1234;;15834427;;10.1016/s0002-9440(10)63945-4;;pmc1850262;;11141480;;12808450;;10.1038/nm890;;10.1016/j.neuron.2005.05.010;;15953415;;10.1016/s0166-2236(03)00062-6;;12689770;;10.1016/j.jns.2005.03.023;;15949495;;15943798;;10.1111/j.1742-4658.2005.04699.x;;12471249;;10.1126/science.1072165;;15619232;;10.1002/jnr.20361;;15184901;;10.1038/nn1261;;10.1111/j.1471-4159.2004.02803.x;;15525355;;12525678;;10.1146/annurev.med.54.101601.152442;;10.1016/s0021-9258(18)61209-8;;3558345;;18559847;;10.1073/pnas.0803557105;;pmc2438394;;7423373;;2761602;;10.1056/nejm198908313210904;;10.1126/science.3919445;;3919445;;10.1002/ana.410250406;;2634975;;10.3171/jns.1989.71.1.0105;;2567778;;2218494;;10.1126/science.2218494;;10.1016/0167-8140(96)01718-5;;8735485;;9038083;;10.1073/pnas.88.5.1864;;1672046;;pmc51126;;8354036;;2009217;;10.1007/bf02175102;;10.1146/annurev.pharmtox.33.1.573;;8494352;;10.1146/annurev.pa.33.040193.003041;;10.1126/science.8493530;;8493530;;10.1146/annurev.bi.62.070193.001203;;10.1146/annurev.biochem.62.1.191;;8352589;;10.1007/978-1-349-11891-5;;8216416;;10.1002/art.1780360907;;8907592;;10.1007/bf02265123;;10.1097/00001756-199604260-00023;;8817534;;8619098;;10.1016/s0889-857x(21)00466-x;;10.1021/jm061152t;;17256834;;15153542;;10.4049/jimmunol.172.11.7177;;2242580;;10.1093/clinchem/36.11.1969;;10.1093/clinchem/45.3.432;;10053055;;10.1016/j.bmcl.2005.11.062;;16343903;;10.1016/j.bmcl.2004.05.062;;15225697;;14535708;;10.1021/ol035323p;;1882703;;10.1002/bio.1170060208;;10.1021/jo980047r;;10.1016/s0040-4020(99)00624-9;;10.1021/ol990141+;;10823204;;10.1021/bc0000280;;10995216;;10.1111/j.1751-1097.1965.tb09300.x;;10931637;;10.1002/1522-7243(200007/08)15:4<245::aid-bio588>3.0.co;2-3;;10.1002/1522-7243(200007/08)15:4<239::aid-bio587>3.0.co;2-w;;10931636;;17723728;;10.1016/j.aca.2006.07.020;;1833457;;10.4049/jimmunol.147.8.2657;;1698283;;10.1093/nar/18.17.5322;;pmc332193;;14579332;;10.1002/prot.10550;;1698283;;10.1093/nar/18.17.5322;;pmc332193;;10.1093/nar/30.2.e9;;pmc99848;;11788735;;15803471;;10.1002/bit.20428,"RIDGWAY JOHN ET AL: ""Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis"", NATURE, NATURE PUBLISHING GROUP, UNITED KINGDOM, vol. 444, no. 7122, 21 December 2006 (2006-12-21), pages 1083 - 1087, XP002489428, ISSN: 0028-0836, DOI: 10.1038/NATURE05313;;GARBER KEN: ""Targeting vessel abnormalization in cancer"", NATIONAL CANCER INSTITUTE. JOURNAL (ONLINE), OXFORD UNIVERSITY PRESS, GB, vol. 99, no. 13, 4 July 2007 (2007-07-04), pages 991 - 995, XP009166794, ISSN: 1460-2105;;THURSTON G ET AL: ""The Delta paradox: DLL4 blockade leads to more tumour vessels but less tumour growth"", NATURE REVIEWS. CANCER, NATUR PUBLISHING GROUP, LONDON, GB, vol. 7, no. 5, 1 January 2007 (2007-01-01), pages 327 - 331, XP002457728, ISSN: 1474-175X, DOI: 10.1038/NRC2130;;CHENGBIN W U ET AL: ""Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin"", NATURE BIOTECHNOLOGY, NATURE PUBLISHING GROUP, NEW YORK, NY, US, vol. 25, no. 11, 1 November 2007 (2007-11-01), pages 1290 - 1297, XP002542446, ISSN: 1087-0156, DOI: 10.1038/NBT1345;;MILSTEIN, C.; A.C. CUELLO, NATURE, vol. 305, no. 5934, 1983, pages 537 - 40;;STAERZ, U.D ET AL., NATURE, vol. 314, no. 6012, 1985, pages 628 - 31;;BRENNAN, M. ET AL., SCIENCE, vol. 229, no. 4708, 1985, pages 81 - 3;;GLENNIE, M.J. ET AL., J. IMMUNOL., vol. 139, no. 7, 1987, pages 2367 - 75;;KRIANGKUM, J. ET AL., BIOMOL. ENG., vol. 18, no. 2, 2001, pages 31 - 40;;ECONOMIDES, A.N. ET AL., NAT. MED., vol. 9, no. 1, 2003, pages 47 - 52;;NAKANISHI, K. ET AL., ANN. REV. IMMUNOL., vol. 19, 2001, pages 423 - 74;;GRACIE, J.A. ET AL., J. CLIN. INVEST., vol. 104, no. 10, 1999, pages 1393 - 401;;LEUNG, B.P. ET AL., J. IMMUNOL., vol. 164, no. 12, 2000, pages 6495 - 502;;ITO, A. ET AL., J. IMMUNOL., vol. 170, no. 9, 2003, pages 4802 - 9;;KAMI, A. ET AL., J. NEUROIMMUNOL., vol. 125, no. 1-2, 2002, pages 134 - 40;;ARNDT, M.; J. KRAUSS, METHODS MOL. BIOL., vol. 207, 2003, pages 305 - 21;;PEIPP, M.; T. VALERIUS, BIOCHEM. SOC. TRANS., vol. 30, no. 4, 2002, pages 507 - 11;;MACK, M. ET AL., PROC. NATL. ACAD. SCI. U S A, vol. 92, no. 15, 1995, pages 7021 - 5;;HOLLIGER, P.; T. PROSPERO; G. WINTER, PROC. NATL. ACAD. SCI. U S A, vol. 90, no. 14, 1993, pages 6444 - 8.18;;HOLLIGER, P.; G. WINTER, CANCER IMMUNOL. IMMUNOTHER., vol. 45, no. 3-4, 1997, pages 128 - 30;;WU, A.M. ET AL., IMMUNOTECHNOLOGY, vol. 2, no. 1, 1996, pages 21 - 36;;WU, A.M. ET AL., IMMUNOTECHNOL., vol. 2, no. 1, 1996, pages 21 - 36;;PLUCKTHUN, A.; P. PACK, IMMUNOTECHNOL., vol. 3, no. 2, 1997, pages 83 - 105;;RIDGWAY, J.B. ET AL., PROTEIN ENGIN., vol. 9, no. 7, 1996, pages 617 - 21;;LU, D. ET AL., J. BIOL. CHEM., vol. 279, no. 4, 2004, pages 2856 - 65;;MILLER, K. ET AL., J. IMMUNOL., vol. 170, no. 9, 2003, pages 4854 - 61;;DUROCHER ET AL., NUCLEIC ACIDS RESEARCH, vol. 30, no. 2, 2002;;MIZUSHIMA, S; NAGATA, S., NUCLEIC ACIDS RESEARCH, vol. 18, no. 17, 1990;;HUBER ET AL., NATURE, vol. 264, pages 415 - 20;;THIES ET AL., J MOL BIOL, vol. 293, 1999, pages 67 - 79;;DALL'ACQUA, BIOCHEMISTRY, vol. 37, 1998, pages 9266 - 73;;SELIGMAN, ANN IMMUNOL, vol. 129, 1978, pages 855 - 70;;BIEWENGA ET AL., CLIN EXP IMMUNOL, vol. 51, 1983, pages 395 - 400;;WEST ET AL., BIOCHEMISTRY, vol. 39, 2000, pages 9698 - 708;;KIM ET AL., EUR J IMMUNOL, vol. 24, 1994, pages 542 - 548;;ANTHONY, R.M. ET AL., SCIENCE, vol. 320, 2008, pages 373 - 376;;WARD ET AL., NATURE, vol. 341, 1989, pages 544 - 546;;BIRD ET AL., SCIENCE, vol. 242, 1988, pages 423 - 426;;HUSTON ET AL., PROC. NATL. ACAD. SCI. USA, vol. 85, 1988, pages 5879 - 5883;;HOLLIGER, P. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 6444 - 6448;;POLJAK, R.J. ET AL., STRUCTURE, vol. 2, 1994, pages 1121 - 1123;;""Antibody Engineering"", 2001, SPRINGER-VERLAG, pages: 790;;ZAPAT ET AL., PROTEIN ENG., vol. 8, no. 10, 1995, pages 1057 - 1062;;STAERZ, U.D. ET AL., NATURE, vol. 314, no. 6012, 1985, pages 628 - 31;;HOLLIGER, P.; T. PROSPERO; G. WINTER, PROC NATL ACAD SCI U S A, vol. 90, no. 14, 1993, pages 6444 - 8.18;;HOOGENBOOM H.R., TIB TECH., vol. 15, 1997, pages 62 - 70;;AZZAZY H.; HIGHSMITH W.E., CLIN. BIOCHEM., vol. 35, 2002, pages 425 - 445;;GAVILONDO J.V.; LARRICK J.W., BIOTECHNIQUES, vol. 29, 2002, pages 128 - 145;;HOOGENBOOM H.; CHAMES P., IMMUNOLOGY TODAY, vol. 21, 2000, pages 371 - 378;;TAYLOR, L. D. ET AL., NUCL. ACIDS RES., vol. 20, 1992, pages 6287 - 6295;;KELLERMANN S-A.; GREEN L.L., CURRENT OPINION IN BIOTECHNOLOGY, vol. 13, 2002, pages 593 - 597;;LITTLE M. ET AL., IMMUNOLOGY TODAY, vol. 21, 2000, pages 364 - 370;;MARKS ET AL., BIDLTECHNOLOGY, vol. 10, 1992, pages 779 - 783;;BARBAS ET AL., PROC NAT. ACAD. SCI, USA, vol. 91, 1994, pages 3809 - 3813;;SCHIER ET AL., GENE, vol. 169, 1995, pages 147 - 155;;YELTON ET AL., J. IMMUNOL., vol. 155, 1995, pages 1994 - 2004;;JACKSON ET AL., J. IMMUNOL., vol. 154, no. 7, 1995, pages 3310 - 9;;HAWKINS ET AL., J. MOL. BIOL, vol. 226, 1992, pages 889 - 896;;KABAT ET AL., ANN. NYACAD, SCI., vol. 190, 1971, pages 382 - 391;;KABAT, E.A. ET AL.: ""Sequences ofProteins oflmmunological Interest"", 1991, NIH PUBLICATION NO. 91-3242;;KABAT ET AL.: ""Sequences of Proteins of Immunological Interest"", 1987, NATIONAL INSTITUTES OF HEALTH;;CHOTHIA; LESK, J. MOL. BIOL., vol. 196, 1987, pages 901 - 917;;CHOTHIA ET AL., NATURE, vol. 342, 1989, pages 877 - 883;;PADLAN, FASEB J., vol. 9, 1995, pages 133 - 139;;MACCALLUM, J MOL BIOL, vol. 262, no. 5, 1996, pages 732 - 45;;SHAPIRO ET AL., CRIT. REV. IMMUNOL., vol. 22, no. 3, 2002, pages 183 - 200;;MARCHALONIS ET AL., ADV EXP MED BIOL., vol. 484, 2001, pages 13 - 30;;J6NSSON, U. ET AL., ANN. BIOL. CLIN., vol. 51, 1993, pages 19 - 26;;J6NSSON, U. ET AL., BIOTECHNIQUES, vol. 11, 1991, pages 620 - 627;;JOHNSSON, B. ET AL., J. MOL. RECOGNIT., vol. 8, 1995, pages 125 - 13 1;;JOHNNSON, B. ET AL., ANAL. BIOCHEM., vol. 198, 1991, pages 268 - 277;;GIEGE, R.; DUCRUIX, A. BARRETT: ""Crystallization of Nucleic Acids and Proteins, a Practical Approach"", 1999, OXFORD UNIVERSITY PRESS, pages: 20 1 - 16;;SAMBROOK ET AL.: ""Molecular Cloning: A Laboratory Manual"", 1989, COLD SPRING HARBOR LABORATORY PRESS;;KYTE ET AL., J. MOL. BIOL., vol. 157, 1982, pages 105 - 132;;HARLOW ET AL.: ""Antibodies: A Laboratory Manual"", 1988, COLD SPRING HARBOR LABORATORY PRESS;;HAMMERLING ET AL.: ""Monoclonal Antibodies and T-Cell Hybridomas"", 1981, ELSEVIER, pages: 563 - 681;;BABCOCK, J.S. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 93, 1996, pages 7843 - 7848;;GREEN ET AL., NATURE GENETICS, vol. 7, 1994, pages 13 - 21;;MENDEZ ET AL., NATURE GENETICS, vol. 15, 1997, pages 146 - 156;;GREEN; JAKOBOVITS, J. EXP. MED., vol. 188, 1998, pages 483 - 495;;FUCHS ET AL., BIOLTECHNOLOGY, vol. 9, 1991, pages 1370 - 1372;;HAY ET AL., HUM ANTIBOD HYBRIDOMAS, vol. 3, 1992, pages 81 - 85;;HUSE ET AL., SCIENCE, vol. 246, 1989, pages 1275 - 1281;;MCCAFFERTY ET AL., NATURE, vol. 348, 1990, pages 552 - 554;;GRIFFITHS ET AL., EMBO J, vol. 12, 1993, pages 725 - 734;;HAWKINS ET AL., J MOL BIOL, vol. 226, 1992, pages 889 - 896;;CLACKSON ET AL., NATURE, vol. 352, 1991, pages 624 - 628;;GRAM ET AL., PNAS, vol. 89, 1992, pages 3576 - 3580;;GARRAD ET AL., BIOLTECHNOLOGY, vol. 9, 1991, pages 1373 - 1377;;HOOGENBOOM ET AL., NUC ACID RES, vol. 19, 1991, pages 4133 - 4137;;BARBAS ET AL., PNAS, vol. 88, 1991, pages 7978 - 7982;;BRINKMAN ET AL., J. IMMUNOL. METHODS, vol. 182, 1995, pages 41 - 50;;AMES ET AL., J. IMMUNOL. METHODS, vol. 184, 1995, pages 177 - 186;;KETTLEBOROUGH ET AL., EUR. J. IMMUNOL., vol. 24, 1994, pages 952 - 958;;PERSIC ET AL., GENE, vol. 187, 1997, pages 9 - 18;;BURTON ET AL., ADVANCES IN IMMUNOLOGY, vol. 57, 1994, pages 191 - 280;;MULLINAX ET AL., BIOTECHNIQUES, vol. 12, no. 6, 1992, pages 864 - 869;;SAWAI ET AL., AJRI, vol. 34, 1995, pages 26 - 34;;BETTER ET AL., SCIENCE, vol. 240, 1988, pages 1041 - 1043;;HUSTON ET AL., METHODS IN ENZYMOLOGY, vol. 203, 1991, pages 46 - 88;;SHU ET AL., PNAS, vol. 90, 1993, pages 7995 - 7999;;SKERRA ET AL., SCIENCE, vol. 240, 1988, pages 1038 - 1040;;ROBERTS, R.W.; SZOSTAK, J.W., PROC. NATL. ACAD. SCI. USA, vol. 94, 1997, pages 12297 - 12302;;PADLAN, MOLECULAR IMMUNOLOGY, vol. 28, no. 4-5, 1991, pages 489 - 498;;STUDNICKA ET AL., PROTEIN ENGINEERING, vol. 7, no. 6, 1994, pages 805 - 814;;ROGUSKA ET AL., PNAS, vol. 91, 1994, pages 969 - 973;;KABAT ET AL.: ""Sequences of Proteins of Immunological Interest"", 1983, U.S. DEPT. HEALTH;;RIECHMANN ET AL., NATURE, vol. 332, 1988, pages 323;;JONES ET AL., NATURE, vol. 321, 1986, pages 522;;VERHOEYEN ET AL., SCIENCE, vol. 239, 1988, pages 1534;;SIMS ET AL., J. IMMUNOL., vol. 151, 1993, pages 2296;;CHOTHIA; LESK, J. MOL. BIOL., vol. 196, 1987, pages 901;;CARTER ET AL., PROC. NATL. ACAD. SCI. U.S.A., vol. 89, 1992, pages 4285;;PRESTA ET AL., J. IMMUNOL., vol. 151, 1993, pages 2623;;LEGROS V. ET AL., PROTEIN SCI., vol. 9, 2000, pages 1002 - 10;;O'CONNOR KH ET AL., J IMMUNOL METHODS, vol. 299, 2005, pages 21 - 35;;WU C. ET AL., J IMMUNOL, vol. 170, 2003, pages 5571 - 7;;JONES, A. J. S.: ""Formulation and delivery ofpeptides and proteins"", 1993, ACS, article ""Analytical methods for the assessment of protein formulations and delivery systems"", pages: 22 - 45;;PEARLMAN, R.; NGUYEN, T. H.: ""Peptide and protein drug delivery"", 1990, MARCEL DEKKER, INC., article ""Analysis of protein drugs"", pages: 247 - 301;;JONES, A. G.: ""Process. Solid-Liq. Suspensions"", 1993, BUTTERWORTH-HEINEMANN, pages: 93 - 117;;PEARLMAN, RODNEY; NGUYEN, TUE H: ""Pept. Protein Drug Delivery"", ADVANCES IN PARENTERAL SCIENCES, vol. 4, 1990, pages 247 - 301;;KIPRIYANOV SM; LITTLE M., MOL BIOTECHNOL., vol. 12, 1999, pages 173 - 201;;CARROLL S; AL-RUBEAI M., EXPERT OPIN BIOL THER., vol. 4, 2004, pages 1821 - 9;;WURM ET AL., NATURE BIOTECHNOLOGY, vol. 22, no. 11, 2004, pages 1393 - 1398;;JIANG ET AL., BIOTECHNOLOGY PROGRESS, vol. 22, no. 1, January 2006 (2006-01-01), pages 313 - 8;;S.L. MORRISO; J. SCHLOM, IMPORTANT ADV. ONCOL., 1990, pages 3 - 18;;RIECHMANN, L.; CLARK, M.; WALDMANN, H.; WINTER, G.: ""Reshaping human antibodies for therapy"", NATURE, vol. 332, 1988, pages 323 - 327;;ROGUSKA-M-A; PEDERSEN-J-T; HENRY-A-H; SEARLE-S-M; ROJA-C-M; AVERY-B; HOFFEE-M; COOK-S; LAMBERT-J-M; BLATTLER-W-A: ""A comparison of two murine mAbs humanized by CDR-grafting and variable domain resurfacing"", PROTEIN ENGINEERING, vol. 9, 1996, pages 895 - 904;;KASHMIRI-SYED-V-S; DE-PASCALIS-ROBERTO; GONZALES-NOREEN-R; SCHLOM-JEFFREY: ""SDR grafting--a new approach to antibody humanization"", METHODS (SAN DIEGO CALIF., vol. 36, no. 1, May 2005 (2005-05-01), pages 25 - 34;;DESMET-JOHAN; MEERSSEMAN-GEERT; BOUTONNET-NATHALIE; PLETINCKX-JURGEN; DE-CLERCQ-KRISTA; DEBULPAEP-MAJA; BRAECKMAN-TESSA; LASTERS-I: ""Anchor profiles of HLA-specific peptides: analysis by a novel affinity scoring method and experimental validation"", PROTEINS, vol. 58, 2005, pages 53 - 69;;STICKLER-M-M; ESTELL-D-A; HARDING-F-A: ""CD4+ T-cell epitope determination using unexposed human donor peripheral blood mononuclear cells"", JOURNAL OF IMMUNOTHERAPY, vol. 23, 2000, pages 654 - 60;;PRESTA GL, ADV. DRUG DELIVERY REV., vol. 58, 2006, pages 640 - 656;;SATOH M.; IIDA S.; SHITARA K., EXPERT OPINION BIOL. THER., vol. 6, 2006, pages 1161 - 1173;;DALL'ACQUA WF; KIENER PA; WU H., J. BIOL. CHEM., vol. 281, 2006, pages 23514 - 23524;;PETKOVA SB.; AKILESH S.; SPROULE TJ. ET AL., INTERNAT. IMMUNOL., vol. 18, 2006, pages 1759 - 1769;;VACCARO C.; BAWDON R.; WANJIE S ET AL., PNAS, vol. 103, 2007, pages 18709 - 18714;;VICTOR, G. ET AL., NATURE BIOTECHNOLOGY, vol. 15, no. 7, 1997, pages 637 - 640;;DALL'ACQUA WILLIAM F ET AL., JOURNAL OF IMMUNOLOGY, vol. 169, no. 9, 2002, pages 5171 - 80;;HINTON, PAUL R. ET AL., JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 279, no. 8, 2004, pages 6213 - 6216;;""Production and quality control of mAbs"", GUIDELINES INCLUDING EC CPMP GUIDELINE III/5271/94, 1997;;""Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use"", US FDA/CBER;;""Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use"", FDA'S GUIDANCE;;""Current Protocols in Protein Science"", vol. 3, JOHN WILEY & SONS INC.;;""Current Protocols in Immunology"", JOHN WILEY & SONS INC;;WING, M. G., THERAPEUTIC IMMUNOLOGY, vol. 2, no. 4, 1995, pages 183 - 190;;""Current Protocols in Pharmacology"", JOHN WILEY & SONS INC;;MADHUSUDAN, S., CLINICAL CANCER RESEARCH, vol. 10, no. 19, 2004, pages 6528 - 6534;;COX, J., METHODS, vol. 38, no. 4, 2006, pages 274 - 282;;CHOI, I., EUROPEAN JOURNAL OF IMMUNOLOGY, vol. 31, no. 1, 2001, pages 94 - 106;;J ALLERGY CLIN IMMUNOL., vol. 116, pages 731 - 6;;MURTHY ET AL., ARCH BIOCHEM BIOPHYS., vol. 252, no. 2, 1987, pages 549 - 60;;RODECK ET AL., J CELL BIOCHEM., vol. 35, no. 4, 1987, pages 315 - 20;;KETTLEBOROUGH ET AL., PROTEIN ENG., vol. 4, no. 7, 1991, pages 773 - 83;;MODJTAHEDI ET AL., J. CELL BIOPHYS., vol. 22, no. 1-3, 1993, pages 129 - 46;;MODJTAHEDI ET AL., BR J CANCER., vol. 67, no. 2, 1993, pages 247 - 53;;MODJTAHEDI ET AL., BR J CANCER, vol. 73, no. 2, 1996, pages 228 - 35;;MODJTAHEDI ET AL., INT J CANCER, vol. 105, no. 2, 2003, pages 273 - 80;;MATEO ET AL., IMMUNOTECHNOLOGY, vol. 3, no. 1, 1997, pages 71 - 81;;JUNGBLUTH ET AL., PROC NATL ACAD SCI USA., vol. 100, no. 2, 2003, pages 639 - 44;;URLAUB; CHASIN, PROC. NATL. ACAD. SCI. USA, vol. 77, 1980, pages 4216 - 4220;;R.J. KAUFMAN; P.A. SHARP, MOL. BIOL., vol. 159, 1982, pages 601 - 621;;R. JEFFERIS, BIOTECHNOL. PROG., vol. 21, 2005, pages 11 - 16;;CO, M.S. ET AL., MOL. IMMUNOL., vol. 30, 1993, pages 1361 - 1367;;WALLICK, S.C. ET AL., EXP. MED., vol. 168, 1988, pages 1099 - 1109;;WRIGHT, A. ET AL., EMBO J., vol. 10, 1991, pages 2717 - 2723;;KANDA, YUTAKA ET AL., JOURNAL OF BIOTECHNOLOGY, vol. 130, no. 3, 2007, pages 300 - 310;;SHIELDS, R. L. ET AL., J. BIOL. CHEM., vol. 277, 2002, pages 26733 - 26740;;UMANA ET AL., NAT. BIOTECH., vol. 17, 1999, pages 176 - 1;;ZOLA H: ""2005 CD molecules 2005: human cell differentiation molecules"", BLOOD, vol. 106, 2005, pages 3123 - 6;;STAMPER, NATURE, vol. 410, 2001, pages 608;;HWANG, JI, vol. 169, 2002, pages 633;;GRIFFIN, JI, vol. 164, 2000, pages 4433;;BURKE, SANDRA E.; KUNTZ, RICHARD E.; SCHWARTZ, LEWIS B.: ""Zotarolimus eluting stents"", ADVANCED DRUG DELIVERY REVIEWS, vol. 58, no. 3, 2006, pages 437 - 446;;HILDEBRAND, H. F.; BLANCHEMAIN, N.; MAYER, G.; CHAI, F.; LEFEBVRE, M.; BOSCHIN, F.: ""Surface coatings for biological activation and functionalization of medical devices"", SURFACE AND COATINGS TECHNOLOGY, vol. 200, no. 22-23, 2006, pages 6318 - 6324;;WU, PENG; GRAINGER, DAVID W.: ""Drug/ device combinations for local drug therapies and infection prophylaxis"", BIOMATERIALS, vol. 27, no. 11, 2006, pages 2450 - 2467;;MARQUES, A. P.; HUNT, J. A; REIS, RUI L.: ""Mediation of the cytokine network in the implantation of orthopedic devices"", TISSUE ENGINEERING AND REGENERATIVE MEDICINE, 2005, pages 377 - 397;;AOJI ET AL., J AM COLL CARDIOL., vol. 45, no. 10, 2005, pages 1574 - 9;;FINOTTO ET AL., INTERNATIONAL IMMUNOLOGY, vol. 17, no. 8, 2005, pages 993 - 1007;;PADILLA ET AL., JOURNAL OF IMMUNOLOGY, vol. 174, no. 12, 2005, pages 8097 - 8105;;COFFMAN ET AL., JOURNAL OF EXPERIMENTAL MEDICINE, vol. 201, no. 12, 2005, pages 1875 - 1879;;LLOYD ET AL., ADVANCES IN IMMUNOLOGY, vol. 77, 2001, pages 263 - 295;;BOYCE ET AL., JOURNAL OF EXPERIMENTAL MEDICINE, vol. 201, no. 12, 2005, pages 1869 - 1873;;SNIBSON ET AL., JOURNAL OF THE BRITISH SOCIETY FOR ALLERGY AND CLINICAL IMMUNOLOGY, vol. 35, no. 2, 2005, pages 146 - 52;;LUSTER ET AL., TOXICOLOGY, vol. 92, no. 1-3, 1994, pages 229 - 43;;DESCOTES ET AL., DEVELOPMENTS IN BIOLOGICAL STANDARDIZATION, vol. 77, 1992, pages 99 - 102;;HART ET AL., JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, vol. 108, no. 2, 2001, pages 250 - 257;;HARRIMAN G; HARPER LK; SCHAIBLE TF: ""Summary of clinical trials in rheumatoid arthritis using infliximab, an anti-TNFalpha treatment"", ANN RHEUM DIS, vol. 58, no. 1, 1999, pages 161 - 4;;NISHIMOTO, NORIHIRO ET AL., ARTHRITIS & RHEUMATISM, vol. 50, no. 6, 2004, pages 1761 - 1769;;GENOVESE MC ET AL.: ""Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition"", N ENGL J MED., vol. 353, 2005, pages 1114 - 23;;BASLUND, BO ET AL., ARTHRITIS & RHEUMATISM, vol. 52, no. 9, 2005, pages 2686 - 2692;;BRAND DD., COMP MED., vol. 55, no. 2, 2005, pages 114 - 22;;SFIKAKIS PP ET AL., CURR OPIN RHEUMATOL, vol. 17, 2005, pages 550 - 7;;PENG SL, METHODS MOL MED., vol. 102, 2004, pages 227 - 72;;STEINMAN L ET AL., TRENDS IMMUNOL., vol. 26, no. 11, 2005, pages 565 - 71;;LUBLIN FD. ET AL., SPRINGER SEMIN IMMUNOPATHOL., vol. 8, no. 3, 1985, pages 197 - 208;;GENAIN CP ET AL., J MOL MED., vol. 75, no. 3, 1997, pages 187 - 97;;TUOHY VK ET AL., J EXP MED., vol. 189, no. 7, 1999, pages 1033 - 42;;OWENS T ET AL., NEUROL CLIN., vol. 13, no. 1, 1995, pages 51 - 73;;HART BA ET AL., J IMMUNOL, vol. 175, no. 7, 2005, pages 4761 - 8;;JONES R.: ""IDrugs"", vol. 3, 2000, ICOS CORP, article ""Rovelizumab"", pages: 442 - 6;;BURAS JA ET AL., NAT REV DRUG DISCOV., vol. 4, no. 10, 2005, pages 854 - 65;;CALANDRA T ET AL., NAT MED., vol. 6, no. 2, 2000, pages 164 - 70;;C.E. SHEPHERD ET AL., NEUROBIOL AGING., 24 October 2005 (2005-10-24);;NELSON RB., CURR PHARM DES., vol. 11, 2005, pages 3335;;WILLIAM L. KLEIN, NEUROCHEM INT., vol. 41, 2002, pages 345;;MICHELLE C JANELSINS ET AL., J NEUROINFLAMMATION., vol. 2, 2005, pages 23;;SOLOMAN B., CURR ALZHEIMER RES., vol. 1, 2004, pages 149;;IGOR KLYUBIN ET AL., NAT MED., vol. 11, 2005, pages 556 - 61;;ARANCIO 0 ET AL., EMBO JOURNAL, 2004, pages 1 - 10;;BORNEMANN KD ET AL., AM J PATHOL., vol. 158, 2001, pages 63;;DEANE R ET AL., NAT MED., vol. 9, 2003, pages 907 - 13;;ELIEZER MASLIAH ET AL., NEURON, vol. 46, 2005, pages 857;;MCGEE AW ET AL., TRENDS NEUROSCI., vol. 26, 2003, pages 193;;MARCO DOMENICONI ET AL., J NEUROL SCI., vol. 233, 2005, pages 43;;MILAN MAKWANAL ET AL., FEBS J., vol. 272, 2005, pages 2628;;BARRY J. DICKSON, SCIENCE, vol. 298, 2002, pages 1959;;FELICIA YU HSUAN TENG ET AL., J NEUROSCI RES., vol. 79, 2005, pages 273;;TARA KARNEZIS ET AL., NATURE NEUROSCIENCE, vol. 7, 2004, pages 736;;GANG XU ET AL., J. NEUROCHEM., vol. 91, 2004, pages 1018;;VON MEHREN M ET AL.: ""Monoclonal antibody therapy for cancer"", ANNU REV MED., vol. 54, 2003, pages 343 - 69;;WU; WU, J. BIOL. CHEM., vol. 262, 1987, pages 4429 - 4432;;CHAKRAVARTY, P. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 105, 2008, pages 8697 - 8702;;SEFTON, CRC CRIT. REF. BIOMED. ENG., vol. 14, 1987, pages 20;;BUCHWALD ET AL., SURGERY, vol. 88, 1980, pages 507;;SAUDEK ET AL., N. ENGL. J. MED., vol. 321, 1989, pages 574;;""Medical Applications of Controlled Release"", 1974, CRC PRES.;;""Controlled Drug Bioavailability, Drug Product Design and Performance"", 1984, WILEY;;RANGER; PEPPAS, J., MACROMOL. SCI. REV. MACROMOL. CHEM., vol. 23, 1983, pages 61;;LEVY ET AL., SCIENCE, vol. 228, 1985, pages 190;;DURING ET AL., ANN. NEUROL., vol. 25, 1989, pages 351;;HOWARD ET AL., J. NEUROSURG., vol. 7 1, 1989, pages 105;;GOODSON, MEDICAL APPLICATIONS OF CONTROLLED RELEASE, vol. 2, 1984, pages 115 - 138;;LANGER, SCIENCE, vol. 249, 1990, pages 1527 - 1533;;NING ET AL.: ""Intratumoral Radioimmunotheraphy of a Human Colon Cancer Xenograft Using a Sustained-Release Gel"", RADIOTHERAPY &ONCOLOGY, vol. 39, 1996, pages 179 - 189;;SONG ET AL.: ""Antibody Mediated Lung Targeting of Long- Circulating Emulsions"", PDA JOURNAL OF PHARMACEUTICAL SCIENCE &TECHNOLOGY, vol. 50, 1995, pages 372 - 397;;CLEEK ET AL.: ""Biodegradable Polymeric Carriers for a bFGF Antibody for Cardiovascular Application"", PRO. INT'L. SYMP. CONTROL. REL. BIOACT. MATER., vol. 24, 1997, pages 853 - 854;;LAM ET AL.: ""Microencapsulation of Recombinant Humanized Monoclonal Antibody for Local Delivery"", PROC. INT'L. SYMP. CONTROL REL. BIOACT. MATER., vol. 24, 1997, pages 759 - 760;;JOLIOT ET AL., PROC. NATL. ACAD. SCI. USA, vol. 88, 1991, pages 1864 - 1868;;""Sustained and Controlled Release Drug Delivery Systems"", 1978, MARCEL DEKKER, INC.;;GOLDSPIEL ET AL., CLINICAL PHARMACY, vol. 12, 1993, pages 488 - 505;;WU; WU, BIOTHERAPY, vol. 3, 1991, pages 87 - 95;;TOLSTOSHEV, ANN. REV. PHARMACOL. TOXICOL., vol. 32, 1993, pages 573 - 596;;MULLIGAN, SCIENCE, vol. 260, 1993, pages 926 - 932;;MORGAN; ANDERSON, ANN. REV. BIOCHEM., vol. 62, 1993, pages 191 - 217;;MAY, TIBTECH, vol. 11, no. 5, 1993, pages 155 - 215;;""Current Protocols in Molecular Biology"", 1993, JOHN WILEY &SONS;;KRIEGLER: ""Gene Transfer and Expression, A Laboratory Manual"", 1990, STOCKTON PRESS;;ARTHRITIS & RHEUMATISM, vol. 37, 1994, pages S295;;J. INVEST. MED., vol. 44, 1996, pages 235A;;ARTHRITIS & RHEUMATISM, vol. 38, 1995, pages S185;;ARTHRITIS & RHEUMATISM, vol. 36, 1993, pages 1223;;ARTHRITIS & RHEUMATISM, vol. 39, no. 9, 1996, pages S2 84;;AMER. J. PHYSIOL. - HEART AND CIRCULATORY PHYSIOLOGY, vol. 268, 1995, pages 37 - 42;;ARTHRITIS & RHEUMATISM, vol. 39, no. 9, 1996, pages S282;;ARTHRITIS & RHEUMATISM, vol. 39, no. 9, 1996, pages S81;;ARTHRITIS & RHEUMATISM, vol. 39, no. 9, 1996, pages S82;;ARTHRITIS & RHEUMATISM, vol. 39, no. 9, 1996, pages S131;;INFLAMMATION RESEARCH, vol. 45, 1996, pages 103 - 107;;ARTHRITIS & RHEUMATISM, vol. 39, no. 9, 1996, pages S284;;ARTHRITIS & RHEUMATISM, vol. 39, no. 9, 1996, pages 5282;;ARTHRITIS & RHEUMATISM, vol. 39, no. 9, 1996, pages 5280;;NEURO REPORT, vol. 7, 1996, pages 1209 - 1213;;ARTHRITIS & RHEUMATISM, vol. 39, no. 9, 1996, pages S281;;ARTHRITIS & RHEUMATISM, vol. 39, no. 9, 1996, pages S296;;ARTHRITIS & RHEUMATISM, vol. 39, no. 9, 1996, pages S308;;ARTHRITIS & RHEUMATISM, vol. 39, no. 9, 1996, pages S120;;DELUCA ET AL., RHEUM. DIS. CLIN. NORTH AM., vol. 21, 1995, pages 759 - 777;;BRUNCKO, MILAN ET AL., JOURNAL OF MEDICINAL CHEMISTRY, vol. 50, no. 4, 2007, pages 641 - 662;;MARQUINA, REGINA ET AL., JOURNAL OF IMMUNOLOGY, vol. 172, no. 11, 2004, pages 7177 - 7185;;YATSCOFF ET AL.: ""Abbott TDx Monoclonal Antibody Assay Evaluated for Measuring Cyclosporine in Whole Blood"", CLIN. CHEM., vol. 36, 1990, pages 1969 - 1973;;WALLEMACQ ET AL.: ""Evaluation of the New AxSYM Cyclosporine Assay: Comparison with TDx Monoclonal Whole Blood and EMIT Cyclosporine Assays"", CLIN. CHEM., vol. 45, 1999, pages 432 - 435;;POLAK; VAN NOORDEN: ""Introduction to Immunocytochemistry"", 1997, SPRINGER VERLAG;;HAUGLAND: ""Handbook of Fluorescent Probes and Research Chemicals"", 1996;;ADAMCZYK ET AL., BIOORG. MED. CHEM. LETT., vol. 16, 2006, pages 1324 - 1328;;ADAMCZYK ET AL., BIOORG. MED. CHEM. LETT., vol. 4, 2004, pages 2313 - 2317;;ADAMCZYK ET AL., BIORG. MED. CHEM. LETT., vol. 14, 2004, pages 3917 - 3921;;ADAMCZYK ET AL., ORG. LETT., vol. 5, 2003, pages 3779 - 3782;;MATTINGLY, J. BIOLUMIN. CHEMILUMIN., vol. 6, 1991, pages 107 - 114;;ADAMCZYK ET AL., J. ORG. CHEM., vol. 63, 1998, pages 5636 - 5639;;ADAMCZYK ET AL., TETRAHEDRON, vol. 55, 1999, pages 10899 - 10914;;ADAMCZYK ET AL., ORG. LETT., vol. 1, 1999, pages 779 - 781;;ADAMCZYK ET AL., BIOCONJUGATE CHEM., vol. 11, 2000, pages 714 - 724;;MATTINGLY ET AL.: ""Luminescence Biotechnology: Instruments and Applications"", 2002, CRC PRESS, pages: 77 - 105;;MCCAPRA ET AL., PHOTOCHEM. PHOTOBIOL., vol. 4, 1965, pages 1111 - 21;;RAZAVI ET AL., LUMINESCENCE, vol. 15, 2000, pages 245 - 249;;RAZAVI ET AL., LUMINESCENCE, vol. 15, 2000, pages 239 - 244;;ADAMCZYK ET AL., ANAL. CHIM. ACTA, vol. 579, no. 1, 2006, pages 61 - 67;;HARLOW, E.; LANE, D.: ""Antibodies: A Laboratory Manual"", 1988;;LUND ET AL., J. IMMUNOL., vol. 147, 1991, pages 2657;;MIZUSHIMA; NAGATA, NUCLEIC ACIDS RESEARCH, vol. 18, 1990, pages 5322;;PETREY, D. ET AL., PROTEINS, vol. 53, no. 6, 2003, pages 430 - 435;;MIZUSHIMA, S.; NAGATA, S., NUCLEIC ACIDS RES., vol. 18, 1990, pages 17;;DUROCHER ET AL., NUCLEIC ACIDS RES., vol. 30, no. 2, 2002, pages E9;;PHAM ET AL., BIOTECH. BIOENGINEERING, vol. 90, no. 3, 2005, pages 332 - 44",DISCONTINUED
161,WO,A3,WO 2009/134776 A3,002-522-090-955-493,2009-12-23,2009,US 2009/0041945 W,2009-04-28,US 12583408 P;;US 13428308 P;;US 19719108 P;;US 19900908 P,2008-04-29,DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND USES THEREOF,"The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.",ABBOTT LAB;;GHAYUR TARIQ;;MORGAN-LAPPE SUSAN E;;REILLY EDWARD B;;KINGSBURY GILLIAN A;;PHILLIPS ANDREW;;WANG JIEYI;;BELL RANDY L;;NORVELL SUZANNE M;;LI YINGCHUN;;LIU JUNJIAN;;YING HUA,GHAYUR TARIQ;;MORGAN-LAPPE SUSAN E;;REILLY EDWARD B;;KINGSBURY GILLIAN A;;PHILLIPS ANDREW;;WANG JIEYI;;BELL RANDY L;;NORVELL SUZANNE M;;LI YINGCHUN;;LIU JUNJIAN;;YING HUA,,https://lens.org/002-522-090-955-493,Search Report,yes,3,0,31,32,0,A61K2039/505;;C07K16/22;;C07K16/28;;C07K16/2863;;C07K16/32;;C07K2317/31;;C07K2317/64;;C07K2317/71;;C07K2317/73;;C07K2317/732;;C07K2317/734;;C07K2317/92;;C07K2319/00;;C07K16/468;;C07K2317/76;;Y10S435/81;;A61P1/04;;A61P1/14;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/06;;A61P11/16;;A61P13/02;;A61P13/08;;A61P13/12;;A61P15/02;;A61P15/08;;A61P17/02;;A61P17/04;;A61P17/06;;A61P17/14;;A61P19/02;;A61P19/04;;A61P19/06;;A61P19/08;;A61P19/10;;A61P21/00;;A61P21/02;;A61P21/04;;A61P25/00;;A61P25/04;;A61P25/08;;A61P25/10;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/24;;A61P25/28;;A61P25/30;;A61P25/32;;A61P27/02;;A61P27/16;;A61P29/00;;A61P3/14;;A61P31/00;;A61P31/04;;A61P31/08;;A61P31/14;;A61P31/16;;A61P31/18;;A61P31/22;;A61P33/00;;A61P33/02;;A61P33/06;;A61P35/00;;A61P35/02;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/00;;A61P43/00;;A61P5/00;;A61P5/14;;A61P5/18;;A61P5/50;;A61P7/02;;A61P7/04;;A61P7/06;;A61P9/04;;A61P9/06;;A61P9/08;;A61P9/10;;A61P9/12;;A61P9/14;;A61P3/10;;Y02A50/30;;A61K2039/505;;C07K16/22;;C07K16/28;;C07K16/2863;;C07K16/32;;C07K2317/31;;C07K2317/64;;C07K2317/71;;C07K2317/73;;C07K2317/732;;C07K2317/734;;C07K2317/92;;C07K2319/00;;Y02A50/30;;C07K16/468;;A61K39/39533;;A61K45/06;;C07K2317/565;;C07K2317/76;;G01N33/6872;;G01N33/74;;G01N2333/515;;G01N2333/705;;Y10S435/81,A61K39/00,,0,0,,,,PENDING
162,CN,A,CN 102076355 A,018-329-290-681-972,2011-05-25,2011,CN 200980125167 A,2009-04-28,US 2009/0041945 W;;US 12583408 P;;US 13428308 P;;US 19719108 P;;US 19900908 P,2008-04-29,Dual varistructure domain immunoglobulins and uses thereof,"The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.",ABBOTT LAB,TARIQ GHAYUR;;MORGAN-LAPPE SUSAN E;;REILLY EDWARD B;;KINGSBURY GILLIAN A;;ANDREW PHILLIPS;;JIEYI WANG;;BELL RANDY L;;NORVELL SUZANNE M;;YINGCHUN LI;;JUNJIAN LIU;;HUA YING,ABBVIE COMPANY (2013-06-21),https://lens.org/018-329-290-681-972,Patent Application,no,5,8,31,32,0,A61K2039/505;;C07K16/22;;C07K16/28;;C07K16/2863;;C07K16/32;;C07K2317/31;;C07K2317/64;;C07K2317/71;;C07K2317/73;;C07K2317/732;;C07K2317/734;;C07K2317/92;;C07K2319/00;;C07K16/468;;C07K2317/76;;Y10S435/81;;A61P1/04;;A61P1/14;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/06;;A61P11/16;;A61P13/02;;A61P13/08;;A61P13/12;;A61P15/02;;A61P15/08;;A61P17/02;;A61P17/04;;A61P17/06;;A61P17/14;;A61P19/02;;A61P19/04;;A61P19/06;;A61P19/08;;A61P19/10;;A61P21/00;;A61P21/02;;A61P21/04;;A61P25/00;;A61P25/04;;A61P25/08;;A61P25/10;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/24;;A61P25/28;;A61P25/30;;A61P25/32;;A61P27/02;;A61P27/16;;A61P29/00;;A61P3/14;;A61P31/00;;A61P31/04;;A61P31/08;;A61P31/14;;A61P31/16;;A61P31/18;;A61P31/22;;A61P33/00;;A61P33/02;;A61P33/06;;A61P35/00;;A61P35/02;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/00;;A61P43/00;;A61P5/00;;A61P5/14;;A61P5/18;;A61P5/50;;A61P7/02;;A61P7/04;;A61P7/06;;A61P9/04;;A61P9/06;;A61P9/08;;A61P9/10;;A61P9/12;;A61P9/14;;A61P3/10;;Y02A50/30;;A61K2039/505;;C07K16/22;;C07K16/28;;C07K16/2863;;C07K16/32;;C07K2317/31;;C07K2317/64;;C07K2317/71;;C07K2317/73;;C07K2317/732;;C07K2317/734;;C07K2317/92;;C07K2319/00;;Y02A50/30;;C07K16/468;;A61K39/39533;;A61K45/06;;C07K2317/565;;C07K2317/76;;G01N33/6872;;G01N33/74;;G01N2333/515;;G01N2333/705;;Y10S435/81,A61K39/00,,5,5,017-924-597-005-768;;049-121-326-213-831;;012-713-614-244-110;;008-411-420-307-533;;040-803-846-951-724,10.1182/blood-2007-08-110072;;pmc2234056;;18025153;;10.1074/jbc.m307002200;;12947084;;12969563;;10.1016/s0022-1759(03)00251-5;;17934452;;10.1038/nbt1345;;10.1038/nbt1107-1233;;17989683,"ZHENGXING QU ET AL:: """"Bispecific anti-CD20/22 antibodies inhibit B-cell lymphoma proliferation by a unique mechanism of action"""", 《BLOOD》;;JENDREYKO NINA ET AL:: """"Intradiabodies, bispecific, tetravalent antibodies for the simultaneous functional knockout of two cell surface receptors"""", 《JOURNAL OF BIOLOGICAL CHEMISTRY》;;LU DAN ET AL:: """"Di-diabody: A novel tetravalent bispecific antibody molecule by design"""", 《JOURNAL OF IMMUNOLOGICAL METHODS》;;CHENGBIN W U ET AL:: """"Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin"""", 《NATURE BIOTECHNOLOGY》;;MORRISON S L:: """"Two heads are better than one"""", 《NATURE BIOTECHNOLOGY》",INACTIVE
163,PE,A1,PE 20091845 A1,191-133-108-125-784,2010-01-08,2010,PE 2009000578 A,2009-04-29,US 12583408 P;;US 13428308 P;;US 19719108 P;;US 19900908 P,2008-04-29,INMUNOGLOBULINAS CON DOMINIO VARIABLE DUAL Y USOS DE LAS MISMAS,"SE REFIERE A UNA PROTEINA DE UNION QUE COMPRENDE: A) UNA PRIMERA CADENA DE POLIPEPTIDOS QUE COMPRENDE: VD1-(X1)n-VD2-C-(X2)n DONDE VD1 Y VD2 SON UN PRIMER Y SEGUNDO DOMINIO VARIABLE DE CADENA PESADA QUE COMPRENDEN UNA SECUENCIA DE AMINOACIDOS TAL COMO SEQ ID Nº 27, SEQ ID Nº 29, SEQ ID Nº 31, SEQ ID Nº 33, ENTRE OTROS; C ES UN DOMINIO CONSTANTE DE LA CADENA PESADA; (X1)n ES UN CONECTOR, QUE NO ES CH1; (X2)n ES UNA REGION Fc DE UNA IgG1, IgG2, IgG3, ENTRE OTROS, CUYA SECUENCIA DE AMINOACIDOS SE SELECCIONA DE LA SEQ ID Nº 1-26; Y B) UNA SEGUNDA CADENA DE POLIPEPTIDOS QUE COMPRENDE: VD1-(X1)n-VD2-C-(X2)n DONDE VD1 Y VD2 SON UN PRIMER Y SEGUNDO DOMINIO VARIABLE DE CADENA LIVIANA QUE COMPRENDEN UNA SECUENCIA DE AMINOACIDOS TAL COMO SEQ ID Nº 28, SEQ ID Nº 30, SEQ ID Nº 32, SEQ ID Nº 34, ENTRE OTROS; C ES UN DOMINIO CONSTANTE DE LA CADENA LIVIANA; (X1)n ES UN CONECTOR, QUE NO ES CH1; (X2)n ES UNA REGION Fc DE UNA IgG1, IgG2, IgG3, ENTRE OTROS, CUYA SECUENCIA DE AMINOACIDOS SE SELECCIONA DE LA SEQ ID Nº 1-26; DONDE DICHOS VD1 Y VD2 DE CADENA PESADA Y DE CADENA LIVIANA SE OBTIENEN DE UN PRIMER Y SEGUNDO ANTICUERPO PARENTAL RESPECTIVAMENTE O DE UNA PORCION DE UNION AL ANTIGENO DEL MISMO. SE REFIERE TAMBIEN A UN PROCEDIMIENTO DE OBTENCION DE UN DOMINIO VARIABLE DUAL DE INMUNOGLOBULINA CAPAZ DE UNIRSE A DOS ANTIGENOS TALES COMO CD20 Y CD19, EGFR Y HER-2, EGFR Y c-MET, ENTRE OTROS",ABBOTT LAB,GHAYUR TARIQ;;MORGAN-LAPPE SUSAN E;;REILLY EDWARD B;;KINGSBURY GILLIAN A;;PHILLIPS ANDREW;;WANG JIEYI;;BELL RANDY L;;NORVELL SUZANNE M;;LI YINGCHUN;;LIU JUNJIAN;;YING HUA,,https://lens.org/191-133-108-125-784,Patent Application,no,0,0,31,32,0,A61K2039/505;;C07K16/22;;C07K16/28;;C07K16/2863;;C07K16/32;;C07K2317/31;;C07K2317/64;;C07K2317/71;;C07K2317/73;;C07K2317/732;;C07K2317/734;;C07K2317/92;;C07K2319/00;;C07K16/468;;C07K2317/76;;Y10S435/81;;A61P1/04;;A61P1/14;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/06;;A61P11/16;;A61P13/02;;A61P13/08;;A61P13/12;;A61P15/02;;A61P15/08;;A61P17/02;;A61P17/04;;A61P17/06;;A61P17/14;;A61P19/02;;A61P19/04;;A61P19/06;;A61P19/08;;A61P19/10;;A61P21/00;;A61P21/02;;A61P21/04;;A61P25/00;;A61P25/04;;A61P25/08;;A61P25/10;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/24;;A61P25/28;;A61P25/30;;A61P25/32;;A61P27/02;;A61P27/16;;A61P29/00;;A61P3/14;;A61P31/00;;A61P31/04;;A61P31/08;;A61P31/14;;A61P31/16;;A61P31/18;;A61P31/22;;A61P33/00;;A61P33/02;;A61P33/06;;A61P35/00;;A61P35/02;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/00;;A61P43/00;;A61P5/00;;A61P5/14;;A61P5/18;;A61P5/50;;A61P7/02;;A61P7/04;;A61P7/06;;A61P9/04;;A61P9/06;;A61P9/08;;A61P9/10;;A61P9/12;;A61P9/14;;A61P3/10;;Y02A50/30;;A61K2039/505;;C07K16/22;;C07K16/28;;C07K16/2863;;C07K16/32;;C07K2317/31;;C07K2317/64;;C07K2317/71;;C07K2317/73;;C07K2317/732;;C07K2317/734;;C07K2317/92;;C07K2319/00;;Y02A50/30;;C07K16/468;;A61K39/39533;;A61K45/06;;C07K2317/565;;C07K2317/76;;G01N33/6872;;G01N33/74;;G01N2333/515;;G01N2333/705;;Y10S435/81,G01N33/53,,0,0,,,,DISCONTINUED
164,AR,A1,AR 071526 A1,077-028-438-716-205,2010-06-23,2010,AR P090101544 A,2009-04-29,US 19719108 P;;US 13428308 P;;US 12583408 P;;US 19900908 P,2008-04-29,PROTEINAS DE UNION MULTIVALENTES CON CAPACIDAD DE UNIR DOS O MAS ANTIGENOS CON ALTA AFINIDAD,"Proteínas de union multivalentes y multiespecíficas disenadas, métodos para elaborarlas y, específicamente, sus usos en la prevencion, el diagnostico y/o el tratamiento de enfermedades inflamatorias agudas y cronicas, cáncer y otras enfermedades. Reivindicacion 1: Una proteína de union, caracterizada porque comprende una cadena de polipéptidos, en donde dicha cadena de polipéptidos comprende VD1-(X1)n-VD2-C-(X2)n, en donde; VD1 es un primer dominio variable de la cadena pesada obtenido a partir de un primer anticuerpo parental o una porcion de union al antígeno del mismo; VD2 es un segundo dominio variable de la cadena pesada obtenido a partir de un segundo anticuerpo parental o una porcion de union al antígeno del mismo; C es un dominio constante de la cadena pesada; (X1)n es un conector con la condicion que no sea CH1, en donde dicho (X1)n está presente o ausente; y (X2)n es una region Fc, en donde dicha (X2)n está presente o ausente, en donde la proteína de union tiene la capacidad de unirse a un par de antígenos seleccionados del grupo que consiste de CD-20 y CD-19; CD-20 y CD-80; CD-20 y CD-22; CD-20 y CD-40; CD-3 y HER-2; CD-3 y CD-19; EGFR y HER-2; EGFR y CD-3; EGFR y IGF1.2; EGFR y IGF1 R; EGFR y RON; EGFR y HGF; EGFR y c-MET; HER-2 y IGF1.2; HER-2 y IGF1R; RON y HGF; VEGF y EGFR; VEGF y HER-2; VEGF y CD-20; VEGF y IGF1.2; VEGF y DLL4; VEGF y HGF; VEGF y RON; VEGF y NRP1; CD-20 y CD3; DLL-4 y PLGF; VEGF y PLGF, ErbB3 y EGFR, HER-2 y ErbB3, ErbB3 y HGF; HER-2 y PLGF, y HER-2 y HER-2.",ABBOTT LAB,KINGSBURY GILLIAN A;;YING HUA;;PHILLIPS ANDREW;;GHAYUR TARIQ;;REILLY EDWARD B;;MORGAN-LAPPE SUSAN E;;BELL RANDY L;;LI YINGCHUN;;WANG JIEYI;;NORVELL SUZANNE M;;LIU JUNJIAN,,https://lens.org/077-028-438-716-205,Patent Application,no,0,0,31,32,0,A61K2039/505;;C07K16/22;;C07K16/28;;C07K16/2863;;C07K16/32;;C07K2317/31;;C07K2317/64;;C07K2317/71;;C07K2317/73;;C07K2317/732;;C07K2317/734;;C07K2317/92;;C07K2319/00;;C07K16/468;;C07K2317/76;;Y10S435/81;;A61P1/04;;A61P1/14;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/06;;A61P11/16;;A61P13/02;;A61P13/08;;A61P13/12;;A61P15/02;;A61P15/08;;A61P17/02;;A61P17/04;;A61P17/06;;A61P17/14;;A61P19/02;;A61P19/04;;A61P19/06;;A61P19/08;;A61P19/10;;A61P21/00;;A61P21/02;;A61P21/04;;A61P25/00;;A61P25/04;;A61P25/08;;A61P25/10;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/24;;A61P25/28;;A61P25/30;;A61P25/32;;A61P27/02;;A61P27/16;;A61P29/00;;A61P3/14;;A61P31/00;;A61P31/04;;A61P31/08;;A61P31/14;;A61P31/16;;A61P31/18;;A61P31/22;;A61P33/00;;A61P33/02;;A61P33/06;;A61P35/00;;A61P35/02;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/00;;A61P43/00;;A61P5/00;;A61P5/14;;A61P5/18;;A61P5/50;;A61P7/02;;A61P7/04;;A61P7/06;;A61P9/04;;A61P9/06;;A61P9/08;;A61P9/10;;A61P9/12;;A61P9/14;;A61P3/10;;Y02A50/30;;A61K2039/505;;C07K16/22;;C07K16/28;;C07K16/2863;;C07K16/32;;C07K2317/31;;C07K2317/64;;C07K2317/71;;C07K2317/73;;C07K2317/732;;C07K2317/734;;C07K2317/92;;C07K2319/00;;Y02A50/30;;C07K16/468;;A61K39/39533;;A61K45/06;;C07K2317/565;;C07K2317/76;;G01N33/6872;;G01N33/74;;G01N2333/515;;G01N2333/705;;Y10S435/81,,,0,0,,,,DISCONTINUED
165,MX,A,MX 2010011955 A,103-802-346-910-642,2011-01-21,2011,MX 2010011955 A,2009-04-28,US 12583408 P;;US 13428308 P;;US 19719108 P;;US 19900908 P;;US 2009/0041945 W,2008-04-29,DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND USES THEREOF.,"The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.",ABBOTT LAB,WANG JIEYI;;REILLY EDWARD B;;GHAYUR TARIQ;;YING HUA;;BELL RANDY L;;MORGAN-LAPPE SUSAN E;;KINGSBURY GILLIAN A;;PHILLIPS ANDREW;;NORVELL SUZANNE M;;LI YINGCHUN;;LIU JUNJIAN,ABBVIE INC. (2013-08-09),https://lens.org/103-802-346-910-642,Patent Application,no,0,0,31,32,0,A61K2039/505;;C07K16/22;;C07K16/28;;C07K16/2863;;C07K16/32;;C07K2317/31;;C07K2317/64;;C07K2317/71;;C07K2317/73;;C07K2317/732;;C07K2317/734;;C07K2317/92;;C07K2319/00;;C07K16/468;;C07K2317/76;;Y10S435/81;;A61P1/04;;A61P1/14;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/06;;A61P11/16;;A61P13/02;;A61P13/08;;A61P13/12;;A61P15/02;;A61P15/08;;A61P17/02;;A61P17/04;;A61P17/06;;A61P17/14;;A61P19/02;;A61P19/04;;A61P19/06;;A61P19/08;;A61P19/10;;A61P21/00;;A61P21/02;;A61P21/04;;A61P25/00;;A61P25/04;;A61P25/08;;A61P25/10;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/24;;A61P25/28;;A61P25/30;;A61P25/32;;A61P27/02;;A61P27/16;;A61P29/00;;A61P3/14;;A61P31/00;;A61P31/04;;A61P31/08;;A61P31/14;;A61P31/16;;A61P31/18;;A61P31/22;;A61P33/00;;A61P33/02;;A61P33/06;;A61P35/00;;A61P35/02;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/00;;A61P43/00;;A61P5/00;;A61P5/14;;A61P5/18;;A61P5/50;;A61P7/02;;A61P7/04;;A61P7/06;;A61P9/04;;A61P9/06;;A61P9/08;;A61P9/10;;A61P9/12;;A61P9/14;;A61P3/10;;Y02A50/30;;A61K2039/505;;C07K16/22;;C07K16/28;;C07K16/2863;;C07K16/32;;C07K2317/31;;C07K2317/64;;C07K2317/71;;C07K2317/73;;C07K2317/732;;C07K2317/734;;C07K2317/92;;C07K2319/00;;Y02A50/30;;C07K16/468;;A61K39/39533;;A61K45/06;;C07K2317/565;;C07K2317/76;;G01N33/6872;;G01N33/74;;G01N2333/515;;G01N2333/705;;Y10S435/81,A61K39/00,,0,0,,,,ACTIVE
166,AU,A1,AU 2003/300686 A1,054-801-771-650-597,2004-06-18,2004,AU 2003/300686 A,2003-11-26,IB 0306448 W;;US 30624802 A;;US 30670502 A,2002-11-27,SOLUTION INFORMATION FOR KNOWLEDGE MANAGEMENT SYSTEM,,ACCENTURE GLOBAL SERVICES GMBH,REID GREGORY S;;RINGO TIMOTHY;;LANE DAVID P;;LIAN ELIZABETH H;;FARRELL DANIEL C;;FENTON CRAIG;;SHEARING ELISE;;BELL RANDY;;WONG SEVASTI;;LINGHAM ANTHONY;;FORRESTER AUDREY;;IVES WILLIAM S,ACCENTURE GLOBAL SERVICES LIMITED (2014-10-16),https://lens.org/054-801-771-650-597,Patent Application,no,0,1,9,13,0,G06Q30/02,G06Q30/00,,0,0,,,,EXPIRED
167,WO,A2,WO 2004/049221 A2,068-991-339-392-857,2004-06-10,2004,IB 0306448 W,2003-11-26,US 30624802 A;;US 30670502 A,2002-11-27,SOLUTION INFORMATION FOR KNOWLEDGE MANAGEMENT SYSTEM,"New functions for a contact center system include: testing user's comprehension of informational messages with a quiz; capturing insight of superior users having a KPI score above a threshold by having those users submit information on why they perform so well; dynamically ordering solutions to issues by re-ranking the solutions periodically based on recency and frequency; integrating information for use by a contact center representative while online with a customer and information for use when not online; storing content items in a telecommunications industry taxonomy; directing user feedback on a content item to the proper owner/manager of that content; communicating solution information using a solutions taxonomy; displaying a dual information system having a CRM application as well as reference material that is context-appropriate; enforcing completion of a group of templates when creating a content item to be published; ensuring a group of templates for a content item are complete before publishing them; and searching within a contact center system portal using a continuum of search functions. In a knowledge management system (such as may be used by a contact center user), a method for communicating solution information to the user may include retrieving solution data from a database. Such a database may be organized to have at least three sections: a first section that provides general information about the solution, a second section that describes situations in which the general information is not applicable, and a third section that sets forth contact information for further assistance with the solution. The first section (which provides general solution information) may itself be divided into two subsections, namely a first subsection that describes common solutions and a second subsection that provides a suggested script for the user. Ordering a list of solutions stored in the knowledge management system is accomplished in one embodiment by providing a set of solutions. The set or a subset of frequently requested solutions can be presented to one or more users. As users access the solutions, their access is tracked so that the sequencing of the solutions may be determined by frequency and/or recency. For example, the most often requested solution may appear first, or the most recently requested solution may appear first. Periodically, the tracked information is used to generate a new subset of solutions to present to the user(s).",ACCENTURE GLOBAL SERVICES GMBH,REID GREGORY S;;RINGO TIMOTHY;;LANE DAVID P;;LIAN ELIZABETH H;;FARRELL DANIEL C;;FENTON CRAIG;;SHEARING ELISE;;BELL RANDY;;WONG SEVASTI;;LINGHAM ANTHONY;;FORRESTER AUDREY;;IVES WILLIAM S,,https://lens.org/068-991-339-392-857,Patent Application,yes,0,2,9,13,0,G06Q30/02,G06Q30/00,,1,0,,,See references of EP 1570403A2,PENDING
168,US,A1,US 2004/0153428 A1,172-845-319-355-148,2004-08-05,2004,US 30624802 A,2002-11-27,US 30624802 A,2002-11-27,Communicating solution information in a knowledge management system,"
   New functions for a contact center system include: testing user's comprehension of informational messages with a quiz; capturing insight of superior users having a KPI score above a threshold by having those users submit information on why they perform so well; dynamically ordering solutions to issues by re-ranking the solutions periodically based on recency and frequency; integrating information for use by a contact center representative while online with a customer and information for use when not online; storing content items in a telecommunications industry taxonomy; directing user feedback on a content item to the proper owner/manager of that content; communicating solution information using a solutions taxonomy; displaying a dual information system having a CRM application as well as reference material that is context-appropriate; enforcing completion of a group of templates when creating a content item to be published; ensuring a group of templates for a content item are complete before publishing them; and searching within a contact center system portal using a continuum of search functions. 
",REID GREGORY S.;;RINGO TIMOTHY;;LANE DAVID P.;;LIAN ELIZABETH H.;;FARRELL DANIEL C;;FENTON CRAIG;;SHEARING ELISE;;BELL RANDY;;WONG SEVASTI;;LINGHAM ANTHONY;;FORRESTER AUDREY;;IVES S. WILLIAM,REID GREGORY S;;RINGO TIMOTHY;;LANE DAVID P;;LIAN ELIZABETH H;;FARRELL DANIEL C;;FENTON CRAIG;;SHEARING ELISE;;BELL RANDY;;WONG SEVASTI;;LINGHAM ANTHONY;;FORRESTER AUDREY;;IVES S WILLIAM,ACCENTURE GLOBAL SERVICES LIMITED (2010-09-01);;ACCENTURE GLOBAL SERVICES GMBH (2003-11-02),https://lens.org/172-845-319-355-148,Patent Application,yes,93,25,3,13,0,G06Q30/02;;G06Q30/02,G06Q30/02,706 5,0,0,,,,EXPIRED
169,JP,A,JP 2009134737 A,011-771-655-956-033,2009-06-18,2009,JP 2009006869 A,2009-01-15,US 30624802 A;;US 30670502 A,2002-11-27,SOLUTION INFORMATION FOR KNOWLEDGE MANAGEMENT SYSTEM,"<P>PROBLEM TO BE SOLVED: To provide a contact center that includes enhanced processes and computerized systems that work to enhance the service to customers and the efficiency. <P>SOLUTION: In a knowledge management system, a method for communicating solution information to a user comprises retrieval of solution data from a database. The database can be organized so as to have at least three sections: a first section for providing general information about the solution; a second section for describing various situations whereto the general information is not applicable; and a third section for detailing contact information for further assistance to accompany the solution. The first section (for providing general solution information) can be divided into two subsections: a first subsection for describing a common solution; and a second subsection for providing a suggested script for the user. <P>COPYRIGHT: (C)2009,JPO&INPIT",ACCENTURE GLOBAL SERVICES GMBH,REID GREGORY S;;RINGO TIMOTHY;;LANE DAVID P;;LIAN ELIZABETH H;;FARRELL DANIEL C;;FENTON CRAIG;;SHEARING ELISE;;BELL RANDY;;WONG SEVASTI;;LINGHAM ANTHONY;;FORRESTER AUDREY;;IVES WILLIAM S,,https://lens.org/011-771-655-956-033,Patent Application,no,3,3,9,13,0,G06Q30/02,G06F17/30;;G06Q30/00,,0,0,,,,PENDING
170,AU,B2,AU 2003/300686 B2,035-017-245-866-875,2007-09-20,2007,AU 2003/300686 A,2003-11-26,IB 0306448 W;;US 30624802 A;;US 30670502 A,2002-11-27,Solution information for knowledge management system,,ACCENTURE GLOBAL SERVICES LTD,LINGHAM ANTHONY;;FORRESTER AUDREY;;FARRELL DANIEL C;;WONG SEVASTI;;BELL RANDY;;LIAN ELIZABETH H;;IVES WILLIAM S;;REID GREGORY S;;SHEARING ELISE;;LANE DAVID P;;RINGO TIMOTHY;;FENTON CRAIG,ACCENTURE GLOBAL SERVICES LIMITED (2014-10-16),https://lens.org/035-017-245-866-875,Granted Patent,no,1,0,9,13,0,G06Q30/02,G06F17/30;;G06Q30/00,,0,0,,,,EXPIRED
171,EC,A,EC SP12011911 A,043-511-545-403-796,2012-07-31,2012,EC SP12011911 A,2012-05-12,US 60509409 A,2009-10-23,INMUNOGLOBULINAS CON DOMINIO VARIABLE DUAL Y USOS DE LAS MISMAS,"Proteínas de unión multivalentes y multiespecíficas diseñadas, métodos para elaborarlas y, específicamente, sus usos en la prevención, el diagnóstico y/o el tratamiento de enfermedades.",ABBOTT LAB,WANG JIEYI;;GHAYUR TARIQ;;YING HUA;;REILLY EDWARD B;;PHILLIPS ANDREW;;BELL RANDY L;;NORVELL SUZANNE M;;LI YINGCHUN;;KINGSBURY GILLIAN A;;MORGAN LAPPE SUSAN;;LIU JUNJIAN;;LIU ZHIHONG,,https://lens.org/043-511-545-403-796,Patent Application,no,0,0,25,25,0,A61K2039/505;;C07K16/22;;C07K16/28;;C07K16/2863;;C07K16/32;;C07K16/468;;C07K2317/73;;C07K2317/92;;C07K2319/00;;C07K2317/76;;A61P1/00;;A61P1/04;;A61P1/16;;A61P1/18;;A61P11/00;;A61P11/02;;A61P11/06;;A61P13/12;;A61P15/00;;A61P15/08;;A61P17/00;;A61P17/02;;A61P17/04;;A61P17/06;;A61P17/14;;A61P19/00;;A61P19/02;;A61P19/08;;A61P19/10;;A61P21/00;;A61P21/02;;A61P21/04;;A61P25/00;;A61P25/02;;A61P25/04;;A61P25/06;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/20;;A61P25/24;;A61P25/28;;A61P25/30;;A61P25/32;;A61P27/02;;A61P29/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P31/14;;A61P31/18;;A61P31/20;;A61P33/00;;A61P33/06;;A61P35/00;;A61P35/02;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/00;;A61P43/00;;A61P5/14;;A61P7/00;;A61P7/02;;A61P7/06;;A61P9/00;;A61P9/04;;A61P9/06;;A61P9/10;;A61P9/12;;A61P3/10;;Y02A50/30;;C07K16/28;;C12N15/11;;A61K39/395;;C07K16/22;;C07K2319/00;;A61K2039/505;;C07K2317/92;;C07K16/468;;C07K16/32;;C07K16/2863;;C07K16/28;;C07K2317/73;;C07K2317/76;;Y02A50/30,A61K39/395;;A61K51/10;;A61P1/00;;A61P1/16;;A61P3/10;;A61P7/00;;A61P9/00;;A61P11/00;;A61P15/00;;A61P17/00;;A61P17/06;;A61P19/02;;A61P21/02;;A61P25/20;;A61P25/28;;A61P29/00;;A61P35/00;;A61P37/06;;C07H21/04;;C07K16/32;;C07K16/46;;C12N1/11;;C12N1/15;;C12N1/19;;C12N1/21;;C12N5/10;;C12N15/63,,0,0,,,,PENDING
172,CA,A1,CA 2507619 A1,072-268-946-172-284,2004-06-10,2004,CA 2507619 A,2003-11-26,IB 0306448 W;;US 30624802 A;;US 30670502 A,2002-11-27,SOLUTION INFORMATION FOR KNOWLEDGE MANAGEMENT SYSTEM,Published without an,ACCENTURE GLOBAL SERVICES GMBH,RINGO TIMOTHY;;LIAN ELIZABETH H;;FENTON CRAIG;;REID GREGORY S;;SHEARING ELISE;;FARRELL DANIEL C;;FORRESTER AUDREY;;IVES WILLIAM S;;LANE DAVID P;;BELL RANDY;;WONG SEVASTI;;LINGHAM ANTHONY,,https://lens.org/072-268-946-172-284,Patent Application,no,0,0,9,13,0,G06Q30/02,G06Q30/00,,0,0,,,,DISCONTINUED
173,US,B2,US 7772231 B2,186-793-478-012-990,2010-08-10,2010,US 61739806 A,2006-12-28,US 61739806 A;;US 75468505 P,2005-12-29,"Substituted pyrazolo[3,4-d]pyrimidines as protein kinase inhibitors","Compounds of formula (25) that inhibit protein kinases, compositions containing the compounds and methods of treating diseases using the compounds are disclosed.",ABBOTT LAB,SHEPPARD GEORGE S;;WANG GARY T;;PALAZZO FABIO;;BELL RANDY L;;MANTEI ROBERT A;;WANG JIEYI;;HUBBARD ROBERT D;;KAWAI MEGUMI;;ERICKSON SCOTT A;;BAMAUNG NWE;;FIDANZE STEVE D,ABBVIE INC (2012-08-01);;ABBOTT LABORATORIES (2007-04-28),https://lens.org/186-793-478-012-990,Granted Patent,yes,8,55,15,15,0,C07D487/04;;A61P35/00;;A61P35/02;;A61P43/00;;C07D487/04,C07D487/04;;A61K31/497;;A61K31/4985;;A61K31/519;;A61K31/5377;;A61P35/00;;C07D413/08,514/234.2;;514/252.16;;514/252.11;;514/262.1;;544/118;;544/262,0,0,,,,INACTIVE
174,EP,A2,EP 1570403 A2,004-797-948-011-481,2005-09-07,2005,EP 03811847 A,2003-11-26,IB 0306448 W;;US 30624802 A;;US 30670502 A,2002-11-27,SOLUTION INFORMATION FOR KNOWLEDGE MANAGEMENT SYSTEM,,ACCENTURE GLOBAL SERVICES GMBH,REID GREGORY S;;RINGO TIMOTHY;;LANE DAVID P;;LIAN ELIZABETH H;;FARRELL DANIEL C;;FENTON CRAIG;;SHEARING ELISE;;BELL RANDY;;WONG SEVASTI;;LINGHAM ANTHONY;;FORRESTER AUDREY;;IVES WILLIAM S,,https://lens.org/004-797-948-011-481,Patent Application,yes,4,0,9,13,0,G06Q30/02,G06Q30/00,,0,0,,,,DISCONTINUED
175,US,B2,US 8275811 B2,015-338-325-742-436,2012-09-25,2012,US 30624802 A,2002-11-27,US 30624802 A,2002-11-27,Communicating solution information in a knowledge management system,A contact center system features: testing comprehension of informational messages with a quiz; capturing insight of users having a KPI score above a threshold by having them describe why they perform so well; dynamically ordering issue solutions by re-ranking the solutions periodically based on recency and frequency; integrating information used by a contact center representative while online with a customer and information for use when not online; storing content in a telecommunications industry taxonomy; directing feedback on a content item to the proper owner/manager of that content; communicating solution information using a solutions taxonomy; displaying a dual information system having a CRM application and reference material that is context-appropriate; enforcing completion of templates when creating a content item to be published; ensuring a group of templates are complete before publishing them; and searching within a contact center system portal using a continuum of search functions.,REID GREGORY S;;RINGO TIMOTHY;;LANE DAVID P;;LIAN ELIZABETH H;;FARRELL DANIEL C;;FENTON CRAIG;;SHEARING ELISE;;BELL RANDY;;WONG SEVASTI;;LINGHAM ANTHONY;;FORRESTER AUDREY;;IVES S WILLIAM;;ACCENTURE GLOBAL SERVICES LTD,REID GREGORY S;;RINGO TIMOTHY;;LANE DAVID P;;LIAN ELIZABETH H;;FARRELL DANIEL C;;FENTON CRAIG;;SHEARING ELISE;;BELL RANDY;;WONG SEVASTI;;LINGHAM ANTHONY;;FORRESTER AUDREY;;IVES S WILLIAM,ACCENTURE GLOBAL SERVICES LIMITED (2010-09-01);;ACCENTURE GLOBAL SERVICES GMBH (2003-11-02),https://lens.org/015-338-325-742-436,Granted Patent,yes,108,10,3,13,0,G06Q30/02;;G06Q30/02,G06F17/30;;G06Q30/02,707/805;;707/790;;707/705,20,0,,,"M.J. Allend and J.P. Furming, ""Methods for Using Global Position System to Find Close Services"", IBM Technical Disclosure Bulletin, Jan. 1998, pp. 693, vol. 41 No. 1.;;Cunliffe, Alison, Super systems capture expertise of the specialist Toronto Star, Nov. 2, 1986.;;Emvolve Performance Manager Release 1.5 Customer Inter@action Solutions, vol. 20, No. 5, Nov. 20, 2001, pp. 53-56.;;ServiceSoft Delivers ""Smart Answers"" at Xerox Business Wire, Aug. 4, 1998.;;Tiwana, Amrit, The Knowledge Management Toolkit Prentice Hall, Dec. 1999, ISN: 0-13-012853-8.;;Office Action issued Sep. 20, 2007 by EPO on Chinese Application No. 200380106314.X.;;Office Action issued Oct. 19, 2007 by US PTO on U.S. Appl. No. 10/305,858.;;Office Action issued by US PTO on U.S. Appl. No. 10/306,705, dated Oct. 9, 2007.;;Office Action issued by EPO on Application No. 03808324.2-2221 dated Jul. 30, 2007 regarding summons to attend oral proceedings on Dec. 13, 2007.;;Alban, Oscar, Customer interaction monitoring: your key to measuring service performance, Australian Banking & Finance, vol. 10, No. 6, Apr. 18, 2001.;;Click2Coach Web Pages, Retrieved from www.envisiontelephony.com, 2001.;;eOn Communications and Eyretel Partner to Deliver Performance Improvement for Contact Centers, PR Newswire, Apr. 4, 2002.;;Feasel, Marnie et al., Training Can Produce Better Reps, Call Center Solutions, vol. 17, No. 4, Oct. 1998, pp. 138-143.;;Kelly Services Expands KellyConnect Call Center Solution, PR Newswire, Jan. 14, 2002.;;Kelly Services Offers Improved Call Center Solution, PR Newswire, Apr. 24, 2000.;;Knowlagent and Eyretel Partner to Deliver Integrated E-Learning Platform to Global Clients, PR Newswire, May 10, 2001.;;Primus Taps OutSights to Deliver Expertise to Customers Shifting to Knowledge-Based Support, Business Wire, Jun. 29, 1999.;;Rosati, Marlene et al., Measuring the Reality of the Customer Experience, Customer Interaction Solutions, May 2002, pp. 38-43.;;Televista Integrates eLearning and Quality Monitoring The Ascent Group, Inc. Call Center E-Journal, Aug. 2001.;;What makes your contact center agents truly effective?, Envision Telephony, Click2Coach, 2000.",ACTIVE
176,US,A1,US 2007/0203143 A1,115-510-687-133-74X,2007-08-30,2007,US 61739806 A,2006-12-28,US 61739806 A;;US 75468505 P,2005-12-29,PROTEIN KINASE INHIBITORS,"Compounds that inhibit protein kinases, compositions containing the compounds and methods of treating diseases using the compounds are disclosed.",SHEPPARD GEORGE S;;WANG GARY T;;PALAZZO FABIO;;BELL RANDY L;;MANTEI ROBERT A;;WANG JIEYI;;HUBBARD ROBERT D;;KAWAI MEGUMI;;ERICKSON SCOTT A;;BAMAUNG NWE;;FIDANZE STEVE D,SHEPPARD GEORGE S;;WANG GARY T;;PALAZZO FABIO;;BELL RANDY L;;MANTEI ROBERT A;;WANG JIEYI;;HUBBARD ROBERT D;;KAWAI MEGUMI;;ERICKSON SCOTT A;;BAMAUNG NWE;;FIDANZE STEVE D,ABBVIE INC (2012-08-01);;ABBOTT LABORATORIES (2007-04-28),https://lens.org/115-510-687-133-74X,Patent Application,yes,0,46,15,15,0,C07D487/04;;A61P35/00;;A61P35/02;;A61P43/00;;C07D487/04,A61K31/53;;A61K31/519,514/243;;514/259.1;;544/281;;544/184,0,0,,,,INACTIVE
177,WO,A8,WO 2004/049221 A8,162-799-823-175-034,2004-08-26,2004,IB 0306448 W,2003-11-26,US 30624802 A;;US 30670502 A,2002-11-27,SOLUTION INFORMATION FOR KNOWLEDGE MANAGEMENT SYSTEM,,ACCENTURE GLOBAL SERVICES GMBH,REID GREGORY S;;RINGO TIMOTHY;;LANE DAVID P;;LIAN ELIZABETH H;;FARRELL DANIEL C;;FENTON CRAIG;;SHEARING ELISE;;BELL RANDY;;WONG SEVASTI;;LINGHAM ANTHONY;;FORRESTER AUDREY;;IVES WILLIAM S,,https://lens.org/162-799-823-175-034,Patent Application,no,0,0,9,13,0,G06Q30/02,G06Q30/00,,0,0,,,,PENDING
178,US,A1,US 2010/0305126 A1,025-032-001-669-958,2010-12-02,2010,US 78800810 A,2010-05-26,US 78800810 A;;US 18156109 P,2009-05-27,Pyrimidine Inhibitors of Kinase Activity,"The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts or solvates thereof, wherein G 1 , R 2 , R 3 , R 4 , R 5 , n, p, q, Ar 1 , and Ar 2 are defined in the description. The present invention relates also to methods of making said compounds, and compositions comprising said compounds which are useful for inhibiting kinases such as IGF-1R.",ABBOTT LAB,CLARK RICHARD F;;BELL RANDY L;;BA-MAUNG NWE Y;;ERICKSON SCOTT A;;FIDANZE STEVE D;;MANTEI ROBERT A;;SHEPPARD GEORGE S;;SORENSEN BRYAN K;;WANG GARY T;;WANG JIEYI,ABBVIE INC (2012-08-01);;ABBOTT LABORATORIES (2010-08-11),https://lens.org/025-032-001-669-958,Patent Application,yes,0,0,10,10,0,A61P35/00;;A61P43/00;;C07D471/04;;C07D471/04;;C07D487/04;;C07D487/04;;C07D513/04;;C07D513/04,A61K31/5377;;A61K31/506;;A61P35/00;;C07D403/14;;C07D413/14,514/235.8;;544/295;;544/122;;514/272,4,2,001-516-175-552-397;;006-339-151-174-691,10.1016/s0169-409x(01)00097-7;;11325474;;10.1021/ar00046a004,"Wolff Manfred E. ""Burger's Medicinal Chemistry, 5ed, Part 1"" John Wiley & Sons, 1995, pages 975-977.;;Vippagunta et al, ""Crystalline Solids"" Advanced Drug Delivery Reviews, vol. 48, pages 3-26 (2001).;;Gavezzotti, ""Are Crystal Structures Predictable?"" Accounts of Chemical Research, vol. 27, pages 309-314 (1994).;;Banker, G.S. et al, ""Modern Pharmaceutices, 3ed."" Marcel Dekker, New York, 1996, pages 451 and 596.",INACTIVE
179,MX,A,MX 2011012631 A,056-106-902-559-426,2012-03-06,2012,MX 2011012631 A,2010-05-26,US 18156109 P;;US 2010/0036185 W,2009-05-27,PYRIMIDINE INHIBITORS OF KINASE ACTIVITY.,"The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts or solvates thereof, wherein G<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, n, p, q, Ar<sup>1</sup>, and Ar<sup>2</sup> are defined in the description. The present invention relates also to methods of making said compounds, and compositions comprising said compounds which are useful for inhibiting kinases such as IGF-IR.",ABBOTT LAB,ERICKSON SCOTT A;;SHEPPARD GEORGE S;;WANG JIEYI;;FIDANZE STEVE D;;WANG GARY T;;SORENSEN BRYAN K;;CLARK RICHARD F;;BELL RANDY L;;MANTEI ROBERT A;;BA-MAUNG NWE Y,ABBVIE INC. (2013-08-09),https://lens.org/056-106-902-559-426,Patent Application,no,0,0,10,10,0,A61P35/00;;A61P43/00;;C07D471/04;;C07D471/04;;C07D487/04;;C07D487/04;;C07D513/04;;C07D513/04,C07D471/04;;A61K31/506;;A61P35/00;;C07D487/04;;C07D513/04,,0,0,,,,ACTIVE
180,MX,A,MX 2012004775 A,087-084-634-828-932,2012-06-01,2012,MX 2012004775 A,2010-10-22,US 60509409 A;;US 2010/0053730 W,2009-10-23,DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND USES THEREOF.,"The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.",ABBOTT LAB,WANG JIEYI;;REILLY EDWARD B;;YING HUA;;GHAYUR TARIQ;;BELL RANDY L;;MORGAN-LAPPE SUSAN E;;KINGSBURY GILLIAN A;;PHILLIPS ANDREW;;NORVELL SUZANNE M;;LI YINGCHUN;;LIU JUNJIAN;;LIU ZHIHONG,ABBVIE INC. (2013-08-09),https://lens.org/087-084-634-828-932,Patent Application,no,0,0,25,25,0,A61K2039/505;;C07K16/22;;C07K16/28;;C07K16/2863;;C07K16/32;;C07K16/468;;C07K2317/73;;C07K2317/92;;C07K2319/00;;C07K2317/76;;A61P1/00;;A61P1/04;;A61P1/16;;A61P1/18;;A61P11/00;;A61P11/02;;A61P11/06;;A61P13/12;;A61P15/00;;A61P15/08;;A61P17/00;;A61P17/02;;A61P17/04;;A61P17/06;;A61P17/14;;A61P19/00;;A61P19/02;;A61P19/08;;A61P19/10;;A61P21/00;;A61P21/02;;A61P21/04;;A61P25/00;;A61P25/02;;A61P25/04;;A61P25/06;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/20;;A61P25/24;;A61P25/28;;A61P25/30;;A61P25/32;;A61P27/02;;A61P29/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P31/14;;A61P31/18;;A61P31/20;;A61P33/00;;A61P33/06;;A61P35/00;;A61P35/02;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/00;;A61P43/00;;A61P5/14;;A61P7/00;;A61P7/02;;A61P7/06;;A61P9/00;;A61P9/04;;A61P9/06;;A61P9/10;;A61P9/12;;A61P3/10;;Y02A50/30;;C07K16/28;;C12N15/11;;A61K39/395;;C07K16/22;;C07K2319/00;;A61K2039/505;;C07K2317/92;;C07K16/468;;C07K16/32;;C07K16/2863;;C07K16/28;;C07K2317/73;;C07K2317/76;;Y02A50/30,C12P21/08,,0,0,,,,ACTIVE
181,EP,A1,EP 2435436 A1,167-174-359-004-320,2012-04-04,2012,EP 10727228 A,2010-05-26,US 2010/0036185 W;;US 18156109 P,2009-05-27,PYRIMIDINE INHIBITORS OF KINASE ACTIVITY,,ABBOTT LAB,CLARK RICHARD F;;BELL RANDY L;;BA-MAUNG NWE Y;;ERICKSON SCOTT A;;FIDANZE STEVE D;;MANTEI ROBERT A;;SHEPPARD GEORGE S;;SORENSEN BRYAN K;;WANG GARY T;;WANG JIEYI,ABBVIE INC. (2013-06-12),https://lens.org/167-174-359-004-320,Patent Application,yes,0,0,10,10,0,A61P35/00;;A61P43/00;;C07D471/04;;C07D471/04;;C07D487/04;;C07D487/04;;C07D513/04;;C07D513/04,C07D471/04;;A61K31/506;;A61P35/00;;C07D487/04;;C07D513/04,,1,0,,,See references of WO 2010138576A1,ACTIVE
182,US,B2,US 8536180 B2,020-066-382-932-038,2013-09-17,2013,US 78791510 A,2010-05-26,US 78791510 A;;US 18155509 P,2009-05-27,Pyrimidine inhibitors of kinase activity,"Described herein are compounds of formula (I) or pharmaceutical acceptable salts or solvates thereof, wherein G 1 , L 1 , R 2 , R 3 , n, p, Ar 1 , and Ar 2 are defined in the description. Methods of making said compounds, and compositions comprising said compounds which are useful for inhibiting kinases such as IGF-1R are also disclosed.",CLARK RICHARD F;;BA-MAUNG NWE Y;;ERICKSON SCOTT A;;FIDANZE STEVE D;;MANTEI ROBERT A;;SHEPPARD GEORGE S;;SORENSEN BRYAN K;;WANG GARY T;;WANG JIEYI;;BELL RANDY L;;ABBVIE INC,CLARK RICHARD F;;BA-MAUNG NWE Y;;ERICKSON SCOTT A;;FIDANZE STEVE D;;MANTEI ROBERT A;;SHEPPARD GEORGE S;;SORENSEN BRYAN K;;WANG GARY T;;WANG JIEYI;;BELL RANDY L,ABBVIE INC (2012-08-01);;ABBOTT LABORATORIES (2010-08-11),https://lens.org/020-066-382-932-038,Granted Patent,yes,4,0,10,10,0,C07D403/14;;C07D471/04;;C07D487/04;;C07D513/04;;A61P35/00;;C07D471/04;;C07D487/04;;C07D513/04;;C07D403/14,A61K31/497;;A61K31/505;;A61K31/535;;C07D403/14;;C07D413/14,514/252.18;;544/122;;544/331,57,56,052-505-137-934-008;;066-219-111-588-400;;070-311-797-413-117;;074-824-348-386-95X;;044-748-831-090-972;;007-364-858-655-289;;018-219-156-278-616;;029-924-070-880-959;;070-792-654-417-452;;008-089-455-773-996;;080-996-521-481-773;;040-239-601-782-040;;028-531-800-105-513;;180-631-728-571-083;;097-392-576-160-344;;042-630-235-998-291;;158-567-940-979-261;;034-722-452-108-337;;096-575-429-954-828;;044-840-255-404-305;;008-885-430-835-895;;095-485-454-240-24X;;038-171-112-628-544;;044-597-437-785-535;;004-488-094-610-499;;064-534-981-503-13X;;080-346-733-584-964;;031-616-493-083-780;;072-621-254-838-609;;099-503-061-558-195;;012-282-318-544-467;;129-970-610-939-855;;065-696-055-011-37X;;003-003-981-633-908;;046-717-070-604-887;;027-931-512-533-165;;045-239-664-066-895;;029-747-914-293-195;;024-924-012-347-732;;075-361-202-778-14X;;032-557-229-419-547;;089-802-856-721-299;;133-233-905-398-202;;031-278-140-393-389;;084-104-328-681-684;;011-001-797-370-811;;026-670-023-742-960;;011-291-416-015-882;;111-677-879-548-551;;071-057-152-903-173;;020-325-142-341-03X;;016-327-462-571-496;;018-470-195-336-786;;036-055-037-431-299;;059-716-462-209-269;;006-946-979-586-164,10961344;;10.1007/pl00000744;;10.1016/j.bcp.2004.05.029;;15313394;;2553250;;10.1007/s00018-006-6036-4;;16786222;;8697095;;10.1016/1357-2725(95)00168-9;;10.1002/jps.2600660104;;833720;;7743492;;14551500;;10.1097/00001813-200310000-00001;;10.1016/j.ijom.2006.09.009;;17113753;;pmc1132689;;1599389;;10.1042/bj2840001;;10.1016/s1097-2765(00)80155-0;;9844629;;10.1073/pnas.93.14.7263;;8692980;;pmc38971;;pmc358831;;8007963;;10.1128/mcb.14.7.4588-4595.1994;;10.1128/mcb.14.7.4588;;10.1351/pac197645010011;;10.1210/endo.139.8.6165;;10.1210/en.139.8.3578;;9681510;;7790393;;10.1002/jcp.1041640126;;12060623;;11550779;;10.1007/s003450100220;;10.1007/s00384-004-0675-4;;15650828;;10.1016/0016-5085(92)70001-r;;1312970;;10.1016/0016-5085(92)90744-j;;10.1002/j.1460-2075.1994.tb06630.x;;8045259;;pmc395225;;10.1007/s10585-005-1198-2;;16035620;;10.1038/sj.onc.1202984;;10557096;;pmc360815;;10.1128/mcb.10.2.464-473.1990;;10.1128/mcb.10.2.464;;2153917;;10.1002/ijc.2910620502;;7665217;;16844299;;10.1016/j.bbcan.2006.05.003;;10.1016/s0304-3835(03)00159-9;;12767520;;8216340;;10.1006/bbrc.1993.2220;;10.1074/jbc.m605269200;;16793764;;10.1177/108705719900400605;;10838427;;7636972;;pmc189367;;10.1128/jvi.69.9.5300-5303.1995;;10.1593/neo.04643;;15967097;;pmc1501162;;10.1016/s0090-4295(01)01004-4;;11445469;;19029956;;10.1038/nrc2536;;10.1038/nrc1387;;15229476;;10.1016/s0091-679x(08)60468-9;;794631;;16328478;;10.1007/s00277-005-0031-y;;16931767;;10.1210/er.2006-0001;;10.1038/sj.onc.1206058;;12447687;;9751624;;10.1128/mcb.14.6.3604;;pmc358728;;8196606;;10.1128/mcb.14.6.3604-3612.1994;;8248231;;10.1073/pnas.90.23.11217;;pmc47953;;15517912;;10791772;;10.1023/a:1009523501499;;16986125;;10.1002/cncr.22214;;10.1073/pnas.89.11.4874;;1594587;;pmc49190;;16997283;;10.1016/j.bcp.2006.08.011;;10.1210/jcem.87.1.8142;;10.1210/jc.87.1.245;;11788654;;11376121;;pmc1187048;;10.1136/mp.54.3.121;;10.1159/000095161;;16917171;;10.1158/1078-0432.ccr-03-0762;;15217929;;10.1038/sj.onc.1209674;;16715137;;10.1097/01.ju.0000036380.10325.2a;;10.1016/s0022-5347(05)63999-7;;10.1097/00005392-200302000-00071;;12544349;;10226794;;10.1055/s-2007-978711;;pmc1187072;;11477136;;10.1136/mp.54.4.227;;12002750;;10.1080/10428190290011958,"Adams T.E., et al., ""Structure and Function of the Type 1 Insulin-Like Growth Factor Receptor,"" Cellular and Molecular Life Sciences, 2000, vol. 57 (7), pp. 1050-1093.;;Alexia C., et al., ""An Evaluation of the Role of Insulin-Like Growth Factors (IGF) and of Type-I IGF Receptor Signalling in Hepatocarcinogenesis and in the Resistance of Hepatocarcinoma Cells against Drug-Induced Apoptosis,"" Biochemical Pharmacology, 2004, vol. 68 (6), pp. 1003-1015.;;Arteaga C.L., et al., ""Growth Inhibition of Human Breast Cancer Cells in Vitro with an Antibody Against the Type I Somatomedin Receptor,"" Cancer Research, 1989, vol. 49 (22), pp. 6237-6241.;;Bateman J.M., et al., ""Insulin/IGF Signalling in Neurogenesis,"" Cellular and Molecular Life Sciences, 2006, vol. 63 (15), pp. 1701-1705.;;Benito M., et al., ""IGF-I: A Mitogen also Involved in Differentiation Processes in Mammalian Cells,"" The International Journal of Biochemistry & Cell Biology, 1996, vol. 28 (5), pp. 499-510.;;Berge, S. M. et al., ""Pharmaceutical Salts,"" Journal of Pharmaceutical Sciences, 1977, vol. 66 (1), pp. 1-19.;;Bergmann U., et al., ""Insulin-Like Growth Factor I Overexpression in Human Pancreatic Cancer: Evidence for Autocrine and Paracrine Roles,"" Cancer Research , 1995, vol. 55 (10), pp. 2007-2011.;;Bohula E.A., et al., ""Targeting the Type 1 Insulin-Like Growth Factor Receptor as Anti-Cancer Treatment,"" Anti-cancer Drugs, 2003, vol. 14 (9), pp. 669-682.;;Brady G., et al., ""Serum Levels of Insulin-Like Growth Factors (IGFS) and their Binding Proteins (IGFPBS), -1, -2, -3, in Oral Cancer,"" International Journal of Oral and Maxillofacal Surgery, 2007, vol. 36 (3), pp. 259-262.;;Brown G.C., ""Control of Respiration and Atp Synthesis in Mammalian Mitochondria and Cells,"" Biochemical, 1992, vol. 248, pp. 1-13.;;Bruning J.C., et al., ""A Muscle-Specific Insulin Receptor Knockout Exhibits Features of the Metabolic Syndrome of NIDDM without Altering Glucose Tolerance,"" Molecular Cell, 1998, vol. 2 (5), pp. 559-569.;;Burfeind P., et al., ""Antisense RNA to the Type I Insulin-Like Growth Factor Receptor Suppresses Tumor Growth and Prevents Invasion by Rat Prostate Cancer Cells in Vivo,"" Proceedings of the National Academy of Sciences of the USA, 1996, vol. 93 (14), pp. 7263-7268.;;Coppola D., et al., ""A Functional Insulin-Like Growth Factor I Receptor is Required for the Mitogenic and Transforming Activities of the Epidermal Growth Factor Receptor,"" Molecular and Cellular Biology, 1994, vol. 14 (7), pp. 4588-4595.;;Cross, L.C. et al., ""IUPAC Commission on Nomenclature of Organic Chemistry: Rules for the Nomenclature of Organic Chemistry, Section E: Stereochemistry,"" Pure and Applied Chemistry, 1976, vol. 45, pp. 11-30.;;Dandekar A.A., et al., ""Comparison of the Signaling Abilities of the Cytoplasmic Domains of the Insulin Receptor and the Insulin Receptor-Related Receptor in 3T3-L1 Adipocytes,"" Endocrinology, 1998, vol. 139 (8), pp. 3578-3584.;;Deangelis T., et al., ""Insulin-Like Growth Factor I Receptor is Required for the Mitogenic and Transforming Activities of the Platelet-Derived Growth Factor Receptor,"" Journal of Cellular Physiology, 1995, vol. 164 (1), pp. 214-221.;;Del Valle L., et al., ""Insulin-Like Growth Factor I Receptor Activity in Human Medulloblastomas,"" Clinical Cancer Research, 2002, vol. 8 (6), pp. 1822-1830.;;Djavan B., et al., ""Insulin-Like Growth Factors and Prostate Cancer,"" World Journal of Urology , 2001, vol. 19 (4), pp. 225-233.;;Durai R., et al., ""The Role of the Insulin-Like Growth Factor System in Colorectal Cancer: Review of Current Knowledge,"" International Journal Colorectal Diseases., 2005, vol. 20 (3), pp. 203-220.;;Greene, T.W., et al., Protective Groups in Organic Synthesis, 3rd Edition, John Wiley and Sons, Inc., 1999, Table of Contents.;;Guo Y.S., et al., ""Characterization of Insulinlike Growth Factor I Receptors in Human Colon Cancer,"" Gastroenterology, 1992, vol. 102 (4 pt 1), pp. 1101-1108.;;Harrington E.A., et al., ""C-Myc-Induced Apoptosis in Fibroblasts is Inhibited by Specific Cytokines,"" The EMBO Journal, 1994, vol. 13 (14), pp. 3286-3295.;;Jiang Y., et al., ""A High Expression Level of Insulin-Like Growth Factor I Receptor is Associated with Increased Expression of Transcription Factor SP1 and Regional Lymph Node Metastasis of Human Gastric Cancer,"" Clinical & Experimental Metastasis, 2004, vol. 21 (8), pp. 755-764.;;Jiang Y., et al., ""Induction of Tumor Suppression and Glandular Differentiation of A549 Lung Carcinoma Cells by Dominant-Negative IGF-I Receptor,"" Oncogene, 1999, vol. 18 , pp. 6071-6077.;;Kaleko M., et al., ""Overexpression of the Human Insulinlike Growth Factor I Receptor Promotes Ligand-Dependent Neoplastic Transformation,"" Molecular and Cellular Biology, 1990, vol. 10 (2), pp. 464-473.;;Kellerer M., et al., ""Insulin- and Insulin-Like Growth-Factor-I Receptor Tyrosine-Kinase Activities in Human Renal Carcinoma,"" International Journal of Cancer, 1995, vol. 62 (5), pp. 501-507.;;Kurmasheva R.T., et al., ""IGF-I Mediated Survival Pathways in Normal and Malignant Cells,"" Biochimica et Biophysica Acta, 2006, vol. 1766 (1), pp. 1-22.;;Leroith D., et al., ""The Insulin-Like Growth Factor System and Cancer,"" Cancer Letters, 2003, vol. 195 (2), pp. 127-137.;;Li S.L., et al. , ""Two New Monoclonal Antibodies against the ? Subunit of the Human Insulin-Like Growth Factor-I Receptor,"" Biochemical and Biophysical Research Communications, 1993, vol. 196 (1), pp. 92-98.;;Li W., et al., ""Role of the Activation Loop Tyrosines in Regulation of the Insulin-Like Growth Factor I Receptor-Tyrosine Kinase,"" The Journal of Biological Chemistry, 2006, vol. 281 (33), pp. 23785-23791.;;Mathis G., ""HTRF(R) Technology ,"" Journal of Biomolecular Screening, 1999, vol. 4 (6), pp. 309-314.;;Morrione A., et al., ""Failure of the Bovine Papillomavirus to Transform Mouse Embryo Fibroblasts with a Targeted Disruption of the Insulin-Like Growth Factor I Receptor Genes,"" Journal of Virology, 1995, vol. 69 (9), pp. 5300-5303.;;Neuvians T.P., et al., ""Differential Expression of IGF Components and Insulin Receptor Isoforms in Human Seminoma Versus Normal Testicular Tissue,"" Neoplasia, 2005, vol. 7 (5), pp. 446-456.;;O'Brien M.F., et al., ""Insulin-Like Growth Factor I and Prostate Cancer,"" Urology, 2001, vol. 58 (1), pp. 1-7.;;Pollak M.N., et al., ""Insulin and Insulin-Like Growth Factor Signalling in Neoplasia,"" Nature Reviews Cancer, 2008, vol. 8 (12), pp. 915-928.;;Pollak M.N., et al., ""Insulin-Like Growth Factors and Neoplasia,"" Nature Reviews Cancer, 2004, vol. 4 (7), pp. 505-518.;;Poste G. et al., ""Lipid Vesicles as Carriers for Introducing Biologically Active Materials into Cells,"" Methods in Cell Biology, 1976, vol. 14, pp. 33-71.;;Qi H., et al., ""Expression of Type 1 Insulin-Like Growth Factor Receptor in Marrow Nucleated Cells in Malignant Hematological Disorders: Correlation with Apoptosis,"" Annals of Hematology, 2006, vol. 85 (2), pp. 95-101.;;Samani A.A., et al., ""The Role of the IGF System in Cancer Growth and Metastasis: Overview and Recent Insights,"" Endocrine Reviews, 2007, vol. 28 (1), pp. 20-47.;;Sciacca L., et al., ""In IGF-I Receptor-Deficient Leiomyosarcoma Cells Autocrine IGF-II Induces Cell Invasion and Protection from Apoptosis Via the Insulin Receptor Isoform A,"" Oncogene, 2002, vol. 21 (54), pp. 8240-8250.;;Scotlandi K., et al., ""Blockage of Insulin-like Growth Factor-I Receptor Inhibits the Growth of Ewing's Sarcoma in Athymic Mice,"" Cancer Research, 1998, vol. 58 (18), pp. 4127-4131.;;Sell C., et al., ""Effect of a Null Mutation of the Insulin-Like Growth Factor I Receptor Gene on Growth and Transformation of Mouse Embryo Fibroblasts,"" Molecular and Cellular Biology, 1994, vol. 14 (6), pp. 3604-3612.;;Sell C., et al., ""Simian Virus 40 Large Tumor Antigen is Unable to Transform Mouse Embryonic Fibroblasts Lacking Type 1 Insulin-Like Growth Factor Receptor,"" Proceedings of the National Academy of Sciences of the USA, 1993, vol. 90 (23), pp. 11217-11221.;;Sohda M., et al., ""The Role of Insulin-Like Growth Factor 1 and Insulin-Like Growth Factor Binding Protein 3 in Human Esophageal Cancer,"" Anticancer Research, 2004, vol. 24 (5A), pp. 3029-3034.;;Surmacz E., ""Function of the IGF-I Receptor in Breast Cancer,"" Journal of Mammary Gland Biology and Neoplasia, 2000, vol. 5 (1), pp. 95-105.;;Trent J.C., et al., ""Early Effects of Imatinib Mesylate on the Expression of Insulin-Like Growth Factor Binding Protein-3 and Positron Emission Tomography in Patients with Gastrointestinal Stromal Tumor,"" Cancer, 2006, vol. 107 (8), pp. 1898-1908.;;Trojan J., et al., ""Loss of Tumorigenicity of Rat Glioblastoma Directed by Episome-Based Antisense CDNA Transcription of Insulin-Like Growth Factor I,"" Proceedings of the National Academy of Sciences of the USA, 1992, vol. 89 (11), pp. 4874-4878.;;Van Nimwegen M.J., et al., ""Focal Adhesion Kinase: A Potential Target in Cancer Therapy,"" Biochemical Pharmacology, 2007, vol. 73 (5), pp. 597-609.;;Vella V., et al., ""A Novel Autocrine Loop Involving IGF-II and the Insulin Receptor Isoform-A Stimulates Growth of Thyroid Cancer,"" The Journal of Clinical Endocrinology and Metabolism, 2002, vol. 87 (1), pp. 245-254.;;Vella V., et al., ""The IGF System in Thyroid Cancer: New Concepts,"" Molecular Pathology, 2001, vol. 54 (3), pp. 121-124.;;Walenkamp M.J., et al., ""Genetic Disorders in the Growth Hormone-Insulin-Like Growth Factor-I Axis,"" Hormone Research, 2006, vol. 66 (5), pp. 221-230.;;Wu X., et al., ""Serum Levels of Insulin Growth Factor (IGF-I) and IGF-Binding Protein Predict Risk of Second Primary Tumors in Patients with Head and Neck Cancer,"" Clinical Cancer Research, 2004, vol. 10 (12 pt 1), pp. 3988-3995.;;Yeh A.H., et al., ""Human Melanoma Cells Expressing V600e B-RAF are Susceptible to IGF1R Targeting by Small Interfering RNAs,"" Oncogene, 2006, vol. 25 (50), pp. 6574-6581.;;Zhao H., et al., ""Plasma Levels of Insulin-Like Growth Factor-1 snd Binding Protein-3, and their Association with Bladder Cancer Risk,"" The Journal of urology, 2003, vol. 169 (2), pp. 714-717.;;Zumkeller W., et al., ""Insulin-Like Growth Factor System in Neuroblastoma Tumorigenesis and Apoptosis: Potential Diagnostic and Therapeutic Perspectives,"" Hormone & Metabolic Research, 1999, vol. 31 (2-3), pp. 138-141.;;Zumkeller W., ""The IGF/IGFBP System in CNS Malignancy,"" Moloclonal Pathology, 2001, vol. 54 (4), pp. 227-229.;;Zumkeller W., ""The Insulin-Like Growth Factor System in Hematopoietic Cells,"" Leukemia & Lymphoma, 2002, vol. 43 (3), pp. 487-491.",INACTIVE
183,ES,T3,ES 2453097 T3,065-881-331-727-695,2014-04-04,2014,ES 10727227 T,2010-05-26,US 18155509 P;;US 2010/0036184 W,2009-05-27,Inhibidores de pirimidina de actividad quinasa,"Un compuesto de fórmula (I)**Fórmula** o una sal o solvato farmacéuticamente aceptable, o una combinación de los mismos, donde G1 corresponde a la fórmula (i), (ii), (iii) o (iv)**Fórmula*+ m es 0, 1, 2, 3 ó 4; m' es 0, 1 ó 2; n es 0, 1 ó 2; p es 0, 1, 2 ó 3; R1, R2 y R3 son substituyentes eventuales y, cuando están presentes, son cada uno independientemente alquilo, halógeno, -O(alquilo), -O(haloalquilo) o haloalquilo; a y b designan los puntos de unión en los que las fórmulas (i), (ii), (iii) y (iv) se unen a la fórmula (I); L1 es un enlace, O, N(H) o (CR4R5)q; R4 y R5, en cada caso, son cada uno independientemente hidrógeno, alquilo, halógeno o haloalquilo; q es 1, 2, 3 ó 4; Ar1 es arilo o heteroarilo, cada uno de los cuales está independientemente sin substituir o substituido con 1, 2, 3, 4 ó 5 substituyentes representados por T, donde cada T es seleccionado entre el grupo consistente en alquilo, alquenilo, alquinilo, halógeno, haloalquilo, oxo, CN, NO2, G2, -OR6, -OC(O)R7, -SR6, -S(O)R7, -S(O)2R7, -S(O)2N(R8)(R9), -N(R8)(R9), -N(R8) C(O)R7, -N(R8)C(O)OR7, -N(R8)S(O)2R7, -N(R8)C(O)N(R8)(R9), -N(R8)C(O)- (alquilenil C1-6)-N(R8)(R9), -N(R8)S(O)2N(R8)(R9), -C(O)R6, -C(O)OR6, -C(O)N(R8)(R9), -(alquilenil C1-6)-G2, -(alquilenil C1-6)-OR6, -(alquilenil C1-6)-OC(O)R7, -(alquilenil C1-6)-SR6, -(alquilenil C1-6)-S(O)R7, -(alquilenil C1-6)- S(O)2R7, -(alquilenil C1-6)-S(O)2N(R8)(R9), -(alquilenil C1-6)-N(R8)(R9), -(alquilenil C1-6)-N(R8)C(O)R7, -(alquilenil C1-6)-N(R8)C(O)OR7, -(alquilenil C1-6)-N(R8)S(O)2R7, -(alquilenil C1-6)-N(R8)C(O)N(R8)(R9), -(alquilenil C1-6)- N(R8)S(O)2N(R8)(R9), -(alquilenil C1-6)-C(O)R6, -(alquilenil C1-6)-C(O)OR6 y -(alquilenil C1-6)-C(O)N(R8)(R9); dos substituyentes sobre los átomos de carbono vicinales de Ar1, junto con los átomos de carbono a los que se unen, forman eventualmente un heterociclo de 5 ó 6 miembros monocíclico que contiene uno o dos heteroátomos seleccionados entre N(H), O, S, S(O) o S(O)2, donde cada uno de los heterociclos monocíclicos está eventualmente sustituido con 1, 2, 3 ó 4 grupos alquilo; cada caso de R6 y R9 es independientemente hidrógeno, alquilo, haloalquilo, -(alquilenil C1-6)-CN, -(alquilenil C1-6)-OH, -(alquilenil C1-6)-C(O)OH, G3 o -(alquilenil C1-6)-G3; cada caso de R es independientemente alquilo, haloalquilo, -(alquilenil C1-6)-CN, -(alquilenil C1-6)-OH, G3 o -(alquilenil C1-6)-G3; cada caso de R8 es independientemente hidrógeno, alquilo o haloalquilo.",ABBVIE INC,CLARK RICHARD F;;BA-MAUNG NWE Y;;ERICKSON SCOTT A;;FIDANZE STEVE D;;MANTEI ROBERT A;;SHEPPARD GEORGE S;;SORENSEN BRYAN K;;WANG GARY T;;WANG JIEYI;;BELL RANDY L,,https://lens.org/065-881-331-727-695,Granted Patent,no,0,0,10,10,0,C07D403/14;;C07D471/04;;C07D487/04;;C07D513/04;;A61P35/00;;C07D471/04;;C07D487/04;;C07D513/04;;C07D403/14,C07D471/04;;A61K31/506;;A61P35/00;;C07D403/14;;C07D487/04;;C07D513/04,,0,0,,,,ACTIVE
184,US,B2,US 8354422 B2,074-962-952-273-930,2013-01-15,2013,US 78800810 A,2010-05-26,US 78800810 A;;US 18156109 P,2009-05-27,Pyrimidine inhibitors of kinase activity,"The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts or solvates thereof, wherein G 1 , R 2 , R 3 , R 4 , R 5 , n, p, q, Ar 1 , and Ar 2 are defined in the description. The present invention relates also to methods of making said compounds, and compositions comprising said compounds which are useful for inhibiting kinases such as IGF-1R.",ABBOTT LAB;;CLARK RICHARD F;;BELL RANDY L;;BA-MAUNG NWE Y;;ERICKSON SCOTT A;;FIDANZE STEVE D;;MANTEI ROBERT A;;SHEPPARD GEORGE S;;SORENSEN BRYAN K;;WANG GARY T;;WANG JIEYI,CLARK RICHARD F;;BELL RANDY L;;BA-MAUNG NWE Y;;ERICKSON SCOTT A;;FIDANZE STEVE D;;MANTEI ROBERT A;;SHEPPARD GEORGE S;;SORENSEN BRYAN K;;WANG GARY T;;WANG JIEYI,ABBVIE INC (2012-08-01);;ABBOTT LABORATORIES (2010-08-11),https://lens.org/074-962-952-273-930,Granted Patent,yes,2,2,10,10,0,A61P35/00;;A61P43/00;;C07D471/04;;C07D471/04;;C07D487/04;;C07D487/04;;C07D513/04;;C07D513/04,C07D403/14;;A61K31/506;;A61K31/5377;;C07D413/14,514/275;;514/248;;544/235;;544/333,61,58,001-516-175-552-397;;006-339-151-174-691;;052-505-137-934-008;;066-219-111-588-400;;070-311-797-413-117;;074-824-348-386-95X;;044-748-831-090-972;;007-364-858-655-289;;018-219-156-278-616;;029-924-070-880-959;;070-792-654-417-452;;008-089-455-773-996;;080-996-521-481-773;;040-239-601-782-040;;028-531-800-105-513;;180-631-728-571-083;;097-392-576-160-344;;042-630-235-998-291;;158-567-940-979-261;;034-722-452-108-337;;096-575-429-954-828;;044-840-255-404-305;;008-885-430-835-895;;095-485-454-240-24X;;038-171-112-628-544;;044-597-437-785-535;;004-488-094-610-499;;064-534-981-503-13X;;080-346-733-584-964;;031-616-493-083-780;;072-621-254-838-609;;099-503-061-558-195;;012-282-318-544-467;;129-970-610-939-855;;065-696-055-011-37X;;003-003-981-633-908;;046-717-070-604-887;;027-931-512-533-165;;045-239-664-066-895;;029-747-914-293-195;;024-924-012-347-732;;075-361-202-778-14X;;032-557-229-419-547;;089-802-856-721-299;;133-233-905-398-202;;031-278-140-393-389;;084-104-328-681-684;;011-001-797-370-811;;026-670-023-742-960;;011-291-416-015-882;;111-677-879-548-551;;071-057-152-903-173;;020-325-142-341-03X;;016-327-462-571-496;;018-470-195-336-786;;036-055-037-431-299;;059-716-462-209-269;;006-946-979-586-164,10.1016/s0169-409x(01)00097-7;;11325474;;10.1021/ar00046a004;;10961344;;10.1007/pl00000744;;10.1016/j.bcp.2004.05.029;;15313394;;2553250;;10.1007/s00018-006-6036-4;;16786222;;8697095;;10.1016/1357-2725(95)00168-9;;10.1002/jps.2600660104;;833720;;7743492;;14551500;;10.1097/00001813-200310000-00001;;10.1016/j.ijom.2006.09.009;;17113753;;pmc1132689;;1599389;;10.1042/bj2840001;;10.1016/s1097-2765(00)80155-0;;9844629;;10.1073/pnas.93.14.7263;;8692980;;pmc38971;;pmc358831;;8007963;;10.1128/mcb.14.7.4588-4595.1994;;10.1128/mcb.14.7.4588;;10.1351/pac197645010011;;10.1210/endo.139.8.6165;;10.1210/en.139.8.3578;;9681510;;7790393;;10.1002/jcp.1041640126;;12060623;;11550779;;10.1007/s003450100220;;10.1007/s00384-004-0675-4;;15650828;;10.1016/0016-5085(92)70001-r;;1312970;;10.1016/0016-5085(92)90744-j;;10.1002/j.1460-2075.1994.tb06630.x;;8045259;;pmc395225;;10.1007/s10585-005-1198-2;;16035620;;10.1038/sj.onc.1202984;;10557096;;pmc360815;;10.1128/mcb.10.2.464-473.1990;;10.1128/mcb.10.2.464;;2153917;;10.1002/ijc.2910620502;;7665217;;16844299;;10.1016/j.bbcan.2006.05.003;;10.1016/s0304-3835(03)00159-9;;12767520;;8216340;;10.1006/bbrc.1993.2220;;10.1074/jbc.m605269200;;16793764;;10.1177/108705719900400605;;10838427;;7636972;;pmc189367;;10.1128/jvi.69.9.5300-5303.1995;;10.1593/neo.04643;;15967097;;pmc1501162;;10.1016/s0090-4295(01)01004-4;;11445469;;19029956;;10.1038/nrc2536;;10.1038/nrc1387;;15229476;;10.1016/s0091-679x(08)60468-9;;794631;;16328478;;10.1007/s00277-005-0031-y;;16931767;;10.1210/er.2006-0001;;10.1038/sj.onc.1206058;;12447687;;9751624;;10.1128/mcb.14.6.3604;;pmc358728;;8196606;;10.1128/mcb.14.6.3604-3612.1994;;8248231;;10.1073/pnas.90.23.11217;;pmc47953;;15517912;;10791772;;10.1023/a:1009523501499;;16986125;;10.1002/cncr.22214;;10.1073/pnas.89.11.4874;;1594587;;pmc49190;;16997283;;10.1016/j.bcp.2006.08.011;;10.1210/jcem.87.1.8142;;10.1210/jc.87.1.245;;11788654;;11376121;;pmc1187048;;10.1136/mp.54.3.121;;10.1159/000095161;;16917171;;10.1158/1078-0432.ccr-03-0762;;15217929;;10.1038/sj.onc.1209674;;16715137;;10.1097/01.ju.0000036380.10325.2a;;10.1016/s0022-5347(05)63999-7;;10.1097/00005392-200302000-00071;;12544349;;10226794;;10.1055/s-2007-978711;;pmc1187072;;11477136;;10.1136/mp.54.4.227;;12002750;;10.1080/10428190290011958,"Wolff Manfred E. ""Burger's Medicinal Chemistry, 5ed, Part 1"" John Wiley & Sons, 1995, pp. 975-977.;;Vippagunta et al, ""Crystalline Solids"" Advanced Drug Delivery Reviews, vol. 48, pp. 3-26 (2001).;;Gavezzotti, ""Are Crystal Structures Predictable?"" Accounts of Chemical Research, vol. 27, pp. 309-314 (1994).;;Banker, G.S. et al, ""Modern Pharmaceutices, 3ed."" Marcel Dekker, New York, 1996, pp. 451 and 596.;;Adams T. E., et al., ""Structure and function of the type 1 insulin-like growth factor receptor"", Cellular and Molecular Life Sciences, 2000, vol. 57 (7), pp. 1050-1093.;;Alexia C., et al., ""An evaluation of the role of insulin-like growth factors (IGF) and of type-I IGF receptor signalling in hepatocarcinogenesis and in the resistance of hepatocarcinoma cells against drug-induced apoptosis"", Biochem Pharmacol, 2004, vol. 68 (6), pp. 1003-1015.;;Arteaga C.L., et al., ""Growth Inhibition of Human Breast Cancer Cells in Vitro with an Antibody Against The Type I Somatomedin Receptor,"" Cancer Research, 1989, vol. 49 (22), pp. 6237-6241.;;Bateman J. M., et al., ""Insulin/IGF Signalling in Neurogenesis,"" Cellular and Molecular Life Sciences, 2006, vol. 63 (15), pp. 1701-1705.;;Benito M., et al., ""IGF-I: A Mitogen also Involved in Differentiation Processes in Mammalian Cells,"" The International Journal of Biochemistry & Cell Biology, 1996, vol. 28 (5), pp. 499-510.;;Berge S. M., et al., ""Pharmaceutical Salts"", J Pharmaceutical Sciences, 1977, vol. 66 (1), pp. 1-19.;;Bergmann U., et al., ""Insulin-like growth factor I overexpression in human pancreatic cancer: evidence for autocrine and paracrine roles"", Cancer Research , 1995, vol. 55 (10), pp. 2007-2011.;;Bohula E. A., et al., ""Targeting the type 1 insulin-like growth factor receptor as anti-cancer treatment"", Anti-cancer Drugs., 2003, vol. 14 (9), pp. 669-682.;;Brady G., et al., ""Serum levels of insulin-like growth factors (IGFs) and their binding proteins (IGFBPs), -1, -2, -3, in oral cancer"", International Journal of Oral and Maxillofacal Surgery, 2007, vol. 36 (3), pp. 259-262.;;Brown Guy C., ""Control of respiration and ATP synthesis in mammalian mitochondria and cells"", Biochemical, 1992, vol. 248, pp. 1-13.;;Bruning Jens C., et al., ""A Muscle-Specific Insulin Receptor Knockout Exhibits Features of the Metabolic Syndrome of NIDDM without Altering Glucose Tolerance"", Molecular Cell, 1998, vol. 2 (5), pp. 559-569.;;Burfeind P., et al., ""Antisense RNA to the type I insulin-like growth factor receptor suppresses tumor growth and prevents invasion by rat prostate cancer cells in vivo"", The Proceedings of the National Academy of Sciences of the United States of America, 1996, vol. 93 (14), pp. 7263-7268.;;Coppola D., et al., ""A Functional Insulin-Like Growth Factor I Receptor is Required for the Mitogenic and Transforming Activities of the Epidermal Growth Factor Receptor,"" Molecular and Cellular Biology, 1994, vol. 14 (7), pp. 4588-4595.;;Cross L.C., et al., ""IUPAC Commission on Nomenclature of Organic Chemistry: Rules for the Nomenclature of Organic Chemistry, Section E: Stereochemistry,"" Pure and Applied Chemistry, 1976, vol. 45, pp. 11-30.;;Dandekar Ajai A., et al., ""Comparison of the Signaling Abilities of the Cytoplasmic Domains of the Insulin Receptor and the Insulin Receptor-Related Receptor in 3T3-L1 Adipocytes"", Endocrinology, 1998, vol. 139 (8), pp. 3578-3584.;;Deangelis T., et al., ""Insulin-Like Growth Factor I Receptor is Required for the Mitogenic and Transforming Activities of the Platelet-Derived Growth Factor Receptor,"" Journal of Cellular Physiology, 1995, vol. 164 (1), pp. 214-221.;;Del Valle L., et al., ""nsulin-like growth factor I receptor activity in human medulloblastomas"", Clinical Cancer Research, 2002, vol. 8 (6), pp. 1822-1830.;;Djavan B., et al., ""Insulin-like growth factors and prostate cancer"", World Journal of Urology , 2001, vol. 19 (4), pp. 225-233.;;Durai R., et al., ""The role of the insulin-like growth factor system in colorectal cancer: review of current knowledge"", International Journal Colorectal Diseases., 2005, vol. 20 (3), pp. 203-220.;;Greene T., et al., ""Protective Groups in Organic Synthesis,"" Protecting Groups in Organic Synthesis, 1999, Third Edition, Table of Contents.;;Guo Y S., et al., ""Characterization of insulinlike growth factor I receptors in human colon cancer"", Gastroenterology, 1992, vol. 102 (4 pt 1), pp. 1101-1108.;;Harrington E. A., et al., ""C-Myc-Induced Apoptosis in Fibroblasts is Inhibited by Specific Cytokines,"" The EMBO Journal, 1994, vol. 13 (14), pp. 3286-3295.;;Jiang Y., et al., ""A high expression level of insulin-like growth factor I receptor is associated with increased expression of transcription factor Sp1 and regional lymph node metastasis of human gastric cancer"", 2004, vol. 21 (8), pp. 755-764.;;Jiang Y., et al., ""Induction of Tumor Suppression and Glandular Differentiation of A549 Lung Carcinoma Cells by Dominant-Negative IGF-I Receptor,"" Oncogene, 1999, vol. 18 (14), pp. 6071-6077.;;Kaleko M., et al., ""Overexpression of the Human Insulinlike Growth Factor I Receptor Promotes Ligand-Dependent Neoplastic Transformation,"" Molecular and Cellular Biology, 1990, vol. 10 (2), pp. 464-473.;;Kellerer M., et al., ""Insulin- and insulin-like growth-factor-I receptor tyrosine-kinase activites in human renal carcinoma"", 1995, vol. 62 (5), pp. 501-507.;;Kurmasheva R.T., et al., ""IGF-I Mediated Survival Pathways in Normal and Malignant Cells,"" Biochimica et Biophysica Acta, 2006, vol. 1766, pp. 1-22.;;Leroith D., et al., ""The Insulin-Like Growth Factor System and Cancer,"" Cancer Letters, 2003, vol. 195, pp. 127-137.;;Li, et al. , ""Two New Monoclonal Antibodies against the ? Subunit of the Human Insulin-Like Growth Factor-I Receptor,"" Biochemical and Biophysical Research Communications, 1993, vol. 196 (1), pp. 92-98.;;Li Wanqing, et al., ""Role of the Activation Loop Tyrosines in Regulation of the Insulin-like Growth Factor I Receptor-tyrosine Kinase"", The Journal of Biological Chemistry, 2006, vol. 281 (33), pp. 23785-23791.;;Mathis G.,, ""HTRF(R) Technology"", J Biomol Screen, 1999, 4 (6), 309-314.;;Morrione A., et al., ""Failure of the Bovine Papillomavirus to Transform Mouse Embryo Fibroblasts with a Targeted Disruption of the Insulin-Like Growth Factor I Receptor Genes,"" Journal of Virology, 1995, vol. 69 (9), pp. 5300-5303.;;Neuvians T P., et al., ""Differential expression of IGF components and insulin receptor isoforms in human seminoma versus normal testicular tissue"", 2005, vol. 7 (5), pp. 446-456.;;O'Brien M F., et al., ""Insulin-like growth factor I and prostate cancer"", Urology, 2001, vol. 58 (1), pp. 1-7.;;Pollak M N., et al., ""Insulin and insulin-like growth factor signalling in neoplasia"", 2008, vol. 8 (12), pp. 915-928.;;Pollak Michael N., et al., ""Insulin-Like Growth Factors and Neoplasia"", Nature Reviews Cancer, 2004, vol. 4, pp. 505-518.;;Prescott et al., ""Lipid Vesicles as Carriers for Introducing Biologically Active Materials into Cells,"" Methods in Cell Biology, 1976, Academic Press, vol. 14 (33) pp. 33-71.;;Qi H., et al., ""Expression of type 1 insulin-like growth factor receptor in marrow nucleated cells in malignant hematological disorders: correlation with apoptosis,"" 2006, vol. 85 (2), pp. 95-101.;;Samani A.A., et al., ""The Role of the IGF System in Cancer Growth and Metastasis: Overview and Recent Insights,"" Endocrine Reviews, 2007, vol. 28 (1), pp. 20-47.;;Sciacca Laura, et al., ""In IGF-I receptor-de®cient leiomyosarcoma cells autocrine IGF-II induces cell invasion and protection from apoptosis via the insulin receptor isoform A"", Oncogene, 2002, vol. 21, pp. 8240-8250.;;Scotlandi K., et al., ""Blockage of Insulin-like Growth Factor-I Receptor Inhibits the Growth of Ewing's Sarcoma in Athymic Mice,"" Cancer Research, 1998, vol. 58, pp. 4127-4131.;;Sell C., et al., ""Effect of a Null Mutation of the Insulin-Like Growth Factor I Receptor Gene on Growth and Transformation of Mouse Embryo Fibroblasts,"" Molecular and Cellular Biology, 1994, vol. 14 (6), pp. 3604-3612.;;Sell C., et al., ""Simian Virus 40 Large Tumor Antigen is Unable to Transform Mouse Embryonic Fibroblasts Lacking Type 1 Insulin-Like Growth Factor Receptor,"" Proceedings of the National Academy of Sciences, 1993, vol. 90, pp. 11217-11221.;;Sohda M., et al., ""The role of insulin-like growth factor 1 and insulin-like growth factor binding protein 3 in human esophageal cancer"", Anticancer Res. , 2004, vol. 24 (5A), pp. 3029-3034.;;Surmacz E., et al., ""Function of the IGF-I Receptor in Breast Cancer,"" Journal of Mammary Gland Biology and Neoplasia, 2000, vol. 5 (1), pp. 95-105.;;Trent J C., et al., ""Early effects of imatinib mesylate on the expression of insulin-like growth factor binding protein-3 and positron emission tomography in patients with gastrointestinal stromal tumor"", Cancer, 2006, vol. 107 (8), pp. 1898-1908.;;Trojan J., et al., ""Loss of tumorigenicity of rat glioblastoma directed by episome-based antisense cDNA transcription of insulin-like growth factor I"", Proc Natl Acad Sci, 1992, vol. 89 (11), pp. 4874-4878.;;Van Nimwegen M. J. et al., ""Focal Adhesion Kinase: A Potential Target in Cancer Therapy,"" Biochemical Pharmacology, 2007, vol. 73, pp. 597-609.;;Vella V., et al., ""A novel autocrine loop involving IGF-II and the insulin receptor isoform-A stimulates growth of thyroid cancer"", J Clin Endocrinol Metab., 2002, vol. 87 (1), pp. 245-254.;;Vella V., et al., ""The IGF system in thyroid cancer: new concepts"", Mol Pathol., 2001, vol. 54 (3), pp. 121-124.;;Walenkamp M.J.E., et al., ""Genetic Disorders in the Growth Hormone-Insulin-Like Growth Factor-I Axis,"" Hormone Research, 2006, vol. 66, pp. 221-230.;;Wu X., et al., ""Serum levels of insulin growth factor (IGF-I) and IGF-binding protein predict risk of second primary tumors in patients with head and neck cancer"", Clinical Cancer Research, 2004, vol. 10 (12 pt 1), pp. 3988-3995.;;Yeh A H., et al., ""Human melanoma cells expressing V600E B-RAF are susceptible to IGF1R targeting by small interfering RNAs"", Oncogene, 2006, vol. 25 (50), pp. 6574-6581.;;Zhao H., et al., ""Plasma levels of insulin-like growth factor-1 and binding protein-3, and their association with bladder cancer risk"", The Journal of urology, 2003, vol. 169 (2), pp. 714-717.;;Zumkeller W., et al., ""Insulin-like growth factor system in neuroblastoma tumorigenesis and apoptosis: potential diagnostic and therapeutic perspectives"", Horm Metab Res. , 1999, vol. 31 (2-3), pp. 138-141.;;Zumkeller W., et al., ""The IGF/IGFBP system in CNS malignancy"", Mol Pathol. , 2001, vol. 54 (4), pp. 227-229.;;Zumkeller W., et al., ""The insulin-like growth factor system in hematopoietic cells"", Leuk Lymphoma. , 2002, vol. 43 (3), pp. 487-491.",INACTIVE
185,WO,A1,WO 2010/138575 A1,106-180-885-913-119,2010-12-02,2010,US 2010/0036184 W,2010-05-26,US 18155509 P,2009-05-27,PYRIMIDINE INHIBITORS OF KINASE ACTIVITY,"Described herein are compounds of formula (I) or pharmaceutical acceptable salts or solvates thereof, wherein G 1 , L 1 , R 2 , R 3 , n, p, Ar 1 , and Ar 2 are defined in the description. Methods of making said compounds, and compositions comprising said compounds which are useful for inhibiting kinases such as IGF-IR are also disclosed.",ABBOTT LAB;;CLARK RICHARD F;;BA-MAUNG NWE Y;;ERICKSON SCOTT A;;FIDANZE STEVE D;;MANTEI ROBERT A;;SHEPPARD GEORGE S;;SORENSEN BRYAN K;;WANG GARY T;;WANG JIEYI;;BELL RANDY L,CLARK RICHARD F;;BA-MAUNG NWE Y;;ERICKSON SCOTT A;;FIDANZE STEVE D;;MANTEI ROBERT A;;SHEPPARD GEORGE S;;SORENSEN BRYAN K;;WANG GARY T;;WANG JIEYI;;BELL RANDY L,,https://lens.org/106-180-885-913-119,Patent Application,yes,3,7,10,10,0,C07D403/14;;C07D471/04;;C07D487/04;;C07D513/04;;A61P35/00;;C07D471/04;;C07D487/04;;C07D513/04;;C07D403/14,A61K31/506;;C07D471/04;;A61P35/00;;C07D403/14;;C07D487/04;;C07D513/04,,61,54,046-717-070-604-887;;052-505-137-934-008;;044-748-831-090-972;;024-924-012-347-732;;097-392-576-160-344;;044-748-831-090-972;;072-621-254-838-609;;008-089-455-773-996;;080-996-521-481-773;;026-670-023-742-960;;071-057-152-903-173;;064-534-981-503-13X;;074-824-348-386-95X;;080-346-733-584-964;;029-747-914-293-195;;044-597-437-785-535;;042-630-235-998-291;;028-531-800-105-513;;012-282-318-544-467;;032-557-229-419-547;;089-802-856-721-299;;008-885-430-835-895;;070-311-797-413-117;;031-616-493-083-780;;075-361-202-778-14X;;038-171-112-628-544;;031-278-140-393-389;;038-171-112-628-544;;034-722-452-108-337;;044-840-255-404-305;;096-575-429-954-828;;004-488-094-610-499;;018-219-156-278-616;;006-946-979-586-164;;045-239-664-066-895;;036-055-037-431-299;;059-716-462-209-269;;158-567-940-979-261;;011-001-797-370-811;;040-239-601-782-040;;020-325-142-341-03X;;011-291-416-015-882;;111-677-879-548-551;;066-219-111-588-400;;129-970-610-939-855;;018-470-195-336-786;;133-233-905-398-202;;095-485-454-240-24X;;070-792-654-417-452;;084-104-328-681-684;;016-327-462-571-496;;029-924-070-880-959;;099-503-061-558-195;;007-364-858-655-289,10.1038/nrc1387;;15229476;;10961344;;10.1007/pl00000744;;8697095;;10.1016/1357-2725(95)00168-9;;10.1038/sj.onc.1206058;;12447687;;10.1210/endo.139.8.6165;;10.1210/en.139.8.3578;;9681510;;8697095;;10.1016/1357-2725(95)00168-9;;10.1074/jbc.m605269200;;16793764;;pmc1132689;;1599389;;10.1042/bj2840001;;10.1016/s1097-2765(00)80155-0;;9844629;;16997283;;10.1016/j.bcp.2006.08.011;;10.1159/000095161;;16917171;;16844299;;10.1016/j.bbcan.2006.05.003;;10.1007/s00018-006-6036-4;;16786222;;10.1016/s0304-3835(03)00159-9;;12767520;;16931767;;10.1210/er.2006-0001;;pmc360815;;10.1128/mcb.10.2.464-473.1990;;10.1128/mcb.10.2.464;;2153917;;7790393;;10.1002/jcp.1041640126;;pmc358831;;8007963;;10.1128/mcb.14.7.4588-4595.1994;;10.1128/mcb.14.7.4588;;7636972;;pmc189367;;10.1128/jvi.69.9.5300-5303.1995;;10.1128/mcb.14.6.3604;;pmc358728;;8196606;;10.1128/mcb.14.6.3604-3612.1994;;8248231;;10.1073/pnas.90.23.11217;;pmc47953;;10.1002/j.1460-2075.1994.tb06630.x;;8045259;;pmc395225;;2553250;;8216340;;10.1006/bbrc.1993.2220;;9751624;;10.1038/sj.onc.1202984;;10557096;;10791772;;10.1023/a:1009523501499;;10.1038/sj.onc.1202984;;10557096;;11550779;;10.1007/s003450100220;;10.1016/0016-5085(92)70001-r;;1312970;;10.1016/0016-5085(92)90744-j;;10.1007/s00384-004-0675-4;;15650828;;10.1002/ijc.2910620502;;7665217;;7743492;;12002750;;10.1080/10428190290011958;;16328478;;10.1007/s00277-005-0031-y;;10226794;;10.1055/s-2007-978711;;pmc1187072;;11477136;;10.1136/mp.54.4.227;;12060623;;10.1073/pnas.89.11.4874;;1594587;;pmc49190;;10.1073/pnas.93.14.7263;;8692980;;pmc38971;;10.1158/1078-0432.ccr-03-0762;;15217929;;10.1210/jcem.87.1.8142;;10.1210/jc.87.1.245;;11788654;;11376121;;pmc1187048;;10.1136/mp.54.3.121;;10.1016/j.bcp.2004.05.029;;15313394;;10.1593/neo.04643;;15967097;;pmc1501162;;10.1097/01.ju.0000036380.10325.2a;;10.1016/s0022-5347(05)63999-7;;10.1097/00005392-200302000-00071;;12544349;;15517912;;10.1007/s10585-005-1198-2;;16035620;;10.1016/j.ijom.2006.09.009;;17113753;;16986125;;10.1002/cncr.22214;;10.1038/sj.onc.1209674;;16715137;;14551500;;10.1097/00001813-200310000-00001;;10.1177/108705719900400605;;10838427;;10.1002/jps.2600660104;;833720,"POLLAK, M N ET AL., NATURE REVIEWS CANCER, vol. 4, no. 7, 2004, pages 505 - 518;;ADAMS ET AL., CELL. MOL. LIFE SCI., vol. 57, 2000, pages 1050 - 1093;;BENITO, M ET AL., INT J BIOCHEM CELL BIOL, vol. 28, no. 5, 1996, pages 499 - 510;;SCIACCA L., ONCOGENE, vol. 21, no. 54, 2002, pages 8240 - 8250;;DANDEKAR, A A ET AL., ENDOCRINOLOGY, vol. 139, no. 8, 1998, pages 3578 - 3584;;BENITO, INT J BIOCHEM CELL BIOL, 1996;;LI, W ET AL., J. BIOL. CHEM., vol. 281, no. 33, 2006, pages 23785 - 23791;;BROWN, G ET AL., BIOCHEM. J, vol. 284, 1992, pages 1 - 13;;BRUNING, J C ET AL., MOL. CELL, vol. 2, no. 5, 1998, pages 559 - 569;;VAN NIMWEGEN, M J ET AL., BIOCHEM. PHARMACOL., vol. 73, no. 5, 2007, pages 597 - 609;;WALENKAMP, M J ET AL., HORM. RES., vol. 66, no. 5, 2006, pages 221 - 230;;KURMASHEVA, R. T ET AL., BIOCHIM. BIOPHYS. ACTA-REV ON CANCER, vol. 1766, no. 1, 2006, pages 1 - 22;;BATEMAN, J M ET AL., CELL. MOL. LIFE SCI., vol. 63, no. 15, 2006, pages 1701 - 1705;;LEROITH, D ET AL., CAN. LETT., vol. 195, 2003, pages 127 - 137;;SAMANI A ET AL., ENDOCRINE REVIEWS, vol. 28, no. 1, pages 20 - 47;;KURMASHEVA, BIOCHIM. BIOPHYS. ACTA, 2006;;KALEKO M ET AL., MOL CELL BIOL., vol. 10, no. 2, 1990, pages 464 - 473;;DEANGELIS T ET AL., CELL. PHYSIOL., vol. 1640, 1995, pages 214 - 221;;COPPOLA D ET AL., MOL. CELL. BIOL., vol. 14, no. 7, 1994, pages 4588 - 4595;;MORRIONE A J, VIROL., 1995, pages 695300 - 5303;;SELL C ET AL., MOL. CELL. BIOL., vol. 14, no. 6, 1994, pages 3604 - 3612;;SELL C ET AL., PROC. NATL. ACAD. SCI. USA, vol. 90, no. 23, 1993, pages 11217 - 11221;;HARRINGTON ET AL., EMBO J., vol. 13, 1994, pages 3286 - 3295;;ARTEAGA C ET AL., CANCER RES., vol. 49, no. 22, 1989, pages 6237 - 6241;;LI ET AL., BIOCHEM. BIOPHYS. RES. COM., vol. 196, no. 1, 1993, pages 92 - 98;;SCOTLANDI K ET AL., CANCER RES., vol. 58, no. 18, 1998, pages 4127 - 4131;;JIANG ET AL., ONCOGENE, vol. 18, no. 44, 1999, pages 6071 - 6077;;SURMACZ, J., MAMMARY GLAND BIO. NEOPLASIA, vol. 5, no. 1, 2000, pages 95 - 105;;LEROITH, CAN. LETT., 2003;;ARTEGA, CANCER RES., 1989;;SCOTLANDI, CANCER RES., 1998;;JIANG, Y ET AL., ONCOGENE, vol. 18, 1999, pages 6071 - 6077;;DJAVAN ET AL., WORLD J UROL., vol. 19, no. 4, 2001, pages 225 - 233;;O'BRIEN ET AL., UROLOGY, vol. 58, no. 1, 2001, pages 1 - 7;;GUO ET AL., GASTROENTEROLOGY, vol. 102, 1992, pages 1101 - 1108;;DURAI, R ET AL., INT. J COLORECTAL DIS., vol. 20, no. 3, 2005, pages 203 - 220;;KELLERER M. ET AL., INT. J. CANCER, vol. 62, no. 5, 1995, pages 501 - 507;;BERGMANN, U ET AL., CANCER RES., vol. 55, no. 10, 1995, pages 2007 - 2011;;ZUMKELLER W ET AL., LEUK. LYMPH, vol. 43, no. 3, 2002, pages 487 - 491;;QI, ANN HEMATOL., vol. 85, 2006, pages 95 - 101;;ZUMKELLER, W ET AL., HORM. METAB. RES., vol. 31, 1999, pages 138 - 141;;ZUMKELLER, W ET AL., MOL. PATHOL., vol. 54, no. 4, 2001, pages 227 - 229;;DEL VALLE L ET AL., CLIN. CANCER RES., vol. 8, 2002, pages 1822 - 1830;;TROJAN ET AL., PROC. NATL. ACAD. SCI. USA, vol. 89, 1992, pages 4874 - 4878;;BURFEIND P ET AL., PNAS, vol. 93, 1996, pages 7263 - 7268;;WU X. ET AL., CLIN. CANCER RES., vol. 10, 2004, pages 3988 - 95;;VELLA V ET AL., J. CLIN. ENDOCRINOL. METAB., vol. 87, 2002, pages 245 - 254;;VELLA V ET AL., MOL. PATHOL., vol. 54, no. 3, 2001, pages 121 - 124;;ALEXIA, C ET AL., BIOCHEM. PHARMACOL., vol. 68, 2004, pages 1003 - 1015;;NEUVIANS T P ET AL., NEOPLASIA, vol. 7, 2005, pages 446 - 56;;ZHAO H. ET AL., J. UROLOGY, vol. 169, 2003, pages 714 - 717;;SOHDA M ET AL., ANTICANCER RESEARCH, vol. 24, 2004, pages 3029 - 3034;;JIANG, Y ET AL., CLINICAL & EXPERIMENTAL METASTASIS, vol. 21, 2004, pages 755 - 64;;BRADY G ET AL., INT. J. OF ORAL & MAXILLOFACIAL SURG., vol. 36, 2007, pages 259 - 62;;TRENT J C ET AL., CANCER, vol. 107, 2006, pages 1898 - 908;;YEH A H ET AL., ONCOGENE, vol. 25, 2006, pages 6574 - 81;;BOHULA E A ET AL., ANTICANCER DRUGS, vol. 14, no. 9, 2003, pages 669 - 682;;PURE APPL. CHEM., vol. 45, 1976, pages 13 - 30;;MATHIS, G.: ""HTRF(R) Technology"", J BIOMOL SCREEN, vol. 4, no. 6, 1999, pages 309 - 314;;NATURE REVIEWS CANCER, vol. 8, 2008, pages 915;;S. M. BERGE ET AL., J. PHARMACEUTICAL SCIENCES, vol. 66, 1977, pages 1",PENDING
186,TW,A,TW 200950805 A,115-048-266-321-796,2009-12-16,2009,TW 98114240 A,2009-04-29,US 12583408 P;;US 13428308 P;;US 19719108 P;;US 19900908 P,2008-04-29,Dual variable domain immunoglobulins and uses thereof,"The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.",ABBOTT LAB,GHAYUR TARIQ;;REILLY EDWARD B;;PHILLIPS ANDREW;;BELL RANDY L;;LI YING-CHUN;;YING HUA;;MORGAN-LAPPE SUSAN E;;KINGSBURY GILLIAN A;;WANG JIEYI;;NORVELL SUZANNE M;;LIU JUN-JIAN,,https://lens.org/115-048-266-321-796,Patent of Addition,no,0,0,31,32,0,A61K2039/505;;C07K16/22;;C07K16/28;;C07K16/2863;;C07K16/32;;C07K2317/31;;C07K2317/64;;C07K2317/71;;C07K2317/73;;C07K2317/732;;C07K2317/734;;C07K2317/92;;C07K2319/00;;C07K16/468;;C07K2317/76;;Y10S435/81;;A61P1/04;;A61P1/14;;A61P1/16;;A61P11/00;;A61P11/02;;A61P11/06;;A61P11/16;;A61P13/02;;A61P13/08;;A61P13/12;;A61P15/02;;A61P15/08;;A61P17/02;;A61P17/04;;A61P17/06;;A61P17/14;;A61P19/02;;A61P19/04;;A61P19/06;;A61P19/08;;A61P19/10;;A61P21/00;;A61P21/02;;A61P21/04;;A61P25/00;;A61P25/04;;A61P25/08;;A61P25/10;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/24;;A61P25/28;;A61P25/30;;A61P25/32;;A61P27/02;;A61P27/16;;A61P29/00;;A61P3/14;;A61P31/00;;A61P31/04;;A61P31/08;;A61P31/14;;A61P31/16;;A61P31/18;;A61P31/22;;A61P33/00;;A61P33/02;;A61P33/06;;A61P35/00;;A61P35/02;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/00;;A61P43/00;;A61P5/00;;A61P5/14;;A61P5/18;;A61P5/50;;A61P7/02;;A61P7/04;;A61P7/06;;A61P9/04;;A61P9/06;;A61P9/08;;A61P9/10;;A61P9/12;;A61P9/14;;A61P3/10;;Y02A50/30;;A61K2039/505;;C07K16/22;;C07K16/28;;C07K16/2863;;C07K16/32;;C07K2317/31;;C07K2317/64;;C07K2317/71;;C07K2317/73;;C07K2317/732;;C07K2317/734;;C07K2317/92;;C07K2319/00;;Y02A50/30;;C07K16/468;;A61K39/39533;;A61K45/06;;C07K2317/565;;C07K2317/76;;G01N33/6872;;G01N33/74;;G01N2333/515;;G01N2333/705;;Y10S435/81,A61K39/395;;C07K16/28,,0,0,,,,PENDING
187,EP,A1,EP 2435435 A1,137-413-400-089-045,2012-04-04,2012,EP 10727227 A,2010-05-26,US 2010/0036184 W;;US 18155509 P,2009-05-27,PYRIMIDINE INHIBITORS OF KINASE ACTIVITY,,ABBOTT LAB,CLARK RICHARD F;;BA-MAUNG NWE Y;;ERICKSON SCOTT A;;FIDANZE STEVE D;;MANTEI ROBERT A;;SHEPPARD GEORGE S;;SORENSEN BRYAN K;;WANG GARY T;;WANG JIEYI;;BELL RANDY L,ABBVIE INC. (2013-06-12),https://lens.org/137-413-400-089-045,Patent Application,yes,0,0,10,10,0,C07D403/14;;C07D471/04;;C07D487/04;;C07D513/04;;A61P35/00;;C07D471/04;;C07D487/04;;C07D513/04;;C07D403/14,C07D471/04;;A61K31/506;;A61P35/00;;C07D403/14;;C07D487/04;;C07D513/04,,0,0,,,,ACTIVE
188,CL,A1,CL 2012000980 A1,120-461-269-198-607,2013-01-11,2013,CL 2012000980 A,2012-04-18,US 60509409 A,2009-10-23,"Inmunoglobulina de dominio variable dual que comprende una cadena de polipeptidos con dos dominios variables que se unen a cd3 y a cd19 y; conjugado con la proteina de union; celula huesped, vector y acido nucleico, metodo de produccion, composicion, metodo in vitro que utiliza la proteina y usos para preparar un medicamento.","Proteina de unión que comprende una cadena de polipéptidos, en donde dicha cadena de polipéptidos comprende dos dominios variables de la cadena pesada y un dominio constante de la cadena pesada; conjugado de una proteína de unión que comprende dicha proteína; célula huesped, vector y ácido nucleico.",ABBOTT LAB,MORGAN-LAPPE SUSAN E;;KINGSBURY GILLIAN A;;PHILLIPS ANDREW;;WANGS JIEVI;;BELL RANDY L;;NORVELL SUZANNE M;;LI YINGCHUN;;LIU JUNJIAN;;YING HUA;;LIU ZHIHONG;;GHAYUR TARIQ;;REILLY EDWARD B,,https://lens.org/120-461-269-198-607,Patent Application,no,0,0,25,25,0,A61K2039/505;;C07K16/22;;C07K16/28;;C07K16/2863;;C07K16/32;;C07K16/468;;C07K2317/73;;C07K2317/92;;C07K2319/00;;C07K2317/76;;A61P1/00;;A61P1/04;;A61P1/16;;A61P1/18;;A61P11/00;;A61P11/02;;A61P11/06;;A61P13/12;;A61P15/00;;A61P15/08;;A61P17/00;;A61P17/02;;A61P17/04;;A61P17/06;;A61P17/14;;A61P19/00;;A61P19/02;;A61P19/08;;A61P19/10;;A61P21/00;;A61P21/02;;A61P21/04;;A61P25/00;;A61P25/02;;A61P25/04;;A61P25/06;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/20;;A61P25/24;;A61P25/28;;A61P25/30;;A61P25/32;;A61P27/02;;A61P29/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P31/14;;A61P31/18;;A61P31/20;;A61P33/00;;A61P33/06;;A61P35/00;;A61P35/02;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/00;;A61P43/00;;A61P5/14;;A61P7/00;;A61P7/02;;A61P7/06;;A61P9/00;;A61P9/04;;A61P9/06;;A61P9/10;;A61P9/12;;A61P3/10;;Y02A50/30;;C07K16/28;;C12N15/11;;A61K39/395;;C07K16/22;;C07K2319/00;;A61K2039/505;;C07K2317/92;;C07K16/468;;C07K16/32;;C07K16/2863;;C07K16/28;;C07K2317/73;;C07K2317/76;;Y02A50/30,A61K39/395,,0,0,,,,PENDING
189,BR,A2,BR 112012009043 A2,159-002-341-093-053,2015-09-08,2015,BR 112012009043 A,2010-10-22,US 2010/0053730 W;;US 60509409 A,2009-10-23,imunoglobulinas de duplo domínio variável e sua utilização,"munoglobulinas de duplo domínio variável e sua utilização. a presenten invenção se refere a proteínas ligantes multivalentes e multiespecíficas produzidas artificialmente, métodos de sua produção, e especificamente aos seus usos na prevenção, diagnóstico e/ou tratamento de doenças.",ABOOTT LAB,PHILLIPS ANDREW;;REILLY EDWARD B;;KINGSBURY GILLIANA A;;YING HUA;;WANG JIEYI;;LIU JUNJIAN;;BELL RANDY L;;MORGAN-LAPPE SUSAN E;;NORVELL SUZANNE M;;GHAYUR TARIQ;;LI YINGCHUN;;LIU ZHIHONG,ABOOTT LABORATORIES (US) (2017-06-06),https://lens.org/159-002-341-093-053,Patent Application,no,0,0,25,25,0,A61K2039/505;;C07K16/22;;C07K16/28;;C07K16/2863;;C07K16/32;;C07K16/468;;C07K2317/73;;C07K2317/92;;C07K2319/00;;C07K2317/76;;A61P1/00;;A61P1/04;;A61P1/16;;A61P1/18;;A61P11/00;;A61P11/02;;A61P11/06;;A61P13/12;;A61P15/00;;A61P15/08;;A61P17/00;;A61P17/02;;A61P17/04;;A61P17/06;;A61P17/14;;A61P19/00;;A61P19/02;;A61P19/08;;A61P19/10;;A61P21/00;;A61P21/02;;A61P21/04;;A61P25/00;;A61P25/02;;A61P25/04;;A61P25/06;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/20;;A61P25/24;;A61P25/28;;A61P25/30;;A61P25/32;;A61P27/02;;A61P29/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P31/14;;A61P31/18;;A61P31/20;;A61P33/00;;A61P33/06;;A61P35/00;;A61P35/02;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/00;;A61P43/00;;A61P5/14;;A61P7/00;;A61P7/02;;A61P7/06;;A61P9/00;;A61P9/04;;A61P9/06;;A61P9/10;;A61P9/12;;A61P3/10;;Y02A50/30;;C07K16/28;;C12N15/11;;A61K39/395;;C07K16/22;;C07K2319/00;;A61K2039/505;;C07K2317/92;;C07K16/468;;C07K16/32;;C07K16/2863;;C07K16/28;;C07K2317/73;;C07K2317/76;;Y02A50/30,C12P21/08,,0,0,,,,DISCONTINUED
190,CN,A,CN 102459265 A,050-952-695-946-363,2012-05-16,2012,CN 201080033877 A,2010-05-26,US 2010/0036184 W;;US 18155509 P,2009-05-27,Pyrimidine inhibitors of kinase activity,"Described herein are compounds of formula (I) or pharmaceutical acceptable salts or solvates thereof, wherein G1, L1, R2, R3, n, p, Ar1, and Ar2 are defined in the description. Methods of making said compounds, and compositions comprising said compounds which are useful for inhibiting kinases such as IGF-IR are also disclosed.",ABBOTT LAB,CLARK RICHARD F;;BA-MAUNG NWE Y;;ERICKSON SCOTT A;;FIDANZE STEVE D;;MANTEI ROBERT A;;SHEPPARD GEORGE S;;SORENSEN BRYAN K;;WANG GARY T;;JIEYI WANG;;BELL RANDY L,ABBVIE COMPANY (2013-06-18),https://lens.org/050-952-695-946-363,Patent Application,no,5,1,10,10,0,C07D403/14;;C07D471/04;;C07D487/04;;C07D513/04;;A61P35/00;;C07D471/04;;C07D487/04;;C07D513/04;;C07D403/14,C07D471/04;;A61K31/506;;A61P35/00;;C07D403/14;;C07D487/04;;C07D513/04,,0,0,,,,DISCONTINUED
191,PE,A1,PE 20121249 A1,136-785-159-091-691,2012-10-06,2012,PE 2012000522 A,2010-10-22,US 60509409 A,2009-10-23,INMUNOGLOBULINAS CON DOMINIO VARIABLE DUAL,"REFERIDA A UNA PROTEINA DE UNION QUE COMPRENDE UNA CADENA DE POLIPEPTIDOS QUE COMPRENDE VD1-(X1)n-VD2-C-(X2)n, DONDE VD1 ES UN PRIMER DOMINIO VARIABLE DE CADENA PESADA, VD2 ES UN SEGUNDO DOMINIO VARIABLE DE CADENA PESADA, C ES UN DOMINIO CONSTANTE DE CADENA PESADA, X1 ES UN CONECTOR CON LA CONDICION QUE NO SEA CH1, X2 ES UNA REGION Fc SELECCIONADA DE UNA REGION Fc DE IgG1, IgG2, IgG3, IgG4, IgA, IgM, IgE E IgD, n ES 0 O 1. DICHA PROTEINA DE UNION TIENE LA CAPACIDAD DE UNIRSE A UN PAR DE ANTIGENOS TALES COMO CD-20 Y CD-19, CD-20 Y CD-80, CD-20 Y CD-22, CD-20 Y CD-40, CD-3 Y HER-2, ENTRE OTROS",ABBOTT LAB,GHAYUR TARIQ;;MORGAN-LAPPE SUSAN E;;REILLY EDWARD B;;KINGSBURY GILLIAN A;;PHILLIPS ANDREW;;WANG JIEYI;;BELL RANDY L;;NORVELL SUZANNE M;;LI YINGCHUN;;LIU JUNJIAN;;YING HUA;;LIU ZHIHONG,,https://lens.org/136-785-159-091-691,Patent Application,no,0,0,25,25,0,A61K2039/505;;C07K16/22;;C07K16/28;;C07K16/2863;;C07K16/32;;C07K16/468;;C07K2317/73;;C07K2317/92;;C07K2319/00;;C07K2317/76;;A61P1/00;;A61P1/04;;A61P1/16;;A61P1/18;;A61P11/00;;A61P11/02;;A61P11/06;;A61P13/12;;A61P15/00;;A61P15/08;;A61P17/00;;A61P17/02;;A61P17/04;;A61P17/06;;A61P17/14;;A61P19/00;;A61P19/02;;A61P19/08;;A61P19/10;;A61P21/00;;A61P21/02;;A61P21/04;;A61P25/00;;A61P25/02;;A61P25/04;;A61P25/06;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/20;;A61P25/24;;A61P25/28;;A61P25/30;;A61P25/32;;A61P27/02;;A61P29/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P31/14;;A61P31/18;;A61P31/20;;A61P33/00;;A61P33/06;;A61P35/00;;A61P35/02;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/00;;A61P43/00;;A61P5/14;;A61P7/00;;A61P7/02;;A61P7/06;;A61P9/00;;A61P9/04;;A61P9/06;;A61P9/10;;A61P9/12;;A61P3/10;;Y02A50/30;;C07K16/28;;C12N15/11;;A61K39/395;;C07K16/22;;C07K2319/00;;A61K2039/505;;C07K2317/92;;C07K16/468;;C07K16/32;;C07K16/2863;;C07K16/28;;C07K2317/73;;C07K2317/76;;Y02A50/30,C07K16/32;;C07K16/46;;C12N1/11;;C12N1/15;;C12N1/19;;C12N1/21,,0,0,,,,DISCONTINUED
192,EP,B1,EP 2435435 B1,186-032-628-200-238,2014-01-29,2014,EP 10727227 A,2010-05-26,US 2010/0036184 W;;US 18155509 P,2009-05-27,PYRIMIDINE INHIBITORS OF KINASE ACTIVITY,,ABBVIE INC,CLARK RICHARD F;;BA-MAUNG NWE Y;;ERICKSON SCOTT A;;FIDANZE STEVE D;;MANTEI ROBERT A;;SHEPPARD GEORGE S;;SORENSEN BRYAN K;;WANG GARY T;;WANG JIEYI;;BELL RANDY L,ABBVIE INC. (2013-06-12),https://lens.org/186-032-628-200-238,Granted Patent,yes,2,0,10,10,0,C07D403/14;;C07D471/04;;C07D487/04;;C07D513/04;;A61P35/00;;C07D471/04;;C07D487/04;;C07D513/04;;C07D403/14,C07D471/04;;A61K31/506;;A61P35/00;;C07D403/14;;C07D487/04;;C07D513/04,,0,0,,,,ACTIVE
193,EP,B1,EP 2435436 B1,048-767-496-786-962,2014-07-30,2014,EP 10727228 A,2010-05-26,US 2010/0036185 W;;US 18156109 P,2009-05-27,PYRIMIDINE INHIBITORS OF KINASE ACTIVITY,,ABBVIE INC,CLARK RICHARD F;;BELL RANDY L;;BA-MAUNG NWE Y;;ERICKSON SCOTT A;;FIDANZE STEVE D;;MANTEI ROBERT A;;SHEPPARD GEORGE S;;SORENSEN BRYAN K;;WANG GARY T;;WANG JIEYI,ABBVIE INC. (2013-06-12),https://lens.org/048-767-496-786-962,Granted Patent,yes,2,0,10,10,0,A61P35/00;;A61P43/00;;C07D471/04;;C07D471/04;;C07D487/04;;C07D487/04;;C07D513/04;;C07D513/04,C07D471/04;;A61K31/506;;A61P35/00;;C07D487/04;;C07D513/04,,0,0,,,,ACTIVE
194,CN,A,CN 102741423 A,053-280-957-409-091,2012-10-17,2012,CN 201080057751 A,2010-10-22,US 2010/0053730 W;;US 60509409 A,2009-10-23,Dual variable domain immunoglobulins and uses thereof,"The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.",ABBOTT LAB,TARIQ GHAYUR;;MORGAN-LAPPE SUSAN E;;REILLY EDWARD B;;KINGSBURY GILLIAN A;;ANDREW PHILLIPS;;JIEYI WANG;;BELL RANDY L;;NORVELL SUZANNE M;;YINGCHUN LI;;JUNJIAN LIU;;HUA YING;;ZHIHON LIU,ABBVIE COMPANY (2013-06-20),https://lens.org/053-280-957-409-091,Patent Application,no,3,10,25,25,0,A61K2039/505;;C07K16/22;;C07K16/28;;C07K16/2863;;C07K16/32;;C07K16/468;;C07K2317/73;;C07K2317/92;;C07K2319/00;;C07K2317/76;;A61P1/00;;A61P1/04;;A61P1/16;;A61P1/18;;A61P11/00;;A61P11/02;;A61P11/06;;A61P13/12;;A61P15/00;;A61P15/08;;A61P17/00;;A61P17/02;;A61P17/04;;A61P17/06;;A61P17/14;;A61P19/00;;A61P19/02;;A61P19/08;;A61P19/10;;A61P21/00;;A61P21/02;;A61P21/04;;A61P25/00;;A61P25/02;;A61P25/04;;A61P25/06;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/20;;A61P25/24;;A61P25/28;;A61P25/30;;A61P25/32;;A61P27/02;;A61P29/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P31/14;;A61P31/18;;A61P31/20;;A61P33/00;;A61P33/06;;A61P35/00;;A61P35/02;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/00;;A61P43/00;;A61P5/14;;A61P7/00;;A61P7/02;;A61P7/06;;A61P9/00;;A61P9/04;;A61P9/06;;A61P9/10;;A61P9/12;;A61P3/10;;Y02A50/30;;C07K16/28;;C12N15/11;;A61K39/395;;C07K16/22;;C07K2319/00;;A61K2039/505;;C07K2317/92;;C07K16/468;;C07K16/32;;C07K16/2863;;C07K16/28;;C07K2317/73;;C07K2317/76;;Y02A50/30,C12P21/08,,1,1,008-411-420-307-533,17934452;;10.1038/nbt1345,"WU CHENGBIN ET AL: ""Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin"", 《NATURE BIOTECHNOLOGY》",DISCONTINUED
195,AR,A1,AR 078728 A1,083-166-792-120-298,2011-11-30,2011,AR P100103871 A,2010-10-22,US 60509409 A,2009-10-23,INMUNOGLOBULINAS CON DOMINIO VARIABLE DUAL Y USOS DE LAS MISMAS,"Proteínas de union multivalentes y multiespecíficas modificadas, métodos para elaborarlas y, específicamente, sus usos en la prevencion, el diagnostico y/o el tratamiento de enfermedades. Reivindicacion 1: Una proteína de union, caracterizada porque comprende una cadena de polipéptidos, en donde dicha cadena de polipéptidos comprende VD1-(X1)n-VD2-C-(X2)n, en donde; VD1 es un primer dominio variable de la cadena pesada; VD2 es un segundo dominio variable de la cadena pesada; C es un dominio constante de la cadena pesada; X1 es un conector con la condicion que no sea CH1; X2 es una region Fc; (X1)n es (X1)0 o (X1)1; y (X2)n es (X2)0 o (X2)1; en donde la proteína de union tiene la capacidad de unirse a un par de antígenos seleccionados del grupo que consiste de CD-20 y CD-19; CD-20 y CD-80; CD-20 y CD-22; CD-20 y CD-40; CD-3 y HER-2; CD-3 y CD-19; EGFR y HER-2; EGFR y CD-3; EGFR y IGF1.2; EGFR y IGF1R; EGFR y RON; EGFR y HGF; EGFR y c-MET; HER-2 y IGF1.2; HER-2 y IGF1R; RON y HGF; VEGF y EGFR; VEGF y HER-2; VEGF y CD-20; VEGF y IGF1.2; VEGF y DLL4; VEGF y HGF; VEGF y RON; VEGF y NRP1; CD-20 y CD3; DLL-4 y PLGF; VEGF y PLGF, ErbB3 y EGFR, ErbB3 y HGF; HER-2 y ErbB3; c-Met y ErB3; PLGF y HER-2 y HER-2 y HER-2.",ABBOTT LAB,KINGSBURY GILLIAN A;;LI YINGCHUN;;LIU JUNJIAN;;PHILLIPS ANDREW;;REILLY EDWARD B;;NORVELL SUZANNE M;;BELL RANDY L;;YING HUA;;GHAYUR TARIQ;;MORGAN-LAPPE SUSAN E;;WANG JIEYI;;LIU ZHIHONG,,https://lens.org/083-166-792-120-298,Patent Application,no,0,0,25,25,0,A61K2039/505;;C07K16/22;;C07K16/28;;C07K16/2863;;C07K16/32;;C07K16/468;;C07K2317/73;;C07K2317/92;;C07K2319/00;;C07K2317/76;;A61P1/00;;A61P1/04;;A61P1/16;;A61P1/18;;A61P11/00;;A61P11/02;;A61P11/06;;A61P13/12;;A61P15/00;;A61P15/08;;A61P17/00;;A61P17/02;;A61P17/04;;A61P17/06;;A61P17/14;;A61P19/00;;A61P19/02;;A61P19/08;;A61P19/10;;A61P21/00;;A61P21/02;;A61P21/04;;A61P25/00;;A61P25/02;;A61P25/04;;A61P25/06;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/20;;A61P25/24;;A61P25/28;;A61P25/30;;A61P25/32;;A61P27/02;;A61P29/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P31/14;;A61P31/18;;A61P31/20;;A61P33/00;;A61P33/06;;A61P35/00;;A61P35/02;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/00;;A61P43/00;;A61P5/14;;A61P7/00;;A61P7/02;;A61P7/06;;A61P9/00;;A61P9/04;;A61P9/06;;A61P9/10;;A61P9/12;;A61P3/10;;Y02A50/30;;C07K16/28;;C12N15/11;;A61K39/395;;C07K16/22;;C07K2319/00;;A61K2039/505;;C07K2317/92;;C07K16/468;;C07K16/32;;C07K16/2863;;C07K16/28;;C07K2317/73;;C07K2317/76;;Y02A50/30,,,0,0,,,,PENDING
196,EP,A4,EP 2491129 A4,148-764-390-617-37X,2013-05-29,2013,EP 10825739 A,2010-10-22,US 60509409 A;;US 2010/0053730 W,2009-10-23,DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND USES THEREOF,,ABBOTT LAB,GHAYUR TARIQ;;MORGAN-LAPPE SUSAN E;;REILLY EDWARD B;;KINGSBURY GILLIAN A;;PHILLIPS ANDREW;;WANG JIEYI;;BELL RANDY L;;NORVELL SUZANNE M;;LI YINGCHUN;;LIU JUNJIAN;;YING HUA;;LIU ZHIHONG,ABBVIE INC. (2013-06-12),https://lens.org/148-764-390-617-37X,Search Report,no,0,0,25,25,0,A61K2039/505;;C07K16/22;;C07K16/28;;C07K16/2863;;C07K16/32;;C07K16/468;;C07K2317/73;;C07K2317/92;;C07K2319/00;;C07K2317/76;;A61P1/00;;A61P1/04;;A61P1/16;;A61P1/18;;A61P11/00;;A61P11/02;;A61P11/06;;A61P13/12;;A61P15/00;;A61P15/08;;A61P17/00;;A61P17/02;;A61P17/04;;A61P17/06;;A61P17/14;;A61P19/00;;A61P19/02;;A61P19/08;;A61P19/10;;A61P21/00;;A61P21/02;;A61P21/04;;A61P25/00;;A61P25/02;;A61P25/04;;A61P25/06;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/20;;A61P25/24;;A61P25/28;;A61P25/30;;A61P25/32;;A61P27/02;;A61P29/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P31/14;;A61P31/18;;A61P31/20;;A61P33/00;;A61P33/06;;A61P35/00;;A61P35/02;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/00;;A61P43/00;;A61P5/14;;A61P7/00;;A61P7/02;;A61P7/06;;A61P9/00;;A61P9/04;;A61P9/06;;A61P9/10;;A61P9/12;;A61P3/10;;Y02A50/30;;C07K16/28;;C12N15/11;;A61K39/395;;C07K16/22;;C07K2319/00;;A61K2039/505;;C07K2317/92;;C07K16/468;;C07K16/32;;C07K16/2863;;C07K16/28;;C07K2317/73;;C07K2317/76;;Y02A50/30,C12P21/08;;C07K16/22;;C07K16/28;;C07K16/32,,8,8,008-411-420-307-533;;021-837-780-755-742;;020-789-896-622-570;;027-477-313-726-928;;003-923-618-715-863;;012-393-258-998-863;;079-158-547-188-622;;101-848-441-376-370,17934452;;10.1038/nbt1345;;pmc2726605;;10.4161/mabs.1.4.8755;;20068402;;10413102;;10.1016/s0014-5793(99)00782-6;;10.1073/pnas.79.6.1979;;pmc346105;;6804947;;10.1007/978-3-642-20910-9_10;;10.1007/978-3-642-01147-4_19;;10.1016/b978-0-12-416039-2.00002-1;;22208980;;21814039;;10.4161/mabs.3.5.16326;;pmc3225853,"WU CHENGBIN ET AL: ""Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin"", NATURE BIOTECHNOLOGY, NATURE PUBLISHING GROUP, NEW YORK, NY, US, vol. 25, no. 11, 1 November 2007 (2007-11-01), pages 1290 - 1297, XP009110104, ISSN: 1087-0156, DOI: 10.1038/NBT1345;;WU CHENGBIN ET AL: ""Molecular construction and optimization of anti-human IL-1 alpha/beta dual variable domain immunoglobulin (DVD-Ig (TM)) molecules"", MABS, LANDES BIOSCIENCE, US, vol. 1, no. 4, 1 July 2009 (2009-07-01), pages 339 - 347, XP002657321, ISSN: 1942-0862;;ALT M ET AL: ""NOVEL TETRAVALENT AND BISPECIFIF IGG-LIKE ANTIBODY MOLECULES COMBINING SINGLE-CHAIN DIABODIES WITH THE IMMUNOGLOBULIN GAMMA1 FC OR CH3 REGION"", FEBS LETTERS, ELSEVIER, AMSTERDAM, NL, vol. 454, no. 1/2, 1 January 1999 (1999-01-01), pages 90 - 94, XP000919188, ISSN: 0014-5793, DOI: 10.1016/S0014-5793(99)00782-6;;RUDIKOFF S ET AL: ""Single amino acid substitution altering antigen-binding specificity"", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, US, vol. 79, 1 March 1982 (1982-03-01), pages 1979 - 1983, XP007901436, ISSN: 0027-8424, DOI: 10.1073/PNAS.79.6.1979;;TARCSA EDIT ET AL: ""Dual-Variable Domain Immunoglobulin (DVD-Ig (TM)) Technology: A Versatile, Novel Format for the Next Generation of Dual-Targeting Biologics"", BISPECIFIC ANTIBODIES SPRINGER, 233 SPRING STREET, NEW YORK, NY 10013, UNITED STATES, 2011, pages 171 - 185, XP009168886;;CHENGBIN WU ET AL: ""Generation and Characterization of a Dual Variable Domain Immunoglobulin (DVD-Ig ) Molecule"", 1 January 2010, ANTIBODY ENGINEERING, PART II, SPRINGER, PAGE(S) 239 - 250, ISBN: 978-3-642-01147-4, XP009160631;;GU JIJIE ET AL: ""GENERATION OF DUAL-VARIABLE-DOMAIN IMMUNOGLOBULIN MOLECULES FOR DUAL-SPECIFIC TARGETING"", METHODS IN ENZYMOLOGY, VOL 502: PROTEIN ENGINEERING FOR THERAPEUTICS, PT A ELSEVIER ACADEMIC PRESS INC, 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA SERIES : METHODS IN ENZYMOLOGY (ISSN 0076-6879(PRINT)), 2012, pages 25 - 41, XP009168885;;DIGIAMMARINO E L ET AL: ""Ligand association rates to the inner-variable-domain of a dual-variable-domain immunoglobulin are significantly impacted by linker design"", MABS 2011 LANDES BIOSCIENCE USA, vol. 3, no. 5, September 2011 (2011-09-01), pages 487 - 494, XP009168882, ISSN: 1942-0862",DISCONTINUED
197,AU,B2,AU 2010/310565 B2,022-266-478-535-757,2013-05-23,2013,AU 2010/310565 A,2010-10-22,US 60509409 A;;US 2010/0053730 W,2009-10-23,Dual variable domain immunoglobulins and uses thereof,"The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.",ABBVIE INC,GHAYUR TARIQ;;MORGAN-LAPPE SUSAN E;;REILLY EDWARD B;;KINGSBURY GILLIAN A;;PHILLIPS ANDREW;;WANG JIEYI;;BELL RANDY L;;NORVELL SUZANNE M;;LI YINGCHUN;;LIU JUNJIAN;;YING HUA;;LIU ZHIHONG,ABBVIE INC. (2013-05-16),https://lens.org/022-266-478-535-757,Granted Patent,no,1,0,25,25,0,A61K2039/505;;C07K16/22;;C07K16/28;;C07K16/2863;;C07K16/32;;C07K16/468;;C07K2317/73;;C07K2317/92;;C07K2319/00;;C07K2317/76;;A61P1/00;;A61P1/04;;A61P1/16;;A61P1/18;;A61P11/00;;A61P11/02;;A61P11/06;;A61P13/12;;A61P15/00;;A61P15/08;;A61P17/00;;A61P17/02;;A61P17/04;;A61P17/06;;A61P17/14;;A61P19/00;;A61P19/02;;A61P19/08;;A61P19/10;;A61P21/00;;A61P21/02;;A61P21/04;;A61P25/00;;A61P25/02;;A61P25/04;;A61P25/06;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/20;;A61P25/24;;A61P25/28;;A61P25/30;;A61P25/32;;A61P27/02;;A61P29/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P31/14;;A61P31/18;;A61P31/20;;A61P33/00;;A61P33/06;;A61P35/00;;A61P35/02;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/00;;A61P43/00;;A61P5/14;;A61P7/00;;A61P7/02;;A61P7/06;;A61P9/00;;A61P9/04;;A61P9/06;;A61P9/10;;A61P9/12;;A61P3/10;;Y02A50/30;;C07K16/28;;C12N15/11;;A61K39/395;;C07K16/22;;C07K2319/00;;A61K2039/505;;C07K2317/92;;C07K16/468;;C07K16/32;;C07K16/2863;;C07K16/28;;C07K2317/73;;C07K2317/76;;Y02A50/30,C07K16/32;;A61K39/395;;A61K51/10;;A61P1/00;;A61P1/16;;A61P3/10;;A61P7/00;;A61P9/00;;A61P11/00;;A61P15/00;;A61P17/00;;A61P17/06;;A61P19/02;;A61P21/02;;A61P25/20;;A61P25/28;;A61P29/00;;A61P35/00;;A61P37/06;;C07H21/04;;C07K16/46;;C12N1/11;;C12N1/15;;C12N1/19;;C12N1/21;;C12N5/10;;C12N15/63;;C12P21/00;;C12P21/08,,0,0,,,,INACTIVE
198,US,A1,US 2010/0305118 A1,180-529-073-405-226,2010-12-02,2010,US 78791510 A,2010-05-26,US 78791510 A;;US 18155509 P,2009-05-27,PYRIMIDINE INHIBITORS OF KINASE ACTIVITY,"Described herein are compounds of formula (I) or pharmaceutical acceptable salts or solvates thereof, wherein G 1 , L 1 , R 2 , R 3 , n, p, Ar 1 , and Ar 2 are defined in the description. Methods of making said compounds, and compositions comprising said compounds which are useful for inhibiting kinases such as IGF-1R are also disclosed.",ABBOTT LAB,CLARK RICHARD F;;BA-MAUNG NWE Y;;ERICKSON SCOTT A;;FIDANZE STEVE D;;MANTEI ROBERT A;;SHEPPARD GEORGE S;;SORENSEN BRYAN K;;WANG GARY T;;WANG JIEYI;;BELL RANDY L,ABBVIE INC (2012-08-01);;ABBOTT LABORATORIES (2010-08-11),https://lens.org/180-529-073-405-226,Patent Application,yes,1,6,10,10,0,C07D403/14;;C07D471/04;;C07D487/04;;C07D513/04;;A61P35/00;;C07D471/04;;C07D487/04;;C07D513/04;;C07D403/14,A61K31/5377;;A61K31/496;;A61K31/506;;A61P35/00;;C07D401/14;;C07D413/14;;C07D417/14,514/233.2;;544/331;;544/122;;514/275;;514/252.18,0,0,,,,INACTIVE
199,CN,A,CN 102459264 A,039-567-818-074-931,2012-05-16,2012,CN 201080033864 A,2010-05-26,US 2010/0036185 W;;US 18156109 P,2009-05-27,Pyrimidine inhibitors of kinase activity,"The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts or solvates thereof, wherein G1, R2, R3, R4, R5, n, p, q, Ar1, and Ar2 are defined in the description. The present invention relates also to methods of making said compounds, and compositions comprising said compounds which are useful for inhibiting kinases such as IGF-IR.",ABBOTT LAB,CLARK RICHARD F;;BELL RANDY L;;BA-MAUNG NWE Y;;ERICKSON SCOTT A;;FIDANZE STEVE D;;MANTEI ROBERT A;;SHEPPARD GEORGE S;;SORENSEN BRYAN K;;WANG GARY T;;JIEYI WANG,ABBVIE COMPANY (2013-06-20),https://lens.org/039-567-818-074-931,Patent Application,no,2,1,10,10,0,A61P35/00;;A61P43/00;;C07D471/04;;C07D471/04;;C07D487/04;;C07D487/04;;C07D513/04;;C07D513/04,C07D471/04;;A61K31/506;;A61P35/00;;C07D487/04;;C07D513/04,,0,0,,,,DISCONTINUED
200,DO,A,DO P2012000117 A,038-446-848-651-560,2012-07-31,2012,DO 2012000117 A,2012-04-19,US 60509409 A,2009-10-23,INMUNOGLOBULINAS CON DOMINIO VARIABLE DUAL Y USOS DE LAS MISMAS,"Proteínas de unión multivalentes y multiespecíficas diseñadas, métodos para elaborarlas y, específicamente, sus usos en la prevención, el diagnóstico y/o el tratamiento de enfermedades.",ABBOTT LAB,GHAYUR TARIQ;;REILLY EDWARD B;;PHILLIPS ANDREW;;WANG JIEYI;;BELL RANDY L;;NORVELL SUZANNE M;;YING HUA;;KINGSBURY GILLIAN A;;MORGAN-LAPPE SUSAN E;;LIU JUNJIAN;;LIU ZHIHONG;;LI YINGEHUN,,https://lens.org/038-446-848-651-560,Patent Application,no,0,0,25,25,0,A61K2039/505;;C07K16/22;;C07K16/28;;C07K16/2863;;C07K16/32;;C07K16/468;;C07K2317/73;;C07K2317/92;;C07K2319/00;;C07K2317/76;;A61P1/00;;A61P1/04;;A61P1/16;;A61P1/18;;A61P11/00;;A61P11/02;;A61P11/06;;A61P13/12;;A61P15/00;;A61P15/08;;A61P17/00;;A61P17/02;;A61P17/04;;A61P17/06;;A61P17/14;;A61P19/00;;A61P19/02;;A61P19/08;;A61P19/10;;A61P21/00;;A61P21/02;;A61P21/04;;A61P25/00;;A61P25/02;;A61P25/04;;A61P25/06;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/20;;A61P25/24;;A61P25/28;;A61P25/30;;A61P25/32;;A61P27/02;;A61P29/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P31/14;;A61P31/18;;A61P31/20;;A61P33/00;;A61P33/06;;A61P35/00;;A61P35/02;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/00;;A61P43/00;;A61P5/14;;A61P7/00;;A61P7/02;;A61P7/06;;A61P9/00;;A61P9/04;;A61P9/06;;A61P9/10;;A61P9/12;;A61P3/10;;Y02A50/30;;C07K16/28;;C12N15/11;;A61K39/395;;C07K16/22;;C07K2319/00;;A61K2039/505;;C07K2317/92;;C07K16/468;;C07K16/32;;C07K16/2863;;C07K16/28;;C07K2317/73;;C07K2317/76;;Y02A50/30,,,0,0,,,,PENDING
201,CO,A2,CO 6541599 A2,096-177-002-758-971,2012-10-16,2012,CO 12079711 A,2012-05-15,US 6509409 A,2009-09-23,INMUNOGLOBULINAS CON DOMINIO VARIABLE DUAL Y USOS DE LAS MISMAS,"Proteínas de unión multivalentes y multiespecíficas diseñadas, métodos para elaborarlas y, específicamente, sus usos en la prevención, el diagnóstico y/o el tratamiento de enfermedades.",ABBOTT LAB,GHAYUR TARIQ;;MORGAN-LAPPE SUSAN E;;LIU ZHIHONG;;YING HUA;;LIU JUNJIAN;;LI YINGCHUN;;NORVELL SUZANNE M;;BELL RANDY;;WANG JIEYI;;PHILLIPS ANDREW;;KING-SBURY GILLIAN A;;REILLY EDWARD B,,https://lens.org/096-177-002-758-971,Patent Application,no,0,0,1,1,0,,C12P21/08,,0,0,,,,PENDING
202,MX,A,MX 2011012629 A,020-876-219-296-590,2012-03-06,2012,MX 2011012629 A,2010-05-26,US 18155509 P;;US 2010/0036184 W,2009-05-27,PYRIMIDINE INHIBITORS OF KINASE ACTIVITY.,"Described herein are compounds of formula (I) or pharmaceutical acceptable salts or solvates thereof, wherein G<sup>1</sup>, L<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, n, p, Ar<sup>1</sup>, and Ar<sup>2</sup> are defined in the description. Methods of making said compounds, and compositions comprising said compounds which are useful for inhibiting kinases such as IGF-IR are also disclosed.",ABBOTT LAB,ERICKSON SCOTT A;;SHEPPARD GEORGE S;;WANG JIEYI;;FIDANZE STEVE D;;WANG GARY T;;SORENSEN BRYAN K;;CLARK RICHARD F;;BELL RANDY L;;MANTEI ROBERT A;;BA-MAUNG NWE Y,ABBVIE INC. (2013-08-09),https://lens.org/020-876-219-296-590,Patent Application,no,0,0,10,10,0,C07D403/14;;C07D471/04;;C07D487/04;;C07D513/04;;A61P35/00;;C07D471/04;;C07D487/04;;C07D513/04;;C07D403/14,A61K31/506;;C07D471/04;;A61P35/00;;C07D403/14;;C07D487/04;;C07D513/04,,0,0,,,,ACTIVE
203,KR,A,KR 20130004563 A,074-318-786-789-458,2013-01-11,2013,KR 20127013242 A,2010-10-22,US 60509409 A;;US 2010/0053730 W,2009-10-23,DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND USES THEREOF,,ABBOTT LAB,GHAYUR TARIQ;;MORGAN LAPPE SUSAN E;;REILLY EDWARD B;;KINGSBURY GILLIAN A;;PHILLIPS ANDREW;;WANG JIEYI;;BELL RANDY L;;NORVELL SUZANNE M;;LI YINGCHUN;;LIU JUNJIAN;;YING HUA;;LIU ZHIHONG,,https://lens.org/074-318-786-789-458,Patent Application,no,0,2,25,25,642,A61K2039/505;;C07K16/22;;C07K16/28;;C07K16/2863;;C07K16/32;;C07K16/468;;C07K2317/73;;C07K2317/92;;C07K2319/00;;C07K2317/76;;A61P1/00;;A61P1/04;;A61P1/16;;A61P1/18;;A61P11/00;;A61P11/02;;A61P11/06;;A61P13/12;;A61P15/00;;A61P15/08;;A61P17/00;;A61P17/02;;A61P17/04;;A61P17/06;;A61P17/14;;A61P19/00;;A61P19/02;;A61P19/08;;A61P19/10;;A61P21/00;;A61P21/02;;A61P21/04;;A61P25/00;;A61P25/02;;A61P25/04;;A61P25/06;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/20;;A61P25/24;;A61P25/28;;A61P25/30;;A61P25/32;;A61P27/02;;A61P29/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P31/14;;A61P31/18;;A61P31/20;;A61P33/00;;A61P33/06;;A61P35/00;;A61P35/02;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/00;;A61P43/00;;A61P5/14;;A61P7/00;;A61P7/02;;A61P7/06;;A61P9/00;;A61P9/04;;A61P9/06;;A61P9/10;;A61P9/12;;A61P3/10;;Y02A50/30;;C07K16/28;;C12N15/11;;A61K39/395;;C07K16/22;;C07K2319/00;;A61K2039/505;;C07K2317/92;;C07K16/468;;C07K16/32;;C07K16/2863;;C07K16/28;;C07K2317/73;;C07K2317/76;;Y02A50/30,C07K16/28;;A61K39/395;;A61P29/00;;C12N15/13,,0,0,,,,DISCONTINUED
204,ES,T3,ES 2520991 T3,151-557-708-877-654,2014-11-12,2014,ES 10727228 T,2010-05-26,US 18156109 P;;US 2010/0036185 W,2009-05-27,Inhibidores de pirimidina de la actividad cinasa,"Un compuesto de la fórmula (I)**Fórmula** o una sal, solvato, farmacéuticamente aceptable, o una combinación de los mismos, donde G1 es de la fórmula (i), (ii), (iii) o (iv)**Fórmula** m es 0, 1, 2, 3 o 4; m' es 0, 1, 2 o 3; m"" es 0, 1 o 2; n es 0, 1 o 2; p es 0, 1, 2, 3 o 4; R1, R2 y R3 son sustituyentes opcionales y, si están presentes, cada uno es de manera independiente alquilo, halógeno, -O(alquilo), -O(haloalquilo) o haloalquilo; a y b designan los puntos de unión en los que las fórmulas (i), (ii), (iii), (iv) se enlazan con la fórmula (I); R4 y R5, en cada aparición, son, cada uno, de manera independiente hidrógeno, alquilo, halógeno o haloalquilo; q es 1, 2, 3 o 4; Ar1 es arilo o heteroarilo; cada uno de los cuales está, de manera independiente, no sustituido o sustituido con 1, 2, 3, 4 o 5 sustituyentes según se representa por T, donde cada T se selecciona de entre el grupo que consiste en oxo, alquilo, alquenilo, alquinilo, halógeno, haloalquilo, CN, NO2, G2, -OR6, -OC(O)R7, -SR6, -S(O)R7, -S(O)2R7, -S(O)2N(R8)(R9), -N(R8)(R9), -N(R8)C(O)R7, -N(R8)C(O)OR7, -N(R8)S(O)2R7, -N(R8)C(O)N(R8)(R9), -N(R8)C(O)- (alquilenilo C1-6)-N(R8)(R9), -N(R8)S(O)2N(R8)(R9), -C(O)R6, -C(O)OR6, -C(O)N(R8)(R9), -(alquilenilo C1-6)-G2, -(alquilenilo C1-6)-OR6, -(alquilenilo C1-6)- OC(O)R7, -(alquilenilo C1-6)-SR6, -(alquilenilo C1-6)-S(O)R7, -(alquilenilo C1- 6)-S(O)2R7, -(alquilenilo C1-6)- S(O)2N(R8)(R9), -(alquilenilo C1-6)-N(R8)(R9), -(alquilenilo C1-6)-N(R8)C(O)R7, -(alquilenilo C1-6)-N(R8)C(O)OR7, -(alquilenilo C1-6)-N(R8)S(O)2R7, -(alquilenilo C1-6)-N(R8)C(O)N(R8)(R9), -(alquilenilo C1-6)-N(R8)S(O)2N(R8)(R9), -(alquilenilo C1-6)-C(O)R6, -(alquilenilo C1-6)-C(O)OR6 y -(alquilenilo C1-6)-C(O)N(R8)(R9), dos sustituyentes en los átomos de carbono vecinales de Ar1, junto con los átomos de carbono a los que estos están unidos, forman opcionalmente un heterociclo de 5 o 6 miembros monocíclico que contiene uno o dos heteroátomos seleccionados de entre N(H), O, S, S(O) o S(O)2, donde cada uno del anillo monocíclico está opcionalmente sustituido con 1, 2, 3 o 4 grupos alquilo; cada aparición de R6 y R9 es, cada una, de manera independiente hidrógeno, alquilo, haloalquilo, -(alquilenilo C1-6)- CN, -(alquilenilo C1-6)- OH, -(alquilenilo C1-6)-C(O)OH, G3 o -(alquilenilo C1-6)-G3; cada aparición de R7 es de manera independiente alquilo, haloalquilo, -(alquilenilo C1-6)-CN, -(alquilenilo C1-6)-OH, G3 o -(alquilenilo C1-6)-G3; cada aparición de R8 es de manera independiente hidrógeno, alquilo o haloalquilo; cada aparición de G2 es de manera independiente arilo, heteroarilo, heterociclo, cicloalquilo o cicloalquenilo, cada uno de los cuales está, de manera independiente, no sustituido o sustituido con 1, 2, 3, 4 o 5 sustituyentes seleccionados de entre el grupo que consiste en G3, -(alquilenilo C1-6)-G3 y R10.",ABBVIE INC,CLARK RICHARD F;;BELL RANDY L;;BA-MAUNG NWE Y;;ERICKSON SCOTT A;;FIDANZE STEVE D;;MANTEI ROBERT A;;SHEPPARD GEORGE S;;SORENSEN BRYAN K;;WANG GARY T;;WANG JIEYI,,https://lens.org/151-557-708-877-654,Granted Patent,no,0,0,10,10,0,A61P35/00;;A61P43/00;;C07D471/04;;C07D471/04;;C07D487/04;;C07D487/04;;C07D513/04;;C07D513/04,C07D471/04;;A61K31/506;;A61P35/00;;C07D487/04;;C07D513/04,,0,0,,,,ACTIVE
205,AU,A1,AU 2010/310565 A1,066-495-351-362-76X,2012-05-31,2012,AU 2010/310565 A,2010-10-22,US 60509409 A;;US 2010/0053730 W,2009-10-23,Dual variable domain immunoglobulins and uses thereof,"The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.",ABBOTT LAB,GHAYUR TARIQ;;MORGAN-LAPPE SUSAN E;;REILLY EDWARD B;;KINGSBURY GILLIAN A;;PHILLIPS ANDREW;;WANG JIEYI;;BELL RANDY L;;NORVELL SUZANNE M;;LI YINGCHUN;;LIU JUNJIAN;;YING HUA;;LIU ZHIHONG,ABBVIE INC. (2013-05-16),https://lens.org/066-495-351-362-76X,Patent Application,no,0,0,25,25,0,A61K2039/505;;C07K16/22;;C07K16/28;;C07K16/2863;;C07K16/32;;C07K16/468;;C07K2317/73;;C07K2317/92;;C07K2319/00;;C07K2317/76;;A61P1/00;;A61P1/04;;A61P1/16;;A61P1/18;;A61P11/00;;A61P11/02;;A61P11/06;;A61P13/12;;A61P15/00;;A61P15/08;;A61P17/00;;A61P17/02;;A61P17/04;;A61P17/06;;A61P17/14;;A61P19/00;;A61P19/02;;A61P19/08;;A61P19/10;;A61P21/00;;A61P21/02;;A61P21/04;;A61P25/00;;A61P25/02;;A61P25/04;;A61P25/06;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/20;;A61P25/24;;A61P25/28;;A61P25/30;;A61P25/32;;A61P27/02;;A61P29/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P31/14;;A61P31/18;;A61P31/20;;A61P33/00;;A61P33/06;;A61P35/00;;A61P35/02;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/00;;A61P43/00;;A61P5/14;;A61P7/00;;A61P7/02;;A61P7/06;;A61P9/00;;A61P9/04;;A61P9/06;;A61P9/10;;A61P9/12;;A61P3/10;;Y02A50/30;;C07K16/28;;C12N15/11;;A61K39/395;;C07K16/22;;C07K2319/00;;A61K2039/505;;C07K2317/92;;C07K16/468;;C07K16/32;;C07K16/2863;;C07K16/28;;C07K2317/73;;C07K2317/76;;Y02A50/30,C07K16/32;;A61K39/395;;A61K51/10;;A61P1/00;;A61P1/16;;A61P3/10;;A61P7/00;;A61P9/00;;A61P11/00;;A61P15/00;;A61P17/00;;A61P17/06;;A61P19/02;;A61P21/02;;A61P25/20;;A61P25/28;;A61P29/00;;A61P35/00;;A61P37/06;;C07H21/04;;C07K16/46;;C12N1/11;;C12N1/15;;C12N1/19;;C12N1/21;;C12N5/10;;C12N15/63;;C12P21/00;;C12P21/08,,0,0,,,,INACTIVE
206,WO,A1,WO 2010/138576 A1,190-617-496-834-578,2010-12-02,2010,US 2010/0036185 W,2010-05-26,US 18156109 P,2009-05-27,PYRIMIDINE INHIBITORS OF KINASE ACTIVITY,"The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts or solvates thereof, wherein G 1 , R 2 , R 3 , R 4 , R 5 , n, p, q, Ar 1 , and Ar 2 are defined in the description. The present invention relates also to methods of making said compounds, and compositions comprising said compounds which are useful for inhibiting kinases such as IGF-IR.",ABBOTT LAB;;CLARK RICHARD F;;BELL RANDY L;;BA-MAUNG NWE Y;;ERICKSON SCOTT A;;FIDANZE STEVE D;;MANTEI ROBERT A;;SHEPPARD GEORGE S;;SORENSEN BRYAN K;;WANG GARY T;;WANG JIEYI,CLARK RICHARD F;;BELL RANDY L;;BA-MAUNG NWE Y;;ERICKSON SCOTT A;;FIDANZE STEVE D;;MANTEI ROBERT A;;SHEPPARD GEORGE S;;SORENSEN BRYAN K;;WANG GARY T;;WANG JIEYI,,https://lens.org/190-617-496-834-578,Patent Application,yes,3,5,10,10,0,A61P35/00;;A61P43/00;;C07D471/04;;C07D471/04;;C07D487/04;;C07D487/04;;C07D513/04;;C07D513/04,C07D471/04;;A61K31/506;;A61P35/00;;C07D487/04;;C07D513/04,,62,55,046-717-070-604-887;;052-505-137-934-008;;044-748-831-090-972;;024-924-012-347-732;;097-392-576-160-344;;044-748-831-090-972;;072-621-254-838-609;;008-089-455-773-996;;080-996-521-481-773;;026-670-023-742-960;;071-057-152-903-173;;064-534-981-503-13X;;074-824-348-386-95X;;080-346-733-584-964;;029-747-914-293-195;;044-597-437-785-535;;042-630-235-998-291;;028-531-800-105-513;;012-282-318-544-467;;032-557-229-419-547;;089-802-856-721-299;;008-885-430-835-895;;070-311-797-413-117;;031-616-493-083-780;;075-361-202-778-14X;;038-171-112-628-544;;031-278-140-393-389;;038-171-112-628-544;;034-722-452-108-337;;044-840-255-404-305;;096-575-429-954-828;;004-488-094-610-499;;018-219-156-278-616;;006-946-979-586-164;;045-239-664-066-895;;036-055-037-431-299;;059-716-462-209-269;;158-567-940-979-261;;011-001-797-370-811;;040-239-601-782-040;;020-325-142-341-03X;;011-291-416-015-882;;111-677-879-548-551;;066-219-111-588-400;;129-970-610-939-855;;018-470-195-336-786;;133-233-905-398-202;;095-485-454-240-24X;;070-792-654-417-452;;084-104-328-681-684;;016-327-462-571-496;;029-924-070-880-959;;029-924-070-880-959;;099-503-061-558-195;;007-364-858-655-289,10.1038/nrc1387;;15229476;;10961344;;10.1007/pl00000744;;8697095;;10.1016/1357-2725(95)00168-9;;10.1038/sj.onc.1206058;;12447687;;10.1210/endo.139.8.6165;;10.1210/en.139.8.3578;;9681510;;8697095;;10.1016/1357-2725(95)00168-9;;10.1074/jbc.m605269200;;16793764;;pmc1132689;;1599389;;10.1042/bj2840001;;10.1016/s1097-2765(00)80155-0;;9844629;;16997283;;10.1016/j.bcp.2006.08.011;;10.1159/000095161;;16917171;;16844299;;10.1016/j.bbcan.2006.05.003;;10.1007/s00018-006-6036-4;;16786222;;10.1016/s0304-3835(03)00159-9;;12767520;;16931767;;10.1210/er.2006-0001;;pmc360815;;10.1128/mcb.10.2.464-473.1990;;10.1128/mcb.10.2.464;;2153917;;7790393;;10.1002/jcp.1041640126;;pmc358831;;8007963;;10.1128/mcb.14.7.4588-4595.1994;;10.1128/mcb.14.7.4588;;7636972;;pmc189367;;10.1128/jvi.69.9.5300-5303.1995;;10.1128/mcb.14.6.3604;;pmc358728;;8196606;;10.1128/mcb.14.6.3604-3612.1994;;8248231;;10.1073/pnas.90.23.11217;;pmc47953;;10.1002/j.1460-2075.1994.tb06630.x;;8045259;;pmc395225;;2553250;;8216340;;10.1006/bbrc.1993.2220;;9751624;;10.1038/sj.onc.1202984;;10557096;;10791772;;10.1023/a:1009523501499;;10.1038/sj.onc.1202984;;10557096;;11550779;;10.1007/s003450100220;;10.1016/0016-5085(92)70001-r;;1312970;;10.1016/0016-5085(92)90744-j;;10.1007/s00384-004-0675-4;;15650828;;10.1002/ijc.2910620502;;7665217;;7743492;;12002750;;10.1080/10428190290011958;;16328478;;10.1007/s00277-005-0031-y;;10226794;;10.1055/s-2007-978711;;pmc1187072;;11477136;;10.1136/mp.54.4.227;;12060623;;10.1073/pnas.89.11.4874;;1594587;;pmc49190;;10.1073/pnas.93.14.7263;;8692980;;pmc38971;;10.1158/1078-0432.ccr-03-0762;;15217929;;10.1210/jcem.87.1.8142;;10.1210/jc.87.1.245;;11788654;;11376121;;pmc1187048;;10.1136/mp.54.3.121;;10.1016/j.bcp.2004.05.029;;15313394;;10.1593/neo.04643;;15967097;;pmc1501162;;10.1097/01.ju.0000036380.10325.2a;;10.1016/s0022-5347(05)63999-7;;10.1097/00005392-200302000-00071;;12544349;;15517912;;10.1007/s10585-005-1198-2;;16035620;;10.1016/j.ijom.2006.09.009;;17113753;;16986125;;10.1002/cncr.22214;;10.1038/sj.onc.1209674;;16715137;;14551500;;10.1097/00001813-200310000-00001;;14551500;;10.1097/00001813-200310000-00001;;10.1177/108705719900400605;;10838427;;10.1002/jps.2600660104;;833720,"POLLAK, M N ET AL., NATURE REVIEWS CANCER, vol. 4, no. 7, 2004, pages 505 - 518;;ADAMS ET AL., CELL. MOL. LIFE SCI., vol. 57, 2000, pages 1050 - 1093;;BENITO, M ET AL., INT J BIOCHEM CELL BIOL, vol. 28, no. 5, 1996, pages 499 - 510;;SCIACCA L., ONCOGENE, vol. 21, no. 54, 2002, pages 8240 - 8250;;DANDEKAR, A A ET AL., ENDOCRINOLOGY, vol. 139, no. 8, 1998, pages 3578 - 3584;;BENITO, INT J BIOCHEM CELL BIOL, 1996;;LI, W ET AL., J. BIOL. CHEM., vol. 281, no. 33, 2006, pages 23785 - 23791;;BROWN, G C ET AL., BIOCHEM. J, vol. 284, 1992, pages 1 - 13;;BRUNING, J C ET AL., MOL. CELL, vol. 2, no. 5, 1998, pages 559 - 569;;VAN NIMWEGEN, M J ET AL., BIOCHEM. PHARMACOL., vol. 73, no. 5, 2007, pages 597 - 609;;WALENKAMP, M J ET AL., HORM. RES., vol. 66, no. 5, 2006, pages 221 - 230;;KURMASHEVA, R. T ET AL., BIOCHIM. BIOPHYS. ACTA-REV ON CANCER, vol. 1766, no. 1, 2006, pages 1 - 22;;BATEMAN, J M ET AL., CELL. MOL. LIFE SCI., vol. 63, no. 15, 2006, pages 1701 - 1705;;LEROITH, D ET AL., CAN. LETT., vol. 195, 2003, pages 127 - 137;;SAMANI A ET AL., ENDOCRINE REVIEWS, vol. 28, no. 1, pages 20 - 47;;KURMASHEVA, BIOCHIM. BIOPHYS. ACTA, 2006;;KALEKO M ET AL., MOL CELL BIOL., vol. 10, no. 2, 1990, pages 464 - 473;;DEANGELIS T ET AL., CELL. PHYSIOL., vol. 1640, 1995, pages 214 - 221;;COPPOLA D ET AL., MOL. CELL. BIOL., vol. 14, no. 7, 1994, pages 4588 - 4595;;MORRIONE A J, VIROL., 1995, pages 695300 - 5303;;SELL C ET AL., MOL. CELL. BIOL., vol. 14, no. 6, 1994, pages 3604 - 3612;;SELL C ET AL., PROC. NATL. ACAD. SCI. USA, vol. 90, no. 23, 1993, pages 11217 - 11221;;HARRINGTON ET AL., EMBO J., vol. 13, 1994, pages 3286 - 3295;;ARTEAGA C ET AL., CANCER RES., vol. 49, no. 22, 1989, pages 6237 - 6241;;LI ET AL., BIOCHEM. BIOPHYS. RES. COM., vol. 196, no. 1, 1993, pages 92 - 98;;SCOTLANDI K ET AL., CANCER RES., vol. 58, no. 18, 1998, pages 4127 - 4131;;JIANG ET AL., ONCOGENE, vol. 18, no. 44, 1999, pages 6071 - 6077;;SURMACZ, J., MAMMARY GLAND BIO. NEOPLASIA, vol. 5, no. 1, 2000, pages 95 - 105;;LEROITH, CAN. LETT., 2003;;ARTEGA, CANCER RES., 1989;;SCOTLANDI, CANCER RES., 1998;;JIANG, Y ET AL., ONCOGENE, vol. 18, 1999, pages 6071 - 6077;;DJAVAN ET AL., WORLD J UROL., vol. 19, no. 4, 2001, pages 225 - 233;;O'BRIEN ET AL., UROLOGY, vol. 58, no. 1, 2001, pages 1 - 7;;GUO ET AL., GASTROENTEROLOGY, vol. 102, 1992, pages 1101 - 1108;;DURAI, R ET AL., INT. J COLORECTAL DIS., vol. 20, no. 3, 2005, pages 203 - 220;;KELLERER M. ET AL., INT. J. CANCER, vol. 62, no. 5, 1995, pages 501 - 507;;BERGMANN, U ET AL., CANCER RES., vol. 55, no. 10, 1995, pages 2007 - 2011;;ZUMKELLER W ET AL., LEUK. LYMPH, vol. 43, no. 3, 2002, pages 487 - 491;;QI, ANN HEMATOL., vol. 85, 2006, pages 95 - 101;;ZUMKELLER, W ET AL., HORM. METAB. RES., vol. 31, 1999, pages 138 - 141;;ZUMKELLER, W ET AL., MOL. PATHOL., vol. 54, no. 4, 2001, pages 227 - 229;;DEL VALLE L ET AL., CLIN. CANCER RES., vol. 8, 2002, pages 1822 - 1830;;TROJAN ET AL., PROC. NATL. ACAD. SCI. USA, vol. 89, 1992, pages 4874 - 4878;;BURFEIND P ET AL., PNAS, vol. 93, 1996, pages 7263 - 7268;;WU X. ET AL., CLIN. CANCER RES., vol. 10, 2004, pages 3988 - 95;;VELLA V ET AL., J. CLIN. ENDOCRINOL. METAB., vol. 87, 2002, pages 245 - 254;;VELLA V ET AL., MOL. PATHOL., vol. 54, no. 3, 2001, pages 121 - 124;;ALEXIA, C ET AL., BIOCHEM. PHARMACOL., vol. 68, 2004, pages 1003 - 1015;;NEUVIANS T P ET AL., NEOPLASIA, vol. 7, 2005, pages 446 - 56;;ZHAO H. ET AL., J. UROLOGY, vol. 169, 2003, pages 714 - 717;;SOHDA M ET AL., ANTICANCER RESEARCH., vol. 24, 2004, pages 3029 - 3034;;JIANG, Y ET AL., CLINICAL & EXPERIMENTAL METASTASIS, vol. 21, 2004, pages 755 - 64;;BRADY G ET AL., INT. J. OF ORAL & MAXILLOFACIAL SURG., vol. 36, 2007, pages 259 - 62;;TRENT J C ET AL., CANCER, vol. 107, 2006, pages 1898 - 908;;YEH A H ET AL., ONCOGENE, vol. 25, 2006, pages 6574 - 81;;BOHULA E A ET AL., ANTICANCER DRUGS, vol. 14, no. 9, 2003, pages 669 - 682;;BOHULA, ANTICANCER DRUGS, 2003;;""IUPAC 1974 Recommendations for Section E, Fundamental Stereochemistry"", PURE APPL. CHEM., vol. 45, 1976, pages 13 - 30;;MATHIS, G., HTRF(R) TECHNOLOGY. J BIOMOL SCREEN, vol. 4, no. 6, 1999, pages 309 - 314;;NATURE REVIEWS CANCER, vol. 8, 2008, pages 915;;S. M. BERGE ET AL., J. PHARMACEUTICAL SCIENCES, vol. 66, 1977, pages 1",PENDING
207,US,A1,US 2010/0260668 A1,071-633-613-676-798,2010-10-14,2010,US 60509409 A,2009-10-23,US 60509409 A;;US 43146009 A;;US 12583408 P;;US 13428308 P;;US 19719108 P;;US 19900908 P,2008-04-29,Dual Variable Domain Immunoglobulins and Uses Thereof,"The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.",ABBOTT LAB,GHAYUR TARIQ;;MORGAN-LAPPE SUSAN E;;REILLY EDWARD B;;KINGSBURY GILLIAN A;;PHILLIPS ANDREW;;WANG JIEYI;;BELL RANDY L;;NORVELL SUZANNE M;;LI YINGCHUN;;LIU JUNJIAN;;YING HUA;;LIU ZHIHONG,ABBVIE INC (2012-08-01);;ABBOTT LABORATORIES (2010-06-08),https://lens.org/071-633-613-676-798,Patent Application,yes,99,104,25,25,935,A61K2039/505;;C07K16/22;;C07K16/28;;C07K16/2863;;C07K16/32;;C07K16/468;;C07K2317/73;;C07K2317/92;;C07K2319/00;;C07K2317/76;;A61P1/00;;A61P1/04;;A61P1/16;;A61P1/18;;A61P11/00;;A61P11/02;;A61P11/06;;A61P13/12;;A61P15/00;;A61P15/08;;A61P17/00;;A61P17/02;;A61P17/04;;A61P17/06;;A61P17/14;;A61P19/00;;A61P19/02;;A61P19/08;;A61P19/10;;A61P21/00;;A61P21/02;;A61P21/04;;A61P25/00;;A61P25/02;;A61P25/04;;A61P25/06;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/20;;A61P25/24;;A61P25/28;;A61P25/30;;A61P25/32;;A61P27/02;;A61P29/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P31/14;;A61P31/18;;A61P31/20;;A61P33/00;;A61P33/06;;A61P35/00;;A61P35/02;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/00;;A61P43/00;;A61P5/14;;A61P7/00;;A61P7/02;;A61P7/06;;A61P9/00;;A61P9/04;;A61P9/06;;A61P9/10;;A61P9/12;;A61P3/10;;Y02A50/30;;C07K16/28;;C12N15/11;;A61K39/395;;C07K16/22;;C07K2319/00;;A61K2039/505;;C07K2317/92;;C07K16/468;;C07K16/32;;C07K16/2863;;C07K16/28;;C07K2317/73;;C07K2317/76;;Y02A50/30,A61K39/395;;A61K51/10;;A61P1/00;;A61P1/16;;A61P3/10;;A61P7/00;;A61P9/00;;A61P11/00;;A61P15/00;;A61P17/00;;A61P17/06;;A61P19/02;;A61P21/02;;A61P25/20;;A61P25/28;;A61P29/00;;A61P35/00;;A61P37/06;;C07H21/04;;C07K16/32;;C07K16/46;;C12N1/11;;C12N1/15;;C12N1/19;;C12N1/21;;C12N5/10;;C12N15/63;;C12P21/00,424/1.49;;530/387.3;;530/387.7;;530/391.7;;530/391.3;;536/23.4;;536/23.53;;424/136.1;;424/178.1;;424/138.1;;435/320.1;;435/252.33;;435/258.1;;435/325;;435/419;;435/254.11;;435/349;;435/348;;435/358;;435/365;;435/254.2;;435/254.21;;435/69.6,0,0,,,,DISCONTINUED
208,DO,A,DO P2012000122 A,121-744-746-968-763,2013-09-15,2013,DO 2012000122 A,2012-04-26,US 60509409 A,2009-10-23,INMUNOGLOBULINAS CON DOMINIO VARIABLE DUAL Y USOS DE LAS MISMAS,"Proteínas de unión multivalentes y multiespecíficas diseñadas, métodos para elaborarlas y, específicamente, sus usos en la prevención, eI diagnóstico y/o el tratamiento de enfermedades.",ABBVIE INC,YING HUA;;GHAYUR TARIQ;;BELL RANDY L;;NORVELL SUZANNE M;;LI YINGCHUN;;KINGSBURY GILLIAN A;;MORGAN-LAPPE SUSAN E;;LIU JUNJIAN;;LIU ZHIHONG;;REILLY EDWARD B;;PHILLIPS ANDREW;;WANG JIEYI,,https://lens.org/121-744-746-968-763,Patent Application,no,0,0,25,25,0,A61K2039/505;;C07K16/22;;C07K16/28;;C07K16/2863;;C07K16/32;;C07K16/468;;C07K2317/73;;C07K2317/92;;C07K2319/00;;C07K2317/76;;A61P1/00;;A61P1/04;;A61P1/16;;A61P1/18;;A61P11/00;;A61P11/02;;A61P11/06;;A61P13/12;;A61P15/00;;A61P15/08;;A61P17/00;;A61P17/02;;A61P17/04;;A61P17/06;;A61P17/14;;A61P19/00;;A61P19/02;;A61P19/08;;A61P19/10;;A61P21/00;;A61P21/02;;A61P21/04;;A61P25/00;;A61P25/02;;A61P25/04;;A61P25/06;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/20;;A61P25/24;;A61P25/28;;A61P25/30;;A61P25/32;;A61P27/02;;A61P29/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P31/14;;A61P31/18;;A61P31/20;;A61P33/00;;A61P33/06;;A61P35/00;;A61P35/02;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/00;;A61P43/00;;A61P5/14;;A61P7/00;;A61P7/02;;A61P7/06;;A61P9/00;;A61P9/04;;A61P9/06;;A61P9/10;;A61P9/12;;A61P3/10;;Y02A50/30;;C07K16/28;;C12N15/11;;A61K39/395;;C07K16/22;;C07K2319/00;;A61K2039/505;;C07K2317/92;;C07K16/468;;C07K16/32;;C07K16/2863;;C07K16/28;;C07K2317/73;;C07K2317/76;;Y02A50/30,C12P21/08,,0,0,,,,PENDING
209,WO,A3,WO 2011/050262 A3,149-601-995-623-705,2011-06-30,2011,US 2010/0053730 W,2010-10-22,US 60509409 A,2009-10-23,DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND USES THEREOF,"The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.",ABBOTT LAB;;GHAYUR TARIQ;;MORGAN-LAPPE SUSAN E;;REILLY EDWARD B;;KINGSBURY GILLIAN A;;PHILLIPS ANDREW;;WANG JIEYI;;BELL RANDY L;;NORVELL SUZANNE M;;LI YINGCHUN;;LIU JUNJIAN;;YING HUA;;LIU ZHIHONG,GHAYUR TARIQ;;MORGAN-LAPPE SUSAN E;;REILLY EDWARD B;;KINGSBURY GILLIAN A;;PHILLIPS ANDREW;;WANG JIEYI;;BELL RANDY L;;NORVELL SUZANNE M;;LI YINGCHUN;;LIU JUNJIAN;;YING HUA;;LIU ZHIHONG,,https://lens.org/149-601-995-623-705,Search Report,yes,2,0,25,25,935,A61K2039/505;;C07K16/22;;C07K16/28;;C07K16/2863;;C07K16/32;;C07K16/468;;C07K2317/73;;C07K2317/92;;C07K2319/00;;C07K2317/76;;A61P1/00;;A61P1/04;;A61P1/16;;A61P1/18;;A61P11/00;;A61P11/02;;A61P11/06;;A61P13/12;;A61P15/00;;A61P15/08;;A61P17/00;;A61P17/02;;A61P17/04;;A61P17/06;;A61P17/14;;A61P19/00;;A61P19/02;;A61P19/08;;A61P19/10;;A61P21/00;;A61P21/02;;A61P21/04;;A61P25/00;;A61P25/02;;A61P25/04;;A61P25/06;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/20;;A61P25/24;;A61P25/28;;A61P25/30;;A61P25/32;;A61P27/02;;A61P29/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P31/14;;A61P31/18;;A61P31/20;;A61P33/00;;A61P33/06;;A61P35/00;;A61P35/02;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/00;;A61P43/00;;A61P5/14;;A61P7/00;;A61P7/02;;A61P7/06;;A61P9/00;;A61P9/04;;A61P9/06;;A61P9/10;;A61P9/12;;A61P3/10;;Y02A50/30;;C07K16/28;;C12N15/11;;A61K39/395;;C07K16/22;;C07K2319/00;;A61K2039/505;;C07K2317/92;;C07K16/468;;C07K16/32;;C07K16/2863;;C07K16/28;;C07K2317/73;;C07K2317/76;;Y02A50/30,C12P21/08,,0,0,,,,PENDING
210,ZA,B,ZA 201203688 B,180-988-113-924-593,2014-12-23,2014,ZA 201203688 A,2012-05-21,US 60509409 A;;US 2010/0053730 W,2009-10-23,DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND USES THEREOF,,ABBVIE INC,GHAYUR TARIQ;;REILLY EDWARD B;;PHILLIPS ANDREW;;BELL RANDY L;;LI YINGCHUN;;YING HUA;;MORGAN-LAPPE SUSAN E;;KINGSBURY GILLIAN A;;WANG JIEYI;;NORVELL SUZANNE M;;LIU JUNJIAN;;LIU ZHIHONG,,https://lens.org/180-988-113-924-593,Granted Patent,no,0,0,25,25,0,A61K2039/505;;C07K16/22;;C07K16/28;;C07K16/2863;;C07K16/32;;C07K16/468;;C07K2317/73;;C07K2317/92;;C07K2319/00;;C07K2317/76;;A61P1/00;;A61P1/04;;A61P1/16;;A61P1/18;;A61P11/00;;A61P11/02;;A61P11/06;;A61P13/12;;A61P15/00;;A61P15/08;;A61P17/00;;A61P17/02;;A61P17/04;;A61P17/06;;A61P17/14;;A61P19/00;;A61P19/02;;A61P19/08;;A61P19/10;;A61P21/00;;A61P21/02;;A61P21/04;;A61P25/00;;A61P25/02;;A61P25/04;;A61P25/06;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/20;;A61P25/24;;A61P25/28;;A61P25/30;;A61P25/32;;A61P27/02;;A61P29/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P31/14;;A61P31/18;;A61P31/20;;A61P33/00;;A61P33/06;;A61P35/00;;A61P35/02;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/00;;A61P43/00;;A61P5/14;;A61P7/00;;A61P7/02;;A61P7/06;;A61P9/00;;A61P9/04;;A61P9/06;;A61P9/10;;A61P9/12;;A61P3/10;;Y02A50/30;;C07K16/28;;C12N15/11;;A61K39/395;;C07K16/22;;C07K2319/00;;A61K2039/505;;C07K2317/92;;C07K16/468;;C07K16/32;;C07K16/2863;;C07K16/28;;C07K2317/73;;C07K2317/76;;Y02A50/30,C12P/,,0,0,,,,ACTIVE
211,CA,A1,CA 2763631 A1,071-272-837-476-84X,2010-12-02,2010,CA 2763631 A,2010-05-26,US 18156109 P;;US 2010/0036185 W,2009-05-27,PYRIMIDINE INHIBITORS OF KINASE ACTIVITY,"The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts or solvates thereof, wherein G1, R2, R3, R4, R5, n, p, q, Ar1, and Ar2 are defined in the description. The present invention relates also to methods of making said compounds, and compositions comprising said compounds which are useful for inhibiting kinases such as IGF-IR.",ABBOTT LAB,CLARK RICHARD F;;BELL RANDY L;;BA-MAUNG NWE Y;;ERICKSON SCOTT A;;FIDANZE STEVE D;;MANTEI ROBERT A;;SHEPPARD GEORGE S;;SORENSEN BRYAN K;;WANG GARY T;;WANG JIEYI,,https://lens.org/071-272-837-476-84X,Patent Application,no,0,0,10,10,0,A61P35/00;;A61P43/00;;C07D471/04;;C07D471/04;;C07D487/04;;C07D487/04;;C07D513/04;;C07D513/04,C07D471/04;;A61K31/506;;A61P35/00;;C07D487/04;;C07D513/04,,0,0,,,,DISCONTINUED
212,WO,A2,WO 2011/050262 A2,185-757-399-182-524,2011-04-28,2011,US 2010/0053730 W,2010-10-22,US 60509409 A,2009-10-23,DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND USES THEREOF,"The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.",ABBOTT LAB;;GHAYUR TARIQ;;MORGAN-LAPPE SUSAN E;;REILLY EDWARD B;;KINGSBURY GILLIAN A;;PHILLIPS ANDREW;;WANG JIEYI;;BELL RANDY L;;NORVELL SUZANNE M;;LI YINGCHUN;;LIU JUNJIAN;;YING HUA;;LIU ZHIHONG,GHAYUR TARIQ;;MORGAN-LAPPE SUSAN E;;REILLY EDWARD B;;KINGSBURY GILLIAN A;;PHILLIPS ANDREW;;WANG JIEYI;;BELL RANDY L;;NORVELL SUZANNE M;;LI YINGCHUN;;LIU JUNJIAN;;YING HUA;;LIU ZHIHONG,,https://lens.org/185-757-399-182-524,Patent Application,yes,0,28,25,25,935,A61K2039/505;;C07K16/22;;C07K16/28;;C07K16/2863;;C07K16/32;;C07K16/468;;C07K2317/73;;C07K2317/92;;C07K2319/00;;C07K2317/76;;A61P1/00;;A61P1/04;;A61P1/16;;A61P1/18;;A61P11/00;;A61P11/02;;A61P11/06;;A61P13/12;;A61P15/00;;A61P15/08;;A61P17/00;;A61P17/02;;A61P17/04;;A61P17/06;;A61P17/14;;A61P19/00;;A61P19/02;;A61P19/08;;A61P19/10;;A61P21/00;;A61P21/02;;A61P21/04;;A61P25/00;;A61P25/02;;A61P25/04;;A61P25/06;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/20;;A61P25/24;;A61P25/28;;A61P25/30;;A61P25/32;;A61P27/02;;A61P29/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P31/14;;A61P31/18;;A61P31/20;;A61P33/00;;A61P33/06;;A61P35/00;;A61P35/02;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/00;;A61P43/00;;A61P5/14;;A61P7/00;;A61P7/02;;A61P7/06;;A61P9/00;;A61P9/04;;A61P9/06;;A61P9/10;;A61P9/12;;A61P3/10;;Y02A50/30;;C07K16/28;;C12N15/11;;A61K39/395;;C07K16/22;;C07K2319/00;;A61K2039/505;;C07K2317/92;;C07K16/468;;C07K16/32;;C07K16/2863;;C07K16/28;;C07K2317/73;;C07K2317/76;;Y02A50/30,A61K39/395;;A61K51/10;;A61P1/00;;A61P1/16;;A61P3/10;;A61P7/00;;A61P9/00;;A61P11/00;;A61P15/00;;A61P17/00;;A61P17/06;;A61P19/02;;A61P21/02;;A61P25/20;;A61P25/28;;A61P29/00;;A61P35/00;;A61P37/06;;C07H21/04;;C07K16/32;;C07K16/46;;C12N1/11;;C12N1/15;;C12N1/19;;C12N1/21;;C12N5/10;;C12N15/63;;C12P21/00,,0,0,,,,PENDING
213,CA,A1,CA 2778176 A1,063-824-493-335-236,2011-04-28,2011,CA 2778176 A,2010-10-22,US 60509409 A;;US 2010/0053730 W,2009-10-23,DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND USES THEREOF,"The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.",ABBOTT LAB,GHAYUR TARIQ;;MORGAN-LAPPE SUSAN E;;REILLY EDWARD B;;KINGSBURY GILLIAN A;;PHILLIPS ANDREW;;WANG JIEYI;;BELL RANDY L;;NORVELL SUZANNE M;;LI YINGCHUN;;LIU JUNJIAN;;YING HUA;;LIU ZHIHONG,,https://lens.org/063-824-493-335-236,Patent Application,no,0,0,25,25,935,A61K2039/505;;C07K16/22;;C07K16/28;;C07K16/2863;;C07K16/32;;C07K16/468;;C07K2317/73;;C07K2317/92;;C07K2319/00;;C07K2317/76;;A61P1/00;;A61P1/04;;A61P1/16;;A61P1/18;;A61P11/00;;A61P11/02;;A61P11/06;;A61P13/12;;A61P15/00;;A61P15/08;;A61P17/00;;A61P17/02;;A61P17/04;;A61P17/06;;A61P17/14;;A61P19/00;;A61P19/02;;A61P19/08;;A61P19/10;;A61P21/00;;A61P21/02;;A61P21/04;;A61P25/00;;A61P25/02;;A61P25/04;;A61P25/06;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/20;;A61P25/24;;A61P25/28;;A61P25/30;;A61P25/32;;A61P27/02;;A61P29/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P31/14;;A61P31/18;;A61P31/20;;A61P33/00;;A61P33/06;;A61P35/00;;A61P35/02;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/00;;A61P43/00;;A61P5/14;;A61P7/00;;A61P7/02;;A61P7/06;;A61P9/00;;A61P9/04;;A61P9/06;;A61P9/10;;A61P9/12;;A61P3/10;;Y02A50/30;;C07K16/28;;C12N15/11;;A61K39/395;;C07K16/22;;C07K2319/00;;A61K2039/505;;C07K2317/92;;C07K16/468;;C07K16/32;;C07K16/2863;;C07K16/28;;C07K2317/73;;C07K2317/76;;Y02A50/30,C07K16/46;;A61K39/395;;A61K47/48;;A61K51/10;;C07K16/22;;C07K16/28;;C12N15/13,,0,0,,,,DISCONTINUED
214,CA,A1,CA 2763624 A1,194-899-482-296-282,2010-12-02,2010,CA 2763624 A,2010-05-26,US 18155509 P;;US 2010/0036184 W,2009-05-27,PYRIMIDINE INHIBITORS OF KINASE ACTIVITY,"Described herein are compounds of formula (I) or pharmaceutical acceptable salts or solvates thereof, wherein G1, L1, R1, R3, n, p, Ar1, and Ax2 are defined in the description. Methods of making said compounds, and compositions comprising said compounds which are useful for inhibiting kinases such as IGF-IR are also disclosed.",ABBOTT LAB,CLARK RICHARD F;;BA-MAUNG NWE Y;;ERICKSON SCOTT A;;FIDANZE STEVE D;;MANTEI ROBERT A;;SHEPPARD GEORGE S;;SORENSEN BRYAN K;;WANG GARY T;;WANG JIEYI;;BELL RANDY L,,https://lens.org/194-899-482-296-282,Patent Application,no,0,0,10,10,0,C07D403/14;;C07D471/04;;C07D487/04;;C07D513/04;;A61P35/00;;C07D471/04;;C07D487/04;;C07D513/04;;C07D403/14,C07D471/04;;A61K31/506;;A61P35/00;;C07D403/14;;C07D487/04;;C07D513/04,,0,0,,,,DISCONTINUED
215,EP,A2,EP 2491129 A2,136-061-062-664-103,2012-08-29,2012,EP 10825739 A,2010-10-22,US 60509409 A;;US 2010/0053730 W,2009-10-23,DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND USES THEREOF,,ABBOTT LAB,GHAYUR TARIQ;;MORGAN-LAPPE SUSAN E;;REILLY EDWARD B;;KINGSBURY GILLIAN A;;PHILLIPS ANDREW;;WANG JIEYI;;BELL RANDY L;;NORVELL SUZANNE M;;LI YINGCHUN;;LIU JUNJIAN;;YING HUA;;LIU ZHIHONG,ABBVIE INC. (2013-06-12),https://lens.org/136-061-062-664-103,Patent Application,yes,0,1,25,25,935,A61K2039/505;;C07K16/22;;C07K16/28;;C07K16/2863;;C07K16/32;;C07K16/468;;C07K2317/73;;C07K2317/92;;C07K2319/00;;C07K2317/76;;A61P1/00;;A61P1/04;;A61P1/16;;A61P1/18;;A61P11/00;;A61P11/02;;A61P11/06;;A61P13/12;;A61P15/00;;A61P15/08;;A61P17/00;;A61P17/02;;A61P17/04;;A61P17/06;;A61P17/14;;A61P19/00;;A61P19/02;;A61P19/08;;A61P19/10;;A61P21/00;;A61P21/02;;A61P21/04;;A61P25/00;;A61P25/02;;A61P25/04;;A61P25/06;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/20;;A61P25/24;;A61P25/28;;A61P25/30;;A61P25/32;;A61P27/02;;A61P29/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P31/14;;A61P31/18;;A61P31/20;;A61P33/00;;A61P33/06;;A61P35/00;;A61P35/02;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/00;;A61P43/00;;A61P5/14;;A61P7/00;;A61P7/02;;A61P7/06;;A61P9/00;;A61P9/04;;A61P9/06;;A61P9/10;;A61P9/12;;A61P3/10;;Y02A50/30;;C07K16/28;;C12N15/11;;A61K39/395;;C07K16/22;;C07K2319/00;;A61K2039/505;;C07K2317/92;;C07K16/468;;C07K16/32;;C07K16/2863;;C07K16/28;;C07K2317/73;;C07K2317/76;;Y02A50/30,C12P21/08;;C07K16/22;;C07K16/28;;C07K16/32,,0,0,,,,DISCONTINUED
216,US,B2,US 8067409 B2,006-771-395-849-598,2011-11-29,2011,US 27483408 A,2008-11-20,US 27483408 A;;US 99033007 P,2007-11-27,Protein kinase inhibitors,"Compounds that inhibit protein kinases, compositions containing the compounds and methods of treating diseases using the compounds are disclosed.",BA-MAUNG NWE Y;;BELL RANDY L;;CLARK RICHARD F;;ERICKSON SCOTT A;;FIDANZE STEVE D;;HUBBARD ROBERT D;;MANTEI ROBERT A;;SHEPPARD GEORGE S;;SORENSEN BRYAN K;;WANG GARY T;;WANG JIEYI;;ABBOTT LAB,BA-MAUNG NWE Y;;BELL RANDY L;;CLARK RICHARD F;;ERICKSON SCOTT A;;FIDANZE STEVE D;;HUBBARD ROBERT D;;MANTEI ROBERT A;;SHEPPARD GEORGE S;;SORENSEN BRYAN K;;WANG GARY T;;WANG JIEYI,ABBVIE INC (2012-08-01);;ABBOTT LABORATORIES (2009-06-12),https://lens.org/006-771-395-849-598,Granted Patent,yes,11,0,7,7,0,A61P35/00;;A61P43/00;;C07D513/04;;C07D513/04,C07D513/04;;A61K31/425,514/228.5;;514/235.8;;514/252.14;;514/252.19;;514/275;;544/58.2;;544/60;;544/61;;544/122;;544/295;;544/331,16,14,090-635-855-523-821;;080-032-056-359-513;;017-094-139-691-027;;005-621-348-559-328;;082-027-526-395-831;;043-546-849-370-25X;;090-462-952-116-23X;;100-242-062-723-667;;099-503-061-558-195;;131-991-682-925-350;;026-774-729-869-767;;000-032-742-203-955;;005-646-055-983-222;;002-475-405-853-127,15812560;;10.1038/sj.bjc.6602408;;pmc2362008;;10.1016/0006-2952(95)02232-5;;8645330;;11287973;;10.1056/nejm200104053441402;;10.1126/science.279.5350.577;;9438854;;10.1016/0304-419x(94)90012-4;;7819273;;10.1210/er.21.3.215;;10.1210/edrv.21.3.0399;;10857553;;6014913;;10.1006/bbrc.1997.8043;;9480838;;10.1177/108705719900400605;;10838427;;10.1016/b978-0-08-021019-3.50003-1;;8899291;;10.1016/1359-6101(96)00016-0;;11248153;;10.1056/nejm200103153441101;;12884910;;10.1023/a:1023772912750;;7678609;;pmc329994;;10.1172/jci116200,"Simone, Oncology: Introduction, Cecil Textbook of Medicine, 20th Edition, vol. 1, pp. 1004-1010, 1996.;;Catrina S-B et al., ""Insulin-like growth factor-I receptor activity is essential for Kaposi's sarcoma growth and survival"", Br. J. Cancer, vol. 92, pp. 1467-147, 2005.;;Davies, D., ""Targeting the Epidermal Growth Factor Receptor for Therapy of Carcinomas"", Biochem. Pharm. vol. 51 (9), pp. 1101-1110, 1996.;;Druker, B., ""Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia Chromosome"", New England J of Medicine, vol. 344, p. 1038, 2001.;;Hirota, S., ""Gain of function Mutations of C-kit in Human Gastrointestinal Stromal Tumors"", Science, vol. 279, p. 577-580, 1998.;;Hynes, N., ""The biology of erbB-2/neu/HER-2 and its role in cancer"", Biochem. Biophys. Acta. vol. 1198, pp. 165-184, 1994.;;Khandwala, H., ""The Effects of Insulin-Like Growth Factors on Tumorigenesis and Neoplastic Growth"", Endocrine Reviews, vol. 21, (3), pp. 215-244, 2000.;;Loewe, et al., ""Ein nener Typ der 4-Amino-chinolin-Reihe"", Zrzeneim. Forsch, vol. 16,p. 1306-1310, 1966.;;Lutz, M.P., ""Overexpression and Activation of the Tyrosine Kinase Src in Human Pancreatic Carcinoma"", Biochemical & Biophysical Research Commun., vol. 243, pp. 503-508, 1998.;;Mathis, G., ""HTRF(R) Technology"", J. Biomol. Screen, vol. 4(6), pp. 309-314, 1999.;;Pure Appl. Chem, ""Rules for the Nomenclature of Organic Chemistry, Section E: Stereochemistry"", IUPAC Commission on Nomenclature of Organic Chemistry, Pergamon Press,vol. 45, pp. 13-20, 1976.;;Rusch, V., ""The Epidermal Growth Factor Receptor and Its Ligands as Therapeutic Targets in Human Tumors"", Cytokine & Growth Factor Rev. vol. 7, pp. 133-141, 1996.;;Slamon, D., ""Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer that Overexpresses HER2"", New England J. Med. vol. 344(11), pp. 783-792, 2001.;;Summy, J., ""Src family kinases in tumor progression and metastasis"", Cancer & Metastasis Rev. vol. 22, p. 337-358, 2003.;;Talamonti, M., ""Increase in Activity and Level of pp60 c-src in Progressive Stages of Human Colorectal Cancer"", J. Clin. Invest. vol. 91, pp. 53-60, 1993.;;PCT Search Report for PCT/US2008/084469 mailed on Mar. 18, 2009.",ACTIVE
217,US,A1,US 2009/0253723 A1,195-957-145-893-640,2009-10-08,2009,US 27483408 A,2008-11-20,US 27483408 A;;US 99033007 P,2007-11-27,PROTEIN KINASE INHIBITORS,"Compounds that inhibit protein kinases, compositions containing the compounds and methods of treating diseases using the compounds are disclosed.",ABBOTT LAB,BA-MAUNG NWE Y;;BELL RANDY L;;CLARK RICHARD F;;ERICKSON SCOTT A;;FIDANZE STEVE D;;HUBBARD ROBERT D;;MANTEI ROBERT A;;SHEPPARD GEORGE S;;SORENSEN BRYAN K;;WANG GARY T;;WANG JIEYI,ABBVIE INC (2012-08-01);;ABBOTT LABORATORIES (2009-06-12),https://lens.org/195-957-145-893-640,Patent Application,yes,0,1,7,7,0,A61P35/00;;A61P43/00;;C07D513/04;;C07D513/04,A61K31/506;;A61P35/00;;C07D239/42,514/275;;544/297,0,0,,,,ACTIVE
218,TW,A,TW 201127956 A,001-960-670-320-340,2011-08-16,2011,TW 99136250 A,2010-10-22,US 60509409 A,2009-10-23,Dual variable domain immunoglobulins and uses thereof,"The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.",ABBOTT LAB,GHAYUR TARIQ;;MORGAN-LAPPE SUSAN E;;REILLY EDWARD B;;KINGSBURY GILLIAN A;;PHILLIPS ANDREW;;WANG JIEYI;;BELL RANDY L;;NORVELL SUZANNE M;;LI YING-CHUN;;LIU JUN-JIAN;;YING HUA;;LIU ZHI-HONG,,https://lens.org/001-960-670-320-340,Patent of Addition,no,0,0,25,25,0,A61K2039/505;;C07K16/22;;C07K16/28;;C07K16/2863;;C07K16/32;;C07K16/468;;C07K2317/73;;C07K2317/92;;C07K2319/00;;C07K2317/76;;A61P1/00;;A61P1/04;;A61P1/16;;A61P1/18;;A61P11/00;;A61P11/02;;A61P11/06;;A61P13/12;;A61P15/00;;A61P15/08;;A61P17/00;;A61P17/02;;A61P17/04;;A61P17/06;;A61P17/14;;A61P19/00;;A61P19/02;;A61P19/08;;A61P19/10;;A61P21/00;;A61P21/02;;A61P21/04;;A61P25/00;;A61P25/02;;A61P25/04;;A61P25/06;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/20;;A61P25/24;;A61P25/28;;A61P25/30;;A61P25/32;;A61P27/02;;A61P29/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P31/14;;A61P31/18;;A61P31/20;;A61P33/00;;A61P33/06;;A61P35/00;;A61P35/02;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/00;;A61P43/00;;A61P5/14;;A61P7/00;;A61P7/02;;A61P7/06;;A61P9/00;;A61P9/04;;A61P9/06;;A61P9/10;;A61P9/12;;A61P3/10;;Y02A50/30;;C07K16/28;;C12N15/11;;A61K39/395;;C07K16/22;;C07K2319/00;;A61K2039/505;;C07K2317/92;;C07K16/468;;C07K16/32;;C07K16/2863;;C07K16/28;;C07K2317/73;;C07K2317/76;;Y02A50/30,C12N15/12;;A61K39/395;;C07K16/18,,0,0,,,,PENDING
219,CA,C,CA 2507310 C,163-997-811-729-371,2022-02-22,2022,CA 2507310 A,2003-11-26,US 30585802 A;;US 0337779 W,2002-11-27,CAPTURING INSIGHT OF SUPERIOR USERS OF A CONTACT CENTER,New functions for a contact center system include: testing user's comprehension of informational messages with a quiz; capturing insight of superior users having a KPI score above a threshold by having those users submit information on why they perform so well; dynamically ordering solutions to issues by re-ranking the solutions periodically based on recency and frequency; integrating information for use by a contact center representative while online with a customer and information for use when not online; storing content items in a telecommunications industry taxonomy; directing user feedback on a content item to the proper owner/manager of that content; communicating solution information using a solutions taxonomy; displaying a dual information system having a CRM application as well as reference material that is context-appropriate; enforcing completion of a group of templates when creating a content item to be published; ensuring a group of templates for a content item are complete before publishing them; and searching within a contact center system portal using a continuum of search functions.,ACCENTURE GLOBAL SERVICES GMBH;;BT GROUP PLC,LANE DAVID P;;REID GREGORY S;;RINGO TIMOTHY;;LIAN ELIZABETH H;;FARRELL DANIEL;;FENTON CRAIG;;SHEARING ELISE;;BELL RANDY;;WONG SEVASTI;;LINGHAM ANTHONY;;FORRESTER AUDREY;;STAUBITZ CLAUDIA;;ADAMS KEVIN;;PICKERING LESLEY;;RITCHIE PAUL,,https://lens.org/163-997-811-729-371,Granted Patent,no,0,0,14,14,0,G06Q10/06393;;G06Q10/06398;;G06Q10/10;;G06Q10/06393;;G06Q10/10;;G06Q10/06398,G06Q10/06;;G06Q10/10,,0,0,,,,EXPIRED
220,US,A1,US 2004/0128294 A1,162-438-206-499-259,2004-07-01,2004,US 30583502 A,2002-11-27,US 30583502 A,2002-11-27,Content management system for the telecommunications industry,"
   New functions for a contact center system include: testing user's comprehension of informational messages with a quiz; capturing insight of superior users having a KPI score above a threshold by having those users submit information on why they perform so well; dynamically ordering solutions to issues by re-ranking the solutions periodically based on recency and frequency; integrating information for use by a contact center representative while online with a customer and information for use when not online; storing content items in a telecommunications industry taxonomy; directing user feedback on a content item to the proper owner/manager of that content; communicating solution information using a solutions taxonomy; displaying a dual information system having a CRM application as well as reference material that is context-appropriate; enforcing completion of a group of templates when creating a content item to be published; ensuring a group of templates for a content item are complete before publishing them; and searching within a contact center system portal using a continuum of search functions. 
",LANE DAVID P.;;REID GREGORY S;;RINGO TIMOTHY;;LIAN ELIZABETH H;;FARRELL DANIEL C;;FENTON CRAIG;;SHEARING ELISE;;BELL RANDY;;WONG SEVASTI;;LINGHAM ANTHONY;;FORRESTER AUDREY;;STAUBITZ CLAUDIA;;ADAMS KEVIN;;PICKERING LESLEY;;RITCHIE PAUL,LANE DAVID P;;REID GREGORY S;;RINGO TIMOTHY;;LIAN ELIZABETH H;;FARRELL DANIEL C;;FENTON CRAIG;;SHEARING ELISE;;BELL RANDY;;WONG SEVASTI;;LINGHAM ANTHONY;;FORRESTER AUDREY;;STAUBITZ CLAUDIA;;ADAMS KEVIN;;PICKERING LESLEY;;RITCHIE PAUL,BT GROUP PLC (2003-11-02);;BRITISH TELECOMMUNICATIONS PLC (2014-04-30);;ACCENTURE GLOBAL SERVICES LIMITED (2010-09-01);;ACCENTURE GLOBAL SERVICES GMBH (2003-11-02),https://lens.org/162-438-206-499-259,Patent Application,yes,41,5,2,21,0,G06Q30/02;;G06Q30/02;;Y10S707/99933;;Y10S707/99931;;Y10S707/99943,G06Q30/02,7071,0,0,,,,EXPIRED
221,AU,B2,AU 2003/295947 B2,042-654-743-193-728,2008-05-29,2008,AU 2003/295947 A,2003-11-26,US 30585802 A;;US 0337779 W,2002-11-27,Capturing insight of superior users of a contact center,,ACCENTURE GLOBAL SERVICES LTD;;BRITISH TELECOMM,RINGO TIMOTHY;;WONG SEVASTI;;ADAMS KEVIN;;FARRELL DANIEL C;;REID GREGORY S;;LINGHAM ANTHONY;;STAUBITZ CLAUDIA;;FENTON CRAIG;;FORRESTER AUDREY;;LANE DAVID P;;SHEARING ELISE;;PICKERING LESLEY;;RITCHIE PAUL;;LIAN ELIZABETH H;;BELL RANDY,BRITISH TELECOMMUNICATIONS PLC; ACCENTURE GLOBAL S (2014-10-02),https://lens.org/042-654-743-193-728,Granted Patent,no,3,0,14,14,0,G06Q10/06393;;G06Q10/06398;;G06Q10/10;;G06Q10/06393;;G06Q10/10;;G06Q10/06398,G06Q10/06;;G06Q10/10,,0,0,,,,EXPIRED
222,US,A1,US 2004/0103019 A1,181-048-856-849-164,2004-05-27,2004,US 30602502 A,2002-11-27,US 30602502 A,2002-11-27,Content feedback in a multiple-owner content management system,"
   New functions for a contact center system include: testing user's comprehension of informational messages with a quiz; capturing insight of superior users having a KPI score above a threshold by having those users submit information on why they perform so well; dynamically ordering solutions to issues by re-ranking the solutions periodically based on recency and frequency; integrating information for use by a contact center representative while online with a customer and information for use when not online; storing content items in a telecommunications industry taxonomy; directing user feedback on a content item to the proper owner/manager of that content; communicating solution information using a solutions taxonomy; displaying a dual information system having a CRM application as well as reference material that is context-appropriate; enforcing completion of a group of templates when creating a content item to be published; ensuring a group of templates for a content item are complete before publishing them; and searching within a contact center system portal using a continuum of search functions. 
",REID GREGORY S.;;RINGO TIMOTHY;;LANE DAVID P.;;LIAN ELIZABETH H.;;FARRELL DANIEL C.;;FENTON CRAIG;;SHEARING ELISE;;BELL RANDY;;WONG SEVASTI;;LINGHAM ANTHONY;;FORRESTER ANDREY;;STAUBITZ CLAUDIA;;ADAMS KEVIN;;PICKERING LESLEY;;RITCHIE PAUL,REID GREGORY S;;RINGO TIMOTHY;;LANE DAVID P;;LIAN ELIZABETH H;;FARRELL DANIEL C;;FENTON CRAIG;;SHEARING ELISE;;BELL RANDY;;WONG SEVASTI;;LINGHAM ANTHONY;;FORRESTER ANDREY;;STAUBITZ CLAUDIA;;ADAMS KEVIN;;PICKERING LESLEY;;RITCHIE PAUL,BT GROUP PLC (2003-11-02);;BRITISH TELECOMMUNICATIONS PLC (2014-04-30);;ACCENTURE GLOBAL SERVICES LIMITED (2014-04-30);;ACCENTURE GLOBAL SERVICES GMBH (2003-11-02),https://lens.org/181-048-856-849-164,Patent Application,yes,96,27,7,21,0,G06Q10/06398;;G06Q10/06398;;G06Q10/063;;G06Q10/063;;G06Q10/06393;;G06Q10/06393;;G06Q10/10;;G06Q10/10;;G06Q30/0601;;G06Q30/0601;;G06Q30/0641;;G06Q30/0641;;G06Q50/184;;G06Q50/184,G06Q10/06;;G06Q10/10;;G06Q30/06;;G06Q50/18,705 1,0,0,,,,EXPIRED
223,US,A1,US 2004/0162800 A1,178-378-556-576-508,2004-08-19,2004,US 30638602 A,2002-11-27,US 30638602 A,2002-11-27,Presenting linked information in a CRM system,"
   New functions for a contact center system include: testing user's comprehension of informational messages with a quiz; capturing insight of superior users having a KPI score above a threshold by having those users submit information on why they perform so well; dynamically ordering solutions to issues by re-ranking the solutions periodically based on recency and frequency; integrating information for use by a contact center representative while online with a customer and information for use when not online; storing content items in a telecommunications industry taxonomy; directing user feedback on a content item to the proper owner/manager of that content; communicating solution information using a solutions taxonomy; displaying a dual information system having a CRM application as well as reference material that is context-appropriate; enforcing completion of a group of templates when creating a content item to be published; ensuring a group of templates for a content item are complete before publishing them; and searching within a contact center system portal using a continuum of search functions. 
",REID GREGORY S.;;RINGO TIMOTHY;;LANE DAVID P.;;LIAN ELIZABETH H.;;FARRELL DANIEL C.;;FENTON CRAIG;;SHEARING ELISE;;BELL RANDY;;WONG SEVASTI;;LINGHAM ANTHONY;;FORRESTER AUDREY;;STAUBITZ CLAUDIA;;ADAMS KEVIN;;PICKERING LESLEY;;RITCHIE PAUL,REID GREGORY S;;RINGO TIMOTHY;;LANE DAVID P;;LIAN ELIZABETH H;;FARRELL DANIEL C;;FENTON CRAIG;;SHEARING ELISE;;BELL RANDY;;WONG SEVASTI;;LINGHAM ANTHONY;;FORRESTER AUDREY;;STAUBITZ CLAUDIA;;ADAMS KEVIN;;PICKERING LESLEY;;RITCHIE PAUL,BT GROUP PLC (2003-11-02);;BRITISH TELECOMMUNICATIONS PLC (2014-04-30);;ACCENTURE GLOBAL SERVICES LIMITED (2014-04-30);;ACCENTURE GLOBAL SERVICES GMBH (2003-11-02),https://lens.org/178-378-556-576-508,Patent Application,yes,79,16,2,21,0,G06Q30/02;;G06Q30/02,G06Q30/02,707/1,0,0,,,,EXPIRED
224,WO,A1,WO 2009/070516 A1,181-878-735-579-99X,2009-06-04,2009,US 2008/0084469 W,2008-11-24,US 99033007 P;;US 27483408 A,2007-11-27,IMIDAZO-THIAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS,"Compounds of formula I that inhibit protein kinases, compositions containing the compounds and methods of treating diseases using the compounds are disclosed. Formula I and therapeutically acceptable salts, prodrugs and salts of prodrugs thereof, wherein X is CH or N; A 1 is R 1 , OR 1 . NHR 1 , N(R 1 ) 2, NHC(O)R 1 , NHC(O)NHR 1 , NHC(O)N(R 1 ) 2 , NHC(O)OR 1 , C(O)NHR 1 , C(O)N(R 1 ) 2 , C=NOR 1 , or C(NH 2 )NOC(O)R 1 ;",ABBOTT LAB;;BAMAUNG NWE Y;;BELL RANDY L;;CLARK RICHARD F;;ERICKSON SCOTT A;;FIDANZE STEVE D;;HUBBARD ROBERT D;;MANTEI ROBERT A;;SHEPPARD GEORGE S;;SORENSEN BRYAN K;;WANG GARY T;;WANG JIEYI;;SARRIS KATHY,BAMAUNG NWE Y;;BELL RANDY L;;CLARK RICHARD F;;ERICKSON SCOTT A;;FIDANZE STEVE D;;HUBBARD ROBERT D;;MANTEI ROBERT A;;SHEPPARD GEORGE S;;SORENSEN BRYAN K;;WANG GARY T;;WANG JIEYI;;SARRIS KATHY,,https://lens.org/181-878-735-579-99X,Patent Application,yes,3,9,7,7,0,A61P35/00;;A61P43/00;;C07D513/04;;C07D513/04,C07D513/04;;A61K31/425;;A61P35/00,,0,0,,,,PENDING
225,WO,A3,WO 2004/051411 A3,173-654-267-046-179,2006-08-03,2006,US 0337779 W,2003-11-26,US 30585802 A,2002-11-27,CAPTURING INSIGHT OF SUPERIOR USERS OF A CONTACT CENTER,New functions for a contact center system include: testing user&apos;s comprehension of informational messages with a quiz; capturing insight of superior users having a KPI score above a threshold by having those users submit information on why they perform so well; dynamically ordering solutions to issues by re-ranking the solutions periodically based on recency and frequency; integrating information for use by a contact center representative while online with a customer and information for use when not online; storing content items in a telecommunications industry taxonomy; directing user feedback on a content item to the proper owner/manager of that content; communicating solution information using a solutions taxonomy; displaying a dual information system having a CRM application as well as reference material that is context-appropriate; enforcing completion of a group of templates when creating a content item to be published; ensuring a group of templates for a content item are complete before publishing them; and searching within a contact center system portal using a continuum of search functions.,ACCENTURE GLOBAL SERVICES GMBH;;BT GROUP PLC,REID GREGORY S;;RINGO TIMOTHY;;LANE DAVID P;;LIAN ELIZABETH H;;FARRELL DANIEL C;;FENTON CRAIG;;SHEARING ELISE;;BELL RANDY;;WONG SEVASTI;;LINGHAM ANTHONY;;FORRESTER AUDREY;;STAUBITZ CLAUDIA;;ADAMS KEVIN;;PICKERING LESLEY;;RITCHIE PAUL,,https://lens.org/173-654-267-046-179,Search Report,yes,10,0,14,14,0,G06Q10/06393;;G06Q10/06398;;G06Q10/10;;G06Q10/06393;;G06Q10/10;;G06Q10/06398,G06F17/30;;G06Q10/06;;G06Q10/10,,0,0,,,,PENDING
226,CA,A1,CA 2507633 A1,196-149-112-878-154,2004-06-10,2004,CA 2507633 A,2003-11-26,IB 0306465 W;;US 30602502 A;;US 30583502 A;;US 30638602 A,2002-11-27,CONTENT FEEDBACK IN A MULTIPLE-OWNER CONTENT MANAGEMENT SYSTEM,"A computer system may include a contact center interface and a presentation interface. The contact center interface may provide a user with access to a contact center application, which manages and renders information pertaining to customer~centric problems. The presentation interface may provide the use r with access to a content management system (or knowledge management system) for information regarding goods, services and associated support. The comput er system may display two simultaneously visible content regions, where the operations in one content region are independent of operations in the second content region. One of the content regions may reflect the contact center interface while the other content region may reflect the information application interface. The two content regions may be dynamic such that whil e the regions are independent, the content displayed within one content region is context-appropriate to the other content region. Such a system may also include a display region for an instant messaging tool. The content manageme nt system may include a database having a set of content items stored in a taxonomy, where the taxonomy has at least two primary categories. The categories may associate items that represent products, items that represent services, items that represent information for campaigns, items that represe nt information for user procedures, and/or items that represent user intentions (customer needs). Each content item in the database may be associated to one or more content~owners. A user may submit feedback for one of the content items. That feedback may be routed to the content-owner associated to the content item without requiring the user to know or to determine who the content-owner is. The content owner may be: a content author, a content manager, an advocate for the content owner, or a team of people. The feedbac k may be a comment explaining any errors in the content item, a rating of the usefulness of the content item, or a comment for content improvement.</SDOAB >",ACCENTURE GLOBAL SERVICES GMBH;;BT GROUP PLC,FORRESTER AUDREY;;RINGO TIMOTHY;;FARRELL DANIEL C;;STAUBITZ CLAUDIA;;LIAN ELIZABETH H;;FENTON CRAIG;;BELL RANDY;;RITCHIE PAUL;;PICKERING LESLEY;;LANE DAVID P;;REID GREGORY S;;ADAMS KEVIN;;WONG SEVASTI;;LINGHAM ANTHONY;;SHEARING ELISE,,https://lens.org/196-149-112-878-154,Patent Application,no,0,0,10,21,0,G06Q30/02,G06F3/048;;G06F3/0482;;G06F3/0484;;G06Q30/00,,0,0,,,,EXPIRED
227,US,A1,US 2004/0102982 A1,005-226-299-341-129,2004-05-27,2004,US 30585802 A,2002-11-27,US 30585802 A,2002-11-27,Capturing insight of superior users of a contact center,"
   New functions for a contact center system include: testing user's comprehension of informational messages with a quiz; capturing insight of superior users having a KPI score above a threshold by having those users submit information on why they perform so well; dynamically ordering solutions to issues by re-ranking the solutions periodically based on recency and frequency; integrating information for use by a contact center representative while online with a customer and information for use when not online; storing content items in a telecommunications industry taxonomy; directing user feedback on a content item to the proper owner/manager of that content; communicating solution information using a solutions taxonomy; displaying a dual information system having a CRM application as well as reference material that is context-appropriate; enforcing completion of a group of templates when creating a content item to be published; ensuring a group of templates for a content item are complete before publishing them; and searching within a contact center system portal using a continuum of search functions. 
",REID GREGORY S.;;RINGO TIMOTHY;;LANE DAVID P.;;LIAN ELIZABETH H.;;FARRELL DANIEL C;;FENTON CRAIG;;SHEARING ELISE;;BELL RANDY;;WONG SEVASTI;;LINGHAM ANTHONY;;FORRESTER ANDREY;;STAUBITZ CLAUDIA;;ADAMS KEVIN;;PICKERING LESLEY;;RITCHIE PAUL,REID GREGORY S;;RINGO TIMOTHY;;LANE DAVID P;;LIAN ELIZABETH H;;FARRELL DANIEL C;;FENTON CRAIG;;SHEARING ELISE;;BELL RANDY;;WONG SEVASTI;;LINGHAM ANTHONY;;FORRESTER ANDREY;;STAUBITZ CLAUDIA;;ADAMS KEVIN;;PICKERING LESLEY;;RITCHIE PAUL,BT GROUP PLC (2003-11-02);;BRITISH TELECOMMUNICATIONS PLC (2014-04-30);;ACCENTURE GLOBAL SERVICES LIMITED (2014-04-30);;ACCENTURE GLOBAL SERVICES GMBH (2003-11-02),https://lens.org/005-226-299-341-129,Patent Application,yes,98,30,14,14,0,G06Q10/06393;;G06Q10/06398;;G06Q10/10;;G06Q10/06393;;G06Q10/10;;G06Q10/06398,G06Q10/06;;G06Q10/10,705/1,0,0,,,,EXPIRED
228,AU,A8,AU 2003/302349 A8,003-301-943-812-740,2004-06-18,2004,AU 2003/302349 A,2003-11-26,IB 0306465 W;;US 30602502 A;;US 30583502 A;;US 30638602 A,2002-11-27,Content feedback in a multiple-owner content management system,,ACCENTURE GLOBAL SERVICES GMBH;;BT GROUP PLC,FORRESTER AUDREY;;STAUBITZ CLAUDIA;;ADAMS KEVIN;;PICKERING LESLEY;;RITCHIE PAUL;;REID GREGORY S;;RINGO TIMOTHY;;LANE DAVID P;;LIAN ELIZABETH H;;FARRELL DANIEL C;;FENTON CRAIG;;SHEARING ELISE;;BELL RANDY;;WONG SEVASTI;;LINGHAM ANTHONY,BRITISH TELECOMMUNICATIONS PLC; ACCENTURE GLOBAL S (2014-10-02),https://lens.org/003-301-943-812-740,Patent Application,no,0,0,10,21,0,G06Q30/02,G06F3/048;;G06F3/0482;;G06F3/0484;;G06Q30/00,,0,0,,,,EXPIRED
229,US,B2,US 8090624 B2,169-673-345-462-637,2012-01-03,2012,US 17942908 A,2008-07-24,US 17942908 A;;US 30602502 A,2002-11-27,Content feedback in a multiple-owner content management system,New functions for a contact center system include: testing user's comprehension of informational messages with a quiz; capturing insight of superior users having a KPI score above a threshold by having those users submit information on why they perform so well; dynamically ordering solutions to issues by re-ranking the solutions periodically based on recency and frequency; integrating information for use by a contact center representative while online with a customer and information for use when not online; storing content items in a telecommunications industry taxonomy; directing user feedback on a content item to the proper owner/manager of that content; communicating solution information using a solutions taxonomy; displaying a dual information system having a CRM application as well as reference material that is context-appropriate; enforcing completion of a group of templates when creating a content item to be published; ensuring a group of templates for a content item are complete before publishing them; and searching within a contact center system portal using a continuum of search functions.,REID GREGORY S;;RINGO TIMOTHY;;LANE DAVID P;;LIAN ELIZABETH H;;FARRELL DANIEL C;;FENTON CRAIG;;SHEARING ELISE;;BELL RANDY;;WONG SEVASTI;;LINGHAM ANTHONY;;FORRESTER AUDREY;;STAUBITZ CLAUDIA;;ADAMS KEVIN;;PICKERING LESLEY;;RITCHIE PAUL;;ACCENTURE GLOBAL SERVICES GMBH,REID GREGORY S;;RINGO TIMOTHY;;LANE DAVID P;;LIAN ELIZABETH H;;FARRELL DANIEL C;;FENTON CRAIG;;SHEARING ELISE;;BELL RANDY;;WONG SEVASTI;;LINGHAM ANTHONY;;FORRESTER AUDREY;;STAUBITZ CLAUDIA;;ADAMS KEVIN;;PICKERING LESLEY;;RITCHIE PAUL,BRITISH TELECOMMUNICATIONS PLC (2014-04-30);;ACCENTURE GLOBAL SERVICES LIMITED (2010-09-01),https://lens.org/169-673-345-462-637,Granted Patent,yes,103,11,7,21,0,G06Q10/06398;;G06Q10/06398;;G06Q10/063;;G06Q10/063;;G06Q10/06393;;G06Q10/06393;;G06Q10/10;;G06Q10/10;;G06Q30/0601;;G06Q30/0601;;G06Q30/0641;;G06Q30/0641;;G06Q50/184;;G06Q50/184,G06Q30/00;;G06Q10/06;;G06Q10/10;;G06Q30/06;;G06Q50/18,705/26.1;;705/27.1;;705/7.11,99,1,071-048-802-012-90X,10.1108/08858620110400205,"Alban, ""Customer Interaction Monitoring: Your Key to Measuring Service Performance,"" Australian Banking & Finance, Apr. 18, 2001, vol. 10, No. 6, 5 pages.;;Allen et al., ""Method for Using Global Position System to Find Close Services,"" IBM Technical Disclosure Bulletin, Jan. 1998, p. 693, vol. 41, No. 1, 1 page.;;Click2Coach Web Pages, Retrieved from www.envisiontelephonv.com, 2001, 2 pages.;;Product Information Brochure, Click2Coach by Envision Telephony, 2001, 6 pages.;;""What Makes Your Contact Center Agents Truly Effective?,"" Click2Coach by Envision Telephony, 2000, 8 pages.;;Cunliffe, ""Super Systems Capture Expertise of the Specialist,"" Toronto Star, Nov. 2, 1986, p. F-4, 3 pages.;;""Emvolve Performance Manager Release 1.5,"" Customer Inter@ction Solutions, Nov. 2001, pp. 53-56, vol. 20, No. 5, 4 pages.;;""eOn Communications and Eyretel Partner to Deliver Performance Improvement for Contact Centers,"" PR Newswire, Apr. 4, 2002, 3 pages.;;Feasel et al., ""Training Can Produce Better Reps,"" Call Center Solutions, Oct. 1998, pp. 138-143, vol. 17, No. 4, 5 pages.;;""Kelly Services Expands KellyConnect Call Center Solution,"" PR Newswire, Jan. 14, 2002, p. 1, 3 pages.;;""Kelly Services® Offers Improved Call Center Solution,"" PR Newswire, Apr. 24, 2000, p. 1, 2 pages.;;""Knowlagent and Eyretel Partner to Deliver Integrated E-Learning Platform to Global Clients,"" PR Newswire, May 10, 2001, 4 pages.;;""Primus Taps OutSights to Deliver Expertise to Customers Shifting to Knowledge-Based Support,"" Business Wire, Jun. 29, 1999, p. 1, 3 pages.;;Rosati, ""Measuring the Reality of the Customer Experience,"" Customer Inter@ction Solutions, May 2002, pp. 38-43, vol. 20, No. 11, 5 pages.;;""ServiceSoft Delivers 'Smart Answers' at Xerox,"" Business Wire, Aug. 4, 1998, 2 pages.;;""Telvista Integrates eLearning and Quality Monitoring,"" The Ascent Group, Inc., Call Center E-Journal, Aug. 2001, 5 pages.;;Tiwana, ""The Knowledge Management Toolkit,"" Prentice Hall, Dec. 6, 1999, ISBN: 0-13-012853-8m 106 pages.;;Office Action issued by EPO on Appl. No. 03808324.2-2221, dated Jul. 30, 2007, regarding summons to attend oral proceedings on Dec. 13, 2007, 8 pages.;;Office Action issued by the Chinese Patent Office on Chinese Appl. No. 200380106314.X, dated Sep. 28, 2007, 14 pages.;;Office Action issued on U.S. Appl. No. 10/306,705, dated Oct. 9, 2007, 11 pages.;;Office Action issued on U.S. Appl. No. 10/305,858, dated Oct. 19, 2007, 25 pages.;;Office Action issued on U.S. Appl. No. 10/306,386, dated Dec. 11, 2007, 12 pages.;;Office Action issued on U.S. Appl. No. 10/306,248, dated Jan. 7, 2008, 17 pages.;;Office Action issued on U.S. Appl. No. 10/306,564, dated Jan. 7, 2008, 20 pages.;;Office Action issued on U.S. Appl. No. 10/306,563, dated Jan. 8, 2008, 12 pages.;;Office Action issued on U.S. Appl. No. 10/305,811, dated Jan. 18, 2008, 15 pages.;;Notice of Allowance issued on U.S. Appl. No. 10/306,026, dated Jan. 28, 2008, 7 pages.;;Office Action issued on U.S. Appl. No. 10/306,386, dated Jan. 29, 2008, 14 pages.;;Dayco Statement Regarding Related Applications dated Dec. 30, 2003 (3 pages).;;Angus, Jeff, Diagnostic Utility Software, InfoWorld, vol. 15, Iss. 18, p. 64, May 3, 1993 (9 pages).;;Arthur Andersen Virtual Learning Network to Focus Competency Management Through Agreement with SkillScape, Business Wire, Aug. 22, 2000 (3 pages).;;CenterForce Technologies and BenchmarkPortal.com Team to Offer Comprehensive Call Center Benchmarking Solution, PR Newswire, Jan. 23, 2001 (2 pages).;;Coen, Dan, Creating a Dynamic Performance Development Program, Direct Marketing, vol. 64, No. 3, p. 44, Jul. 2001 (2 pages).;;Cooper, Kenneth Carlton, Effective Competency Modeling & Reporting, AMA Publications, 2000, ISBN 0-8144-0548-7 (37 pages).;;Do Your Benchmarks Cover All the Media Your Company Uses, Managing Customer Service, p. 2, Mar. 1, 2001 (5 pages).;;E.piphany E.6 Smart CRM Strategy of Next Generation Commerce Sites as Told by CEO Roger Siboni, Computopia, p. 58, 2002 (11 pages) (English Translation of Japanese Article).;;Elwell, Ron, When You Think 'Monitoring,' Think 'John Smith,' Call Center Solutions, vol. 17, No. 12, p. 60, Jun. 1999 (5 pages).;;Gillis, Marge and Katherine Beauchemin, The Ideal Rep., Pharmaceutical Executive, vol. 20, No. 12, p. 52 Dec. 2001 (7 pages).;;Google home page, http://web.archive.org/web/20020523134510/http://www2.google.com/, retrieved May 23, 2002 (1 page).;;Hicks, Ray, Companies Put Stock in Benchmarking, Direct Marketing, vol. 65, No. 6, p. 12, Oct. 2002 (4 pages).;;Homer, Alex et al., Professional Active Server Pages, Wrox Press, ISBN 1-861000-82-3, 1997 (16 pages).;;Kent, Les, Tape Backup Solutions, InfoWorld, vol. 13, Iss. 38, p. 64, Mar. 8, 1993 (2 pages).;;McNichols, Chuck, Script Junkie, New.Architect, Jun. 1999 (7 pages).;;Mehta, Diane and Henry McCracken, Seeing Is Believing, InfoWorld, vol. 16, Iss. 35, p. 68, Aug. 29, 1994 (3 pages).;;Miciak et al., Benchmarking Service Quality Performance at Business-to-Business and Business-to-Consumer Call Centers, The Journal of Business & Industrial Marketing, vol. 16, No. 5, p. 340, MCB University Press, 2001 (14 pages).;;Overview of SkillScape Competence Manager, SkillScape, 2000 (10 pages).;;Pels, Mary Ann and Suzanne Wright, Benchmarking Call Center Performance, Credit Union Executive Journal, vol. 39, No. 4, p. 38, Jul./Aug. 1999 (5 pages).;;Perkins, Debra S. and Jon Anton, Best Practices for Customer Service Call Centers-An Exclusive Statistical Study, Telemarketing & Call Center Solutions, vol. 15, No. 10, p. 80, Apr. 1997 (6 pages).;;Shared Services, Price Waterhouse Coopers, Apr. 8, 2006 (26 pages) (English Translation of Japanese Article).;;University Metes Out Data on Measuring Call Center Agents, Service News, vol. 18, No. 13, p. 2, Dec. 1998 (1 page).;;Van Den Broek, Dianne, Monitoring and Surveillance in Call Centres: Some Responses From Australian Workers, Labour & Industry, vol. 12, No. 3, Apr. 2002 (15 pages).;;Office Action, dated Dec. 23, 2004, issued on U.S. Appl. No. 10/305,811 (6 pages).;;Office Action, dated May 23, 2005, issued on U.S. Appl. No. 10/305,811 (7 pages).;;Advisory Office Action, dated Aug. 11, 2005, issued on U.S. Appl. No. 10/305,811 (3 pages).;;Office Action, dated Nov. 22, 2005, issued on U.S. Appl. No. 10/305,811 (7 pages).;;Office Action, dated Aug. 14, 2006, issued on U.S. Appl. No. 10/305,811 (7 pages).;;Miscellaneous Office Action, dated Jul. 11, 2007, issued on U.S. Appl. No. 10/305,811 (4 pages).;;Miscellaneous Office Action, dated Jul. 18, 2007, issued on U.S. Appl. No. 10/305,811 (4 pages).;;Advisory Office Action, dated Oct. 14, 2008, issued on U.S. Appl. No. 10/305,811 (3 pages).;;Office Action, dated Jul. 9, 2008, issued on U.S. Appl. No. 10/305,811 (9 pages).;;Office Action, dated Feb. 4, 2009, issued on U.S. Appl. No. 10/305,811 (7 pages).;;Office Action, dated Jul. 27, 2009, issued on U.S. Appl. No. 10/305,811 (8 pages).;;Miscellaneous Action, dated Jul. 21, 2004, issued on U.S. Appl. No. 10/305,835 (2 pages).;;Miscellaneous Action, dated Aug. 2, 2005, issued on U.S. Appl. No. 10/305,835 (2 pages).;;Office Action, dated Sep. 9, 2005, issued on U.S. Appl. No. 10/305,835 (7 pages).;;Notice of Allowance, dated Dec. 28, 2005, issued on U.S. Appl. No. 10/305,835, with Examiner-Initiated Interview Summary, dated Dec. 14, 2005 (10 pages).;;Office Action, dated Jun. 22, 2007, issued on U.S. Appl. No. 10/305,858 (19 pages).;;Office Action, dated Jul. 1, 2008, issued on U.S. Appl. No. 10/305,858 (16 pages).;;Office Action, dated Jan. 13, 2009, issued on U.S. Appl. No. 10/305,858 (22 pages).;;Office Action, dated Jun. 18, 2009, issued on U.S. Appl. No. 10/305,858 (22 pages).;;Office Action, dated Oct. 22, 2009, issued on U.S. Appl. No. 10/305,858 (25 pages).;;Notice of Allowance, dated Mar. 25, 2010, issued on U.S. Appl. No. 10/305,858 (7 pages).;;Office Action, dated May 5, 2005, issued on U.S. Appl. No. 10/306,026 (10 pages).;;Office Action, dated Oct. 14, 2005, issued on U.S. Appl. No. 10/306,026 (12 pages).;;Office Action, dated Apr. 11, 2006, issued on U.S. Appl. No. 10/306,026 (13 pages).;;Advisory Action, dated Aug. 22, 2006, issued on U.S. Appl. No. 10/306,026 (3 pages).;;Office Action, dated Dec. 28, 2006, issued on U.S. Appl. No. 10/306,026 (15 pages).;;Notice of Allowance, dated Aug. 8, 2007, issued on U.S. Appl. No. 10/306,026 (2 pages).;;Miscellaneous Action, dated Nov. 8, 2007, issued on U.S. Appl. No. 10/306,026 (2 pages).;;Office Action, dated Apr. 15, 2005, issued on U.S. Appl. No. 10/306,248 (7 pages).;;Office Action, dated Oct. 20, 2005, issued on U.S. Appl. No. 10/306,248 (12 pages).;;Advisory Action, dated Jan. 9, 2006, issued on U.S. Appl. No. 10/306,248 (2 pages).;;Office Action, dated May 30, 2006, issued on U.S. Appl. No. 10/306,248 (10 pages).;;Office Action, dated Dec. 7, 2006, issued on U.S. Appl. No. 10/306,248 (12 pages).;;Advisory Action, dated May 14, 2007, issued on U.S. Appl. No. 10/306,248 (3 pages).;;Office Action, dated Jul. 24, 2007, issued on U.S. Appl. No. 10/306,248 (9 pages).;;Miscellaneous Action, dated May 29, 2008, issued on U.S. Appl. No. 10/306,248 (2 pages).;;Examiner's Answer to Appeal Brief, dated Jan. 7, 2009, issued on U.S. Appl. No. 10/306,248 (16 pages).;;Office Action, dated Apr. 15, 2005, issued on U.S. Appl. No. 10/306,386 (6 pages).;;Office Action, dated Sep. 27, 2005, issued on U.S. Appl. No. 10/306,386 (9 pages).;;Advisory Action, dated Dec. 7, 2005, issued on U.S. Appl. No. 10/306,386 (3 pages).;;Office Action, dated Feb. 15, 2006, issued on U.S. Appl. No. 10/306,386 (7 pages).;;Office Action, dated Oct. 24, 2006, issued on U.S. Appl. No. 10/306,386 (9 pages).;;Office Action, dated May 30, 2007, issued on U.S. Appl. No. 10/306,386 (8 pages).;;Advisory Action, dated Apr. 23, 2008, issued on U.S. Appl. No. 10/306,386 (2 pages).;;Office Action, dated Jul. 7, 2008, issued on U.S. Appl. No. 10/306,386 (13 pages).;;Office Action, dated Jan. 5, 2009, issued on U.S. Appl. No. 10/306,386 (12 pages).;;Advisory Action, dated Apr. 15, 2009, issued on U.S. Appl. No. 10/306,386 (3 pages).;;Office Action, dated Jul. 21, 2009, issued on U.S. Appl. No. 10/306,386 (11 pages).",INACTIVE
230,WO,A2,WO 2004/051411 A2,053-735-383-532-514,2004-06-17,2004,US 0337779 W,2003-11-26,US 30585802 A,2002-11-27,CAPTURING INSIGHT OF SUPERIOR USERS OF A CONTACT CENTER,New functions for a contact center system include: testing user&apos;s comprehension of informational messages with a quiz; capturing insight of superior users having a KPI score above a threshold by having those users submit information on why they perform so well; dynamically ordering solutions to issues by re-ranking the solutions periodically based on recency and frequency; integrating information for use by a contact center representative while online with a customer and information for use when not online; storing content items in a telecommunications industry taxonomy; directing user feedback on a content item to the proper owner/manager of that content; communicating solution information using a solutions taxonomy; displaying a dual information system having a CRM application as well as reference material that is context-appropriate; enforcing completion of a group of templates when creating a content item to be published; ensuring a group of templates for a content item are complete before publishing them; and searching within a contact center system portal using a continuum of search functions.,ACCENTURE GLOBAL SERVICES GMBH;;BT GROUP PLC,REID GREGORY S;;RINGO TIMOTHY;;LANE DAVID P;;LIAN ELIZABETH H;;FARRELL DANIEL C;;FENTON CRAIG;;SHEARING ELISE;;BELL RANDY;;WONG SEVASTI;;LINGHAM ANTHONY;;FORRESTER AUDREY;;STAUBITZ CLAUDIA;;ADAMS KEVIN;;PICKERING LESLEY;;RITCHIE PAUL,,https://lens.org/053-735-383-532-514,Patent Application,yes,0,1,14,14,0,G06Q10/06393;;G06Q10/06398;;G06Q10/10;;G06Q10/06393;;G06Q10/10;;G06Q10/06398,G06Q10/06;;G06Q10/10,,0,0,,,,PENDING
231,AU,B2,AU 2003/302349 B2,184-538-854-515-68X,2008-08-28,2008,AU 2003/302349 A,2003-11-26,IB 0306465 W;;US 30602502 A;;US 30583502 A;;US 30638602 A,2002-11-27,Content feedback in a multiple-owner content management system,,ACCENTURE GLOBAL SERVICES LTD;;BRITISH TELECOMM,STAUBITZ CLAUDIA;;REID GREGORY S;;RITCHIE PAUL;;FORRESTER AUDREY;;BELL RANDY;;SHEARING ELISE;;LANE DAVID P;;PICKERING LESLEY;;LIAN ELIZABETH H;;FARRELL DANIEL C;;WONG SEVASTI;;ADAMS KEVIN;;RINGO TIMOTHY;;FENTON CRAIG;;LINGHAM ANTHONY,BRITISH TELECOMMUNICATIONS PLC; ACCENTURE GLOBAL S (2014-10-02),https://lens.org/184-538-854-515-68X,Granted Patent,no,3,0,10,21,0,G06Q30/02,G06F3/048;;G06F3/0482;;G06F3/0484;;G06Q30/00,,0,0,,,,EXPIRED
232,EP,A4,EP 1573470 A4,043-554-460-405-733,2007-12-26,2007,EP 03787162 A,2003-11-26,US 0337779 W;;US 30585802 A,2002-11-27,CAPTURING INSIGHT OF SUPERIOR USERS OF A CONTACT CENTER,,ACCENTURE GLOBAL SERVICES GMBH;;BT GROUP PLC,REID GREGORY S;;RINGO TIMOTHY;;LANE DAVID P;;LIAN ELIZABETH H;;FARRELL DANIEL C;;FENTON CRAIG;;SHEARING ELISE;;BELL RANDY;;WONG SEVASTI;;LINGHAM ANTHONY;;FORRESTER AUDREY;;STAUBITZ CLAUDIA;;ADAMS KEVIN;;PICKERING LESLEY;;RITCHIE PAUL,,https://lens.org/043-554-460-405-733,Search Report,no,0,0,14,14,0,G06Q10/06393;;G06Q10/06398;;G06Q10/10;;G06Q10/06393;;G06Q10/10;;G06Q10/06398,G06Q10/06;;G06Q10/10,,1,0,,,No Search,DISCONTINUED
233,US,B2,US 7769622 B2,093-219-382-471-81X,2010-08-03,2010,US 30585802 A,2002-11-27,US 30585802 A,2002-11-27,System and method for capturing and publishing insight of contact center users whose performance is above a reference key performance indicator,New functions for a contact center system include: testing user's comprehension of informational messages with a quiz; capturing insight of superior users having a KPI score above a threshold by having those users submit information on why they perform so well; dynamically ordering solutions to issues by re-ranking the solutions periodically based on recency and frequency; integrating information for use by a contact center representative while online with a customer and information for use when not online; storing content items in a telecommunications industry taxonomy; directing user feedback on a content item to the proper owner/manager of that content; communicating solution information using a solutions taxonomy; displaying a dual information system having a CRM application as well as reference material that is context-appropriate; enforcing completion of a group of templates when creating a content item to be published; ensuring a group of templates for a content item are complete before publishing them; and searching within a contact center system portal using a continuum of search functions.,BT GROUP PLC;;ACCENTURE GLOBAL SERVICES GMBH,REID GREGORY S;;RINGO TIMOTHY;;LANE DAVID P;;LIAN ELIZABETH H;;FARRELL DANIEL C;;FENTON CRAIG;;SHEARING ELISE;;BELL RANDY;;WONG SEVASTI;;LINGHAM ANTHONY;;FORRESTER AUDREY;;STAUBITZ CLAUDIA;;ADAMS KEVIN;;PICKERING LESLEY;;RITCHIE PAUL,BT GROUP PLC (2003-11-02);;BRITISH TELECOMMUNICATIONS PLC (2014-04-30);;ACCENTURE GLOBAL SERVICES LIMITED (2014-04-30);;ACCENTURE GLOBAL SERVICES GMBH (2003-11-02),https://lens.org/093-219-382-471-81X,Granted Patent,yes,124,20,14,14,0,G06Q10/06393;;G06Q10/06398;;G06Q10/10;;G06Q10/06393;;G06Q10/10;;G06Q10/06398,G06F17/30;;G06Q10/06;;G06Q10/10,705/10,135,1,071-048-802-012-90X,10.1108/08858620110400205,"Feasel, Marnie et al., Training Can Produce Better Reps Call Center Solutions, vol. 17, No. 4, Oct. 1998, pp. 138-143.;;Primus Taps OutSights to Deliver Expertise to Customers Shifting to Knowledge-Based Support Business Wire, Jun. 29, 1999.;;Kelly Services Offers Improved Call Center Solution PR Newswire, Apr. 24, 2000.;;What makes your contact center agents truly effective? Envision Telephony, Click2Coach, 2000.;;Alban, Oscar, Customer interaction monitoring: your key to measuring service performance Australian Banking & Finance, vol. 10, No. 6, Apr. 18, 2001.;;Knowlagent and Eyretel Partner to Deliver Integrated E-Learning Platform to Global Clients PR Newswire, May 10, 2001.;;Televista Integrates eLearning and Quality Monitoring The Ascent Group, Inc. Call Center E-Journal, Aug. 2001.;;Kelly Services Expands KellyConnect Call Center Solution PR Newswire, Jan. 14, 2002.;;eOn Communications and Eyretel Partner to Deliver Performance Improvement For Contact Centers PR Newswire, Apr. 4, 2002.;;Rosati, Marlene et al., Measuring the Reality of the Customer Experience Customer Interaction Solutions, May 2002, pp. 38-43.;;Click2Coach Web Pages Retrieved from www.envisiontelephony.com, 2001.;;Cunliffe, Alison, Super systems capture expertise of the specialist Toronto Star, Nov. 2, 1986.;;Emvolve Performance Manager Release 1.5 Customer Inter@action Solutions, vol. 20, No. 5, Nov. 20, 2001, pp. 53-56.;;ServiceSoft Delivers ""Smart Answers"" at Xerox Business Wire, Aug. 4, 1998.;;Tiwana, Amrit, The Knowledge Management Toolkit Prentice Hall, Dec. 1999, ISN: 0-13-012853-8.;;Tape backup solutions Kent, Les, Goldberg, Cheryl. InfoWorld. San Mateo: Mar. 8, 1993. vol. 15, Iss. 10; p. 64, 9 pgs.;;Product Comparison: Electronic Mail Gets Its Wings Carlton, Russ. InfoWorld. San Mateo: Sep. 23, 1991. vol. 13, Iss. 38; p. 49 (9 pages).;;Diagnostic utility software Angus, Jeff. InfoWorld. San Mateo: May 3, 1993. vol. 15, Iss. 18; p. 64, 8 pgs.;;Seeing is believing Mehta, Diane, McCracken, Harry. InfoWorld. San Mateo: Aug. 29, 1994. vol. 16, Iss. 35; p. 68, 9 pgs.;;Gillis, Marget et al., The Ideal Rep. Pharmacutical Executive, vol. 20 No. 12, Dec. 2001.;;Overview of SkillScape Competence Manager SkillScape, 2000.;;Arthur Andersen Virtual Learning Network to Focus Competency Management Through Agreement with SkillScape, Business Wire, Aug. 22, 2000.;;Cooper, Kenneth Carlton, Effective Competency Modeling & Reporting AMA Publications, 2000, ISBN 0-8144-0548-7.;;Perkins, Debra S. et al, Best Practices For Customer Service Call Centers-An Exclusive Statistical Study Telemarketing & Call Center Solutions, vol. 15, No. 10, Apr. 1997.;;Pels, Mary Ann et al., Benchmarking call center performance Credit Union Executive Journal, vol. 39, No. 4, Jul./Aug. 1999.;;Coen, Dan, Creating a dynamic performance development program Direct Marketing, vol. 64, No. 3, Jul. 2001.;;Do Your Benchmarks Cover All the Media Your Company Uses Managing Customer Service, Mar. 1, 2001.;;Hicks, Ray, Companies put stock in benchmarking Direct Marketing, vol. 65, No. 6, Oct. 2002.;;van den Broek, Diane, Monitoring and survelliance in call centres: some responses from Australian workers Labour & Industry, vol. 12, No. 3, Apr. 2002.;;Miciak, Alan et al., Benchmarking service quality performance at business-to-business and business-to-consumer call centers The Journal of Business & Industrial Marketing, vol. 16, No. 5, 2001.;;Elwell, Ron et al., When you think ""monitoring,"" think ""john Smith"" Call Center Solutions, vol. 17, No. 12, Jun. 1999.;;CenterForce Technologies and BenchmarkPortal.com Team to Offer Comprehensive Call Center Benchmarking Solution PR Newswire, Jan. 23, 2001.;;University metes out data on measuring call center agents Service News, vol. 18, No. 13, Dec. 1998.;;van der Broek, Diane, Monitoring and survelliance in call centers Labour & Industry, vol. 12, No. 3, Apr. 2002.;;Rosatti et al., Measuring the reality of the customer experience Customer Inter@ction Solutions, vol. 20, No. 11, May 2002.;;Gillis, Marge, The Ideal Rep Pharmacutical Executive, vol. 20, No. 12, Dec. 2000.;;M.J. Allend and J.P. Furming, ""Methods for Using Global Position System to Find Close Services"", IBM Technical Disclosure Bulletin, Jan. 1998, pp. 693, vol. 41 No. 1.;;Dayco Statement Regarding Related Applications.;;Office Action issued Sep. 20, 2007 by EPO on Chinese Application No. 200380106314.X.;;Office Action issued Dec. 11, 2007 by US PTO on U.S. Appl. No. 10/306,025.;;Office Action issued Dec. 11, 2007 by US PTO on U.S. Appl. No. 10/306,386.;;Office Action issued Jan. 7, 2008 by US PTO on U.S. Appl. No. 10/306,248.;;Office Action issued Jan. 7, 2008 by US PTO on U.S. Appl. No. 10/306,564.;;Office Action issued Jan. 8, 2008 by US PTO on U.S. Appl. No. 10/306,563.;;Office Action issued Jan. 18, 2008 by US PTO on U.S. Appl. No. 10/305,811.;;Office Action issued Jan. 28, 2008 by US PTO on U.S. Appl. No. 10/306,026.;;Office Action issued Jan. 29, 2008 by US PTO on U.S. Appl. No. 10/306,386.;;Office Action issued Dec. 8, 2007 by EPO on Japanese Application No. 2004-554864.;;Office Action issued Dec. 8, 2007 by EPO on Japanese Application No. 2004-554863.;;Office Action issued Dec. 8, 2007 by EPO on Japanese Application No. 2004-554862.;;Office Action issued Dec. 8, 2007 by EPO on Japanese Application No. 2004-554870.;;Office Action issued Feb. 22, 2008 by EPO regarding decision on oral proceedings on Application No. 03808324.2-2221.;;Office Action issued Mar. 19, 2008 by US PTO on U.S. Appl. No. 10/306,705.;;Notice of Allowance issued Apr. 9, 2008 by the US PTO on U.S. Appl. No. 10/306,025.;;Office Action issued by US PTO on U.S. Appl. No. 10/306,705, dated Oct. 9, 2007.;;Office Action issued by EPO on Application No. 03808324.2-2221 dated Jul. 30, 2007 regarding summons to attend oral proceedings on Dec. 13, 2007.;;Notice of Allowance issued Jun. 6, 2008 by the US PTO on U.S. Appl. No. 10/306,563.;;Examiner's Report No. 2 issued by IP Australia May 29, 2008 on Application #2003302349.;;Office Action issued Jun. 9, 2008 by US PTO on U.S. Appl. No. 10/306,564.;;Office Action issued Jul. 7, 2008 by US PTO on U.S. Appl. No. 10/306,386.;;Office Action issued Jul. 9, 2008 by US PTO on U.S. Appl. No. 10/305,811.;;Office Action issued Jul. 14, 2008 by EPO on Canadian Application No. 2,507,519.;;Product Information Brochure, Click2Coach by Envision Telephony, 2001, 6 pages.;;Office Action, dated Mar. 22, 2007, issued on Australian Appl. No. 2003295947 (2 pages).;;Office Action, dated Apr. 26, 2007, issued on Australian Appl. No. 2003300686 (1 page).;;Office Action, dated Apr. 23, 2007, issued on Australian Appl. No. 2003302251 (2 pages).;;Office Action, dated Apr. 11, 2007, issued on Australian Appl. No. 2003302349 (2 pages).;;Office Action, dated Apr. 18, 2007, issued on Australian Appl. No. 2003302350 (2 pages).;;Office Action, dated Apr. 11, 2007, issued on Australian Appl. No. 2003304335 (2 pages).;;Office Action, dated Jul. 20, 2007, issued on European Appl. No. 03808339.0-2201 (4 pages).;;Office Action, dated Nov. 18, 2005, issued on European Appl. No. 03808324.2-2221 (6 pages).;;Office Action, dated Dec. 15, 2005, issued on European Appl. No. 03808332.5-1238 (5 pages).;;Office Action, dated Feb. 26, 2007, issued on European Appl. No. 03811847.7-1238 (5 pages).;;Office Action, dated Sep. 14, 2005, issued on European Appl. No. 03817417.3-2221 (6 pages).;;Office Action, dated Sep. 16, 2008, issued on Japanese Appl. No. 2004-554862 (2 pages).;;Office Action, dated Jan. 8, 2008, issued on Japanese Appl. No. 2004-554862 (4 pages).;;Office Action, dated Sep. 16, 2008, issued on Japanese Appl. No. 2004-554863 (3 pages).;;Office Action, dated Jan. 8, 2008, issued on Japanese Appl. No. 2004-554863 (6 pages).;;Office Action, dated Sep. 16, 2008, issued on Japanese Appl. No. 2004-554864 (3 pages).;;Office Action, dated Jan. 8, 2008, issued on Japanese Appl. No. 2004-554864 (5 pages).;;Office Action, dated Jan. 8, 2008, issued on Japanese Appl. No. 2004-554870 (6 pages).;;Office Action, dated Apr. 8, 2008, issued on Japanese Appl. No. 2004-557320 (13 pages).;;Office Action, dated Apr. 15, 2008, issued on Japanese Appl. No. 2005-503834 (3 pages).;;Office Action, dated Feb. 20, 2009, issued on Chinese Appl. No. 200380106314.X (4 pages).;;Office Action, dated Oct. 10, 2008, issued on Chinese Appl. No. 200380106314.X (8 pages).;;Office Action, dated Jan. 23, 2009, issued on Chinese Appl. No. 200380106321.X (6 pages).;;Office Action, dated Feb. 27, 2009, issued on Chinese Appl. No. 200380106329.6 (5 pages).;;Office Action, dated Feb. 15, 2008, issued on Chinese Appl. No. 200380106330.9 (7 pages).;;Office Action, dated Sep. 12, 2008, issued on Chinese Appl. No. 200380106330.9 (7 pages).;;Office Action, dated Aug. 3, 2006, issued on Indian Appl. No. 2589/DELNP/2005 (2 pages).;;Office Action, dated Oct. 5, 2006, issued on Indian Appl. No. 2589/DELNP/2005 (1 page).;;Office Action, dated Mar. 28, 2006, issued on Indian Appl. No. 2614/DELNP/2005 (2 pages).;;Office Action, dated May 2, 2006, issued on Indian Appl. No. 2687/DELNP/2005 (2 pages).;;Office Action, dated Mar. 20, 2006, issued on Indian Appl. No. 2688/DELNP/2005 (2 pages).;;Office Action, dated Apr. 12, 2006, issued on Indian Appl. No. 2693/DELNP/2005 (2 pages).;;Office Action, dated Apr. 26, 2006, issued on Indian Appl. No. 2694/DELNP/2005 (2 pages).;;Office Action, dated Feb. 4, 2009, issued on U.S. Appl. No. 10/305,811 (7 pages).;;Office Action, dated Aug. 14, 2006, issued on U.S. Appl. No. 10/305,811 (7 pages).;;Office Action, dated Nov. 22, 2005, issued on U.S. Appl. No. 10/305,811 (7 pages).;;Office Action, dated Apr. 15, 2005, issued on U.S. Appl. No. 10/306,248 (7 pages).;;Office Action, dated Oct. 20, 2005, issued on U.S. Appl. No. 10/306,248 (12 pages).;;Office Action, dated May, 30, 2006, issued on U.S. Appl. No. 10/306,248 (10 pages).;;Office Action, dated Dec. 7, 2006, issued on U.S. Appl. No. 10/306,248 (12 pages).;;Office Action, dated Jul. 24, 2007, issued on U.S. Appl. No. 10/306,248 (9 pages).;;Office Action, dated Aug. 26, 2005, issued on U.S. Appl. No. 10/306,563 (8 pages).;;Office Action, dated Feb. 13, 2006, issued on U.S. Appl. No. 10/306,563 (8 pages).;;Office Action, dated Oct. 6, 2006, issued on U.S. Appl. No. 10/306,563 (9 pages).;;Office Action, dated Jun. 28, 2007, issued on U.S. Appl. No. 10/306,563 (11 pages).;;Office Action, dated May 3, 2005, issued on U.S. Appl. No. 10/306,564 (8 pages).;;Office Action, dated Oct. 13, 2005, issued on U.S. Appl. No. 10/306,564 (11 pages).;;Office Action, dated Jun. 13, 2006, issued on U.S. Appl. No. 10/306,564 (10 pages).;;Office Action, dated Jan. 22, 2007, issued on U.S. Appl. No. 10/306,564 (12 pages).;;Office Action, dated Jul. 24, 2007, issued on U.S. Appl. No. 10/306,564 (9 pages).;;Office Action, dated Nov. 26, 2008, issued on U.S. Appl. No. 10/306,564 (16 pages).;;Office Action, dated Jan. 10, 2007, issued on U.S. Appl. No. 10/306,705 (7 pages).;;Office Action, dated Oct. 14, 2008, issued on U.S. Appl. No. 10/306,705 (13 pages).;;Office Action, dated Apr. 20, 2005, issued on U.S. Appl. No. 10/306,577 (6 pages).;;Office Action, dated Oct. 3, 2005, issued on U.S. Appl. No. 10/306,577 (5 pages).;;Advisory Action, dated Dec. 29, 2005, issued on U.S. Appl. No. 10/306,577 (3 pages).;;Office Action, dated May 4, 2006, issued on U.S. Appl. No. 10/306,577 (6 pages).;;Office Action, dated Sep. 9, 2005, issued on U.S. Appl. No. 10/305,835 (7 pages).;;Advisory Action, dated Apr. 23, 2008, issued on U.S. Appl. No. 10/306,386 (2 pages).;;Office Action, dated May 30, 2007, issued on U.S. Appl. No. 10/306,386 (8 pages).;;Office Action, dated Oct. 24, 2006, issued on U.S. Appl. No. 10/306,386 (9 pages).;;Office Action, dated Feb. 15, 2006, issued on U.S. Appl. No. 10/306,386 (7 pages).;;Office Action, dated Apr. 15, 2005, issued on U.S. Appl. No. 10/306,386 (6 pages).;;Office Action, dated Sep. 27, 2005, issued on U.S. Appl. No. 10/306,386 (9 pages).;;Advisory Action, dated Dec. 7, 2005, issued on U.S. Appl. No. 10/306,386 (3 pages).;;Office Action, dated Jan. 5, 2009, issued on U.S. Appl. No. 10/306,386 (12 pages).;;Office Action, dated May 5, 2005, issued on U.S. Appl. No. 10/306,026 (10 pages).;;Office Action, dated Oct. 14, 2005, issued on U.S. Appl. No. 10/306,026 (12 pages).;;Office Action, dated Apr. 11, 2006, issued on U.S. Appl. No. 10/306,026 (13 pages).;;Office Action, dated Dec. 28, 2006, issued on U.S. Appl. No. 10/306,026 (15 pages).;;Notice of Allowance, dated Dec. 28, 2005, issued on U.S. Appl. No. 10/305,835, with Examiner-Initiated Interview Summary, dated Dec. 14, 2005 (10 pages).;;Notice of Allowance, dated Dec. 5, 2006, issued on U.S. Appl. No. 10/306,577 (12 pages).",ACTIVE
234,CA,A1,CA 2507519 A1,093-444-015-767-644,2004-06-10,2004,CA 2507519 A,2003-11-26,IB 0306479 W;;US 30656402 A,2002-11-27,SEARCHING WITHIN A CONTACT CENTER PORTAL,New functions for a contact center system include: testing user~s comprehension of informational messages with a quiz; capturing insight of superior users having a KPI score above a threshold by having those users submit informationon why they perform so well; dynamically ordering solution s to issues by re-ranking the solutions periodically based on recency and frequency; integrating information for use by a contact center representativ e while online with a customer and information for use when not online; storin g content items in a telecommunications industry taxonomy; directing user feedback on a content item to the proper owner/manager of that content; communicating solution information using a solutions taxonomy; displaying a dual information system having a CRM application as well as reference materi al that is context-appropriate; enforcing completion of a group of templates wh en creating a content item to be published; ensuring a group of templates for a content item are complete before publishing them; and searching within a contact center system portal using a continuum of search functions.,ACCENTURE GLOBAL SERVICES GMBH,SHEARING ELISE;;FARRELL DANIEL C;;REID GREGORY S;;ADAMS KEVIN;;WONG SEVASTI;;LANE DAVID P;;FENTON CRAIG;;PICKERING LESLEY;;RITCHIE PAUL;;BELL RANDY;;STAUBITZ CLAUDIA;;LINGHAM ANTHONY;;RINGO TIMOTHY;;LIAN ELIZABETH H;;FORRESTER AUDREY,,https://lens.org/093-444-015-767-644,Patent Application,no,0,0,14,14,0,G06Q30/02;;G06Q30/02,G06Q30/02,,0,0,,,,EXPIRED
235,US,A1,US 2008/0288534 A1,092-963-281-752-398,2008-11-20,2008,US 17942908 A,2008-07-24,US 17942908 A;;US 30602502 A,2002-11-27,CONTENT FEEDBACK IN A MULTIPLE-OWNER CONTENT MANAGEMENT SYSTEM,New functions for a contact center system include: testing user's comprehension of informational messages with a quiz; capturing insight of superior users having a KPI score above a threshold by having those users submit information on why they perform so well; dynamically ordering solutions to issues by re-ranking the solutions periodically based on recency and frequency; integrating information for use by a contact center representative while online with a customer and information for use when not online; storing content items in a telecommunications industry taxonomy; directing user feedback on a content item to the proper owner/manager of that content; communicating solution information using a solutions taxonomy; displaying a dual information system having a CRM application as well as reference material that is context-appropriate; enforcing completion of a group of templates when creating a content item to be published; ensuring a group of templates for a content item are complete before publishing them; and searching within a contact center system portal using a continuum of search functions.,ACCENTURE LLP,REID GREGORY S;;RINGO TIMOTHY;;LANE DAVID P;;LIAN ELIZABETH H;;FARRELL DANIEL C;;FENTON CRAIG;;SHEARING ELISE;;BELL RANDY;;WONG SEVASTI;;LINGHAM ANTHONY;;FORRESTER AUDREY;;STAUBITZ CLAUDIA;;ADAMS KEVIN;;PICKERING LESLEY;;RITCHIE PAUL,BRITISH TELECOMMUNICATIONS PLC (2014-04-30);;ACCENTURE GLOBAL SERVICES LIMITED (2010-09-01),https://lens.org/092-963-281-752-398,Patent Application,yes,99,5,7,21,0,G06Q10/06398;;G06Q10/06398;;G06Q10/063;;G06Q10/063;;G06Q10/06393;;G06Q10/06393;;G06Q10/10;;G06Q10/10;;G06Q30/0601;;G06Q30/0601;;G06Q30/0641;;G06Q30/0641;;G06Q50/184;;G06Q50/184,G06F17/30;;G06Q10/06;;G06Q10/10;;G06Q30/06;;G06Q50/18,707103 R;;X707E17009,0,0,,,,EXPIRED
236,WO,A8,WO 2004/049098 A8,175-965-805-420-65X,2005-08-04,2005,IB 0306479 W,2003-11-26,US 30656402 A,2002-11-27,SEARCHING WITHIN A CONTACT CENTER PORTAL,New functions for a contact center system include: testing user's comprehension of informational messages with a quiz; capturing insight of superior users having a KPI score above a threshold by having those users submit informationon why they perform so well; dynamically ordering solutions to issues by re-ranking the solutions periodically based on recency and frequency; integrating information for use by a contact center representative while online with a customer and information for use when not online; storing content items in a telecommunications industry taxonomy; directing user feedback on a content item to the proper owner/manager of that content; communicating solution information using a solutions taxonomy; displaying a dual information system having a CRM application as well as reference material that is context-appropriate; enforcing completion of a group of templates when creating a content item to be published; ensuring a group of templates for a content item are complete before publishing them; and searching within a contact center system portal using a continuum of search functions.,ACCENTURE GLOBAL SERVICES GMBH;;BT GROUP PLC,LANE DAVID P;;REID GREGORY S;;RINGO TIMOTHY;;LIAN ELIZABETH H;;FARRELL DANIEL C;;FENTON CRAIG;;SHEARING ELISE;;BELL RANDY;;WONG SEVASTI;;LINGHAM ANTHONY;;FORRESTER AUDREY;;STAUBITZ CLAUDIA;;ADAMS KEVIN;;PICKERING LESLEY;;RITCHIE PAUL,,https://lens.org/175-965-805-420-65X,Patent Application,no,0,0,14,14,0,G06Q30/02;;G06Q30/02,G06Q30/02,,0,0,,,,PENDING
237,WO,A3,WO 2004/049097 A3,033-705-653-377-401,2004-10-07,2004,IB 0306465 W,2003-11-26,US 30602502 A;;US 30583502 A;;US 30638602 A,2002-11-27,CONTENT FEEDBACK IN A MULTIPLE-OWNER CONTENT MANAGEMENT SYSTEM,"A computer system may include a contact center interface and a presentation interface. The contact center interface may provide a user with access to a contact center application, which manages and renders information pertaining to customer&shy;centric problems. The presentation interface may provide the user with access to a content management system (or knowledge management system) for information regarding goods, services and associated support. The computer system may display two simultaneously visible content regions, where the operations in one content region are independent of operations in the second content region. One of the content regions may reflect the contact center interface while the other content region may reflect the information application interface. The two content regions may be dynamic such that while the regions are independent, the content displayed within one content region is context-appropriate to the other content region. Such a system may also include a display region for an instant messaging tool. The content management system may include a database having a set of content items stored in a taxonomy, where the taxonomy has at least two primary categories. The categories may associate items that represent products, items that represent services, items that represent information for campaigns, items that represent information for user procedures, and/or items that represent user intentions (customer needs). Each content item in the database may be associated to one or more content&shy;owners. A user may submit feedback for one of the content items. That feedback may be routed to the content-owner associated to the content item without requiring the user to know or to determine who the content-owner is. The content owner may be: a content author, a content manager, an advocate for the content owner, or a team of people. The feedback may be a comment explaining any errors in the content item, a rating of the usefulness of the content item, or a comment for content improvement.",ACCENTURE GLOBAL SERVICES GMBH;;BT GROUP PLC,REID GREGORY S;;RINGO TIMOTHY;;LANE DAVID P;;LIAN ELIZABETH H;;FARRELL DANIEL C;;FENTON CRAIG;;SHEARING ELISE;;BELL RANDY;;WONG SEVASTI;;LINGHAM ANTHONY;;FORRESTER AUDREY;;STAUBITZ CLAUDIA;;ADAMS KEVIN;;PICKERING LESLEY;;RITCHIE PAUL,,https://lens.org/033-705-653-377-401,Search Report,yes,3,0,10,21,0,G06Q30/02,G06F3/048;;G06F3/0482;;G06F3/0484;;G06Q30/00,,0,0,,,,PENDING
238,CA,A1,CA 2507310 A1,086-639-618-583-832,2004-06-17,2004,CA 2507310 A,2003-11-26,US 30585802 A;;US 0337779 W,2002-11-27,CAPTURING INSIGHT OF SUPERIOR USERS OF A CONTACT CENTER,New functions for a contact center system include: testing user's comprehension of informational messages with a quiz; capturing insight of superior users having a KPI score above a threshold by having those users submit information on why they perform so well; dynamically ordering solutio ns to issues by re-ranking the solutions periodically based on recency and frequency; integrating information for use by a contact center representativ e while online with a customer and information for use when not online; storin g content items in a telecommunications industry taxonomy; directing user feedback on a content item to the proper owner/manager of that content; communicating solution information using a solutions taxonomy; displaying a dual information system having a CRM application as well as reference materi al that is context-appropriate; enforcing completion of a group of templates wh en creating a content item to be published; ensuring a group of templates for a content item are complete before publishing them; and searching within a contact center system portal using a continuum of search functions.,ACCENTURE GLOBAL SERVICES GMBH;;BT GROUP PLC,RINGO TIMOTHY;;ADAMS KEVIN;;BELL RANDY;;STAUBITZ CLAUDIA;;LANE DAVID P;;LIAN ELIZABETH H;;FARRELL DANIEL C;;FENTON CRAIG;;SHEARING ELISE;;PICKERING LESLEY;;REID GREGORY S;;FORRESTER AUDREY;;LINGHAM ANTHONY;;WONG SEVASTI;;RITCHIE PAUL,,https://lens.org/086-639-618-583-832,Patent Application,no,0,0,14,14,0,G06Q10/06393;;G06Q10/06398;;G06Q10/10;;G06Q10/06393;;G06Q10/10;;G06Q10/06398,G06Q10/06;;G06Q10/10,,0,0,,,,EXPIRED
239,JP,A,JP 2009151797 A,122-911-395-989-360,2009-07-09,2009,JP 2009006636 A,2009-01-15,US 30656402 A,2002-11-27,SEARCHING WITHIN CONTACT CENTER PORTAL,"<P>PROBLEM TO BE SOLVED: To provide a contact center including an improved process and a computerized system for working in order to improve service to a customer and efficiency in its performance. <P>SOLUTION: A collection composed of the searching function is provided for a user for searching in a contact center portal, and the whole these searching functions are simultaneously presented on the same screen. The user can search a contents management system by determining a result by using the first searching function. If a response cannot be detected, the user can search the contents management system by determining the result by using the second searching function. If the response cannot be detected yet, the user can search the contents management system by determining the result by using the third searching function. A specific database can store a collection composed of information items on a product or the service on a customer needs searching characteristic. A group of these information items can be associated with specific customer needs or an intention. <P>COPYRIGHT: (C)2009,JPO&INPIT",ACCENTURE GLOBAL SERVICES GMBH;;BT GROUP PLC,LANE DAVID P;;REID GREGORY S;;RINGO TIMOTHY;;LIAN ELIZABETH H;;FARRELL DANIEL C;;FENTON CRAIG;;SHEARING ELISE;;BELL RANDY;;WONG SEVASTI;;LINGHAM ANTHONY;;FORRESTER AUDREY;;STAUBITZ CLAUDIA;;ADAMS KEVIN;;PICKERING LESLEY;;RITCHIE PAUL,,https://lens.org/122-911-395-989-360,Patent Application,no,4,0,14,14,0,G06Q30/02;;G06Q30/02,G06F17/30;;G06Q30/02,,0,0,,,,PENDING
240,US,B2,US 9785906 B2,145-710-830-236-851,2017-10-10,2017,US 201113313316 A,2011-12-07,US 201113313316 A;;US 17942908 A;;US 30602502 A,2002-11-27,Content feedback in a multiple-owner content management system,New functions for a contact center system include: testing user's comprehension of informational messages; capturing insight users having a KPI score above a threshold by having those users submit information on why they perform well; dynamically ordering solutions to issues by re-ranking the solutions periodically based on recency and frequency; integrating information for use by a contact center representative while online with a customer and information for use when not online; storing content items in a telecommunications industry taxonomy; directing user feedback on a content item to the proper owner/manager of that content; communicating solution information using a solutions taxonomy; displaying a dual information system having a CRM application and reference material that's context-appropriate; enforcing completion of a group of templates when creating a content item to be published; ensuring a group of templates for a content item are complete before publishing them; and searching within a contact center system.,REID GREGORY S;;RINGO TIMOTHY;;LANE DAVID P;;LIAN ELIZABETH H;;FARRELL DANIEL C;;FENTON CRAIG;;SHEARING ELISE;;BELL RANDY;;WONG SEVASTI;;LINGHAM ANTHONY;;FORRESTER AUDREY;;STAUBITZ CLAUDIA;;ADAMS KEVIN;;PICKERING LESLEY;;RITCHIE PAUL;;ACCENTURE GLOBAL SERVICES LTD,REID GREGORY S;;RINGO TIMOTHY;;LANE DAVID P;;LIAN ELIZABETH H;;FARRELL DANIEL C;;FENTON CRAIG;;SHEARING ELISE;;BELL RANDY;;WONG SEVASTI;;LINGHAM ANTHONY;;FORRESTER AUDREY;;STAUBITZ CLAUDIA;;ADAMS KEVIN;;PICKERING LESLEY;;RITCHIE PAUL,BRITISH TELECOMMUNICATIONS PLC (2014-04-30);;ACCENTURE GLOBAL SERVICES LIMITED (2014-04-30),https://lens.org/145-710-830-236-851,Granted Patent,yes,188,0,7,21,0,G06Q10/06398;;G06Q10/06398;;G06Q10/063;;G06Q10/063;;G06Q10/06393;;G06Q10/06393;;G06Q10/10;;G06Q10/10;;G06Q30/0601;;G06Q30/0601;;G06Q30/0641;;G06Q30/0641;;G06Q50/184;;G06Q50/184,G06Q10/00;;G06Q10/06;;G06Q10/10;;G06Q30/06;;G06Q50/18,,133,1,071-048-802-012-90X,10.1108/08858620110400205,"Thomas Li-Ping, Tang, and Sarsfield-Baldwin, Linda. “Distributive and Procedural Justice as Related to Satisfaction and Commitment”. Houston, TX: 1996. Print.;;Alban, “Customer Interaction Monitoring: Your Key to Measuring Service Perfonmance,” Australian Banking & Finance, Apr. 18, 2001, vol. 10, No. 6, 5 pages.;;Allen et al., “Method for Using Global Position System to Find Close Services,” IBM Technical Disclosure Bulletin, Jan. 1998, p. 693, vol. 41, No. 1, 1 page.;;Click2Coach Web Pages, Retrieved from www.envisiontelephony.com 2001, 2 pages.;;Product Infonmation Brochure, Click2Coach by Envision Telephony, 2001, 6 pages.;;“What Makes Your Contact Center Agents Truly Effective?,” Click2Coach by Envision Telephony, 2000, 8 pages.;;Cunliffe, “Super Systems Capture Expertise of the Specialist,” Toronto Star, Nov. 2, 1986, p. F-4, 3 pages.;;“Emvolve Perfonmance Manager Release 1.5,” Customer Inter@ction Solutions, Nov. 2001, pp. 53-56, vol. 20, No. 5, 4 pages.;;“eOn Communications and Eyretel Partner to Deliver Performance Improvement for Contact Centers,” PR Newswire, Apr. 4, 2002, 3 pages.;;Feasel et al., “Training Can Produce Better Reps,” Call Center Solutions, Oct. 1998, pp. 138-143, vol. 17, No. 4, 5 pages.;;“Kelly Services Expands KellyConnect Call Center Solution,” PR Newswire, Jan. 14, 2002, p. 1, 3 pages.;;“Kelly Services® Offers Improved Call Center Solution,” PR Newswire, Apr. 24, 2000, p. 1, 2 pages.;;“Knowlagent and Eyretel Partner to Deliver Integrated E-Learning Platform to Global Clients,” PR Newswire, May 10, 2001,4 pages.;;“Primus Taps OutSights to Deliver Expertise to Customers Shifting to Knowledge-Based Support,” Business Wire, Jun. 29, 1999, p. 1, 3 pages.;;Rosati, “Measuring the Reality of the Customer Experience,” Customer Inter@ction Solutions, May 2002, pp. 38-43, vol. 20, No. 11, 5 pages.;;“ServiceSoft Delivers ‘Smart Answers’ at Xerox,” Business Wire, Aug. 4, 1998, 2 pages.;;“Telvista Integrates eLearning and Quality Monitoring,” The Ascent Group, Inc., Call Center E-Journal, Aug. 2001, 5 pages.;;Tiwana, “The Knowledge Management Toolkit,” Prentice Hall, Dec. 6, 1999, ISBN: 0-13-012853-8m 106 pages.;;Office Action issued by EPO on Appl. No. 03808324.2-2221, dated Jul. 30, 2007, regarding summons to attend oral proceedings on Dec. 13, 2007, 8 pages.;;Office Action issued by the Chinese Patent Office on Chinese Appl. No. 200380106314.X, dated Sep. 28, 2007, 14 pages.;;Office Action issued on U.S. Appl. No. 10/306,705, dated Oct. 9, 2007, 11 pages.;;Office Action issued on U.S. Appl. No. 10/305,858, dated Oct. 19, 2007, 25 pages.;;Office Action issued on U.S. Appl. No. 10/306,386, dated Dec. 11, 2007, 12 pages.;;Office Action issued on U.S. Appl. No. 10/306,248, dated Jan. 7, 2008, 17 pages.;;Office Action issued on U.S. Appl. No. 10/306,564, dated Jan. 7, 2008, 20 pages.;;Office Action issued on U.S. Appl. No. 10/306,563, dated Jan. 8, 2008, 12 pages.;;Office Action issued on U.S. Appl. No. 10/305,811, dated Jan. 18, 2008, 15 pages.;;Notice of Allowance issued on U.S. Appl. No. 10/306,026, dated Jan. 28, 2008, 7 pages.;;Office Action issued on U.S. Appl. No. 10/306,386, dated Jan. 29, 2008, 14 pages.;;Dayco Statement Regarding Related Applications dated Dec. 30, 2003 (3 pages).;;Angus, Jeff, Diagnostic Utility Software, InfoWorld, vol. 15, Iss. 18, p. 64, May 3, 1993 (9 pages).;;Arthur Andersen Virtual Learning Network to Focus Competency Management Through Agreement with SkiiiScape, Business Wire, Aug. 22, 2000 (3 pages).;;CenterForce Technologies and BenchmarkPortal.com Team to Offer Comprehensive Call Center Benchmarking Solution, PR Newswire, Jan. 23, 2001 (2 pages).;;Coen, Dan, Creating a Dynamic Performance Development Program, Direct Marketing, vol. 64, No. 3, p. 44, Jul. 2001 (2 pages).;;Cooper, Kenneth Carlton, Effective Competency Modeling & Reporting, AMA Publications, 2000, ISBN 0-8144-0548-7 (37 pages).;;Do Your Benchmarks Cover All the Media Your Company Uses, Managing Customer Service, p. 2, Mar. 1, 2001 (5 pages).;;E.piphany E.6 Smart CRM Strategy of Next Generation Commerce Sites as Told by CEO Roger Siboni, Computopia, p. 58, 2002 (11 pages) (English Translation of Japanese Article).;;Elwell, Ron, When You Think ‘Monitoring,’ Think ‘John Smith,’ Call Center Solutions, vol. 17, No. 12, p. 60, Jun. 1999 (5 pages).;;Gillis, Marge and Katherine Beauchemin, The Ideal Rep., Pharmaceutical Executive, vol. 20, No. 12, p. 52 Dec. 2001 (7 pages).;;Google home page, http:/lweb.archive.org/web/2002052313451O/http://www2.google.com/, retrieved May 23, 2002 (1 page).;;Hicks, Ray, Companies Put Stock in Benchmarking, Direct Marketing, vol. 65, No. 6, p. 12, Oct. 2002 (4 pages).;;Homer, Alex et al., Professional Active Server Pages, Wrox Press, ISBN 1-861000-82-3, 1997 (16 pages).;;Kent, Les, Tape Backup Solutions, InfoWorld, vol. 13, Iss. 38, p. 64, Mar. 8, 1993 (2 pages).;;McNichols, Chuck, Script Junkie, New.Architect, Jun. 1999 (7 pages).;;Mehta, Diane and Henry McCracken, Seeing Is Believing, InfoWorld, vol. 16, Iss. 35, p. 68, Aug. 29, 1994 (3 pages).;;Miciak et al., Benchmarking Service Quality Performance at Business-to-Business and Business-to-Consumer Call Centers, The Journal of Business & Industrial Marketing, vol. 16, No. 5, p. 340, MCB University Press, 2001 (14 pages).;;Overview of SkiiiScape Competence Manager, SkiiiScape, 2000 (10 pages).;;Pels, Mary Ann and Suzanne Wright, Benchmarking Call Center Performance, Credit Union Executive Journal, vol. 39, No. 4, p. 38, Jul./Aug. 1999 (5 pages).;;Perkins, Debra S. and Jon Anton, Best Practices for Customer Service Call Centers—An Exclusive Statistical Study, Telemarketing & Call Center Solutions, vol. 15, No. 10, p. 80, Apr. 1997 (6 pages).;;Shared Services, Price Waterhouse Coopers, Apr. 8, 2006 (26 pages) (English Translation of Japanese Article).;;University Metes Out Data on Measuring Call Center Agents, Service News, vol. 18, No. 13, p. 2, Dec. 1998 (1 page).;;Van Den Broek, Dianne, Monitoring and Surveillance in Call Centres: Some Responses From Australian Workers, Labour & Industry, vol. 12, No. 3, Apr. 2002 (15 pages).;;Office Action, dated Dec. 23, 2004, issued on U.S. Appl. No. 10/305,811 (6 pages).;;Office Action, dated May 23, 2005, issued on U.S. Appl. No. 10/305,811 (7 pages).;;Advisory Office Action, dated Aug. 11, 2005, issued on U.S. Appl. No. 10/305,811 (3 pages).;;Office Action, dated Nov. 22, 2005, issued on U.S. Appl. No. 10/305,811 (7 pages).;;Office Action, dated Aug. 14, 2006, issued on U.S. Appl. No. 10/305,811 (7 pages).;;Miscellaneous Office Action, dated Jul. 11, 2007, issued on U.S. Appl. No. 10/305,811 (4 pages).;;Miscellaneous Office Action, dated Jul. 18, 2007, issued on U.S. Appl. No. 10/305,811 (4 pages).;;Advisory Office Action, dated Oct. 14, 2008, issued on U.S. Appl. No. 10/305,811 (3 pages).;;Office Action, dated Jul. 9, 2008, issued on U.S. Appl. No. 10/305,811 (9 pages).;;Office Action, dated Feb. 4, 2009, issued on U.S. Appl. No. 10/305,811 (7 pages).;;Office Action, dated Jul. 27, 2009, issued on U.S. Appl. No. 10/305,811 (8 pages).;;Miscellaneous Action, dated Jul. 21, 2004, issued on U.S. Appl. No. 10/305,835 (2 pages).;;Miscellaneous Action, dated Aug. 2, 2005, issued on U.S. Appl. No. 10/305,835 (2 pages).;;Office Action, dated Sep. 9, 2005, issued on U.S. Appl. No. 10/305,835 (7 pages).;;Notice of Allowance, dated Dec. 28, 2005, issued on U.S. Appl. No. 10/305,835, with Examiner-Initiated Interview Summary, dated Dec. 14, 2005 (10 pages).;;Office Action, dated Jun. 22, 2007, issued on U.S. Appl. No. 10/305,858 (19 pages).;;Office Action, dated Jul. 1, 2008, issued on U.S. Appl. No. 10/305,858 (16 pages).;;Office Action, dated Jan. 13, 2009, issued on U.S. Appl. No. 10/305,858 (22 pages).;;Office Action, dated Jun. 18, 2009, issued on U.S. Appl. No. 10/305,858 (22 pages).;;Office Action, dated Oct. 22, 2009, issued on U.S. Appl. No. 10/305,858 (25 pages).;;Notice of Allowance, dated Mar. 25, 2010, issued on U.S. Appl. No. 10/305,858 (7 pages).;;Office Action, dated May 5, 2005, issued on U.S. Appl. No. 10/306,026 (10 pages).;;Office Action, dated Oct. 14, 2005, issued on U.S. Appl. No. 10/306,026 (12 pages).;;Office Action, dated Apr. 11, 2006, issued on U.S. Appl. No. 10/306,026 (13 pages).;;Advisory Action, dated Aug. 22, 2006, issued on U.S. Appl. 10/306,026 (3 pages).;;Office Action, dated Dec. 28, 2006, issued on U.S. Appl. No. 10/306,026 (15 pages).;;Notice of Allowance, dated Aug. 8, 2007, issued on U.S. Appl. No. 10/306,026 (2 pages).;;Miscellaneous Action, dated Nov. 8, 2007, issued on U.S. Appl. No. 10/306,026 (2 pages).;;Office Action, dated Apr. 15, 2005, issued on U.S. Appl. No. 10/306,248 (7 pages).;;Office Action, dated Oct. 20, 2005, issued on U.S. Appl. No. 10/306,248 (12 pages).;;Advisory Action, dated Jan. 9, 2006, issued on U.S. Appl. No. 10/306,248 (2 pages).;;Office Action, dated May 30, 2006, issued on U.S. Appl, No. 10/306,248 (10 pages).;;Office Action, dated Dec. 7, 2006, issued on U.S. Appl. No. 10/306,248 (12 pages).;;Advisory Action, dated May 14, 2007, issued on U.S. Appl. No. 10/306,248 (3 pages).;;Office Action, dated Jul. 24, 2007, issued on U.S. Appl. No. 10/306,248 (9 pages).;;Miscellaneous Action, dated May 29, 2008, issued on U.S, Appl. No. 10/306,248 (2 pages).;;Examiner's Answer to Appeal Brief, dated Jan. 7, 2009, issued on U.S. Appl. No. 10/306,248 (16 pages).;;Office Action, dated Apr. 15, 2005, issued on U.S. Appl. No. 10/306,386 (6 pages).;;Office Action, dated Sep. 27, 2005, issued on U.S. Appl. No. 10/306,386 (9 pages).;;Advisory Action, dated Dec. 7, 2005, issued on U.S. Appl. No. 10/306,386 (3 pages).;;Office Action, dated Feb. 15, 2006, issued on U.S. Appl. No. 10/306,386 (7 pages).;;Office Action, dated Oct. 24, 2006, issued on U.S. Appl. No. 10/306,386 (9 pages).;;Office Action, dated May 30, 2007, issued on U.S. Appl. No. 10/306,386 (8 pages).;;Advisory Action, dated Apr. 23, 2008, issued on U.S. Appl. No. 10/306,386 (2 pages).;;Office Action, dated Jul. 7, 2008, issued on U.S. Appl. No. 10/306,386 (13 pages).;;Office Action, dated Jan. 5, 2009, issued on U.S. Appl. No. 10/306,386 (12 pages).;;Advisory Action, dated Apr. 15, 2009, issued on U.S. Appl. No. 10/306,386 (3 pages).;;Office Action, dated Jul. 21, 2009, issued on U.S. Appl. No. 10/306,386 (11 pages).;;Office Action, dated Jan. 22, 2010, issued on U.S. Appl. No. 10/306,386 (10 pages).;;Examiners Answer to Appeal Brief, dated Jul. 19, 2010, issued on U.S. Appl. No. 10/306,386 (11 pages).;;Office Action, dated Aug. 26, 2005, issued on U.S. Appl. No. 10/306,563 (8 pages).;;Office Action, dated Feb. 13, 2006, issued on U.S. Appl. No. 10/306,563 (8 pages).;;Office Action, dated Oct. 6, 2006, issued on U.S. Appl. No. 10/306,563 (9 pages).;;Office Action, dated Jun. 28, 2007, issued on U.S. Appl. No. 10/306,563 (11 pages).;;Advisory Action, dated Sep. 14, 2007, issued on U.S. Appl. No. 10/306,563 (3 pages).;;Notice of Allowance, dated Jun. 6, 2008, issued on U.S. Appl. No. 10/306,563 (4 pages).;;Notice of Allowance, dated Dec. 23, 2008, issued on Application No. 10/306,563 (2 pages).;;Office Action, dated May 3, 2005, issued on U.S. Appl. No. 10/306,564 (8 pages).;;Office Action, dated Oct. 13, 2005, issued on U.S. Appl. No. 10/306,564 (11 pages).;;Advisory Action, dated Jan. 17, 2006, issued on U.S. Appl. No. 10/306,564 (3 pages).;;Office Action, dated Jun. 13, 2006, issued on U.S. Appl. No. 10/306,564 (10 pages).;;Office Action, dated Jan. 22, 2007, issued on U.S. Appl. No. 10/306,564 (12 pages).;;Advisory Action, dated Apr. 16, 2007, issued on U.S. Appl. No. 10/306,564 (3 pages).;;Office Action, dated Jul. 24, 2007, issued on U.S. Appl. No. 10/306,564 (9 pages).;;Office Action, dated Mar. 13, 2008, issued on U.S. Appl. No. 10/306,564 (3 pages).;;Office Action, dated Jun. 9, 2008, issued on U.S. Appl. No. 10/306,564 (15 pages).;;Office Action, dated Nov. 26, 2008, issued on U.S. Appl. No. 10/306,564 (16 pages).;;Advisory Action, dated Mar. 18, 2009, issued on U.S. Appl. No. 10/306,564 (3 pages).;;Office Action, dated Jun. 2, 2009, issued on U.S. Appl. No. 10/306,564 (14 pages).;;Office Action, dated Dec. 17, 2009, issued on U.S. Appl. No. 10/306,564 (13 pages).;;Examiners Answer to Appeal Brief, dated Aug. 5, 2010, issued on U.S. Appl. No. 10/306,564 (1 page).;;Office Action, dated Apr. 20, 2005, issued on U.S. Appl. No. 10/306,577 (6 pages).;;Office Action, dated Oct. 3, 2005, issued on U.S. Appl. No. 10/306,577 (5 pages).;;Advisory Action, dated Dec. 29, 2005, issued on U.S. Appl. No. 10/306,577 (3 pages).;;Office Action, dated May 4, 2006, issued on U.S. Appl. No. 10/306,577 (6 pages).;;Notice of Allowance, dated Dec. 5, 2006, issued on U.S. Appl. No. 10/306,577 (12 pages).;;Office Action, dated Jan. 10, 2007, issued on U.S. Appl. No. 10/306,705 (7 pages).;;Advisory Action, dated Dec. 18, 2007, issued on U.S. Appl. No. 10/306,705 (3 pages).;;Office Action, dated Mar. 19, 2008, issued on U.S. Appl. No. 10/306,705 (10 pages).;;Office Action, dated Oct. 14, 2008, issued on U.S. Appl. No. 10/306,705 (13 pages).;;Office Action, dated Apr. 27, 2009, issued on U.S. Appl. No. 10/306,705 (12 pages).",EXPIRED
241,EP,A2,EP 1573470 A2,162-472-826-229-080,2005-09-14,2005,EP 03787162 A,2003-11-26,US 0337779 W;;US 30585802 A,2002-11-27,CAPTURING INSIGHT OF SUPERIOR USERS OF A CONTACT CENTER,,ACCENTURE GLOBAL SERVICES GMBH;;BT GROUP PLC,REID GREGORY S;;RINGO TIMOTHY;;LANE DAVID P;;LIAN ELIZABETH H;;FARRELL DANIEL C;;FENTON CRAIG;;SHEARING ELISE;;BELL RANDY;;WONG SEVASTI;;LINGHAM ANTHONY;;FORRESTER AUDREY;;STAUBITZ CLAUDIA;;ADAMS KEVIN;;PICKERING LESLEY;;RITCHIE PAUL,,https://lens.org/162-472-826-229-080,Patent Application,yes,0,0,14,14,0,G06Q10/06393;;G06Q10/06398;;G06Q10/10;;G06Q10/06393;;G06Q10/10;;G06Q10/06398,G06F17/30;;G06Q10/06;;G06Q10/10,,0,0,,,,DISCONTINUED
242,CA,C,CA 2507519 C,003-149-434-752-862,2018-07-31,2018,CA 2507519 A,2003-11-26,IB 0306479 W;;US 30656402 A,2002-11-27,SEARCHING WITHIN A CONTACT CENTER PORTAL,New functions for a contact center system include: testing user~s comprehension of informational messages with a quiz; capturing insight of superior users having a KPI score above a threshold by having those users submit informationon why they perform so well; dynamically ordering solutions to issues by re-ranking the solutions periodically based on recency and frequency; integrating information for use by a contact center representative while online with a customer and information for use when not online; storing content items in a telecommunications industry taxonomy; directing user feedback on a content item to the proper owner/manager of that content; communicating solution information using a solutions taxonomy; displaying a dual information system having a CRM application as well as reference material that is context-appropriate; enforcing completion of a group of templates when creating a content item to be published; ensuring a group of templates for a content item are complete before publishing them; and searching within a contact center system portal using a continuum of search functions.,ACCENTURE GLOBAL SERVICES GMBH;;BT GROUP PLC,LANE DAVID P;;REID GREGORY S;;RINGO TIMOTHY;;LIAN ELIZABETH H;;FARRELL DANIEL C;;FENTON CRAIG;;SHEARING ELISE;;BELL RANDY;;WONG SEVASTI;;LINGHAM ANTHONY;;FORRESTER AUDREY;;STAUBITZ CLAUDIA;;ADAMS KEVIN;;PICKERING LESLEY;;RITCHIE PAUL,,https://lens.org/003-149-434-752-862,Granted Patent,no,0,0,14,14,0,G06Q30/02;;G06Q30/02,G06F17/30;;G06Q30/02,,0,0,,,,EXPIRED
243,US,A1,US 2012/0150574 A1,043-270-303-966-700,2012-06-14,2012,US 201113313316 A,2011-12-07,US 201113313316 A;;US 17942908 A;;US 30602502 A,2002-11-27,CONTENT FEEDBACK IN A MULTIPLE-OWNER CONTENT MANAGEMENT SYSTEM,New functions for a contact center system include: testing user's comprehension of informational messages; capturing insight users having a KPI score above a threshold by having those users submit information on why they perform well; dynamically ordering solutions to issues by re-ranking the solutions periodically based on recency and frequency; integrating information for use by a contact center representative while online with a customer and information for use when not online; storing content items in a telecommunications industry taxonomy; directing user feedback on a content item to the proper owner/manager of that content; communicating solution information using a solutions taxonomy; displaying a dual information system having a CRM application and reference material that's context-appropriate; enforcing completion of a group of templates when creating a content item to be published; ensuring a group of templates for a content item are complete before publishing them; and searching within a contact center system.,REID GREGORY S;;RINGO TIMOTHY;;LANE DAVID P;;LIAN ELIZABETH H;;FARRELL DANIEL C;;FENTON CRAIG;;SHEARING ELISE;;BELL RANDY;;WONG SEVASTI;;LINGHAM ANTHONY;;FORRESTER ANDREY;;STAUBITZ CLAUDIA;;ADAMS KEVIN;;PICKERING LESLEY;;RITCHIE PAUL;;ACCENTURE LLP,REID GREGORY S;;RINGO TIMOTHY;;LANE DAVID P;;LIAN ELIZABETH H;;FARRELL DANIEL C;;FENTON CRAIG;;SHEARING ELISE;;BELL RANDY;;WONG SEVASTI;;LINGHAM ANTHONY;;FORRESTER ANDREY;;STAUBITZ CLAUDIA;;ADAMS KEVIN;;PICKERING LESLEY;;RITCHIE PAUL,BRITISH TELECOMMUNICATIONS PLC (2014-04-30);;ACCENTURE GLOBAL SERVICES LIMITED (2014-04-30),https://lens.org/043-270-303-966-700,Patent Application,yes,14,13,7,21,0,G06Q10/06398;;G06Q10/06398;;G06Q10/063;;G06Q10/063;;G06Q10/06393;;G06Q10/06393;;G06Q10/10;;G06Q10/10;;G06Q30/0601;;G06Q30/0601;;G06Q30/0641;;G06Q30/0641;;G06Q50/184;;G06Q50/184,G06Q10/00;;G06Q10/06;;G06Q10/10;;G06Q30/06;;G06Q50/18,705/7.11,1,0,,,"Thomas Li-Ping, Tang, and Sarsfield-Baldwin, Linda. ""Distributive and Procedural Justice as Related to Satisfaction and Commitment."". Houston, TX: 1996. Print.",EXPIRED
244,EP,A2,EP 1570401 A2,054-754-715-171-031,2005-09-07,2005,EP 03808332 A,2003-11-26,IB 0306465 W;;US 30602502 A;;US 30583502 A;;US 30638602 A,2002-11-27,CONTENT FEEDBACK IN A MULTIPLE-OWNER CONTENT MANAGEMENT SYSTEM,,ACCENTURE GLOBAL SERVICES GMBH;;BT GROUP PLC,REID GREGORY S;;RINGO TIMOTHY;;LANE DAVID P;;LIAN ELIZABETH H;;FARRELL DANIEL C;;FENTON CRAIG;;SHEARING ELISE;;BELL RANDY;;WONG SEVASTI;;LINGHAM ANTHONY;;FORRESTER AUDREY;;STAUBITZ CLAUDIA;;ADAMS KEVIN;;PICKERING LESLEY;;RITCHIE PAUL,BRITISH TELECOMMUNICATIONS PLC (2014-08-27);;ACCENTURE GLOBAL SERVICES LIMITED (2014-08-27),https://lens.org/054-754-715-171-031,Patent Application,yes,1,0,10,21,0,G06Q30/02,G06F3/048;;G06F3/0482;;G06F3/0484;;G06Q30/00,,1,0,,,"KENNETH COX ET AL: ""A Multi-Modal Natural Language Interface to an Information Visualization Environment"", INTERNATIONAL JOURNAL OF SPEECH TECHNOLOGY, 1 July 2001 (2001-07-01), Boston, pages 297 - 314, XP055144203, Retrieved from the Internet <URL:http://download.springer.com/static/pdf/902/art%3A10.1023%2FA%3A1011368926479.pdf?auth66=1412432568_09cb21c451c99ff11c20c3f8cad65fa8&ext=.pdf> DOI: 10.1023/A:1011368926479",DISCONTINUED
245,US,B2,US 9396473 B2,083-466-139-947-086,2016-07-19,2016,US 30656402 A,2002-11-27,US 30656402 A,2002-11-27,Searching within a contact center portal,New functions for a contact center system include: testing user's comprehension of informational messages with a quiz; capturing insight of superior users having a KPI score above a threshold by having those users submit information on why they perform so well; dynamically ordering solutions to issues by re-ranking the solutions periodically based on recency and frequency; integrating information for use by a contact center representative while online with a customer and information for use when not online; storing content items in a telecommunications industry taxonomy; directing user feedback on a content item to the proper owner/manager of that content; communicating solution information using a solutions taxonomy; displaying a dual information system having a CRM application as well as reference material that is context-appropriate; enforcing completion of a group of templates when creating a content item to be published; ensuring a group of templates for a content item are complete before publishing them; and searching within a contact center system portal using a continuum of search functions.,LANE DAVID P;;REID GREGORY S;;RINGO TIMOTHY;;LIAN ELIZABETH H;;FARRELL DANIEL C;;FENTON CRAIG;;SHEARING ELISE;;BELL RANDY;;WONG SEVASTI;;LINGHAM ANTHONY;;FORRESTER AUDREY;;STAUBITZ CLAUDIA;;ADAMS KEVIN;;PICKERING LESLEY;;RITCHIE PAUL;;ACCENTURE GLOBAL SERVICES LTD;;BRITISH TELECOMM,LANE DAVID P;;REID GREGORY S;;RINGO TIMOTHY;;LIAN ELIZABETH H;;FARRELL DANIEL C;;FENTON CRAIG;;SHEARING ELISE;;BELL RANDY;;WONG SEVASTI;;LINGHAM ANTHONY;;FORRESTER AUDREY;;STAUBITZ CLAUDIA;;ADAMS KEVIN;;PICKERING LESLEY;;RITCHIE PAUL,BT GROUP PLC (2003-11-02);;BRITISH TELECOMMUNICATIONS PLC (2014-04-30);;ACCENTURE GLOBAL SERVICES LIMITED (2014-04-30);;ACCENTURE GLOBAL SERVICES GMBH (2003-11-02),https://lens.org/083-466-139-947-086,Granted Patent,yes,113,0,14,14,0,G06Q30/02;;G06Q30/02,G06F17/30;;G06Q30/02,,95,1,071-048-802-012-90X,10.1108/08858620110400205,"M. J. Allen and J. P. Furming, ""Method for Using Global Position System to Find Close Services"", IBM Technical Disclosure Bulletin, vol. 41 No. 1, Jan. 1998, pp. 693-694.;;Dayco Statement Regarding Related Applications.;;Alban, Oscar, Customer interaction monitoring: your key to measuring service performance, Australian Banking & Finance, vol. 10, No. 6, Apr. 18, 2001.;;Click2Coach Web Pages, Retrieved from www.envisiontelephony.com, 2001.;;eOn Communications and Eyretel Partner to Deliver Performance Improvement for Contact Centers, PR Newswire, Apr. 4, 2002.;;Feasel, Marnie et al., Training Can Produce Better Reps, Call Center Solutions, vol. 17, No. 4, Oct. 1998, pp. 138-143.;;Kelly Services Expands KellyConnect Call Center Solution, PR Newswire, Jan. 14, 2002.;;Kelly Services Offers Improved Call Center Solution, PR Newswire, Apr. 24, 2000.;;Knowlagent and Eyretel Partner to Deliver Integrated E-Learning Platform to Global Clients, PR Newswire, May 10, 2001.;;Primus Taps OutSights to Deliver Expertise to Customers Shifting to Knowledge-Based Support, Business Wire, Jun. 29, 1999.;;Rosati, Marlene et al., Measuring the Reality of the Customer Experience, Customer Interaction Solutions, May 2002, pp. 38-43.;;Televista Integrates eLearning and Quality Monitoring the Ascent Group, Inc. Call Center E-Journal, Aug. 2001.;;What makes your contact center agents truly effective?, Envision Telephony, Click2Coach, 2000.;;Office Action Issued by US PTO on U.S. Appl. No. 10/306,705, dated Oct. 9, 2007.;;Office Action issued by EPO on Application No. 03808324.2-2221 dated Jul. 30, 2007 regarding summons to attend oral proceedings on Dec. 13, 2007.;;Cunliffe, Alison, Super systems capture expertise of the specialist Toronto Star, Nov. 2, 1986.;;Emvolve Performance Manager Release 1.5 Customer Inter@action Solutions, vol. 20, No. 5, Nov. 20, 2001, pp. 53-56.;;ServiceSoft Delivers ""Smart Answers"" at Xerox Business Wire, Aug. 4, 1998.;;Tiwana, Amrit, The Knowledge Management Toolkit Prentice Hall, Dec. 1999, ISN: 0-13-012853-8.;;Office Action issued Sep. 20, 2007 by EPO on Chinese Application No. 200380106314.X.;;Office Action Issued Oct. 19, 2007 by US PTO on U.S. Appl. No. 10/305,858.;;Office Action issued Dec. 11, 2007 by US PTO on U.S. Appl. No. 10/306,025.;;Office Action issued Dec. 11, 2007 by US PTO on U.S. Appl. No. 10/306,386.;;Office Action issued Jan. 7, 2008 by US PTO on U.S. Appl. No. 10/306,248.;;Office Action issued Jan. 8, 2008 by US PTO on U.S. Appl. No. 10/306,563.;;Office Action issued Jan. 18, 2008 by US PTO on U.S. Appl. No. 10/305,811.;;Office Action issued Jan. 28, 2008 by US PTO on U.S. Appl. No. 10/306,026.;;Office Action issued Jan. 29, 2008 by US PTO on U.S. Appl. No. 10/306,386.;;Office Action issued Dec. 8, 2007 by EPO on Japanese Application No. 2004-554864.;;Office Action issued Dec. 8, 2007 by EPO on Japanese Application No. 2004-554863.;;Office Action issued Dec. 8, 2007 by EPO on Japanese Application No. 2004-554862.;;Office Action issued Dec. 8, 2007 by EPO on Japanese Application No. 2004-554870.;;Office Action issued Feb. 22, 2008 by EPO regarding decision on oral proceedings on Application No. 03808324.2-2221.;;Office Action issued Mar. 19, 2008 by US PTO on U.S. Appl. No. 10/306,705.;;Notice of Allowance issued Apr. 9, 2008 by the US PTO on U.S. Appl. No. 10/306,025.;;Notice of Allowance issued Jun. 6, 2008 by the US PTO on U.S. Appl. No. 10/306,563.;;Examiner's Report No. 2 issued by IP Australia May 29, 2008 on Application #2003302349.;;Arthur Andersen Virtual Learning Network to Focus Competency Management Through Agreement with SkillScape, Business Wire, Aug. 22, 2000.;;Cooper, Kenneth Carlton, Effective Competency Modeling & Reporting AMA Publications, 2000, ISBN 0-8144-0548-7.;;Gillis, Marget et al., The Ideal Rep. Pharmaceutical Executive, vol. 20. No. 12, Dec. 2001.;;Overview of SkillScape Competence Manager SkillScape, 2000.;;Office Action issued Jul. 1, 2008 by US PTO on U.S. Appl. No. 10/305,858.;;Office Action issued Jul. 7, 2008 by US PTO on U.S. Appl. No. 10/306,386.;;Office Action issued Jul. 9, 2008 by US PTO on U.S. Appl. No. 10/305,811.;;Office Action issued Jul. 14, 2008 by EPO on Canadian Application No. 2,507,519.;;Coen, ""Creating a Dynamic Performance Development Program,"" Direct Marketing, vol. 64, No. 3, pp. 44-45, Jul. 2001.;;Elwell, Ron, ""When You Think Monitoring,"" Think ""John Smith,"" Call Center Solutions, vol. 17, No. 12, pp. 60-66, Jun. 1999.;;Hicks, Ray, ""Companies Put Stock in Benchmarking,"" Direct Marketing, vol. 65, No. 6, Oct. 2002.;;Miciak et al., ""Benchmarking Service Quality Performance at Business-to-Business and Business-to-Consumer Call Centers,"" The Journal of Business & Industrial Marketing, vol. 16, No. 5, pp. 340-353, 2001.;;Pels et al., ""Benchmarking Call Center Performance,"" Credit Union Executive Journal, vol. 39, No. 4, pp. 38-42, Jul./Aug. 1999.;;Perkins et al., ""Best Practices for Customer Service Call Centers-An Exclusive Statistical Study,"" Telemarketing & Call Center Solutions, vol. 15, No. 10, pp. 80-88, Apr. 1997.;;Van Den Broek, Diane, ""Monitoring and Surveillance in Call Centres: Some Responses From Australian Workers,"" Labour & Industry, vol. 12, No. 3, Apr. 2002.;;Product Information Brochure, Click2Coach by Envision Telephony, 2001, 6 pages.;;""CenterForce Technologies and BenchmarkPortal.com Team to Offer Comprehensive Call Center Benchmarking Solution,"" PR Newswire, Jan. 23, 2001.;;""Do Your Benchmarks Cover All the Media Your Company Uses,"" Managing Customer Service, pp. 2-4, Mar. 1, 2001.;;""University Metes Out Data on Measuring Call Center Agents,"" Service News, vol. 18, No. 13, p. 2, Dec. 1998.;;Office Action, dated Feb. 4, 2009, issued on U.S. Appl. No. 10/305,811 (7 pages).;;Office Action, dated Aug. 14, 2006, issued on U.S. Appl. No. 10/305,811 (7 pages).;;Office Action, dated Nov. 22, 2005, issued on U.S. Appl. No. 10/305,811 (7 pages).;;Office Action, dated Jan. 13, 2009, issued on U.S. Appl. No. 10/305,858 (22 pages).;;Office Action, dated Jun. 22, 2007, issued on U.S. Appl. No. 10/305,858 (18 pages).;;Office Action, dated Apr. 15, 2005, issued on U.S. Appl. No. 10/306,248 (7 pages).;;Office Action, dated Oct. 20, 2005, issued on U.S. Appl. No. 10/306,248 (12 pages).;;Office Action, dated May 30, 2006, issued on U.S. Appl. No. 10/306,248 (10 pages).;;Office Action, dated Dec. 7, 2006, issued on U.S. Appl. No. 10/306,248 (11 pages).;;Office Action, dated Jul. 24, 2007, issued on U.S. Appl. No. 10/306,248 (9 pages).;;Office Action, dated Aug. 26, 2005, issued on U.S. Appl. No. 10/306,563 (8 pages).;;Office Action, dated Feb. 13, 2006, issued on U.S. Appl. No. 10/306,563 (8 pages).;;Office Action, dated Oct. 6, 2006, issued on U.S. Appl. No. 10/306,563 (9 pages).;;Office Action, dated Jun. 28, 2007, issued on U.S. Appl. No. 10/306,563 (11 pages).;;Notice of Allowance, dated Jan. 28, 2008, issued on U.S. Appl. No. 10/306,026 (5 pages).;;Office Action, dated Mar. 22, 2007, issued by the Australian Patent Office for Australian Appl. No. 2003295947 (2 pages).;;Office Action, dated Apr. 18, 2007, issued by the Australian Patent Office for Australian Appl. No. 2003302350 (2 pages).;;Office Action, dated Apr. 23, 2007, issued by the Australian Patent Office for Australian Appl. No. 2003302251 (2 pages).;;Office Action, dated Oct. 10, 2008, issued by the Chinese Patent Office on Chinese Appl. No. 200380106314.X (8 pages).;;Office Action, dated Feb. 20, 2009, issued by the Chinese Patent Office on Chinese Appl. No. 200380106314.X (3 pages).;;Office Action, dated Feb. 15, 2008, issued by the Chinese Patent Office on Chinese Appl. No. 200380106330.9 (7 pages).;;Office Action, dated Sep. 12, 2008, issued by the Chinese Patent Office on Chinese Appl. No. 200380106330.9 (7 pages).;;Office Action, dated Jan. 23, 2009, issued by the Chinese Patent Office on Chinese Appl. No. 200380106321.X (6 pages).;;Office Action, dated Jul. 20, 2007, issued by EPO on European Appl. No. 03808339.0-2201 (4 pages).;;Office Action, dated Nov. 18, 2005, issued by EPO on European Appl. No. 03808324.2-2221 (6 pages).;;Office Action, dated Dec. 15, 2005, issued by EPO on European Appl. No. 03808332.5-1238 (5 pages).;;Office Action, dated May 2, 2006, issued by the India Patent Office on Indian Appl. No. 02687/DELNP/2005 (2 pages).;;Office Action, dated Mar. 20, 2006, issued by the India Patent Office on Indian Appl. No. 02688/DELNP/2005 (2 pages).;;Office Action, dated Sep. 4, 2008, issued by Japanese Patent Office on Japanese Appl. No. 2004-554862 (5 pages).;;Office Action, dated Dec. 20, 2007, issued by Japanese Patent Office on Japanese Appl. No. 2004-554862 (4 pages).;;Office Action, dated Sep. 4, 2008, issued by Japanese Patent Office on Japanese Appl. No. 2004-554863 (5 pages).;;Office Action, dated Dec. 20, 2007, issued by Japanese Patent Office on Japanese Appl. No. 2004-554863 (7 pages).;;Office Action, dated Sep. 4, 2008, issued by Japanese Patent Office on Japanese Appl. No. 2004-554864 (6 pages).;;Office Action, dated Dec. 20, 2007, issued by Japanese Patent Office on Japanese Appl. No. 2004-554870 (7 pages).;;Office Action, dated Mar. 26, 2008, issued by Japanese Patent Office on Japanese Appl. No. 2004-557320 (13 pages).;;PCT International Search Report for International Appl. No. PCT/US03/37779, dated Jun. 16, 2006 (4 pages).;;Canadian Intellectual Property Office, Official Communication, Canadian Patent Application No. 2,507,619, May 8, 2014.;;Google, ""Google"", http://web.archive.org/web/20020523134510/http://www2.google.com, 2002 1 page.;;Communication from Canadian Intellectual Property Office corresponding to Canada Application No. 2,507,519, dated Jun. 8, 2015, 10 pages.",EXPIRED
246,EP,A2,EP 1573590 A2,010-438-426-681-480,2005-09-14,2005,EP 03808339 A,2003-11-26,IB 0306479 W;;US 30656402 A,2002-11-27,SEARCHING WITHIN A CONTACT CENTER PORTAL,,ACCENTURE GLOBAL SERVICES GMBH;;BT GROUP PLC,LANE DAVID P;;REID GREGORY S;;RINGO TIMOTHY;;LIAN ELIZABETH H;;FARRELL DANIEL C;;FENTON CRAIG;;SHEARING ELISE;;BELL RANDY;;WONG SEVASTI;;LINGHAM ANTHONY;;FORRESTER AUDREY;;STAUBITZ CLAUDIA;;ADAMS KEVIN;;PICKERING LESLEY;;RITCHIE PAUL,BRITISH TELECOMMUNICATIONS PLC (2014-08-27);;ACCENTURE GLOBAL SERVICES LIMITED (2018-01-03);;BRITISH TELECOMMUNICATIONS PUBLIC LIMITED COMPANY (2018-01-03),https://lens.org/010-438-426-681-480,Patent Application,yes,0,1,14,14,0,G06Q30/02;;G06Q30/02,G06Q30/02,,1,0,,,See references of WO 2004049098A3,DISCONTINUED
247,AU,B2,AU 2003/302350 B2,011-501-920-168-741,2008-07-03,2008,AU 2003/302350 A,2003-11-26,IB 0306479 W;;US 30656402 A,2002-11-27,Searching within a contact center portal,,ACCENTURE GLOBAL SERVICES LTD;;BRITISH TELECOMM,RITCHIE PAUL;;FORRESTER AUDREY;;FENTON CRAIG;;LANE DAVID P;;PICKERING LESLEY;;LINGHAM ANTHONY;;ADAMS KEVIN;;REID GREGORY S;;WONG SEVASTI;;SHEARING ELISE;;STAUBITZ CLAUDIA;;RINGO TIMOTHY;;BELL RANDY;;LIAN ELIZABETH H;;FARRELL DANIEL C,ACCENTURE GLOBAL SERVICES LIMITED; BRITISH TELECOM (2014-10-02),https://lens.org/011-501-920-168-741,Granted Patent,no,6,0,14,14,0,G06Q30/02;;G06Q30/02,G06Q30/02,,0,0,,,,EXPIRED
248,US,B2,US 7062505 B2,035-687-277-085-558,2006-06-13,2006,US 30583502 A,2002-11-27,US 30583502 A,2002-11-27,Content management system for the telecommunications industry,New functions for a contact center system include: testing user's comprehension of informational messages with a quiz; capturing insight of superior users having a KPI score above a threshold by having those users submit information on why they perform so well; dynamically ordering solutions to issues by re-ranking the solutions periodically based on recency and frequency; integrating information for use by a contact center representative while online with a customer and information for use when not online; storing content items in a telecommunications industry taxonomy; directing user feedback on a content item to the proper owner/manager of that content; communicating solution information using a solutions taxonomy; displaying a dual information system having a CRM application as well as reference material that is context-appropriate; enforcing completion of a group of templates when creating a content item to be published; ensuring a group of templates for a content item are complete before publishing them; and searching within a contact center system portal using a continuum of search functions.,ACCENTURE GLOBAL SERVICES GMBH,LANE DAVID P;;REID GREGORY S;;RINGO TIMOTHY;;LIAN ELIZABETH H;;FARRELL DANIEL C;;FENTON CRAIG;;SHEARING ELISE;;BELL RANDY;;WONG SEVASTI;;LINGHAM ANTHONY;;FORRESTER AUDREY;;STAUBITZ CLAUDIA;;ADAMS KEVIN;;PICKERING LESLEY;;RITCHIE PAUL,BT GROUP PLC (2003-11-02);;BRITISH TELECOMMUNICATIONS PLC (2014-04-30);;ACCENTURE GLOBAL SERVICES LIMITED (2010-09-01);;ACCENTURE GLOBAL SERVICES GMBH (2003-11-02),https://lens.org/035-687-277-085-558,Granted Patent,yes,54,19,2,21,0,G06Q30/02;;G06Q30/02;;Y10S707/99933;;Y10S707/99931;;Y10S707/99943,G06Q30/02;;G06F17/00,707/102;;707/1;;707/3;;707/100;;707/200,1,0,,,Dayco Statement Regarding Related Applications.,ACTIVE
249,CA,A1,CA 2705906 A1,048-037-420-243-561,2009-06-04,2009,CA 2705906 A,2008-11-24,US 99033007 P;;US 27483408 A;;US 2008/0084469 W,2007-11-27,IMIDAZO-THIAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS,"Compounds of formula I that inhibit protein kinases, compositions containing the compounds and methods of treating diseases using the compounds are disclosed. Formula I and therapeutically acceptable salts, prodrugs and salts of prodrugs thereof, wherein X is CH or N; A1 is R1, OR1. NHR1, N(R1)2, NHC(O)R1, NHC(O)NHR1, NHC(O)N(R1)2, NHC(O)OR1, C(O)NHR1, C(O)N(R1)2, C=NOR1, or C(NH2)NOC(O)R1;",ABBOTT LAB,BAMAUNG NWE Y;;BELL RANDY L;;CLARK RICHARD F;;ERICKSON SCOTT A;;FIDANZE STEVE D;;HUBBARD ROBERT D;;MANTEI ROBERT A;;SHEPPARD GEORGE S;;SORENSEN BRYAN K;;WANG GARY T;;WANG JIEYI;;SARRIS KATHY,,https://lens.org/048-037-420-243-561,Patent Application,no,0,0,7,7,0,A61P35/00;;A61P43/00;;C07D513/04;;C07D513/04,C07D513/04;;A61K31/425;;A61P35/00,,0,0,,,,DISCONTINUED
250,US,A1,US 2004/0162812 A1,052-055-185-111-174,2004-08-19,2004,US 30656402 A,2002-11-27,US 30656402 A,2002-11-27,Searching within a contact center portal,"
   New functions for a contact center system include: testing user's comprehension of informational messages with a quiz; capturing insight of superior users having a KPI score above a threshold by having those users submit information on why they perform so well; dynamically ordering solutions to issues by re-ranking the solutions periodically based on recency and frequency; integrating information for use by a contact center representative while online with a customer and information for use when not online; storing content items in a telecommunications industry taxonomy; directing user feedback on a content item to the proper owner/manager of that content; communicating solution information using a solutions taxonomy; displaying a dual information system having a CRM application as well as reference material that is context-appropriate; enforcing completion of a group of templates when creating a content item to be published; ensuring a group of templates for a content item are complete before publishing them; and searching within a contact center system portal using a continuum of search functions. 
",LANE DAVID P.;;REID GREGORY S.;;RINGO TIMOTHY;;LIAN ELIZABETH H.;;FARRELL DANIEL C.;;FENTON CRAIG;;SHEARING ELISE;;BELL RANDY;;WONG SEVASTI;;LINGHAM ANTHONY;;FORRESTER AUDREY;;STAUBITZ CLAUDIA;;ADAMS KEVIN;;PICKERING LESLEY;;RITCHIE PAUL,LANE DAVID P;;REID GREGORY S;;RINGO TIMOTHY;;LIAN ELIZABETH H;;FARRELL DANIEL C;;FENTON CRAIG;;SHEARING ELISE;;BELL RANDY;;WONG SEVASTI;;LINGHAM ANTHONY;;FORRESTER AUDREY;;STAUBITZ CLAUDIA;;ADAMS KEVIN;;PICKERING LESLEY;;RITCHIE PAUL,BT GROUP PLC (2003-11-02);;BRITISH TELECOMMUNICATIONS PLC (2014-04-30);;ACCENTURE GLOBAL SERVICES LIMITED (2014-04-30);;ACCENTURE GLOBAL SERVICES GMBH (2003-11-02),https://lens.org/052-055-185-111-174,Patent Application,yes,96,45,14,14,0,G06Q30/02;;G06Q30/02,G06Q30/02,707/3,0,0,,,,EXPIRED
251,EP,A1,EP 2222682 A1,163-997-533-929-655,2010-09-01,2010,EP 08855224 A,2008-11-24,US 2008/0084469 W;;US 99033007 P;;US 27483408 A,2007-11-27,IMIDAZO-THIAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS,,ABBOTT LAB,BAMAUNG NWE Y;;BELL RANDY L;;CLARK RICHARD F;;ERICKSON SCOTT A;;FIDANZE STEVE D;;HUBBARD ROBERT D;;MANTEI ROBERT A;;SHEPPARD GEORGE S;;SORENSEN BRYAN K;;WANG GARY T;;WANG JIEYI;;SARRIS KATHY,ABBVIE INC. (2013-06-12),https://lens.org/163-997-533-929-655,Patent Application,yes,0,0,7,7,0,A61P35/00;;A61P43/00;;C07D513/04;;C07D513/04,C07D513/04;;A61K31/425;;A61P35/00,,1,0,,,See references of WO 2009070516A1,DISCONTINUED
252,AU,A8,AU 2003/295947 A8,087-146-944-245-557,2004-06-23,2004,AU 2003/295947 A,2003-11-26,US 30585802 A;;US 0337779 W,2002-11-27,Capturing insight of superior users of a contact center,,ACCENTURE GLOBAL SERVICES GMBH;;BT GROUP PLC,SHEARING ELISE;;BELL RANDY;;WONG SEVASTI;;LINGHAM ANTHONY;;FORRESTER AUDREY;;STAUBITZ CLAUDIA;;ADAMS KEVIN;;PICKERING LESLEY;;RITCHIE PAUL;;REID GREGORY S;;RINGO TIMOTHY;;LANE DAVID P;;LIAN ELIZABETH H;;FARRELL DANIEL C;;FENTON CRAIG,BRITISH TELECOMMUNICATIONS PLC; ACCENTURE GLOBAL S (2014-10-02),https://lens.org/087-146-944-245-557,Patent Application,no,0,0,14,14,0,G06Q10/06393;;G06Q10/06398;;G06Q10/10;;G06Q10/06393;;G06Q10/10;;G06Q10/06398,G06Q10/06;;G06Q10/10,,0,0,,,,EXPIRED
253,AU,A1,AU 2003/295947 A1,027-721-862-179-092,2004-06-23,2004,AU 2003/295947 A,2003-11-26,US 30585802 A;;US 0337779 W,2002-11-27,CAPTURING INSIGHT OF SUPERIOR USERS OF A CONTACT CENTER,,ACCENTURE GLOBAL SERVICES GMBH,PICKERING LESLEY;;RITCHIE PAUL;;REID GREGORY S;;RINGO TIMOTHY;;LANE DAVID P;;LIAN ELIZABETH H;;FARRELL DANIEL C;;FENTON CRAIG;;SHEARING ELISE;;BELL RANDY;;WONG SEVASTI;;LINGHAM ANTHONY;;FORRESTER AUDREY;;STAUBITZ CLAUDIA;;ADAMS KEVIN,BRITISH TELECOMMUNICATIONS PLC; ACCENTURE GLOBAL S (2014-10-02),https://lens.org/027-721-862-179-092,Patent Application,no,0,1,14,14,0,G06Q10/06393;;G06Q10/06398;;G06Q10/10;;G06Q10/06393;;G06Q10/10;;G06Q10/06398,G06Q10/06;;G06Q10/10,,0,0,,,,EXPIRED
254,WO,A3,WO 2004/049098 A3,107-700-122-268-433,2004-10-28,2004,IB 0306479 W,2003-11-26,US 30656402 A,2002-11-27,SEARCHING WITHIN A CONTACT CENTER PORTAL,New functions for a contact center system include: testing user's comprehension of informational messages with a quiz; capturing insight of superior users having a KPI score above a threshold by having those users submit informationon why they perform so well; dynamically ordering solutions to issues by re-ranking the solutions periodically based on recency and frequency; integrating information for use by a contact center representative while online with a customer and information for use when not online; storing content items in a telecommunications industry taxonomy; directing user feedback on a content item to the proper owner/manager of that content; communicating solution information using a solutions taxonomy; displaying a dual information system having a CRM application as well as reference material that is context-appropriate; enforcing completion of a group of templates when creating a content item to be published; ensuring a group of templates for a content item are complete before publishing them; and searching within a contact center system portal using a continuum of search functions.,ACCENTURE GLOBAL SERVICES GMBH;;BT GROUP PLC,LANE DAVID P;;REID GREGORY S;;RINGO TIMOTHY;;LIAN ELIZABETH H;;FARRELL DANIEL C;;FENTON CRAIG;;SHEARING ELISE;;BELL RANDY;;WONG SEVASTI;;LINGHAM ANTHONY;;FORRESTER AUDREY;;STAUBITZ CLAUDIA;;ADAMS KEVIN;;PICKERING LESLEY;;RITCHIE PAUL,,https://lens.org/107-700-122-268-433,Search Report,yes,3,0,14,14,0,G06Q30/02;;G06Q30/02,G06Q30/02,,0,0,,,,PENDING
255,MX,A,MX 2010005787 A,144-124-710-685-97X,2010-06-09,2010,MX 2010005787 A,2008-11-24,US 99033007 P;;US 27483408 A;;US 2008/0084469 W,2007-11-27,IMIDAZO-THIAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS.,"Compounds of formula I that inhibit protein kinases, compositions containing the compounds and methods of treating diseases using the compounds are disclosed. Formula I and therapeutically acceptable salts, prodrugs and salts of prodrugs thereof, wherein X is CH or N; A1 is R1, OR1. NHR1, N(R1)2, NHC(O)R1, NHC(O)NHR1, NHC(O)N(R1)2, NHC(O)OR1, C(O)NHR1, C(O)N(R1)2, C=NOR1, or C(NH2)NOC(O)R1;.",ABBOTT LAB,ERICKSON SCOTT A;;BAMAUNG NWE Y;;SHEPPARD GEORGE S;;WANG JIEYI;;FIDANZE STEVE D;;WANG GARY T;;SORENSEN BRYAN K;;CLARK RICHARD F;;SARRIS KATHY;;BELL RANDY L;;HUBBARD ROBERT D;;MANTEI ROBERT A,,https://lens.org/144-124-710-685-97X,Patent Application,no,0,0,7,7,0,A61P35/00;;A61P43/00;;C07D513/04;;C07D513/04,C07D513/04;;A61K31/425;;A61P35/00,,0,0,,,,ACTIVE
256,CA,C,CA 2507633 C,051-965-781-545-725,2013-02-12,2013,CA 2507633 A,2003-11-26,IB 0306465 W;;US 30602502 A;;US 30583502 A;;US 30638602 A,2002-11-27,CONTENT MANAGEMENT SYSTEM,"A computer system may include a contact center interface and a presentation interface. The contact center interface may provide a user with access to a contact center application, which manages and renders information pertaining to customer~centric problems. The presentation interface may provide the user with access to a content management system (or knowledge management system) for information regarding goods, services and associated support. The computer system may display two simultaneously visible content regions, where the operations in one content region are independent of operations in the second content region. One of the content regions may reflect the contact center interface while the other content region may reflect the information application interface. The two content regions may be dynamic such that while the regions are independent, the content displayed within one content region is context-appropriate to the other content region. Such a system may also include a display region for an instant messaging tool. The content management system may include a database having a set of content items stored in a taxonomy, where the taxonomy has at least two primary categories. The categories may associate items that represent products, items that represent services, items that represent information for campaigns, items that represent information for user procedures, and/or items that represent user intentions (customer needs). Each content item in the database may be associated to one or more content~owners. A user may submit feedback for one of the content items. That feedback may be routed to the content-owner associated to the content item without requiring the user to know or to determine who the content-owner is. The content owner may be: a content author, a content manager, an advocate for the content owner, or a team of people. The feedback may be a comment explaining any errors in the content item, a rating of the usefulness of the content item, or a comment for content improvement.",ACCENTURE GLOBAL SERVICES GMBH;;BT GROUP PLC,REID GREGORY S;;RINGO TIMOTHY;;LANE DAVID P;;LIAN ELIZABETH H;;FARRELL DANIEL C;;FENTON CRAIG;;SHEARING ELISE;;BELL RANDY;;WONG SEVASTI;;LINGHAM ANTHONY;;FORRESTER AUDREY;;STAUBITZ CLAUDIA;;ADAMS KEVIN;;PICKERING LESLEY;;RITCHIE PAUL,,https://lens.org/051-965-781-545-725,Granted Patent,no,0,0,10,21,0,G06Q30/02,G06F17/30;;G06F3/048;;G06F3/0482;;G06F3/0484;;G06Q30/00,,0,0,,,,EXPIRED
257,AU,A1,AU 2003/302349 A1,058-463-543-065-27X,2004-06-18,2004,AU 2003/302349 A,2003-11-26,IB 0306465 W;;US 30602502 A;;US 30583502 A;;US 30638602 A,2002-11-27,CONTENT FEEDBACK IN A MULTIPLE-OWNER CONTENT MANAGEMENT SYSTEM,,ACCENTURE GLOBAL SERVICES GMBH,FORRESTER AUDREY;;STAUBITZ CLAUDIA;;ADAMS KEVIN;;PICKERING LESLEY;;RITCHIE PAUL;;REID GREGORY S;;RINGO TIMOTHY;;LANE DAVID P;;LIAN ELIZABETH H;;FARRELL DANIEL C;;FENTON CRAIG;;SHEARING ELISE;;BELL RANDY;;WONG SEVASTI;;LINGHAM ANTHONY,BRITISH TELECOMMUNICATIONS PLC; ACCENTURE GLOBAL S (2014-10-02),https://lens.org/058-463-543-065-27X,Patent Application,no,0,1,10,21,0,G06Q30/02,G06F3/048;;G06F3/0482;;G06F3/0484;;G06Q30/00,,0,0,,,,EXPIRED
258,CN,B,CN 1726493 B,032-723-361-619-985,2010-04-28,2010,CN 200380106314 A,2003-11-26,IB 0306479 W;;US 30656402 A,2002-11-27,Searching within a contact center portal,New functions for a contact center system include: testing user's comprehension of informational messages with a quiz; capturing insight of superior users having a KPI score above a threshold by having those users submit information on why they perform so well; dynamically ordering solutions to issues by re-ranking the solutions periodically based on recency and frequency; integrating informationfor use by a contact center representative while online with a customer and information for use when not online; storing content items in a telecommunications industry taxonomy; directing user feedbackon a content item to the proper owner/manager of that content; communicating solution information using a solutions taxonomy; displaying a dual information system having a CRM application as well asr eference material that is context-appropriate; enforcing completion of a group of templates when creating a content item to be published; ensuring a group of templates for a content item are complete before publishing them; and searching within a contact center system portal using a continuum of search functions.,ACCENTURE GLOBAL SERVICES GMBH;;BT GROUP PLC,RANDY BELL;;AUDREY FORRESTER;;LANE DAVID P;;CLAUDIA STAUBITZ;;LESLEY PICKERING;;ANTHONY LINGHAM;;ELISE SHEARING;;REID GREGORY S;;TIMOTHY RINGO;;LIAN ELIZABETH H;;FARRELL DANIEL C;;SEVASTI WONG;;KEVIN ADAMS;;PAUL RITCHIE;;CRAIG FENTON,"BRITISH TELECOM GROUP PLC (2014-09-04);;ACCENTURE GLOBAL SERVICES GMBH (2014-09-04);;ACCENTURE INTERNATIONAL CO., LTD. (2014-09-04)",https://lens.org/032-723-361-619-985,Granted Patent,no,0,0,14,14,0,G06Q30/02;;G06Q30/02,G06F17/30;;G06Q30/02,,0,0,,,,EXPIRED
259,US,B2,US 8572058 B2,043-285-259-538-355,2013-10-29,2013,US 30638602 A,2002-11-27,US 30638602 A,2002-11-27,Presenting linked information in a CRM system,New functions for a contact center system include: testing user's comprehension of informational messages with a quiz; capturing insight of superior users having a KPI score above a threshold by having those users submit information on why they perform so well; dynamically ordering solutions to issues by re-ranking the solutions periodically based on recency and frequency; integrating information for use by a contact center representative while online with a customer and information for use when not online; storing content items in a telecommunications industry taxonomy; directing user feedback on a content item to the proper owner/manager of that content; communicating solution information using a solutions taxonomy; displaying a dual information system having a CRM application as well as reference material that is context-appropriate; enforcing completion of a group of templates when creating a content item to be published; ensuring a group of templates for a content item are complete before publishing them; and searching within a contact center system portal using a continuum of search functions.,REID GREGORY S;;RINGO TIMOTHY;;LANE DAVID P;;LIAN ELIZABETH H;;FARRELL DANIEL C;;FENTON CRAIG;;SHEARING ELISE;;BELL RANDY;;WONG SEVASTI;;LINGHAM ANTHONY;;FORRESTER AUDREY;;STAUBITZ CLAUDIA;;ADAMS KEVIN;;PICKERING LESLEY;;RITCHIE PAUL;;ACCENTURE GLOBAL SERVICES LTD,REID GREGORY S;;RINGO TIMOTHY;;LANE DAVID P;;LIAN ELIZABETH H;;FARRELL DANIEL C;;FENTON CRAIG;;SHEARING ELISE;;BELL RANDY;;WONG SEVASTI;;LINGHAM ANTHONY;;FORRESTER AUDREY;;STAUBITZ CLAUDIA;;ADAMS KEVIN;;PICKERING LESLEY;;RITCHIE PAUL,BT GROUP PLC (2003-11-02);;BRITISH TELECOMMUNICATIONS PLC (2014-04-30);;ACCENTURE GLOBAL SERVICES LIMITED (2014-04-30);;ACCENTURE GLOBAL SERVICES GMBH (2003-11-02),https://lens.org/043-285-259-538-355,Granted Patent,yes,103,9,2,21,0,G06Q30/02;;G06Q30/02,G06F17/30;;G06Q30/02,707/705,43,0,,,"Dayco Statement Regarding Related Applications.;;M.J. Allend and J.P. Furming, ""Methods for Using Global Position System to Find Close Services"", IBM Technical Disclosure Bulletin, Jan. 1998, pp. 693, vol. 41 No. 1.;;Alban, Oscar, Customer interaction monitoring: your key to measuring service performance, Australian Banking & Finance, vol. 10, No. 6, Apr. 18, 2001.;;Click2Coach Web Pages, Retrieved from www.envisiontelephony.com, 2001.;;eOn Communications and Eyretel Partner to Deliver Performance Improvement for Contact Centers, PR Newswire, Apr. 4, 2002.;;Feasel, Marnie et al., Training Can Produce Better Reps, Call Center Solutions, vol. 17, No. 4, Oct. 1998, pp. 138-143.;;Kelly Services Expands KellyConnect Call Center Solution, PR Newswire, Jan. 14, 2002.;;Kelly Services Offers Improved Call Center Solution, PR Newswire, Apr. 24, 2000.;;Knowlagent and Eyretel Partner to Deliver Integrated E-Learning Platform to Global Clients, PR Newswire, May 10, 2001.;;Primus Taps OutSights to Deliver Expertise to Customers Shifting to Knowledge-Based Support, Business Wire, Jun. 29, 1999.;;Rosati, Marlene et al., Measuring the Reality of the Customer Experience, Customer Interaction Solutions, May 2002, pp. 38-43.;;Televista Integrates eLearning and Quality Monitoring The Ascent Group, Inc. Call Center E-Journal, Aug. 2001.;;What makes your contact center agents truly effective?, Envision Telephony. Click2Coach, 2000.;;Office Action issued by US PTO on U.S. Appl. No. 10/306,705, dated Oct. 9, 2007.;;Office Action issued by EPO on Application No. 03808324.2-2221 dated Jul. 30, 2007 regarding summons to attend oral proceedings on Dec. 13, 2007.;;Cunliffe, Alison, Super systems capture expertise of the specialist Toronto Star, Nov. 2, 1986.;;Emvolve Performance Manager Release 1.5 Customer Inter@action Solutions, vol. 20, No. 5, Nov. 20, 2001, pp. 53-56.;;ServiceSoft Delivers ""Smart Answers"" at Xerox Business Wire, Aug. 4, 1998.;;Tiwana, Amrit, The Knowledge Management Toolkit Prentice Hall, Dec. 1999, ISN: 0-13-012853-8.;;Office Action issued Sep. 20, 2007 by EPO on Chinese Application No. 200380106314.X.;;Office Action issued Oct. 19, 2007 by US PTO on U.S. Appl. No. 10/305,858.;;Office Action issued Dec. 11, 2007 by US PTO on U.S. Appl. No. 10/306,025.;;Office Action issued Jan. 7, 2008 by US PTO on U.S. Appl. No. 10/306,248.;;Office Action issued Jan. 7, 2008 by US PTO on U.S. Appl. No. 10/306,564.;;Office Action issued Jan. 8, 2008 by US PTO on U.S. Appl. No. 10/306,563.;;Office Action issued Jan. 18, 2008 by US PTO on U.S. Appl. No. 10/305,811.;;Office Action issued Jan. 28, 2008 by US PTO on U.S. Appl. No. 10/306,026.;;Office Action issued Dec. 8, 2007 by EPO on Japanese Application No. 2004-554864.;;Office Action issued Dec. 8, 2007 by EPO on Japanese Application No. 2004-554863.;;Office Action issued Dec. 8, 2007 by EPO on Japanese Application No. 2004-554862.;;Office Action issued Dec. 8, 2007 by EPO on Japanese Application No. 2004-554870.;;Office Action issued Feb. 22, 2008 by EPO regarding decision on oral proceedings on Application No. 03808324.2-2221.;;Office Action issued Mar. 19, 2008 by US PTO on U.S. Appl. No. 10/306,705.;;Notice of Allowance issued Apr. 9, 2008 by the US PTO on U.S. Appl. No. 10/306,025.;;Examiner's Report No. 2 issued by IP Australia May 29, 2008 on Application #2003302349.;;Office Action issued Jun. 9, 2008 by US PTO on U.S. Appl. No. 10/306,564.;;Arthur Andersen Virtual Learning Network to Focus Competency Management Through Agreement with SkillScape, Business Wire, Aug. 22, 2000.;;Cooper, Kenneth Carlton, Effective Competency Modeling & Reporting AMA Publications, 2000, ISBN 0-8144-0548-7.;;Gillis, Marget et al., The Ideal Rep. Pharmaceutical Executive, vol. 20. No. 12, Dec. 2001.;;Overview of SkillScape Competence Manager SkillScape, 2000.;;Office Action issued Jul. 1, 2008 by US PTO on U.S. Appl. No. 10/305,858.;;Office Action issued Jul. 9, 2008 by US PTO on U.S. Appl. No. 10/305,811.;;Office Action issued Jul. 14, 2008 by EPO on Canadian Application No. 2,507,519.",ACTIVE
260,WO,A2,WO 2004/049097 A2,042-996-636-098-960,2004-06-10,2004,IB 0306465 W,2003-11-26,US 30602502 A;;US 30583502 A;;US 30638602 A,2002-11-27,CONTENT FEEDBACK IN A MULTIPLE-OWNER CONTENT MANAGEMENT SYSTEM,"A computer system may include a contact center interface and a presentation interface. The contact center interface may provide a user with access to a contact center application, which manages and renders information pertaining to customer&shy;centric problems. The presentation interface may provide the user with access to a content management system (or knowledge management system) for information regarding goods, services and associated support. The computer system may display two simultaneously visible content regions, where the operations in one content region are independent of operations in the second content region. One of the content regions may reflect the contact center interface while the other content region may reflect the information application interface. The two content regions may be dynamic such that while the regions are independent, the content displayed within one content region is context-appropriate to the other content region. Such a system may also include a display region for an instant messaging tool. The content management system may include a database having a set of content items stored in a taxonomy, where the taxonomy has at least two primary categories. The categories may associate items that represent products, items that represent services, items that represent information for campaigns, items that represent information for user procedures, and/or items that represent user intentions (customer needs). Each content item in the database may be associated to one or more content&shy;owners. A user may submit feedback for one of the content items. That feedback may be routed to the content-owner associated to the content item without requiring the user to know or to determine who the content-owner is. The content owner may be: a content author, a content manager, an advocate for the content owner, or a team of people. The feedback may be a comment explaining any errors in the content item, a rating of the usefulness of the content item, or a comment for content improvement.",ACCENTURE GLOBAL SERVICES GMBH;;BT GROUP PLC,REID GREGORY S;;RINGO TIMOTHY;;LANE DAVID P;;LIAN ELIZABETH H;;FARRELL DANIEL C;;FENTON CRAIG;;SHEARING ELISE;;BELL RANDY;;WONG SEVASTI;;LINGHAM ANTHONY;;FORRESTER AUDREY;;STAUBITZ CLAUDIA;;ADAMS KEVIN;;PICKERING LESLEY;;RITCHIE PAUL,,https://lens.org/042-996-636-098-960,Patent Application,yes,0,3,10,21,0,G06Q30/02,G06F3/048;;G06F3/0482;;G06F3/0484;;G06Q30/00,,0,0,,,,PENDING
261,UY,A,UY 32965 A,056-574-909-454-376,2011-02-28,2011,UY 32965 A,2010-10-22,US 60509409 A,2009-10-23,INMUNOGLOBULINAS CON DOMINIO VARIABLE DUAL Y USOS DE LAS MISMAS,"Proteínas de unión multivalentes y multiespecíficas diseñadas, métodos para elaborarlas y, específi camente, sus usos en la prevención, el diagnóstico y/o el tratamiento de enfermedades",ABBOTT LAB,MORGAN-LAPPE TARIQ GHAYUR SUSAN E;;MORGAN-LAPPE SUSAN E;;REILLY EDWARD B;;KINGSBURY GILLIAN A;;BELL RANDY L;;NORVELL SUZANNE M;;HUA YING;;ZHIHONG LIU;;ANDREW PHILLIPS;;JIEYI WANG;;YINGCHUN LI;;JUNJIAN LIU,,https://lens.org/056-574-909-454-376,Patent Application,no,0,0,25,25,0,A61K2039/505;;C07K16/22;;C07K16/28;;C07K16/2863;;C07K16/32;;C07K16/468;;C07K2317/73;;C07K2317/92;;C07K2319/00;;C07K2317/76;;A61P1/00;;A61P1/04;;A61P1/16;;A61P1/18;;A61P11/00;;A61P11/02;;A61P11/06;;A61P13/12;;A61P15/00;;A61P15/08;;A61P17/00;;A61P17/02;;A61P17/04;;A61P17/06;;A61P17/14;;A61P19/00;;A61P19/02;;A61P19/08;;A61P19/10;;A61P21/00;;A61P21/02;;A61P21/04;;A61P25/00;;A61P25/02;;A61P25/04;;A61P25/06;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/20;;A61P25/24;;A61P25/28;;A61P25/30;;A61P25/32;;A61P27/02;;A61P29/00;;A61P31/04;;A61P31/10;;A61P31/12;;A61P31/14;;A61P31/18;;A61P31/20;;A61P33/00;;A61P33/06;;A61P35/00;;A61P35/02;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/00;;A61P43/00;;A61P5/14;;A61P7/00;;A61P7/02;;A61P7/06;;A61P9/00;;A61P9/04;;A61P9/06;;A61P9/10;;A61P9/12;;A61P3/10;;Y02A50/30;;C07K16/28;;C12N15/11;;A61K39/395;;C07K16/22;;C07K2319/00;;A61K2039/505;;C07K2317/92;;C07K16/468;;C07K16/32;;C07K16/2863;;C07K16/28;;C07K2317/73;;C07K2317/76;;Y02A50/30,A61K39/395;;C07K16/22;;C07K16/28;;C07K16/46;;C07K19/00;;C12N5/10;;C12N15/09;;C12N15/12;;C12N15/13;;C12N15/63;;C12N15/80;;C12N15/81;;C12N15/85,,0,0,,,,DISCONTINUED
262,WO,A2,WO 2004/049098 A2,143-299-845-652-903,2004-06-10,2004,IB 0306479 W,2003-11-26,US 30656402 A,2002-11-27,SEARCHING WITHIN A CONTACT CENTER PORTAL,New functions for a contact center system include: testing user's comprehension of informational messages with a quiz; capturing insight of superior users having a KPI score above a threshold by having those users submit informationon why they perform so well; dynamically ordering solutions to issues by re-ranking the solutions periodically based on recency and frequency; integrating information for use by a contact center representative while online with a customer and information for use when not online; storing content items in a telecommunications industry taxonomy; directing user feedback on a content item to the proper owner/manager of that content; communicating solution information using a solutions taxonomy; displaying a dual information system having a CRM application as well as reference material that is context-appropriate; enforcing completion of a group of templates when creating a content item to be published; ensuring a group of templates for a content item are complete before publishing them; and searching within a contact center system portal using a continuum of search functions.,ACCENTURE GLOBAL SERVICES GMBH;;BT GROUP PLC,LANE DAVID P;;REID GREGORY S;;RINGO TIMOTHY;;LIAN ELIZABETH H;;FARRELL DANIEL C;;FENTON CRAIG;;SHEARING ELISE;;BELL RANDY;;WONG SEVASTI;;LINGHAM ANTHONY;;FORRESTER AUDREY;;STAUBITZ CLAUDIA;;ADAMS KEVIN;;PICKERING LESLEY;;RITCHIE PAUL,,https://lens.org/143-299-845-652-903,Patent Application,yes,0,1,14,14,0,G06Q30/02;;G06Q30/02,G06Q30/02,,0,0,,,,PENDING
263,US,B2,US 7418403 B2,181-716-652-894-749,2008-08-26,2008,US 30602502 A,2002-11-27,US 30602502 A,2002-11-27,Content feedback in a multiple-owner content management system,New functions for a contact center system include: testing user's comprehension of informational messages with a quiz; capturing insight of superior users having a KPI score above a threshold by having those users submit information on why they perform so well; dynamically ordering solutions to issues by re-ranking the solutions periodically based on recency and frequency; integrating information for use by a contact center representative while online with a customer and information for use when not online; storing content items in a telecommunications industry taxonomy; directing user feedback on a content item to the proper owner/manager of that content; communicating solution information using a solutions taxonomy; displaying a dual information system having a CRM application as well as reference material that is context-appropriate; enforcing completion of a group of templates when creating a content item to be published; ensuring a group of templates for a content item are complete before publishing them; and searching within a contact center system portal using a continuum of search functions.,BT GROUP PLC;;ACCENTURE GLOBAL SERVICES GMBH,REID GREGORY S;;RINGO TIMOTHY;;LANE DAVID P;;LIAN ELIZABETH H;;FARRELL DANIEL C;;FENTON CRAIG;;SHEARING ELISE;;BELL RANDY;;WONG SEVASTI;;LINGHAM ANTHONY;;FORRESTER AUDREY;;STAUBITZ CLAUDIA;;ADAMS KEVIN;;PICKERING LESLEY;;RITCHIE PAUL,BT GROUP PLC (2003-11-02);;BRITISH TELECOMMUNICATIONS PLC (2014-04-30);;ACCENTURE GLOBAL SERVICES LIMITED (2014-04-30);;ACCENTURE GLOBAL SERVICES GMBH (2003-11-02),https://lens.org/181-716-652-894-749,Granted Patent,yes,110,11,7,21,0,G06Q10/06398;;G06Q10/06398;;G06Q10/063;;G06Q10/063;;G06Q10/06393;;G06Q10/06393;;G06Q10/10;;G06Q10/10;;G06Q30/0601;;G06Q30/0601;;G06Q30/0641;;G06Q30/0641;;G06Q50/184;;G06Q50/184,G06Q10/06;;G06Q10/10;;G06Q30/06;;G06Q50/18,705/26;;705/27;;705/11;;705/7,28,0,,,"Dayco Statement Regarding Related Applications.;;M.J. Allend and J.P. Furming, ""Methods for Using Global Position System to Find Close Services"", IBM Technical Disclosure Bulletin, Jan. 1998, pp. 693, vol. 41 No. 1.;;Alban, Oscar, Customer interaction monitoring: your key to measuring service performance, Australian Banking & Finance, vol. 10, No. 6, Apr. 18, 2001.;;Click2Coach Web Pages, Retrieved from www.envisiontelephony.com, 2001.;;eOn Communications and Eyretel Partner to Deliver Performance Improvement For Contact Centers, PR Newswire, Apr. 4, 2002.;;Feasel, Marnie et al., Training Can Produce Better Reps, Call Center Solutions, vol. 17, No. 4, Oct. 1998. pp. 138-143.;;Kelly Services Expands KellyConnect Call Center Solution, PR Newswire, Jan. 14, 2002.;;Kelly Services Offers Improved Call Center Solution. PR Newswire. Apr. 24, 2000.;;Knowlagent and Eyretel Partner to Deliver Integrated E-Learning Platform to Global Clients, PR Newswire, May 10, 2001.;;Primus Taps OutSights to Deliver Expertise to Customers Shifting to Knowledge-Based Support, Business Wire, Jun. 29, 1998.;;Rosati, Marlene et al., Measuring the Reality of the Customer Experience, Customer Interaction Solutions, May 2002, pp. 36-43.;;Televista Integrates eLearning and Quality Monitoring The Ascent Group, Inc. Call Center E-Journal, Aug. 2001.;;Office Action issued by U.S. Appl. No. 10/306,705, dated Oct. 9, 2007.;;Office Action issued by EPO on Application No. 03808324.2-2221 dated Jul. 30, 2007 regarding summons to attend oral proceedings on Dec. 13, 2007.;;Cunliffe, Alison, Super systems capture expertise of the specialist Toronto Star, Nov. 2, 1986.;;Emvolve Performance Manager Release 1.5 Customer Inter@action Solutions, vol. 20, No. 5, Nov. 20, 2001, pp. 53-56.;;ServiceSoft Delivers ""Smart Answers"" at Xerox Business Wire, Aug. 4, 1998.;;Tiwana, Amrit, The Knowledge Management Toolkit Prentice Hall, Dec. 1999, ISN: 0-13-012853-8.;;Office Action issued Sep. 20, 2007 by EPO on Chinese Application No. 200380106314.X.;;Office Action issued Oct. 19, 2007 by US PTO on U.S. Appl. No. 10/305,858.;;Office Action issued Dec. 11, 2007 by US PTO on U.S. Appl. No. 10/306,386.;;Office Action issued Jan. 7, 2008 by US PTO on U.S. Appl. No. 10/306,248.;;Office Action issued Jan. 7, 2008 by US PTO on U.S. Appl. No. 10/306,564.;;Office Action issued Jan. 8, 2008 by US PTO on U.S. Appl. No. 10/306,563.;;Office Action issued Jan. 18, 2008 by US PTO on U.S. Appl. No. 10/305,811.;;Office Action issued Jan. 28, 2008 by US PTO on U.S. Appl. No. 10/306,026.;;Office Action issued Jan. 29, 2008 by US PTO on U.S. Appl. No. 10/306,386.;;What makes your contact center agents truly effective? Envision Telephony, Click2Coack, 2000.",EXPIRED
264,AU,A1,AU 2003/302350 A1,012-347-447-658-131,2004-06-18,2004,AU 2003/302350 A,2003-11-26,IB 0306479 W;;US 30656402 A,2002-11-27,SEARCHING WITHIN A CONTACT CENTER PORTAL,,ACCENTURE GLOBAL SERVICES GMBH,BELL RANDY;;WONG SEVASTI;;LINGHAM ANTHONY;;FORRESTER AUDREY;;STAUBITZ CLAUDIA;;ADAMS KEVIN;;PICKERING LESLEY;;RITCHIE PAUL;;PLC BT GROUP;;LANE DAVID P;;REID GREGORY S;;RINGO TIMOTHY;;LIAN ELIZABETH H;;FARRELL DANIEL C;;FENTON CRAIG;;SHEARING ELISE,ACCENTURE GLOBAL SERVICES LIMITED; BRITISH TELECOM (2014-10-02),https://lens.org/012-347-447-658-131,Patent Application,no,0,0,14,14,0,G06Q30/02;;G06Q30/02,G06Q30/02,,0,0,,,,EXPIRED
